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The BB/E rat spontaneously develops a syndrome closely
resembling human Type 1 (insulin-dependent) diabetes
mellitus (IDDM). These studies were aimed at
determining the sequence of pancreatic events that lead
to the mass destruction of pancreatic beta cells, by
correlating changes in humoral and cellular immunity
with pancreatic morphology in the prediabetic period.
In addition, the resulting effects of treatment with the
immunosuppressant cyclosporine (CSA) on these events and
the incidence of diabetes was examined.
Use of serial pancreatic biopsy within individual rats,
and monoclonal antibodies (MoAb) against rat major
histocompatibility complex (MHC) antigens, lymphocyte
and macrophage subsets has enabled the following
sequence of pancreatic events leading to the development
of IDDM in the BB/E rat to be described. The first
change observed, occurs in some pancreatic lobules about
30 days before the onset of diabetes and consists of
increased expression of MHC class I molecules within
islets and on the vascular endothelium. Between 2 and 3
weeks ^before disease onset, expression of MHC class II
antigens on vascular endothelial cells accompanies the
marked recruitment and accumulation of a population of
macrophages at perivascular and periductal sites. These
recruited macrophages subsequently infiltrate the
adjacent islets thereby initiating insulitis. Further
recruitment of other immunocytes including T-helper and
T-cytotoxic/suppressor cells, NK cells and B-lymphocytes
soon follows such that by 10 days before disease onset,
insulitis and resulting beta cell destruction is
observed in most of the islets. At this stage,
hyperexpression of MHC class I antigens within
infiltrated islets is markedly enhanced, extending
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beyond the islet periphery into the surrounding exocrine
tissue, and although expression of MHC class II
molecules was mainly restricted to the infiltrating
cells, occasional insulin-containing cells were found to
express class II MHC molecules. However, aberrant MHC
class II expression on beta cells was never observed in
non-infiltrated islets suggesting that it is a secondary
rather than a primary initiating event.
This was supported by in vitro studies which showed that
islets isolated from 90 day old diabetes-prone (DP) rats
expressed MHC class II molecules on 50% of the beta
cells when cultured with lOOU/ml of rat recombinant
interferon-gamma for 4 days. In contrast, expression of
class II MHC antigens was never observed on: (i)
glucagon or somatostatin cells from any rats; (ii) beta
cells from either normal Wistar or diabetes-resistant
BB/E rats, or (iii) beta cells from young (30 day old)
DP BB/E rats. This suggested the possibility that
islets isolated from the older DP rats may have been
rendered susceptible to induction of class II MHC
antigens by interferon-gamma because of previous
cytokine mediated damage in vivo.
Administration of CSA from 30-100 days of age completely
prevented the development of diabetes up to 150 days of
age and reduced the incidence to approximately 50% of
controls (37% v 66%) at 450 days. Whereas islet cell
surface antibodies paralleled the development of
diabetes, insulin autoantibodies were unrelated to
diabetes onset and were unaffected by CSA therapy.
Pancreatic biopsies from CSA treated animals showed that
CSA had no effect on pancreatic hyperexpression of MHC
class I molecules, but inhibited the accumulation of
macrophages at extra islet sites, the subsequent
recruitment of other immune effector cells and islet
infiltration. This resulted in a delay on the onset of
ii
diabetes in some rats and prevention in others.
Commencement of CSA therapy at diagnosis of diabetes
failed to induce remission of diabetes or reduce the
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CHAPTER 1 - GENERAL INTRODUCTION
"Falstaff: Sirrah, you giant, what says the doctor to
my water?
Page: He said, Sir, the water itself was a good
healthy water; but, for the party that owed
it, he might have more diseases than he
knew of".
William Shakespeare - Henry IV, Part II
Act I, Scene 2.
HISTORICAL PERSPECTIVES ON DIABETES MELLITUS
Knowledge of diabetes dates back to centuries before
Christ. The Egyptian Papyrus Ebers (ca. 1500 B.C.)
described an illness associated with the passage of much
urine (polyuria). However the name diabetes, meaning a
siphon, was given l?y the Greek Physician Aretaeus of
Cappadocia (30 A.D. - 90 A.D.) when he made the first
clinical description, describing it as "a wonderful
affection, not very frequent in men, being a melting down
of the flesh and limbs into urine". Thus, it was long
thought that diabetes resulted from kidney disease. The
Ayur Veda of Susruta, a Hindu manuscript (6th century
A.D.), describes the disease as "madhumeha" or honey
urine. However, it was not until centuries later that
knowledge of the disease appeared in European writings
when Thomas Willis (1621 - 1675) wrote of "the diabetes
or pissing evil" and described the urine as "wonderfully
sweet as if it were imbued with honey or sugar", thus
establishing the name diabetes mellitus. Willis believed
that acid salts in the blood, resulting from "immoderate
use of wine and cider", were the causative agents
responsible for the disease.
In 1776 Matthew Dobson confirmed that the sweetness was
indeed due to sugar, but this did not establish the
source of the excess sugar. It was Richard Mead (1673 -
1754) who first considered diabetes as a disease of the
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liver, an idea subsequently propagated by Claude Bernard
(1813 - 78). He observed that the kidney did not produce
sugar but excreted the excess into the urine and that it
was the liver which normally produced the sugar which it
spilled into the circulation. Thus it was thought that
diabetes resulted from an overproduction of sugar by the
liver. However, another discovery by Bernard; that
puncture of the floor of the fourth ventricle of the
brain caused glycosuria, was less constructive in its
influence since it led to a widely held belief that
diabetes resulted from disease of the nervous system.
Within the past century, the association between diabetes
and the pancreas has been established. The association
began in 1889 when Von Mering and Minkowski reported that
pancreatectomy in * dogs produced the symptoms of
polydipsia and polyuria normally associated with diabetes
(1). Prior to this, in 1869, Paul Langerhans, in his
doctoral thesis, described discrete groups of cells or
"islets" embedded within the main tissue of the rabbit
pancreas which could be differentiated from the rest of
the tissue by histological means (2). At this time,
Langerhans did not record any opinion as to their
physiological significance. The name "ilots de
Langerhans" was proposed by Laguesse (1893), after he had
recognised numerous groups of cells in human pancreas as
being similar to those described by Langerhans for rabbit
pancreas (3).
Following the observation by Dogiel (1893), that there
were no direct connections between these islets and the
duct system of the pancreas, Laguesse suggested the
possibility that the islets, constituting an endocrine
organ, secreted a substance into the "milieu interieur"
(3). Further connections, as to the role of the islets
of Langerhans in the genesis of diabetes, were
established by the observations of Opie (1901) in which
he described the abnormal appearance of the islets from
some cases with diabetes (4).
The experiments of Von Mering and Minkowski (1) led to a
surge of attempts to prepare an extract of pancreatic
tissue that would replace the unknown missing substance
of human diabetes. In 1908, Zuelzer prepared a
pancreatic extract which he subsequently injected
intravenously into 8 diabetic patients which were
maintained on a constant diet. The extract was prepared
following ethanol extraction of the juice from pressed
pancreas which was then evaporated to dryness, with the
water soluble residue constituting the final extract for
injection (5). Following injection of the extract, the
excretion of acetone and sugar in the urine of the
patients decreased • or disappeared and their general
diabetic condition improved. However the injections were
followed by severe chills, fever and vomiting, thereby
discouraging further experiments.
In spite of these studies, the idea persisted that the
pancreatic islets were the source of a hypoglycaemic
agent, which prompted Jean de Meyer in 1909 to christen
the, as yet, undiscovered substance "insuline" (6), a
name adopted by Banting when in 1921 he finally succeeded
in isolating the active secretion of the islets.
Frederick Banting met Charles Best in Toronto in the
autumn of 1920 and invited him to assist in some
experiments aimed at isolating insulin. In May 1921 they
commenced work on the project when, in order to eliminate
the proteolytic effects of the enzymes derived from the
exocrine tissue, they ligated the pancreatic ducts of
dogs for 7-10 weeks to allow atrophy of the acinar
tissue. The degenerated pancreas was removed, placed in
a mortar containing chilled Ringers solution and
macerated. The material was then filtered through paper
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and the filtrate injected into dogs that had been
pancreatectomized a few days earlier. A rapid fall in
blood sugar concentration was observed and the general
condition of the dogs improved.
To avoid the need for ligation of the pancreatic duct, an
attempt was made to prepare insulin from foetal calf
pancreas. The pancreas of the calf foetus does not
produce trypsin until after the fourth month of embryonic
life, and therefore proteolysis of any extracted insulin
should be greatly reduced. The insulin solutions
obtained were clear and very potent, containing 15-20
units/ml after sterilization.
Although good use of this extract was made
experimentally, Bant-ing decided that for clinical trials
the source of material should be a commercially viable
one. Therefore an acid alcohol extract of normal beef
pancreas was prepared and, although less potent than the
foetal extract, it proved a suitable source of insulin
for use in treating diabetes in man.
The first announcement of Banting and Best's discovery,
was made to the Medical Faculty of the University of
Toronto- on the 11th November, 1921. These findings were
sent to the Journal of Laboratory and Clinical Medicine,
where they appeared in February 1922 (7). Clinical
trials of insulin treatment of human diabetes began in
January 1922 under Drs Walter Campbell and Almon Fletcher
at Toronto General Hospital, with the results published
later in 1922 (8). Large scale production of insulin
followed, supervised by Dr Clowes, Research Director of
Eli Lilly and Company, working under an exclusive one
year licence granted by the Insulin Committee of the
University of Toronto. The final steps in the
purification of insulin were achieved in 1926 when Abel
produced the first crystalline insulin (9) and Scott
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(1934) showed that crystallization of the zinc salt was a
simple and practical proposition in its commercial
manufacture (10).
The discovery of insulin was a major medical triumph,
causing death from ketoacidosis to be vastly reduced.
Indeed, during the 1920s and for many years afterwards,
it was believed that diabetes mellitus had been "cured".
However, in the 1940s and particularly the 1950s,
diabetic subjects, now in their 4th and 5th decades who
had been presumed "cured" by insulin, were developing the
so-called specific "diabetic complications" of
retinopathy, nephropathy and neuropathy.
After 20 years of diabetes, 80% had retinopathy and of
these subjects approximately 50% were destined to die of
kidney failure within another 10-15 years. Thus,
although insulin provided an effective treatment for
sustaining the life of the diabetic patient, the
threatening excess morbidity and mortality, with long
term insulin therapy, necessitated further research to
find a "cure" for the "pissing evil".
Over the past 15 years, there has been an immense renewal
of research pertaining to understand the mechanisms
underlying the aetiology and pathogenesis of diabetes
mellitus. This increased interest in diabetes research
reflects and derives its impetus from the tremendous
advances that have occurred in basic immunology over the
past 30 years. For many years diabetes mellitus per se,
being a group of disorders having in common
hyperglycaemia, was broadly classified by clinicians into
either juvenile-onset (insulin requiring) or maturity-
onset (non-insulin requiring).
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In the early 1970s evidence was accumulating to indicate
that these two forms of hyperglycaemia were, in fact, two
distinct disease entities. In particular, the evidence
of an HLA association with insulin-dependent (IDDM) but
not non-insulin-dependent (NIDDM) diabetes mellitus (11),
and the involvement of antipancreatic cell-mediated
immunity in IDDM (12), suggested distinctly separate
aetiologies for the two conditions.
This thesis will deal virtually exclusively with IDDM or
Type 1 diabetes (13) and the increasing awareness of the
autoimmune phenomena underlying its aetiology. However,
in order to provide a conceptual framework for
understanding the aetiology of IDDM, I shall initially
review some of the literature pertaining to the history
of autoimmunity and its counterpart of immunological
tolerance.
AUTOIMMUNITY AND TOLERANCE
Immunological tolerance refers to a specific state of
unresponsiveness or hyporesponsiveness which has been
induced by prior exposure to a given antigen. When the
given antigen is a self antigen then unresponsiveness to
self components i.e. self tolerance is established. If
self tolerance is somehow terminated, autoimmunity is
assumed to ensue with the formation of autoantibodies and
T lymphocyte reactivity against self antigens.
HISTORICAL PERSPECTIVES ON AUTOIMMUNITY
The concept of autoimmunity was first postulated in 1901
by Paul Ehrlich and Julius Morgenroth (14). They found
that goats immunized with their own erythrocytes failed
to produce antibodies against them, and thus formulated
the concept of "horror autotoxicus" to explain the
animals failure to elicit an immune response against
itself. Nevertheless, they recognised that autoimmunity
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might occur as an aberration and lead to disease, when
they stated: "In the explanation of many disease
phenomena, it will in the future be necessary to consider
the possible failure of the internal regulation, as well
as the action of directly injurious exogenous or
endogenous substances" (14).
Subsequently in 1904, Donath and Landsteiner showed that
formation of autoantibodies were possible, being
responsible for paroxysmal cold haemaglobinuria in
syphilis (15). For many years however Ehrlich's dictum
that the animal body would not form harmful immunologic
reactions against itself was accepted. Half a century
later, this concept was expressed by Burnet and Fenner as
self tolerance, in which they proposed thymic censorship
to prevent the appearance of "forbidden clones" (16, 17).
Early investigations using antigens from diverse sources
e.g. spermatozoa for immunization, led to the discovery
of cytotoxic antibodies in the animals immunized with the
antigens (18), and thereby initiated the concept of
autoallergy whereby an animal mounts an immune response
against its own self antigens. Early discoveries about
eye diseases in which autoallergy was responsible,
included phacoanaphylaxis caused by inflammatory
reactivity against protein antigens released from a
traumatized lens capsule (19).
In 1942 Freund described the efficiency of water-in-oil
emulsions for potentiating the antibody response to a
variety of antigens (20). It was soon found that
incorporation of various normal tissues into Freund's
adjuvant could lead to the production of an autoimmune
response in the animal. Voisin, reported the development
of aspermatogenesis, following the injection of
testicular tissue, combined with Freund's adjuvant (21).
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Later it was postulated that, with reference to Burnet's
clonal selection theory of acquired immunity (17), the
use of adjuvants might cause stimulation of so-called
"forbidden clones" and that these forbidden clones might
augment an immune response against self antigens causing
pathological disease. Thus, by the 1950s the conceptual
occurrence of autoimmunity and its possible pathological
sequelae was gaining increasing credibility as a distinct
immunological phenomenon.
In 1957 an attempt to establish criteria for determining
the relationship of immunologic phenomena to disease
aetiology was presented by Witebsky (22). According to
these criteria, an autoimmune response should be
considered the cause of a human disease if: (i) the
autoimmune response* is regularly associated with the
disease; (ii) immunization of an experimental animal with
antigen from the appropriate tissue causes the animal to
make an immune response; (iii) associated with this
response, the animal develops pathological changes that
are basically similar to those of the human and, (iv) the
experimental disease can be transferred to non-immunized
animals by serum or by lymphoid cells.
Witebsky's postulates were based on Koch's postulates in
bacteriology and reflected the thinking of that period,
concerning autoimmunity, when a single cause was believed
to be responsible for an autoimmune disease, just as a
single microorganism was proven to be the aetiologic
agent of an infectious disease.
Recent research now indicate
have a multifactorial ae
environmental and hormonal fa
immune regulation, combine
autoimmune disease.
s that autoimmune diseases
tiology, where genetics,
ctors, along with defective
in concert to produce an
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DIVERSIFICATION, CO-OPERATION AND REGULATION OF THE
IMMUNE SYSTEM
The continued advancement of research into autoimmunity
was only possible following the proliferation of basic
cellular immunology which, although not exclusively, was
in part inspired from Burnet's hypothesis on the "clonal
selection theory of acquired immunity" (17). This led to
the demise of Ehrlich's template theory of antibody
production, with Burnet proposing lymphoid cells being
genetically programmed to synthesize one type of
antibody. The cell surface antibody would serve as
receptor for antigen and proliferate into a clone of
cells producing antibody of that specificity. Burnet
introduced the "forbidden clone" concept to account for
autoimmunity. Cells capable of forming antibody against
a normal self-antigen were "forbidden" and presumably
eliminated during embryonic development. However,
autoimmunity was envisaged as occurring if somatic
mutation of lymphocytes generated "forbidden clones"
capable of reacting with autoantigens.
There were other notable investigations which greatly
influenced our understanding of cellular immunology. In
1948 the role of the plasma cell in antibody production
was established by Fagraeus (23). The development of the
fluorescent antibody technique by Coons et al,
revolutionized the ability to detect antigen within
tissues (24).
In 1956 the bursa dependence of antibody formation was
demonstrated by Glick et al, following the failure to
produce antibodies in animals in which the bursa of
Fabricius had been removed (25). This was shortly
followed by studies from Miller (26) and Good et al (27)
establishing the role of the thymus in the generation of
immune responses. Thus the immune system could be
separated into a bursa-dependent antibody producing
JO
component and a thymus-dependent cell-mediated component.
Later it was found that co-operation between these two
limbs was necessary for the production of many immune
responses (28, 29). Subsequently the subdivision of the
thymus-dependent limb into T lymphocytes, demonstrating
helper activity (30) and those described by Gershon and
Kondo (31) which brought about suppression, suggested
that regulation of the immune system depended in part
upon a delicate balance between helper T lymphocytes and
T suppressor cells. Thus it was envisaged that
disturbances of this balance, creating either
hyperactivity of T helper cells or defective suppressor
cell function, could result in the production of
autoimmunity.
A further restraint directed towards immunoregulation,
was proposed by Jerne in his network theory of the immune
response (32). This proposes that antibody stimulated by
antigen expresses a specific idiotype that elicits the
production of anti-idiotypic antibodies. The idiotypes
of these latter antibodies in turn stimulate the
production of anti-anti-idiotypic antibodies leading to
an open-ended network consisting of a circular
configuration of idiotypes and anti-idiotypes. Similar
considerations can be made for idiotypic regulation of
the T cell repertoire where it has been shown that anti¬
idiotypes can activate the formation of idiotype-specific
suppressor lymphocytes (33).
The elucidation of T and B lymphocyte populations and T
cell subsets, and their role in immunoregulation, was
requisite in providing the platform for further
investigations into the aetiology of autoimmunity.
An equally important contribution to the future
understanding of autoimmunity, was the demonstrations by
Benacerraf and McDevitt (34) and McDevitt and Chinitz
II
(35) of the significant role played by gene products of
the major histocompatibility complex (MHC) in controlling
the specificity and regulation of T cell-dependent immune
responses.
In 1972 Kindred and Shreffler described experiments
indicating that co-operation between T and B lymphocytes
was restricted by the MHC (36). In 1973, Rosenthal
reported that the presentation of macrophage-associated
antigen to lymphocytes, required identity between
macrophage and lymphocyte at some portion of the MHC
(37) .
In 1974, Zinkernagel and Doherty demonstrated genetic
restriction for T cell-mediated lysis of virally infected
cells, thereby formulating their concept of "dual
recognition" for MHC restriction of antigen recognition
processes (38). These findings created the central
paradox pertaining to T cell tolerance, whereby the
immune system must select a repertoire of T cells which
can recognize MHC molecules when they are associated with
foreign antigens but ignore them when they are not.
SELF TOLERANCE AND INDUCED UNRESPONSIVENESS
The term tolerance was first applied in 1945 by Owen
(39), on noting the acquisition of unresponsiveness to
allogeneic antigens in dizygotic cattle twins. He
observed that binovular twin cattle sharing a common
placenta produced a chimaeric state whereby erythrocyte
precursors from each twin foetus had become established
in the other. This conferred a tolerance towards foreign
cells enabling acceptance of skin allografts between the
dizygotic twins. Earlier, Traub (40) had noted that mice
infected in utero with lymphocytic choriomeningitis virus
(LCMV), carried the virus in their blood and tissues
throughout life without an apparent immune response,
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whereas mice first infected in adult life made a brisk
antibody response. These observations led Burnet and
Fenner (16) to predict that antigen, introduced into the
body during embryonic life, before the immune system had
developed, would be mistaken for self, and that it would
not evoke antibody formation then or if reencountered
later in life. Support for this theory came from the
experiments of Billingham et al (41) on "acquired
immunological tolerance" to allogeneic skin grafts.
Thus, neonatal injections of CBA mouse cells into newborn
A strain mice permits the survival of a CBA skin graft in
adult life.
In addition, Triplett (42) showed that extirpation of the
pituitary from the tree frog during early ontogeny, led
to a loss of tolerance to the pituitary such that later
grafting of pituitary tissue led to rejection, whereas if
only part of the organ was removed the frogs tolerated
the graft. These studies led to the widespread belief
that self antigens were recognised during ontogeny with
resultant establishment of tolerance, and that antigens
introduced in the perinatal period preferentially caused
tolerance. Tolerance induced in adult animals, by lethal
doses of X-irradiation and allo-or xenografting (43), was
explained on the postulate that the repopulating lymphoid
system recapitulated the events of early ontogeny.
In 1962 the dogma of the uniqueness of the newborn state
came under scrutiny. Dresser (44) found that by
ultracentrifuging gamma globulin to remove all aggregated
material, intravenous injection of small amounts of the
deaggregated material into normal adult animals
preferentially induced unresponsiveness, whereas the
aggregated material favoured an immune response. It was
perceived that unprocessed antigen, acting alone, was
insufficient to trigger an immune response, but that some
accessory stimulus was required. Dresser (44) used the
term "adjuvanticity" for this extra stimulus necessary
for activation of immunocompetent cells.
This concept of a stimulus not directly dependent on
antigen, was elaborated by Bretscher and Cohn (45) into
their two signal theory of lymphocyte activation. This
states that lymphocytes require two inductive signals to
become activated. One is provided by antigen occupying
the receptor for antigen; the other is provided by the
action of a helper T cell. If the first signal acts
alone, in the absence of the second, the result is a
negative signal or tolerance.
Cleveland and Claman (46) were able to induce tolerance
to l-fluoro-2, 4-dinitrobenzene-modified self antigens in
mice by injecting haptenised cells intravenously.
Surprisingly, an additional injection of concanavalin A
(Con A), a lectin capable of inducing interleukin-2 (IL-
2) production, changed the tolerogenic nature of the
haptenised cells into an immunogenic one. This
observation was followed up by Malkovsky et al (47) who
showed that administration of exogenous IL-2 to newborn
CBA mice, annulled the tolerogenic potential of
semiallogeneic cells previously injected into the CBA
mice. "Thus, since newborn mice fail to produce IL-2 (48)
and the induction of neonatal tolerance could be
abrogated by exogenous IL-2, neonatal tolerance was
interpreted as a consequence of the exposure of the
immune system to antigen in the absence of IL-2.
Zonal Tolerance and Suppression
As mentioned earlier, the elucidation of the immune
system into T and B lymphocyte compartments
revolutionised the study of immunology. The impact of
these discoveries on research into tolerance was equally
profound. Weigle et al (49) showed that human gamma
globulin, injected into adult mice, produced tolerance in
the T cell compartment more rapidly and at a much lower
dose of antigen than for B lymphocytes. The greater ease
of tolerance induction in T cells was similarly reflected
in the system of high-zone and low-zone tolerance
established by Mitchison (50).
In 1949, Felton (51) had reported that supraimmunogenic
amounts of pneumococcal polysaccharide could cause non
reactivity in normal adult mice. However, at that time
the concept of the uniqueness of the perinatal state
persisted and this observation was overlooked.
In contrast to Felton's studies, the equally unexplained
observations of Shellam and Nossal (52), where femtogram
amounts of flagellar antigens were able to induce
tolerance, were subsequently explained by the presence of
T suppressor cells (31).
During the last 15-20 years, numerous models of
unresponsiveness involving suppressor cells have been
described (for reviews see references 53-55). Eardley et
al (56) demonstrated, in an in vitro model, that exposure
of T cells to high doses of sheep erythrocytes led to the
stimulation of a regulatory subset which was able to
activate other T cells into becoming functional
suppressor cells. The target antigen for the modulation
of the humoral response appeared to be the helper T cell.
Jandinski et al (57) showed that class I
histocompatibility antigens were required on the carrier
cell to elicit active suppressor cells, and Pierres et al
(58) demonstrated that H-2 negative cell lines were
inefficient at suppressor cell induction. Thus the
crucial role of MHC antigens in regulating immune
responses, mentioned previously, was equally apparent for
restricting the transfer of suppression.
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Parameters of Induced Unresponsiveness
Although the induction of tolerance in the newborn is no
longer unique, nevertheless, tolerance is more readily
induced and of longer duration in immature animals than
in adult animals. This probably reflects the
differential sensitivity of immature and mature
lymphocytes to tolerizing signals transduced via their
membrane antigen receptors. The studies of Dresser (44)
inferred the importance of antigen composition, whereby
materials which are readily phagocytosed are potent
immunogens, whereas those which are poorly phagocytosed
are highly tolerogenic.
Further, Pike et al (59) showed the effects of altering
the molecular arrangement of haptens and carrier
molecules on their efficacy as tolerogens. Thus, by
coupling increasing numbers of fluorescein (FLU) residues
as haptens onto either human gamma globulin (HGG), the
F(ab-'_)2 fragment of HGG or bovine serum albumin (BSA),
they found the higher the hapten density, the lower the
concentration of antigen required for induction of
tolerance.
The early investigations of Sulzberger (60) and Chase
(61), indicated an important consideration in inducing
tolerance as being the route in which the antigen was
administered. Antigens administered systemically, by
intravenous or oral routes, tend to favour
unresponsiveness, whereas local deposition of antigen
intradermally or subcutaneously is usually immunogenic.
Chiller et al (62) demonstrated that maintenance of
specific unresponsiveness to an antigen depended on the
continual presence of the antigen, with tolerance
diminishing as the antigen concentration fell below a
critical level.
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Finally, Mitchison (50) demonstrated that for some T
dependent antigens, tolerance could be induced at two
dose ranges; one lower and one higher than that used for
optimal immunization. As such, the dose, composition,
route of administration and persistence of antigen, along
with the age of the animal, are all important parameters
to be considered in models for studying the mechanisms of
tolerance induction.
MECHANISMS OF TOLERANCE
Many models have been developed to study the mechanisms
underlying the induction of tolerance.
I do not intend to review this vast area but suggest, to
the interested readdr, the reviews of Weigle (63), Nossal
(64) and Scott (65). Use of these models has led to the
provision, of several possible mechanisms for tolerance.
The three most commonly pursued being: (i) clonal anergy,
reflecting functional inactivation of self reactive
lymphocytes; (ii) clonal suppression, mediated by antigen
specific T suppressor cells or regulatory elements of an
idiotypic network and (iii) clonal deletion where self
reactive lymphocytes are assumedly eliminated from,, the
pre-immune repertoire. It must be stressed that noTi^-
of these mechanisms should be thought of as mutually
exclusive, nor universally applicable, for all antigens.
Indeed, given the importance of avoiding uncontrolled
autoimmunity, it would not be surprising that the immune
system has evolved whereby provision of a suppressor
system may act as a fail-safe mechanism to an initial
repertoire-purging mechanism. Presently, controversy in
distinguishing between these mechanisms still persists.
One of the difficulties contributing to this controversy
stems from the difficulty in determing the fate of anti-
self lymphocytes which are generated at very low
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frequencies. Thus, although self reactive lymphocytes
can be detected in secondary lymphoid tissues (66), their
functional significance remains unclear for two reasons.
First, their detection has relied on the use of
complicated functional assays, where measurement of the
reactivity (or lack of it) cannot distinguish between
clonal deletion, anergy or suppression; secondly, the
cells represent an unknown fraction of the total output
of anti-self lymphocytes from the thymus or bone marrow.
Several recent papers have circumvented these
difficulties and illustrate how different mechanisms may
be applicable in different systems and, indeed, suggest
that the mechanisms of tolerance are different for T
cells and B cells.
Anergy in the B Cell Component
Goodnow and colleagues (67) were able to generate high
frequencies of anti-self lymphocytes in the pre-immune
repertoire, by introducing immunoglobulin genes into the
germline of transgenic mice. Transgenic mice carrying
rearranged immunoglobulin heavy and light chain genes,
encoding a high-affinity anti-lysozyme antibody, were
created. This resulted in having mice in which most of
the B lymphocytes bind with high affinity to hen egg
lysozyme (HEL).
A second transgenic animal was established in which the
gene encoding lysozyme was introduced into the germ line,
yielding mice for which lysozyme was a tolerated self
component in both the T and B cell compartments. By
mating the two kinds of transgenic mice, "double-
transgenic" offspring carrying lysozyme and
immunoglobulin transgenes were produced. Many lysozyme
specific B cells were found in the spleen and lymph nodes
of these mice. However, despite the many antigen
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specific B cells, the mice failed to make antibody-
responses to lysozyme.
To test the functional capability of the B cells, small
numbers of spleen cells were transferred into non-
transgenic mice previously exposed to HEL and therefore
containing lysozyme specific helper T cells. In this
environment, the lysozyme specific B cells still failed
to make an antibody response. The authors argue that the
inability to respond is a property of the B cells and not
of another transferred cell such as a suppressor T cell,
because only 10^ cells were transferred. Thus, in this
example, tolerance was achieved by rendering anergy of
the B cells.
Deletion in the T Cell Component
Another approach to follow the fate of self reactive
lymphocytes, has involved the identification of naturally
occurring situations in which the frequency of T cells,
specific for certain polymorphic cellular antigens, is
relatively high and can be measured directly by anti-T
cell receptor (TCR) monoclonal antibodies (MoAb)(69-72).
The MoAb KJ23a reacts with TCR's utilizing the V/3 segment
V^17a, and T cells bearing V/?17a+ receptors react with
very high frequency with the MHC class II protein, IE
(68).
Kappler et al (69) have used this MoAb to follow the fate
of T cells expressing V/'17a+ receptors in mice which have
a functional IE molecule. Their results indicated that
cells with V^?17a+ receptors occur at normal levels among
immature thymocytes, but are severely depleted among
mature thymocytes and peripheral T cells. Therefore,
clonal deletion as a mechanism for inducing T cell
tolerance to self MHC antigens was indicated.
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Subsequently, Kappler et al (70) and MacDonald et al (71)
reported a similar mechanism for tolerance induction to
the Mis (minor lymphocyte stimulating) antigen. T
lymphocytes reactive with the product of the Mlsa allele
use a predominant ICR beta chain variable gene segment,
8.1 (70) or V^6 (71). It was found that mice expressing
the Mlsa allele had few or no T cells bearing receptors
containing the specific /S chain variable regions V/s8.1 or
V^6. Thus tolerance in this system was mediated via the
intrathymic elimination of self reactive cells rather
than by clonal anergy or peripheral suppression.
A further paper using the anti-Vje 6 MoAb on cryostat
sections of thymus, indicated that 6 expressing
cortical T cells were present at high density in both
Mlsa and Mis*3 mice," but did not appear in the medullary
region of Mlsa animals (72). Tolerance induction
therefore appeared to occur at the cortico-medullary
junction, where it may be mediated by dendritic cells
which are found in this region.
Selection and Tolerance - The Paradox
The above mentioned papers (69-72) also shed some light
in explaining the paradox of MHC restriction and
tolerance mentioned previously. Thus during selection in
the thymus, cells are both positively selected and
deleted because of interactions between their receptors
and what appears to be the same ligands, the products of
self MHC.
Traditionally, the paradox has been explained by
suggesting that positive selection picks out thymocytes
bearing receptors with a wide range of affinities for
self MHC. Tolerance on the other hand, deletes only
those thymocytes bearing receptors with high affinity for
self MHC, allowing cells with low affinity receptors to
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escape into the periphery where they form the pool of
self restricted mature T cells.
Marrack and Kappler (73) have suggested an "altered
ligand" hypothesis to account for the paradox of
selection for, and tolerance to, self MHC. The
hypothesis uses the recent discovery by Bjorkman and
colleagues (74) that MHC proteins bind peptides in a
pocket on the external surface of the molecule, and the
concept that in the absence of foreign antigen, self MHC
is bound to peptides derived from self proteins (75). In
addition, the spectrum of peptides bound to MHC may vary
from tissue to tissue (76). Thus, self MHC molecules on
thymic epithelial cells are not bound to the same
spectrum of self peptides as MHC molecules on B cells and
macrophages. Therefore thymocytes may be positively
selected by interaction of their receptors with self MHC
plus epithelial cell peptides, but clonally deleted by
interaction of their receptors with self MHC plus
peptides expressed on bone marrow derived cells such as
dendritic cells at the cortico-medullary junction.
Evidence Against Clonal Deletion
Clonal deletion however cannot be true for all models of
unresponsiveness. Transplantation models have involved
the induction of tolerance to transplanted allogeneic
tissue, without the loss of T cells reactive to the
foreign MHC antigens(77). In addition, numerous examples
document the presence of lymphocytes from normal
individuals and animals which are capable of binding to
self antigens (78, 79). Autoantibodies are found in the
sera of normal individuals (80), and in mice
autoantibodies that react with multiple organs are a
common feature of the normal immune repertoire (81).
Moreover, autoantibody production by lymphocytes from
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normal individuals (82) and animals (83) can follow
stimulation by non specific mitogens.
The affinity of antibodies varies greatly and cross-
reactivities among unrelated antigens and antibodies are
common. Also, with the number and diversity of self
antigens being very large, clonal deletion of all cells
with any self reactivity could, via cross reactivity,
result in eliminating the total immune repertoire (64).
Thus consideration of clonal deletion as the mechanism of
tolerance, should be qualified with exemptions such as
for sequestered antigens or antigens present in low
concentrations in extracellular fluids. Therefore, when
considering a selective immune system, geared to react to
the unknown where factors determining the generation of
immunologic diversity never cease, there should be a
mechanism in adult as well as foetal life for clonal
deletion. Thus, although the controversy between the
mechanisms of self tolerance persists, it would not be
surprising to find that the immune system has developed a
cascade of mechanisms to operate at various stages of
ontogeny. These mechanisms need not be seen to act in
isolation of one another, but rather, may act in concert
to prevent the "horror autotoxicus".
AUTOIMMUNITY : PATHOLOGIC OR PHYSIOLOGIC
The theories, hypothesises and suggestions propagated to
account for the development of autoimmune diseases, are
as abundant as the diseases themselves. Indeed, this is
perhaps as it should be since the multifactorial nature
of autoimmune diseases allows different mechanisms to
apply to different diseases, and even can permit a
heterogeneous pathogenesis between individuals with the
same diseases. However, there must be distinctions drawn
between autoimmunity per se, and the establishment of
autoimmune disease, for not all autoimmune phenomena are
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necessarily pathologic. The self recognition that takes
place in the normal immune response represents a
fundamental form of autoimmunity. For cells to
communicate with one another in immunoregulation, they
must recognise and interact with self determinants on
each others surface. Likewise, anti-idiotypic
antibodies, against antibody formed in response to
selected antigens, represents another form of physiologic
autoimmunity (32).
Grabar (84) has suggested that autoimmunity represents a
normal mechanism for the transport of autoantigen not
degraded by the body's enzyme system. It is postulated
that immune phenomena developed in evolution as
physiologic rather than as defence mechanisms, to handle
metabolic and catabolic substances. In his view, both
autologous and exogenous materials of the body undergo
degradation by specific enzymes, such as autolytic
enzymes, under normal conditions. He suggests that those
substances not degraded in this manner elicit the
formation of antibodies that serve as transporters and
assist in the preparation of such substances for
phagocytosis.
The removal of senescent red blood cells by macrophages,
after coating the cells with IgG, may represent a
physiologic role for the immune system (85). In
addition, the low levels of autoantibodies detectable in
the sera of normal individuals (80), may reflect
breakdown or alteration of tissue components by external
factors. Their purpose could be to merely facilitate the
removal of the altered products.
A further distinction is required to separate the
production of autoantibodies per se, from the
pathogenicity of the autoantibody formed. Anti-heart
antibodies may be generated after the heart has been
injured by a pathologic process such as myocardial
infarction (86). As such they represent mere sequelae of
a pathologic event.
Autoreactive plaque forming cells (PFC), specific for
DNA, can be detected simply by culturing murine spleen
cells with or without the presence of mitogen. When the
specificity of the PFC is ascertained by plaque
inhibition, it is found that they are of low affinity
(87). However, similarly detected PFC found in spleens
of autoimmune susceptible mouse strains are of high
affinity. Thus autoantibody per se need not necessarily
be deemed the avoidable "horror" initially predicted by
Ehrlich. High affinity autoantibody which can be
pathologic, may only be found when the immune system
suffers a major disturbance.
Pathogenic sequelae may be generated against self
antigens either as (i) an abnormal immune response to a
normal self antigen, (ii) a normal immune response to
antigens which show cross-reactivity with antigenic
determinants on normal cells, or (iii) following exposure
of sequestered antigens. Sequestered self antigens, such
as those of the testes, brain and lens of the eye, are
not normally in contact with circulating immunocompetent
lymphocytes. However, traumatic injury or infection may
expose antigens of these tissues to immunocompetent
cells, leading to activation of an autoimmune response
against these normal tissue antigens. Thus,
phacoanaphylaxis caused by inflammatory reactivity
against protein antigens released from a traumatized lens
capsule (19), and aspermatogenesis induced by the
formation of antisperm antibodies following vasectomy
(88), may occur.
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In an attempt to account for the diverse concepts of
autoimmunity, such as those of Ehrlich and Morgenroth
(14) and Burnet (17), that stressed the pathogenic role
of autoimmunity, as well as the theories of Boyden (89)
and Grabar (84) that emphasized physiologic autoimmunity,
Beutner et al (90) developed their "unifying concept of
autoimmunity". They state that common features of
physiologic and pathologic autoimmunity include (i) the
demonstration of autoantibodies or cell-mediated immune
reactivity by in vitro assays using the hosts self tissue
antigens, (ii) antigen identification, and (iii) evidence
of in vivo reactivity between homologous antigen and the
host autoimmune response.
The key factor in distinguishing between physiologic and
pathologic autoimmunity is whether the autoimmune
reactivity serves a helpful function or constitutes part
of a pathologic process. They describe autoantigens as
either accessible (A-self) or hidden (H-self). Then
reflecting on Witebsky's postulates (22), Beutner et al
suggest that pathologic and physiologic autoimmunity
differ in whether or not (i) the antigen is accessible or
hidden, (ii) the autoimmune response is specific for a
certain disease, (iii) pathologic changes by anti-
accessible responses can be induced passively in
experimental animals, (iv) anti-hidden self antigen
responses can actively prevent a host from the injurious
action of excessive quantities of undegraded hidden self
antigens, and (v) autoimmune responses and the associated
diseases can be induced in normal subjects by actively
immunizing them with the autoantigens.
Subsequently, Smith and Steinberg (91) described a
further conceptual framework for considering autoimmune
diseases. They emphasized that controlled self
reactivity represents a normal event; that self reactions
are important mechanisms of normal immune reactivity and
IS
normal immune regulation; and that disease results from
quantitative abnormalities (e.g. amount of stem cell
proliferation; degree of autoantibody production or
levels of immune complexes). They also stressed that
autoimmune diseases have a multifactorial aetiology
rather than a single cause. Individual genes may
predispose an individual to develop certain abnormalities
associated with an autoimmune disease, but environmental
factors that stimulate the immune system and interfere
with normal immune regulation, are among the
precipitating factors that lead to the manifestation of
disease.
MECHANISMS OF AUTOIMMUNITY
As mentioned previously, tolerance to normally
sequestered antigens can be broken following any trauma
which allows contact of those antigens with the immune
system. Further mechanisms which can induce autoimmunity
include any procedure which can bypass the requirement
for specific T cell help when immunocompetent B cells are
present.
Cross-Reacting Antigens
Extensive research from Weigle and his colleagues has
demonstrated that T cell tolerance can be overcome by,
for example, the use of cross-reacting antigens (63, 92,
93). Thus, rabbits made unresponsive to BSA at birth,
make an antibody response to BSA when injected as adults
with human serum albumin (HSA)(92). Since HSA shares
only 15% homology with BSA, it leaves antigenic
determinants free to permit T helper cells to provide
support not only for B cells reacting specifically with
HSA, but also for those B cells reactive against cross-
reactive determinants on BSA. In addition,
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unresponsiveness to BSA can also be circumvented using
BSA complexed with anti-HSA antibodies (93). Equally,
autoantibodies against self thyroglobulin may be elicited
in rabbits following immunization with cross-reacting
antigens on bovine thyroglobulin (94). Infection with
group A beta-haemolytic streptococci can lead to an
immune response in susceptible individuals, where
antibodies against the streptococci can cross-react with
antigens of the heart (95).
Viruses, Drugs and Polyclonal Activation
The combination of autoantigens and antigenic
determinants from exogenous substances, may form
immunogenic units that are capable of stimulating T
helper cells that can activate B cells to produce
autoantibody. Types of helper antigenic determinants
include agents such as bacteria, viruses or drugs.
Autoimmunity may occur following interaction of viruses
with the immune system. Epstein-Barr virus (EBV) infects
B lymphocytes causing B lymphocyte proliferation and
inducing immunoglobulin secretion. This leads to
induction of autoantibodies which tend to react with more
than one organ or tissue (96). Shared determinants
between reovirus Type 1 and certain tissue antigens
results in the formation of various autoantibodies (97).
Polyclonal activation is also observed in mice infected
with lactate dehydrogenase virus (LDV)(98). Cross-
reactive autoimmune responses against intermediate
filaments are found following infections with vaccinia
(99), or measles and herpes simplex viruses (100).
Antibodies formed to paramyxovirus also react with
antigens found on brain tissue (101). Myelin basic
protein (MBP) is an immunogen of importance in the
genesis of demyelinating diseases, where the
encepha1itogenic site is a known decapeptide. When viral
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proteins that have been sequenced were screened by
computer for sharing of 6-10 consecutive amino acids with
the encephalitogenic site of MBP, shared sequences were
found in polypeptides of many common viruses, including
adenoviruses, influenza A, EBV and measles virus (102).
Presumably, however, depending on additional factors,
only a few of these shared sequences would be able to
induce significant autoimmune responses, otherwise
autoimmune disease would be an all too common occurrence
following viral infections.
Certain drugs may elicit the production of autoantibodies
in otherwise normal individuals. The drug or its
metabolites may bind to an autoantigen, the combination
of which may activate T helper cells to provide help for
B cells specific. for the autoantigen to make
autoantibodies. For example, hydralazine or
procainamide-treated patients can form antinuclear
antibodies that resemble those of patients with systemic
lupus erythematosus (SLE)(103). Increased helper cell
activity has been reported in procainamide-induced lupus
(104). This response may be brought about by the drug or
its metabolites interrupting the normal immunoregulatory
balance between T helper and T suppressor cells. Thus
procainamide may inhibit cyclic AMP, an effect which can
either stimulate helper cell activity, or equally,
inhibit T suppressor cells (105). Further, alpha-
methyldopa is a drug which can cause autoimmune
haemolytic anaemia (106). The drug activates cyclic
AMP, an effect which inhibits suppressor cells.
Diminished suppressor activity can allow helper T cells
to activate immunocompetent B cells to produce antibodies
which often have an antirhesus specificity, to combine
with the drug attached to the cell surface; fix
complement and thereby induce a bystander type of
complement-mediated lysis (107). Thus, autoimmunity may
result from either stimulatory or inhibitory effects of a
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drug on immunoregulatory cells. In addition, anti-
lipomodulin autoantibodies found in patients with SLE,
rheumatoid arthritis and dermatomyositis (108), can
disrupt immunoregulation by reducing the formation of
prostaglandins, and hence impair prostaglandin-dependent
suppressor cells (109).
Bacterial endotoxins; lipopolysaccharides (LPS)
are substances whose biological effects on immunological
processes permit a response to a variety of antigens, in
the absence of specific T helper cells. Endotoxins may
exert mitogenic effects on B lymphocytes (110). They can
substitute for helper T cell function in the antibody
response to sheep erythrocytes (111), or bypass the
requirement for T cells in a hapten-carrier system (112).
Also, induced unresponsiveness to human gamma globulin
can be terminated by the administration of the antigen
with endotoxin (113). Likewise, any other vehicle which
stimulates lymphocytes non specifically, such as
immunologic adjuvants or allogeneic cells that mediate
graft-versus-host reactions (GVHR), may activate the
formation of autoantibodies, through bypassing T cell
specificity.
If par-ental strain T lymphocytes are injected into adult
FI hybrid mice, the recipients are genetically tolerant
of parental donor strain cells. However, the grafted T
lymphocytes can react against allogeneic MHC antigens of
the host and induce a spectrum of pathological changes,
resulting in graft-versus-host disease. In this
situation, it is found that a spectrum of autoantibodies,
similar to that found in SLE i.e. antibodies against
epithelial cells, erythrocytes, thymocytes, nuclear
antigens and double-stranded DNA, are produced (114).
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Autoantigen
A further constraint in the generation of autoimmunity is
the nature and role played by the autoantigen (115).
Thus it was found that a mouse autoreactive T cell clone,
specific for murine thyroglobulin, differed in its
ability to recognize human thyroglobulins depending on
their degree of iodination. Thyroglobulins with low
levels of iodine reacted poorly with the T cells (116).
It was also shown that poorly iodinated thyroglobulin is
unable to induce thyroiditis in mice when injected with
adjuvant, although it is only slightly less effective
than iodinated thyroglobulin in eliciting autoantibody
production (116). Thus, iodination of thyroglobulin may
be necessary for recognition by T cells involved in the
pathogenesis of thyroiditis, but not for all T helper
cells involved in autoantibody production.
Equally, autosensitization of serum IgG may be important
in the pathogenesis of rheumatoid arthritis. Recently,
Parekh et al (117) reported reduced glycosylation of
oligosaccharides in the IgG of patients with both
juvenile and adult onset rheumatoid arthritis. The
defect in glycosylation is associated with the
oligosaccharides of the Fc portion rather than the Fab
fragment. The two N-linked Fc oligosaccharides, one
originating from each C^2 domain, form a bridge to hold
the C*2 domains apart, while the terminal galactose
residues sit in a pocket on the surface of each domain
(118). This glycosylation defect was not a general
feature of rheumatological disorders, being confined to
rheumatoid arthritis, tuberculosis and Crohn's disease.
The low galactose levels were not due to chronic
excessive IgG synthesis, since normal glycosylation is
seen in primary SLE and leprosy diseases where raised IgG
levels exceed those seen in rheumatoid arthritis (117).
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Axford et al (119), reported that the activity of
galactosyltransferase, the enzyme which catalyses the
addition of galactose to the oligosaccharide chains, was
considerably lower in the circulating B cells of patients
with rheumatoid arthritis. Diminished galacto¬
syltransferase activity is also found in the peripheral
blood cells of patients with untreated tuberculosis and
active Crohn's disease (118). These studies suggest a
possible mechanism for the pathogenesis of rheumatoid
arthritis, where IgG rheumatoid factors form self-
associated complexes which stimulate a chronic
inflammatory response resulting in the formation of an
erosive pannus. Thus, since the Fab oligosaccharides of
rheumatoid patients are glycosylated normally, self-
associated complexes may form when a Fab galactose region
inserts into the Fc' pocket left vacant by a galactose-
deficient C2f2 oligosaccharide (118).
Idiotypes and Autoimmunity
Immunoglobulin (Ig) idiotypes are essentially phenotypic
markers of the V genes used to encode Ig molecules either
as soluble antibody molecules or as lymphocyte receptors.
Idiotypes are therefore serologically defined
determinants present in the Fab region of Igs, where they
represent novel antigenic determinants which can be
recognized in turn by anti-idiotypic antibodies.
Idiotype anti-idiotype reactions occur spontaneously in
many autoimmune diseases including SLE (120), myasthenia
gravis (121) and rheumatoid arthritis (122). Several
investigators have demonstrated the occurrence of
spontaneous autoanti-idiotypic antibodies directed at
cell receptors following immunization with the receptor
ligand. Wasserman et al (123), immunized rabbits with
BisQ; a synthetic agonist of the acetylcholine receptor
(AChR), to produce anti-BisQ antibodies. Those
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antibodies were used to immunize a further group of
rabbits which produced anti-idiotypic antibodies i.e.
anti-(anti-BisQ) antibodies. It was found that the anti-
idiotypic antibodies bound not only to the anti-BisQ
antibodies but also to the AChR causing, in some animals,
a myasthenia gravis like syndrome.
Equally, Shechter et al (124), found that mice immunized
with bovine or porcine insulin produced both anti-insulin
antibodies and autoanti-idiotypes that were anti-(anti-
insulin) antibodies. The anti-idiotypic antibodies were
reactive to the insulin receptor on fat cells where they
partially mimic the action of insulin and block the
binding of insulin itself. A similar effect is also seen
in rabbits immunized with thyroid stimulating hormone
(TSH). Anti-idiotypic antibodies to anti-TSH antibodies
can mimic the thyroid stimulatory activity of TSH thereby
causing Graves' disease (125). Recently, Zuberi et al
(126) found that injection of mouse interleukin-1 (IL-1)
into rabbits firstly produced anti-IL-1 antibodies and
later anti-idiotypic antibodies which mimicked IL-1
activity by augmenting the in vitro proliferation of PHA-
stimulated thymocytes.
Several) investigators have proposed that autoantibodies
per se, are anti-idiotypic antibodies produced against
anti-microbial antibodies (127, 128). As such, they
would carry the internal image of the microbial antigen
and bind to the microbial receptor on cells. By use of
an anti-idiotypic serum, a structure homologous to the
idiotype of anti-reovirus antibodies was identified on
neurons (129). Thus, encephalitis caused by reovirus
Type 3 infection, need not necessarily involve the direct
interaction of virus on target cells, but an immunologic
attack by anti-idiotypes on viral receptors.
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Similarly, idiotypic complementarity has been suggested
between rheumatoid factor (RF) and some anti-bacterial
antibodies. Immunization of both mice and rabbits with
affinity-purified human RF induces antibodies reactive
both with a streptococcal peptidoglycan polysaccharide
(PGPS) antigen and human RF. Thus, rheumatoid factor is
either anti-idiotypic to anti-PGPS antibodies or it
carries an internal image of a PGPS epitope (130).
Conversely, anti-idiotypic antibodies to monoclonal RF
were found in a patient with IgM RF gammopathy two weeks
after a pneumococcal bacteraemia (131). Thus, it has
been suggested that rheumatoid factors are anti-idiotypic
antibodies against virus-induced anti-Fc receptor
antibodies (132). Furthermore, myasthenia gravis has
been reported to occur in 5 patients shortly after
vaccination against rabies virus (133). The rabies virus
binds to the AChR and thus a consequence of the anti¬
viral response is that some anti-idiotypic antibodies
were anti-receptor, and invoked transient myasthenia
gravis .
Autoantibodies may arise when cross-reacting idiotypes on
the autoantibodies, appear on non-specific parallel
immunoglobulin sets i.e. antibodies with the cross-
reacting idiotype but a differing antigenic specificity.
Thus, following infection T helper cells with specificity
for the cross-reacting idiotype may be generated and
provide helper activity for all B cells carrying the
cross-reactive idiotype to secrete antibody, some of
which may be pathogenic. Connectivity between the AChR
and -1,3-dextran (DEX) has been demonstrated, in that an
ant i-idio type from the DEX immune response was also an
autoantibody against the AChR (134). Since the DEX
determinant is present in some gut commensal organisms
e.g. Enterobacter cloacae, there may be an idiotypic
connection between antibody responses to the AChR and
certain bacterial antigens.
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An idiotypic relationship may also exist between anti-DNA
antibodies bearing the common 16/6 idiotype and
antibodies to Klebsiella (135). Patients with Klebsiella
infections have an increased incidence of high 16/6
idiotype titres compared to other gram negative
infections and normal controls. Furthermore, Klebsiella
antigens can activate normal peripheral blood lymphocytes
to secrete significantly increased levels of 16/6
idiotype compared to other polyclonal activators (136).
This implies the 16/6 idiotype is present on antibodies
binding Klebsiella antigens in non-autoimmune subjects
and on autoantibodies to DNA in patients with SLE. Thus,
autoimmune phenomena with pathologic sequelae may
unfortunately develop following idiotype-(anti-idiotype)
interactions arising from the normal functioning of the
idiotype network in- response to endogenous or exogenous
antigens.
Thus far, I have outlined some of the developments which
have paved the way to elucidating current understanding
of the aetiological factors contributing to autoimmunity
and autoimmune disease. The evidence indicates that
propagation of autoimmunity involves consideration of
several elements including genetic, immunological and
environmental factors. It is perhaps only when the
"pieces" combine and the "mosaic" is complete that
pathologic as distinct from physiologic autoimmunity
ensues.
Having established this background information, I now
intend to review the evidence which suggests that
insulin-dependent diabetes mellitus is an organ-specific
autoimmune disease.
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CHAPTER 2 - TYPE 1 DIABETES : AN AUTOIMMUNE DISEASE
(Human Studies)
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Type 1 or insulin-dependent diabetes mellitus, contrary
to clinical impression, is a chronic disease (137)
characterized by hyperglycaemia, ketosis and
insulinopenia, necessitating the administration of
exogenous insulin to sustain life. Epidemiologic studies
indicate the incidence of IDDM varies between 7.7-30 per
100,000 population per year, with the peak incidence
during adolescence (138). The majority of studies report
that both sexes are equally affected but in some studies
a slight preponderance of males in younger children is
reported (139). Seasonal variations, with autumn and
winter providing the largest numbers of new cases,
suggest that viral infections may be important
precipitating factors in the pathogenesis of IDDM (140).
Although a major li*fe saving treatment, insulin therapy
is still associated with reduced life expectancy (141),
increased morbidity (142) and increased perinatal
mortality rates, even in specialist centres (143). These
factors clearly stress the importance of research into
the aetiological factors associated with this disease,
with the aim of developing protocols leading to
prevention of the disease.
Major advances have been achieved over the past 15 years
in improving our understanding of the pathogenesis of
IDDM. The use of animal models and observations of
various immune phenomena in IDDM patients have suggested
an autoimmune pathogenesis for Type 1 diabetes.
AUTOIMMUNE ASSOCIATIONS IN IDDM
One of the earliest indications for the role of
autoimmunity in IDDM was the observation that it often
occurs in association with other endocrine diseases of
suspected autoimmune character. Insulin-dependent
diabetes mellitus was reported in 15% of patients with
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Addison's disease, and in 7-10% of patients with
Hashimoto's thyroiditis (144). Equally, other autoimmune
endocrinologic disorders are 4-5 times more likely to
occur among IDDM patients than the non-diabetic
population, with autoantibodies against various endocrine
cells, other than pancreatic cells, a common occurrence
(145). The nature of increased susceptibility to
autoimmunity in IDDM remains unexplained, however, a
significant advance was the realisation of a link between
IDDM and certain haplotypes of the MHC (146).
HLA ANTIGENS
Genes of the major histocompatibility complex known as
the HLA system in man, and located on chromosome 6,
encode for three major classes of proteins (147, 148):
Class I genes code for the classic transplantation
antigens (HLA-A, B, C); Class II genes (HLA-DP, DQ, DR);
and Class III genes which code for some components of the
complement system (C2, Bf, C4a, C4b). Class I and class
II antigens are heterodimeric cell surface glycoproteins.
Class I antigens are composed of a 44KD transmembrane
glycoprotein which is noncovalently associated with the
12KD protein ^2-microgl°bulin (which is encoded on
chromosome 15).
The HLA-A,B,C molecules are polymorphic and are present
on virtually all nucleated cells, where they function as
targets for cytotoxic T lymphocytes (149). The class II
antigens, which are also highly polymorphic, are involved
in communication between cells that regulate the immune
response (148). Class II antigens consist of two
transmembrane glycoproteins with a light or beta chain
(27-29KD) noncovalently bound to a heavy or alpha chain
(33-35KD), both of which are encoded in the MHC. Class
II antigens are normally restricted to the cell surfaces
of B lymphocytes, activated T cells and antigen
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presenting cells (APC) such as dendritic cells and cells
of the macrophage/myeloid series (150). Therefore, each
of these sets of antigens plays an important role in the
control and functioning of certain aspects of immune
responses.
HLA ANTIGENS AND IDDM SUSCEPTIBILITY
The early 1970's provided the first reports that
demonstrated an association of IDDM with certain alleles
of the HLA-B locus; namely, HLA-B8 and -B15 (11, 151).
The use of mixed lymphocyte culture (MLC) typing
established that a further stronger association existed
with another locus in the HLA region, other than the B
locus. Soon, the B locus association (due to linkage
disequilibrium) was superseded by associations with the
class II region genes, HLA-D/DR (152, 153).
In population studies, 90-95% of IDDM patients express
the HLA-DR3 and/or DR4 haplotypes, with an excess of HLA-
DR3/4 heterozygotes (154, 155). Indeed, the odds ratio
or relative risk for the HLA-DR3/4 heterozygotes is
greater than that for both the homozygous HLA-DR3 and
HLA-DR4 patients (155, 156), suggesting the effects of
HLA-DR3 and DR4 may be additive.
Studies in identical twin pairs where the concordance for
IDDM is 30-50% (157, 158), have shown that the
heterozygous HLA-DR3/4 phenotype was more prevalent in
concordant pairs (59%) than with discordant pairs
(28%)(159). In addition, a report by Knip et al (160)
indicates that diabetic children who are HLA DR3/4
heterozygotes show a more rapid destruction of pancreatic
beta cells than diabetic children who do not possess both
DR3 and DR4.
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Family studies also reflect the association of IDDM with
particular MHC haplotypes (152). The prevalence of
diabetes in parents of Type 1 diabetic children is about
10% (161), although IDDM is more likely in the progeny of
diabetic fathers than diabetic mothers (161, 162). If
one child has IDDM, the risk of diabetes in its siblings
is related to the number of haplotypes the sibling shares
with the diabetic proband (163). Thus, if two haplotypes
are shared, the risk of developing IDDM is 10-20%; if one
haplotype is shared it is 5%, and if neither haplotype is
shared it is 1% (152, 163). However, if the shared
haplotype is the heterozygous DR3/4, then the absolute
risk of IDDM is 1 in 4 (164).
When this is compared with the absolute risk of IDDM for
HLA-DR3/4 heterozygotes in the normal population being
reported as approximately 1 in 40 (165, 166), then
penetrance is stronger in familial than in sporadic cases
and HLA typing is 6-10 times less powerful as a predictor
of IDDM in the population than in affected families
(166).
The existence of clinically distinct types of IDDM being
associated with different HLA-DR phenotypes has been
proposed (167). This is supported by the observations of
a milder, more slowly progressing disease associated with
HLA-DR3 (168); and as mentioned previously, the more
rapid destruction of residual beta cell function in HLA-
DR3/4 heterozygotes (160).
Whereas susceptibility to IDDM is associated with HLA DR3
and/or DR4, the presence of HLA-DR2 positivity is rarely
found in patients with IDDM (about 2% compared with 30%
in the normal population)(155), and the relative risk of
IDDM in HLA-DR2 subjects is about 75 times less than that
of the HLA-DR3/4 heterozygotes (146). Therefore, the
presence of the HLA-DR2 gene or a gene in close linkage
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disequilibrium with it, may protect individuals against
IDDM.
Further serological and cellular typing analysis has
subdivided the DR4 locus into five different subtypes
(Dw4, DwlO and Dwl3-15) (170), of which only the Dw4 and
DwlO subtypes are associated with IDDM (171). Subsequent
serological and DNA analysis identified the DQ3.2 allele
of the DQB1 locus as a diabetes-associated subset of DR4
bearing haplotypes. Thus, approximately 95% of HLA-DR4
positive IDDM patients, but only 60-70% of DR4 positive
controls, carry the DQ3.2 allele (172, 173).
When populations are screened for these markers, it is
found that the extended haplotype profile increases the
predictive value when compared with HLA-DR serology
alone. Thus the absolute risk for subjects heterozygous
HLA-DR3/Dw4-DQ3.2 or DR3/Dwl0-DQ3.2 is increased to 1 in
15 (166). However, this is still less than the 1 in 4
risk in familial cases when HLA identical siblings share
the DR3/4 haplotype, and therefore suggests that
additional non-HLA genes and/or environmental factors are
involved in the susceptibility to IDDM.
The usefulness of the above serological and genetic
markers is limited by their high frequency in the normal
population. Accordingly, another approach was to look
for disease associated restriction fragment length
polymorphisms (RFLPs) in the DNA of individuals with
IDDM.
Studies using RFLP analysis have indicated that the HLA-
DQ genes which are in linkage disequilibrium with HLA-DR,
are more strongly associated with IDDM than the DR genes
(172-176). Owerbach et al (174) was the first to
describe a decreased frequency in HLA-DR4 and DR3/4 IDDM
patients of an RFLP obtained with the restriction enzyme
BamHI, and identified with a DQ beta gene probe. The
identified 3.7Kb fragment was frequent among HLA-DR4 and
DR3/4 controls (30-40%), but was rarely detected in IDDM
patients (0-2%). Studies by Cohen-Haguenauer et al (175)
and Festenstein et al (176) have identified other DQ beta
chain RFLPs, predominantly associated with the HLA-DR
susceptibility to IDDM. Use of the restriction enzyme
TaqI produced a band pattern designated DQR4 (175) with a
high specificity for IDDM in HLA-DR3/4 heterozygote
patients.
When calculating the relative risk for IDDM among HLA-
DR3/4 positive subjects with this band, it was 10 times
the relative risk, calculated on the basis of
serologically defined markers alone (175). However,
despite these associations no single RFLP has been found
that is common to the several HLA haplotypes positively
associated with IDDM.
Recently, Todd et al (177) have reported that the genetic
susceptibility of IDDM associated with genes of the HLA-
DQ locus is mainly dependent on the identity of a single
amino acid residue at position 57 of the DQ beta chain.
As mentioned previously, about 95% of IDDM patients carry
the HLA-DQ3.2 allele whereas another DQ allele (DQ3.1) is
negatively associated with IDDM (173). Comparison of the
amino acid sequences revealed that the DQ3.1 allele DQ
beta chain first domain sequence had four amino acid
differences from the DQ3.2 allele beta chain at positions
13, 26, 45 and 57. It was inferred that one or more of
these four beta chain amino acid substitutions accounted
for the positive association with IDDM of the DQ3.2
allele relative to the DQ3.1 allele.
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Todd and colleagues cloned and sequenced the gene
segments encoding the first domains of the four major
expressed polymorphic class II gene products (HLA-DQ
beta, DQ alpha, DR beta I and DR beta II). All sequences
found in IDDM patients were also found in normal non-
diabetic controls, indicating that IDDM susceptibility is
not due to mutant HLA class II alleles. However, it was
demonstrated that susceptibility to IDDM was conferred by
the presence or absence of aspartic acid (Asp) at
position 57 of the N-terminal B1 domain of the HLA-DQ
beta chain. Thus, all the DQ beta alleles that were
positively associated with IDDM had either alanine,
valine or serine residues at position 57. Aspartic acid
was present at position 57 in all the DQ beta alleles
which were neutral or negatively associated with IDDM.
Accordingly, the possession of two Asp-57-positive DQ
beta alleles provides almost complete resistance to IDDM,
whereas DQ beta Asp-57-negative homozygosity confers
maximum susceptibility (90% of IDDM patients), and Asp-57
heterozygosity carries a much lower risk of developing
IDDM (10% of IDDM patients).
The mode of inheritance for IDDM is unknown, but is
clearly polygenic (178). It is proposed that at least
two genes; one associated with HLA-DR3 and one with HLA-
DR4, but not necessarily these genes themselves, are
required for diabetes to develop (137). It has been
estimated that 50% of the heritability of IDDM is
contributed by genes within the HLA-D region (179), which
allows consideration for the involvement of non-HLA
genes.
Consequently, recent studies have reported the
association of IDDM with RFLPs at a locus near the
insulin gene located on the short arm of chromosome 11
(180, 181, 182). Equally, susceptibility to IDDM may be
linked with DNA polymorphisms of the switch region of
^2.
immunoglobulin heavy chain genes (183) or genes encoding
the T cell receptor (184).
The precise role of the MHC class II gene products in
determining the susceptibility to IDDM is not known. It
is widely accepted that the MHC class II genes determine
the host immune responsiveness to foreign antigens (150).
Thus, individuals with different HLA-DR haplotypes can
respond differently to identical antigenic stimuli (185).
The MHC class II gene associated susceptibility to IDDM,
is assumed to reflect differences between the different
HLA-D region haplotypes in their ability to recognize and
present antigen to the various subsets of T lymphocytes.
Thus, Todd et al (177) suggest that the difference
between diabetes susceptible (DQ beta Asp-57-negative)
and diabetes resistant (DQ beta Asp-57-positive)
individuals, is that the "diabetogenic" peptide cannot
effectively bind into the Asp-57-positive MHC class II
containing groove. Thus failure of antigen presentation
or inadequate presentation of the appropriate antigen is
assumed to occur in the diabetes resistant individuals.
An alternative proposal by Nerup et al (146) suggests
that specific "qualitative" IDDM genes do not exist, but
rather- the HLA associations with IDDM reflect
"quantitative" differences whereby the different class II
genes control different levels of cytokine production,
and thereby influence the magnitude of the immune
response.
In conclusion, although possession of certain HLA
haplotypes appears linked with an increased propensity to
develop IDDM, mere possession of the DR3 and/or DR4
haplotypes is not sufficient for development of IDDM.
Accordingly, 50-55% of the normal population also carry
the HLA-DR3 and/or DR4 haplotypes and do not develop IDDM
thereby suggesting the involvement of non-HLA genes
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(186). Furthermore, the low concordance rate of IDDM
between identical twins (157, 158) suggests that
exogenous (environmental) factors play an important role
in the manifestation of Type 1 diabetes.
HUMORAL IMMUNITY
Further indications for an autoimmune component in the
pathogenesis of IDDM shortly followed the initial reports
of HLA-IDDM associations, when autoantibodies directed
towards pancreatic islet cells were detected in the sera
of IDDM patients.
Islet Cell Cytoplasmic Antibodies
In 1974 the first reports were made on the presence of
circulating cytoplasmic islet cell antibodies (ICA) in
IDDM patients. In the initial reports (187, 188), ICA
were found in patients with coexistent polyendocrine
disease, but subsequently were found in most IDDM
patients at onset of disease (189). Islet cell
antibodies are detected on cryostat sections of human
pancreas from blood group 0 donors (this is to prevent
interfering staining of the acinar tissue due to
expression of blood group antigens), with standard
indirect immunofluorescence techniques. Islet cell
antibodies are found in 0.5% of the normal population, 3%
of healthy first degree relatives of ICA positive
subjects, 10% of NIDDM patients and in 6% of patients
with other organ-specific autoimmune diseases (189, 190).
The prevalence of ICA is relatively high (70-90%) in
newly diagnosed IDDM patients (189, 191). The frequency
of ICA decreases with the duration of IDDM such that only
20% of patients remain positive after 2-5 years (192).
This probably reflects the gradual loss of antigenic
stimulus, as islet cell destruction progresses to a total
absence of beta cells.
Sera positive for ICA react not only with the cytoplasm
of islet beta cells, but with all islet endocrine cell
types (glucagon, somatostatin and pancreatic polypeptide
(PP) cells). Neither the subcellular localization of the
antibody binding site nor the nature of the antigen(s),
to which ICA react, have been determined. However, the
antibody activity is not absorbed with insulin or
glucagon (191) and some evidence suggests that a sialic
acid containing glycolipid may be involved (193).
Since only beta cells are depleted in the course of
developing IDDM (194), ICA, because of their broad cell
specificity, are unlikely to play a direct role in beta
cell destruction. Indeed, ICA do not show cytotoxicity
towards cultured rodent islets (189) and in a study
documenting the transplacental passage of ICA from
diabetic mothers to their offspring, ICA did not
contribute to any clinical or metabolic alterations
observed in the infants (195). It is likely that ICA
develop secondarily as a response to islet cell damage
and, therefore, may be useful as a marker of ongoing beta
cell destruction and hence have some potential for
predicting future IDDM patients.
The prognostic value of ICA has been ascertained by
several groups. Irvine et al (196) showed that ICA
positivity was a predictor for future development of IDDM
in diabetic patients maintained with oral hypoglycaemic
agents. Others have reported the predictive value of ICA
positivity in gestational diabetes where, in one study,
73% of gestational diabetics who were ICA positive
subsequently developed overt IDDM within 10 years, while
none of 12 ICA negative patients became insulin-dependent
(197). Studies on families of patients with IDDM,
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indicate that ICA may be present several years prior to
the onset of clinical diabetes thereby suggesting a long
latent or prediabetic period (198, 199).
In one study 38 of 135 subjects, at high risk of
developing IDDM, were ICA positive and 14 subsequently
progressed to diabetes after one month to several years
(200). In a further prospective study of a set of
monozygotic triplets and a set of monozygotic twins
initially discordant for IDDM, ICA preceded the onset of
overt diabetes in the twin by 5 years and by 8 years in
one of the two remaining non diabetic triplets (201).
However, the predictive value of ICA alone is limited.
Islet cell antibody positivity was only followed by IDDM
in about 30% of ICA positive unaffected first degree
relatives of IDDM patients followed for 5 years (202).
Thus, the false positive rate is relatively high.
Equally, IDDM can occur in ICA negative subjects (203)
and ICA may appear and disappear in non diabetic
individuals (202), although the latter is unconfirmed in
other studies (204).
Therefore, current opinion would suggest that ICA develop
in response to beta cell injury and, as such, represent a
marker of ongoing beta cell destruction, but are not
ultimately predictive of impending Type 1 diabetes.
Equally, their lack of specificity suggests that they are
not pathogenetically involved in the initiation of beta
cell damage.
Reports of a separate variant of ICA which can fix
complement, stimulated a revived pathogenetic importance
for ICA (205). Complement-fixing ICA (CF-ICA) are also
detected by indirect immunofluorescence on pancreatic
tissue sections. It is generally found that about 50% of
conventional ICA are also complement fixing, but
complement fixation does not occur without the presence
of cytoplasmic ICA (206). However, at onset, about 80%
of cytoplasmic ICA may also be CF-ICA. On follow up,
over 1-18 months, about 35% of patients lose the
complement fixing capacity (205).
Since CF-ICA appeared more closely related to the onset
of clinical disease; more specific for beta cells and
disappeared more quickly than conventional ICA, it was
suggested that CF-ICA more selectively reflected the
damage of pancreatic beta cells and, therefore, are a
better predictive marker than ICA (205).
In a study reported on 13 patients with polyendocrine
disease and ICA, 9 of the patients were also CF-ICA
positive, of whom A -subsequently became diabetic within 5
years (207). The value of CF-ICA is however uncertain,
since several studies indicate that CF-ICA merely
represent high titred conventional ICA and are not a
separate species of ICA (208, 209).
Islet Cell Surface Antibodies
In 1975, MacLaren and co-workers found antibodies
*
reactive with the surface{cultured human insulinoma cells
in 3A out of 39 diabetic patients (210). Subsequently,
Lernmark et al (211) described the presence of antibodies
to the plasma membranes of islet cells; islet cell
surface antibodies (ICSA) in the sera from newly
diagnosed IDDM patients. These antibodies, as with ICA,
were detected by indirect immunofluorescence. Later,
quantitative analysis of ICSA, using radiolabelled
protein A, was reported (212). Islet cell surface
antibodies can also be detected using cultured rat
insulinoma cells (213) and human foetal (21A) or adult
(215) islets. Islet cell surface antibodies are found in
70-80% of newly diagnosed IDDM patients and subsequently
decrease with increasing duration of diabetes (216-218).
Although ICA and ICSA are both usually present
concurrently (218), they do not always correlate (216).
Unlike ICA, ICSA appear preferentially beta cell specific
(218-221). In a study by Van De Winkel et al (221), 21
out of 38 diabetic patients were ICSA positive.
Subclasses of ICSA, with varying degrees of specificity
for the different islet cell types, were identified.
Whereas sera from ICSA patients aged under 30 years were
found to bind exclusively to beta cells, ICSA positive
serum from a few older diabetics preferentially bound to
glucagon and PP cells. Equally, ICSA are not exclusive
to IDDM, being found in Type II diabetes (221) and in 30%
of nondiabetic patients with autoimmune thyroid disease
(211).
The prognostic value of ICSA is unclear, since an
unacceptably high proportion (25%) of healthy first
degree relatives are also positive for ICSA (218),
whereas only 5% will ultimately develop IDDM. In
addition, no correlation was detected between ICSA status
and insulin secretion after an oral glucose load in
nondiabetic relatives of IDDM probands (222).
Serum positive for ICSA obtained from children with
recently diagnosed diabetes, were found to
immunoprecipitate a 64 kilodalton (KD) protein obtained
from human islets (223). Antibodies recognizing the 64KD
islet protein may be detected up to 8 years prior to the
onset of IDDM (224). However, it is not known to what
extent the 64KD protein is specific for islet beta cells.
Islet cell surface antibodies in contrast to ICA may have
some pathological importance in the development of IDDM.
In the presence of complement, ICSA positive sera can
cause lysis of cultured islets (218-220, 225). Using a
double fluorescence technique, that identified lysed
cells by their capacity to take up ethidium bromide and
beta cells by their staining with a fluorescein-
conjugated antibody to insulin, it was shown that ICSA
complement-dependent cytotoxicity was preferentially
directed towards beta cells (218, 219), although
approximately 10% of non-beta cells were also lysed
(219). Equally, treatment of islet cell cultures with
ICSA positive serum and complement, inhibited glucose
stimulated insulin release (220, 226), but arginine
stimulated glucagon release was unaffected (220).
Furthermore, in the absence of complement, perifusion of
dispersed rat islet cells with purified IgG from ICA,
ICSA and anti-64KD positive sera has been shown to also
inhibit glucose induced insulin release (227).
Islet cell surface antibodies may mediate cytotoxicity
via antibody dependent cellular cytotoxicity (ADCC)
whereby ICSA bind to the Fc receptors on cells such as
macrophages, K and NK cells. Accordingly ADCC of
lymphocytes and serum from diabetic patients directed
against human insulinoma cells was described (228). In
addition, increased K cell levels have been reported in
newly diagnosed IDDM patients (229, 230). However, this
represented non-specific ADCC directed against human
erythrocytes and was also found in unaffected siblings at
comparable levels (230). Specific ADCC directed towards
rat islet cells has been reported, however, there was no
significant increase in ADCC activity amongst IDDM
patients (231).
Although ICSA precede the onset of IDDM, and in vitro
exert complement-dependent cytotoxicity towards cultured
islet cells, 25% of first degree relatives also show ICSA
positivity with accompanying beta cell cytotoxicity but
without diabetes (218). Furthermore, the presence of
ICSA in 2 out of 4 subjects, in whom diabetes developed
following ingestion of the rodenticide "Vacor" (232),
suggests that as with ICA, ICSA develop following beta
cell injury and therefore represent a further marker of
ongoing beta cell destruction.
Insulin Autoantibodies
Autoantibodies against insulin have been reported in some
rare cases of hypoglycaemia in patients which had not
been treated with insulin (233, 234). More recently,
Palmer et al (235) described the presence of circulating
insulin autoantibodies (IAA) in children at diagnosis of
TDDM. In this initial report; using a liquid phase
radio-immuno-assay (RIA) and a porcine insulin tracer,
18% of children at diagnosis were positive for IAA and
IAA were not detected amongst the siblings of the
diabetic probands. Insulin autoantibodies that develop
spontaneously must be distinguished from insulin
antibodies that occur following injection of exogenous
insulin and, as such, are common amongst insulin treated
IDDM patients. Following the initial report by Palmer
and colleagues, several other groups have confirmed the
presence of IAA in the sera of newly diagnosed IDDM
patients (236-240). However, controversy persists
amongst the different centres regarding the prevalence
and the predictive value of IAA as a marker for IDDM. To
a large extent, this is due to the use of different assay
systems (enzyme-linked immunosorbent assay (ELISA) versus
RIA) and the use of different insulin species (human
versus porcine or bovine) as substrate. However, as a
consensus, 20-40% of IDDM patients, at onset, are
positive for IAA (236-239) and IAA can be detected
several years prior to the onset of IDDM (241-243).
Accordingly, some groups have reported a correlation
between IAA and ICA (238, 242, 243), although other
groups do not confirm this association (236, 237, 239).
Equally, some reports document an association between IAA
and HLA-DR3 or DR4 haplotypes (238), whereas others do
not (237, 239).
Further discrepancies have been reported regarding the
frequency of IAA amongst discordant identical twins. In
one study, the overall frequency of IAA amongst
discordant twins was 47% (239); furthermore, 14 out of 39
twins which were ICA negative were positive for IAA.
This contrasts with another study in which IAA were
present in only 1 of 22 ICA negative twins (242).
Since IAA were found in 7 of 14 nondiabetic twins of
longstanding diabetics (duration of discordance 15 years
or more) (239), by which time the risk of developing
diabetes is only about 3% (158), the pathogenetic
importance of IAA would appear minimal and the prognostic
value of IAA when considered singularly is poor.
However, if IAA is evaluated in conjunction with other
islet cell antibodies, the combined presence of several
autoantibodies within the same subject represents a
higher"predictive index than the presence of any marker
alone (238, 242, 243). Thus, in studies on beta cell
function, insulinopenia following intravenous glucose
stimulation was present in 70% of ICA positive IAA
positive subjects, compared to 23% of ICA positive, IAA
negative individuals (238).
Other Autoantibodies
In addition to IAA, autoantibodies against the insulin
precursor; proinsulin, have been reported. In a study
where only IAA negative subjects were screened,




recent onset IDDM patients (244). Inhibition of PAA
binding was achieved by the addition of proinsulin or C-
peptide, but not with insulin.
Diabetes incurred by insulin resistance following anti-
insulin receptor antibodies impeding the binding of
insulin with its receptor is associated with the rare
condition acanthosis nigricans (245). Although anti-
insulin receptor antibodies have been reported in 40-45%
of newly diagnosed IDDM patients (246, 247), the severe
insulin resistance associated with acanthosis nigricans
is absent. In some IDDM patients, anti-insulin receptor
antibodies may represent anti-idiotypic antibodies to
anti-insulin antibodies (124, 248). The anti-idiotype or
insulin receptor antibody may be formed following release
of insulin antigens *from damaged beta cells and, as such,
provide another marker of ongoing beta cell destruction.
Aside from the specific humoral autoimmunity aimed
towards the islet cell, several studies show a general
hyperactivity of the humoral immune system amongst IDDM
patients.
An increased incidence of autoantibodies against thyroid,
adrenal"" and parietal cells, was found in children with
IDDM (145, 249) and their first degree relatives (250).
The presence of multiple autoantibodies in IDDM patients
is in accord with the demonstration of polyclonal B cell
activation in recent-onset IDDM (251). Furthermore, 7
out of 9 human hybridomas prepared from peripheral blood
lymphocytes, from patients with IDDM, were found to react
with antigens present in multiple endocrine organs
(anterior pituitary, gastric mucosa, thyroid and
pancreatic islets), reflecting a common antigenic
determinant amongst these organs (252).
Finally, as is common in other autoimmune conditions,
lymphocytotoxic antibodies are found in the sera of IDDM
patients (253). The parallelism of these antibodies
occurring in different autoimmune diseases, suggests that
they are part of a generalized immune response of
autoimmune diseases.
In summary : Various parameters of humoral immunity have
been described amongst IDDM patients and their first
degree relatives. Islet cell antibodies and ICSA are
detectable several years prior to the onset of IDDM and
ICSA can participate in complement-dependent, antibody
mediated, cell cytotoxicity to xenogeneic islet cells in
vitro. Nevertheless, these antibodies are also present
in healthy subjects without causing disease and
therefore, must be considered of limited value as
predictive markers of IDDM. Equally, since IAA, which
carry minimal pathogenetic potential, can be detected as
early as ICA or ICSA in the prediabetic period, the mere
presence of any of these antibodies is not indicative of
a pathogenetic role. Indeed, most islet cell antibodies
are not beta cell specific and no one has been able to
transfer IDDM from affected to unaffected individuals
using any of the islet cell directed antibodies; although
one report describes a lower glucose stimulated insulin
release in immunosuppressed mice treated with IgG from
diabetic children as compared with mice injected with IgG
from non diabetic children (254).
In general, most evidence suggests that anti islet cell
antibodies result from polyclonal B cell activation
following release of islet antigens from damaged beta
cells, and therefore are probably of secondary
pathogenetic importance. As such, they represent markers
of beta cell injury but not necessarily impending IDDM.
However, it is possible that they may be involved in the




The characteristic pathological finding in the pancreata
of IDDM patients, at onset of disease, is that of
mononuclear cellular infiltration within the pancreatic
islets. Von Meyenburg termed this infiltration
"insulitis" (255) and insulitis accompanied by selective
beta cell destruction (256) are the pathological
hallmarks of Type 1 diabetes (194, 257-259). It has been
estimated that approximately 90% of all beta cell mass
has to be destroyed before the clinical signs of IDDM are
manifest (257). The actual frequency of insulitis
remains a contentious issue.
In a 25 year review of deaths in patients aged under 20
years, insulitis was present in 47 of 60 patients with
recent onset disease (259). In a study by Gepts (257),
islets from 16 of 23 patients with recent onset IDDM
revealed insulitis. In another study, 6 of 11 patients
who died within 2 months of the onset of IDDM, presented
with insulitis (258). However, Doniach and Morgan failed
to observe insulitis in any of 13 patients with recent
onset disease (260). The extent of insulitis within
individual IDDM patients is also variable, affecting 13-
75% of islets and is more pronounced among young
patients. (258).
Many of the discrepancies over the frequency and extent
of insulitis are due to the heterogenous pathology of
IDDM. Gepts (257) reported large areas of the pancreas
showing only inconspicuous pseudoatrophic islets i.e.
islets devoid of beta cells and insulitis. In other
pancreatic lobules, many large islets, predominantly
composed of hyperactive beta cells, were found. Some of
these islets were free from insulitis, whereas others
contained only a few infiltrating lymphocytes. But, in
some partly shrunken islets, lymphocytic infiltration was
found along with a reduced proportion of beta cells.
Thus, tissue sampling from a diseased organ with such a
heterogenous and patchy pathology will obviously give
rise to discrepancies between different studies.
However, in most cases, insulitis is observed only in
islets still containing insulin (259), indicating it
disappears once the beta cells are destroyed.
Consequently, insulitis is rarely found in IDDM patients
with a disease duration longer than a year (259).
In one patient with recent onset IDDM, who died within 24
hours of diagnosis, immunofluorescence studies were
performed to characterize the phenotypes of the
infiltrating cells (261). Most of the infiltrated cells
were CD8+ T cy totoxic/suppressor (T cyt/supp) cells,
although CD4+ T helper (Tf{) cells, NK cells and B
lymphocytes were also present. Furthermore, T cells,
mainly T cyt/supp, as well as macrophages contributed to
the insulitis found in long term IDDM patients with
recurrent disease having received segmental pancreatic
transplants from their discordant identical twins (262).
Cell- Mediated Immunity
In 1971 Nerup et al (12), using the leucocyte migration
inhibition test and a homogenate prepared from pooled
porcine pancreas, first demonstrated the presence of
lymphocytes with reactivity for pancreatic antigens in
the circulation of recently diagnosed IDDM patients.
Moreover, a subcutaneous injection of pancreatic
homogenate into 4 of 6 patients, whose leucocytes were
inhibited in the migration test, led to a Type IV
hypersensitivity reaction, indicating that the in vivo
assay reflected cell-mediated immunity (CMI) towards the
pancreas. Leucocyte migration inhibition activity
accordingly decreases with increasing disease duration.
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Huang and MacLaren (228), using a dye exclusion test to
determine cell death, were the first to report that
lymphocytes from acutely diabetic children showed
increased cytoadherence and cytotoxicity towards a human
insulinoma cell line. Boitard et al (263) reported that
mononuclear cells from 80-90% of IDDM patients inhibited
glucose stimulated insulin release from mouse islets in
vitro. The inhibition was specific for insulin since
arginine stimulated glucagon release was unaffected
(264). It was further noted that the 0KT3+ 0KT4- E
rosette forming cells were responsible for mediating this
effect (264).
The passive transfer of diabetes with specific effector
lymphocytes from a diseased donor to a healthy recipient,
in accordance with * Witebsky's criteria for autoimmune
diseases (22), has not been achieved. Buschard et al
(265) reported elevated blood glucose levels in athymic
nude mice which received intraperitoneal injections of
peripheral blood lymphocytes derived from newly diagnosed
IDDM patients. However, other investigators have been
unable to confirm this finding (266, 267). Furthermore,
results from passive transfer studies involving
allogeneic or xenogeneic transfer require consideration
of possible GVHD, which has been shown to cause insulitis
(268).
The importance of CMI in the pathogenesis of IDDM was
highlighted in the evaluation of pancreatic transplants
between identical twins. Sutherland et al (269)
transplanted the tail of the pancreas from 3 normal
monozygotic twins who were ICA negative, into their
diabetic twins, all of whom had been diabetic for over 15
years. Since the twins were identical, it was deemed
unnecessary to give immunosuppression.
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Initially the grafts reversed the diabetic condition, but
within a few weeks the islets in the pancreatic grafts
became infiltrated, predominantly by activated T
lymphocytes; beta cell destruction followed and diabetes
recurred (262., 269). In a fourth patient, who received a
similar transplant but also received immunosuppression
with azathioprine, insulitis or diabetes was not
recurrent (269).
Circulating Lymphocytes and Abnormal Immnoregulation
Studies of circulating lymphocytes in IDDM patients have
yielded conflicting results. This may be accounted for
by the use of different assays and the selection of
patients at different stages of disease. Equally,
hyperglycaemia and ketoacidosis per se can have effects
on lymphocyte function and distribution (270, 271).
Nevertheless, in some studies normal total T and B
lymphocyte numbers have been found regardless of the
degree of glycaemic control (272, 273). Other studies
have documented a decrease in T lymphocytes that were
either dependent (274) or independent (275) of the level
of glycaemia.
The use of monoclonal antibodies to perform lymphocyte
subset analysis has provided a further spate of
conflicting studies. Horita et al (276) reported that
the ratio of helper/suppressor cells was increased in
IDDM patients of disease duration less than 2 months,
which then later returned to normal. Ilonen et al (277)
however reported a decrease in the ratio of
helper/suppressor cells. Most studies are agreed that
the frequency o f TH cells in IDDM patients at onset of
disease are normal (277-279). However, T cyt/supp cells
are variously reported as normal (278, 280), increased
(272, 277) or decreased (273, 279).
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Several studies report an increase in the number of
activated T cells in the circulation of recently
diagnosed IDDM patients (272, 277, 278, 280-282). This
phenomena was first described by Jackson et al (278); in
which 9 of 11 diabetic patients were found to have
approximately 10% of their circulating T lymphocytes
bearing MHC class II or la antigens, whereas controls had
1% la-positive T cells.
In another study, raised levels of HLA DR expressing T
cells were found in 14 of 15 recently diagnosed
diabetics, but in only 7 of 28 patients with disease
duration longer than 3 years (281). De Berardinis et al
(282), further describes the presence of IL-2 receptor
(IL-2R) bearing T cells in 13 of 25 recently diagnosed
IDDM patients. Furthermore, they demonstrated that most
of the activated T cells were confined to the CD4
population of cells (282). The CD4 population has been
subdivided into two groups; helper-inducer (CDw29), which
are the helper cells for antibody production (283) and
suppressor-inducer (CD45R) cells (284). In other
autoimmune disease such as SLE (285) and multiple
sclerosis (286), immunoregulatory disturbances with
decreased numbers of suppressor-inducer cells are found.
However, in IDDM patients there was no decrease in either
of the CD4 subsets, and the increase in IL-2R positive
cells was present in both populations of CD4 cells (282).
The presence of increased numbers of la-positive T cells
at onset of IDDM, suggested that this may prove useful as
a predictive marker for IDDM. Accordingly, Alviggi et al
(281) reported increased levels of activated T cells in 5
of 7 unaffected co-twins of recently diagnosed IDDM
patients. In two of the twins, retested 6 months later,
the raised levels of HLA DR expressing T cells persisted
and impaired glucose tolerance had developed. Equally,
increased numbers of la-positive T cells were reported in
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5 of 10 ICA positive normoglycaemic siblings of IDDM
patients (272).
Although disturbances in the cellular composition of
peripheral blood lymphocytes from IDDM patients have been
reported, it is necessary to emphasize that these changes
may not be a true reflection of the pathologic processes
occurring in the islets of Langerhans. However, in one
study, peripheral blood lymphocytes from 5 patients with
recent onset IDDM, were isolated, radiolabelled and
autologous transfusions performed by reinjecting the
lymphocytes into the same patient from which they were
removed (287). Using an emission-computerized scanner,
radiolabelled lymphocytes were detected in the vicinity
of the pancreas in 3 of the 5 patients.
Numerous studies have investigated the functional status
of lymphocytes from IDDM patients. Natural killer cell
activity is reportedly decreased (288), although K cell
activity is increased (229). Several in vitro studies
have suggested that suppressor T cell activity in recent
onset IDDM is decreased (289-292). However, abnormal T
suppressor cell function has also been demonstrated in
non diabetic subjects who are HLA DR3 (293) and in
approximately 20% of healthy first degree relatives of
IDDM patients (294), suggesting that decreased suppressor
cell activity may be an abnormality related to genetic
background. Equally, altered suppressor cell activity
may be a consequence of the disturbed carbohydrate
metabolism of IDDM patients (292).
Deficient production of IL-2 has been demonstrated in
several autoimmune disorders (295), including Type 1
diabetes (296, 297). However, in IDDM patients the
deficiency represents an acquired defect in response to
beta cell destruction, rather than a precipitating factor
of IDDM (297). The decreased IL-2 production is
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unrelated to the degree of glycaemic control and, unlike
other autoimmune phenomena found in IDDM patients,
appears to persist for several years after the onset of
disease (297).
In conclusion : Many of the studies herein described
suggest a strong role for cell-mediated immunity in the
pathogenesis of Type 1 diabetes mellitus. However, as
mentioned in the case of humoral immunity, there have
been no reports of the successful transfer of diabetes
using peripheral blood lymphocytes derived from IDDM
patients. This indicates the requirement of an initial
triggering stimulus prior to the activation of
autoreactive lymphocytes. Phenotypic analysis of
circulating lymphocytes in IDDM patients have provided
variable results which, in any case, may not be
representative of the intra-islet events leading to the
development of IDDM. Phenotypic characterization of the
insulitis has identified a variety of infiltrating cells
including T cells (T cyt/supp and Tjj) , B lymphocytes, NK
cells and macrophages. The difficulty lies in
distinguishing which (if any) of these cells are
responsible for directing the demolition of beta cells;
and those which are merely innocent bystanders.
Furthermore, these studies are performed at a stage of
disease development when more than 90* of the insulin-
producing beta cells are destroyed and, as such, give
little information on the early initiating events of the
prediabetic period.
Thus far, I have described a variety of evidence which
suggests that autoimmune phenomena are involved in the
pathogenesis of Type 1 diabetes mellitus. Since IDDM is
still associated with increased morbidity and mortality
rates, the ultimate aim of diabetes research is to
prevent the disease.
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The development of a rational therapeutic approach to
prevention, depends however on (i) the identification of
accurate markers for the development of clinical disease,
as distinct from genetic susceptibility, (ii) elucidation
of the precise sequence of events leading to mass (more
than 90%) destruction of islet beta cells, and (iii)
detailed examination of the immediate and long-term
effects of possible therapeutic intervention.
Obvious difficulties in studying these areas, in man,
include the practical difficulties involved in conducting
longitudinal prospective studies of genetically
susceptible cohorts. Furthermore there are the
difficulties in correlating cellular and humoral immunity
with pancreatic morphology and function, and the
inability to standardise and control genetic factors in a
condition whose clinical expression is determined by the
interaction of genetic susceptibility and environment.
Finally, there may be ethical problems for the
application of certain intervention studies. This
dictates the need for studies using animal models to
precede and complement those involving the human IDDM
patient.
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CHAPTER 3 - THE BB RAT AND OTHER ANIMAL MODELS
OF TYPE 1 DIABETES MELLITUS
Numerous animal species displaying either spontaneous or
induced hyperglycaemia have been described (298). This
thesis will describe studies performed on one such animal
model; the spontaneously diabetic BB rat. In addition,
reference will also be made to two other commonly used
animal models of IDDM, namely the non-obese diabetic
(NOD) mouse and multiple low-dose streptozotocin-induced
diabetes of mice.
THE SPONTANEOUSLY DIABETIC BB RAT
The spontaneously diabetic BB rat was discovered
serendipitously in 1974 by Drs Reginald and Clifford
Chappel in a colony of albino Wistar rats, maintained at
the BioBreeding Laboratories (from which the BB
designation is derived) in Ottawa, Canada (299).
In 1977 a breeding colony of BB rats was established at
the Animal Resources Division of Health and Welfare in
Canada. This colony subsequently supplied animals to
establish other colonies including our own in Edinburgh.
In accord with the recommended nomenclature, the original
colony is designated BB, the colony in Edinburgh BB/E,
that at Worcester BB/W and so on (302).
Particularly attractive features of this animal model, as
a research tool for work in IDDM, include a prediabetic
period of about 3 months; involvement of both genetic and
immunological factors in the aetiology; the fact that not
all animals in diabetes-prone (DP) litters develop
clinically overt insulin-dependent diabetes; the absence
of obesity; and the occurrence of functional and
structural changes in the retina, kidneys and nerves of
established diabetic animals.
The main disadvantages of the model relate to its
increased susceptibility to infection (300); difficulty
in animal care and breeding; the need to create, by long
term selective breeding, a subline of diabetes-resistant
(DR) BB rats to serve as controls, so that it can be
determined whether any observed changes are diabetes
rather than strain related. It is important to emphasize
that it is inappropriate to use non diabetic littermates
of animals with IDDM as normal controls, since many of
these animals have abnormal blood glucose profiles,
whilst not requiring insulin to survive (301). In
addition, the incidence of diabetes among DP litters
varies widely not only between colonies, but also within
the same colony, where inadvertent environmental changes
may influence the incidence of diabetes. Environmental
factors identified a-s affecting the incidence of diabetes
include diet (303), stress (304) and infection (305).
GENERAL CHARACTERISTICS
The first papers describing the metabolic and morphologic
characteristics of the diabetic syndrome in the BB rat,
were from Nakhooda et al (301, 306, 307). Unlike the
non-obese diabetic (NOD) mouse model, where diabetes
preferentially affects females (308), diabetes in the BB
rat equally affects both sexes. Diabetes in the BB rat
occurs between 60-140 days of age, coinciding with rat
puberty, although it is not uncommon for diabetes to
develop later in some animals.
The BB rat displays all the clinical symptoms
characteristic of the human disorder including polyuria,
polydipsia, glycosuria and severe weight loss, despite
hyperphagia (306). Diabetic animals succumb from
ketoacidosis within 2 weeks of onset, unless exogenous
insulin is administered. At onset, hyperglycaemia is
associated with hypoinsulinaemia, hyperglucagonaemia,
hyperketonaemia, hyperlipidaemia and uraemia. Blood
levels of branched chain amino acids and taurine,
glycine, tyrosine, phenylalanine, ornithine and lysine
are all raised, while alanine and lactate are decreased
(309). Increased serum levels of 3-methylhistidine
(reflecting muscle protein breakdown) together with
enhanced ammoniagenesis suggest a generalized catabolic
state (310).
Both glucose tolerance and the clinical expression of
diabetes, correlate with the insulin response to a
glucose challenge, which in turn correlates with the
presence of insulitis (311).
The degree of insulitis varies between animals, but
always precedes overt hyperglycaemia and corresponds to
the severity of the diabetic symptoms (312). Thus, mild
patchy insulitis commonly exists without any detectable
impairment of either glucose tolerance or insulin
secretion. Other more severe and extensive insulitis is
associated with impaired glucose tolerance and reduced
glucose-induced but not arginine-induced secretion of
insulin (313), with first phase insulin being
particularly affected (537). At onset, massive insulitis
and a —decrease in the number and size of pancreatic
islets is found (312). However, progression through
these phases is not inevitable (301) and whilst IDDM
never occurs without insulitis, animals with insulitis do
not always develop IDDM.
The BB rat appears very susceptible to the development of
pulmonary and other infections by common varieties of
bacteria, mycoplasma and viruses (314), and to the
development of lymphoproliferative disorders (315). This
may be related to the lymphopenia commonly, but not
invariably, seen in these animals. Initially it was
thought that this was mandatory for the development of
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IDDM (316, 317) and since lymphopenia is not a feature of
human IDDM, this appeared to represent a major difference
between IDDM in man and the BB rat model. However, it is
now established that not only is lymphopenia frequently
present without diabetes, but also that IDDM can develop
in the absence of lymphopenia (318, 319).
Organ system changes suggestive of human diabetic
complications are also found in well established insulin
treated diabetic BB rats. Although the classical
clinical features of diabetic retinopathy are not seen on
ophthalmoscopy in the BB rat; retinopathology including
pericyte degeneration and loss, endothelial cell
degeneration and basement membrane thickening, have been
described (320).
Diabetic neuropathy is the most common complication of
diabetes and altered nerve conduction and morphological
changes in somatic peripheral and autonomic nerves,
characteristic of human diabetic neuropathy, are
reproduced in the BB rat (321, 322). As with
retinopathy, the pathological and clinical features of
severe nephropathy found in human IDDM are not observed
in the BB rat, although proteinuria and thickening of the
glomerular basement membrane occur after a few months of
diabetes (323).
Alterations in hepatic metabolism (324) and gonadal
dysfunction (325) have also been reported. Although
changes in myocardial biochemistry have been reported
(326), atherosclerosis and severe microangiopathy, which
are common in human IDDM, have not been found in the BB
rat (327).
As is the case with human IDDM, where other endocrine
glands are sometimes also affected, thyroiditis is found
in some BB rats (328, 329) but occurs independently of
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insulitis and diabetes (329) and is not of sufficient
severity to cause thyroid failure (328). The incidence
of thyroiditis can, however, be increased by the
administration of dietary iodide (330).
Thus it can be seen that many features of diabetes in the
BB rat closely resemble those found in human IDDM
patients. Many of the immunological parameters prevalent
amongst IDDM patients described in Chapter 2 are also
found in the BB rat. Indeed, assuming that diabetes in
the BB rat is reflective of IDDM in man, much of the
evidence obtained from studies on the BB rat has further
substantiated and propagated the involvement of
autoimmunity in the aetiology of IDDM.
GENETICS
Susceptibility to IDDM in the BB rat, as with human IDDM,
is linked to a gene or gene cluster located within the
rat MHC (331), although several non-MHC modifying genes
affect the frequency and time of disease onset (332).
The rat MHC, known as RTl, resembles the mouse MHC (H-2)
in that the class II loci (RT1B and RTlD) are flanked by
the class I RT1A locus and the class I RTlE and RT1C loci
(333). As with the Wistar Furth (WF) rat, from which it
is derived, the BB rat carries the RT1U haplotype.
A series of breeding studies (331, 334, 335) determined
the importance of the u haplotype for the development of
IDDM. Initially BB diabetic males were crossed with
females of the inbred Lewis (Lew) strain (RTl"'-) or
Buffalo (Buf) strain (RTl'5). In the initial F2
generation all the diabetics were homozygous RT1U^U
(331). Continued breeding studies produced diabetics
which were RTl11/1 or RTlu/b, but no diabetics carried the
genotype RTl1/1 or RTlb/b (331, 334). Thus, at least one
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u haplotype is a necessary prerequisite for the disease
expression.
There is no apparent difference between the homozygous
and heterozygous u haplotype bearing diabetics in
relation to the age of disease onset or sex related
incidence of diabetes, although IDDM occurs more
frequently in the homozygous RT1U/'U animals (335). As in
human IDDM where affected siblings usually have one, and
often both, haplotypes in common with the propositus,
irrespective of the HLA determinants making up the
haplotype, so within BB rat litters where MHC haplotypes
are segrating, diabetes occurs in animals with the same
genotype. Thus, if the first animal to develop IDDM is
RTlu/u) subsequent diabetic animals will also be RTlu>/u.
If the first diabetic animal is RTlU//x, subsequent
diabetics will also be RT1U/X (336).
To determine what regions of the associated MHC
contribute to disease susceptibility, breeding studies
have been performed that place recombinant haplotypes
bearing the associated u haplotype in defined regions of
the MHC onto the BB rat genetic background (337, 338).
Transmission of the recombinant haplotypes is tracked in
the resulting diabetic progeny using Southern blot
hybridization with locus specific MHC probes. The
results indicate that the IDDM susceptibility gene(s) map
to the right of RT1A and to the left of RT1C and are
probably associated with the class II RT1D region.
However, the MHC genes determining disease susceptibility
were not unique to the BB rat (338).
This is supported by the findings of Holowachuk and Greer
(339), where nucleotide sequence analysis indicates that
the beta chains of the class II RT1B and RT1D molecules
of the u haplotype from BB DP, BB DR and WF rats are
identical. This suggests that class II molecules from BB
DP rats are not variant or unique and that unaltered
class II molecules of the u haplotype support the
autoimmune response in the BB rat. Thus, these reports
correspond with the findings of Todd et al (177) which
showed that human IDDM was not due to mutant class II
genes.
Since the incidence of IDDM in crosses between WF rats
(RTlu) and BB rats is only slightly greater than crosses
between BB rats and non-RTlu animals, it suggested the
presence of an IDDM resistance gene within the MHC (340).
However, in recent breeding studies by Ono et al (338),
diabetic animals homozygous for the WF derived RT1U
haplotype were identified, suggesting that any putative
IDDM resistance genes are located outside the MHC.
Furthermore, they report that although immunoregulatory
defects e.g. lymphopenia, characteristic of some BB rats,
may enhance the incidence of IDDM they are not obligatory
for the expression of diabetes (338).
Recently workers from McDevitt's group in Stanford have
investigated whether or not the aspartic acid negativity,
at position 57 of the class II beta chains conferring
susceptibility in human IDDM (177), is applicable to the
BB rat~model of IDDM (341). cDNA clones encoding the
class II MHC genes of BB DP and BB DR rats were isolated
and sequenced. The nucleotide sequences of the first
domains of the RT1B beta and RTlD beta molecules were
found to be identical in both the diabetes prone and
diabetes resistant rats.
Although the BB rat was found to have a serine residue at
position 57, in both the RTlB beta and RTlD beta
sequences and therefore appeared consistent with the
human studies (177), both the BB DP and BB DR rats
possess the same sequence. Furthermore, they found that
the region around amino acid 57 in the first domain of
both the RT1B beta and RTlD beta chains of the non
diabetic Lewis rat (RTl^) are identical to those of the
BB rat. Moreover, the Buf rat (RTl^) has a serine at
position 57 as well (342). Thus, the allelic form of
amino acid 57 does not appear to be a disease
susceptibility marker in the BB rat model of IDDM.
However, the absence of differences between the BB DP and
BB DR sublines, in their class II beta chain sequences,
does not exclude these genes from being involved in the
pathogenesis of the disease. Indeed, since with human
IDDM susceptibility to diabetes is multigenic (336), the
difference between the BB rat sublines may be due to
genes outside the MHC.
To further define the BB rat's RTl-linked diabetogenic
gene(s), restriction endonucleases and MHC probes have
been used to detect RFLP's between the BB rat and control
strains at the genomic level (343-346). Buse et al (343,
344), using the restriction endonucleases BamHI and EcoRl
in conjunction with a mouse class II (I-A alpha) gene
probe, identified 4 polymorphic chromosome types (la, lb,
Ila, lib) in the BB DR rats, whereas all the BB DP rats
were homozygous (Ila/IIa). However, Kastern et al (345)
failed to detect any class II gene polymorphisms using a
human DR-alpha gene probe. The possibility that this
probe lacked sufficient homology with the analogous rat
genes, was subsequently tested using mouse genomic probes
for I-A alpha, I-A beta, I-E alpha and I-E beta, but
again no polymorphic bands were detected between the BB
DP and BB DR rats (346).
Polymorphisms have however been reported using mouse
class I MHC gene probes (344-346). Specifically, a 2Kb
BamHI fragment was found in all BB DR rats, but absent in
BB DP rats (345). Furthermore, a 40bP cDNA probe,
representing part of the second extracellular domain of a
class I antigen, identified 2 fragments; 15Kb and 7Kb in
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the BB DR rats but only the 15Kb fragment in the BB DP
rats (346). It was suggested that the gene contained in
the 7Kb fragment may be deleted in the BB DP animals.
Other polymorphisms, including those at the 5'-flanking
region of the rat insulin I gene; but not the insulin II
gene, have been reported although the insulin gene
alleles do not associate with IDDM in the BB rat (347).
In conclusion, diabetes in the spontaneously diabetic BB
rat is inherited as an autosomal recessive trait (348),
where susceptibility is linked to at least one gene
associated with the rat MHC, but disease penetrance is
modified by non-MHC genes. The presence of at least one
u haplotype appears to be a necessary prerequisite for
disease development. Specifically, disease
susceptibility appears to be linked to gene(s) that map
to the class II RT1D locus. However, the MHC class II
genes determining disease susceptibility are not unique
to the BB rat and, therefore, unaltered class II
molecules of the u haplotype can support the autoimmune
response leading to IDDM in the BB rat.
HUMORAC IMMUNITY
Unlike human IDDM, antibodies to islet cell cytoplasmic
antigens are not found in the serum of BB rats (349,
350). However, islet cell surface antibodies are present
in the BB rat.
Islet cell surface antibodies were first reported by
Dyrberg et al (351) using a 125I-protein A radioligand
assay with dispersed Wistar rat islet cells, in 12 of 14
diabetic BB rats studied 3-11 days after diagnosis of
IDDM. Subsequently, using the rat insulinoma cell line
RINm5F (352), they found ICSA in the prediabetic period
in 16 of 22 BB DP rats (353). Islet cell surface
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antibodies were present in some animals at weaning and
therefore present at an age when no morphological or
metabolic disturbances of the diabetic condition were
detected. In these studies (351, 353), the presence of
ICSA also correlated with that of anti lymphocyte
antibodies, although the time course of the two
antibodies varied (353).
The frequency of ICSA in the prediabetic period, and
their subsequent predictive value for impending IDDM, is
a contentious issue. Pollard et al (354), using an
indirect immunofluorescence assay on pancreatic islet
cell suspensions from cultured rat islets, detected ICSA
in all of 12 prediabetic and 11 diabetic BB rats. More
recently, Pipeleers et al (355) reported ICSA in diabetic
but not prediabetic 'BB rats. The occurrence of ICSA was
related to the time of clinical onset and to the age of
the animals, with ICSA more frequent in animals
developing IDDM at an earlier age. Although ICSA can be
detected prior to the onset of IDDM (353), in one study
there was no correlation between the development of IDDM,
glucose intolerance or insulitis and the levels of ICSA
(356).
Monoclonal islet cell surface antibodies have been
produced by fusing diabetic BB rat splenocytes with rat
myelomas (357-359). One such MoAb termed IC2 bound to
the surface of 56% of normal rat islet cells and 72% of
rat insulinoma cells (357). In subsequent double
labelling experiments, with an anti-insulin antibody,
only insulin positive cells bound the IC2 antibody thus
showing its beta cell specificity (358). However,
expression of the cell surface antigen depended on the
functional state of the beta cells, since islet cells
isolated from 24-hour fasted animals showed a marked
reduction in the number of insulin positive cells that
bound the IC2 antibody.
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Recently another ICSA MoAb, termed EC52, was identified
and was cytotoxic to RINm5F cells but not other non-
insulinoma cell lines (359). The EC52 antigen is present
in normal pancreatic islets but is hidden by sialic acid
residues and can be exposed following neuraminidase
treatment. Following neuraminidase treatment, EC52 was
found to stain 75% of insulin positive cells, but none of
the insulin negative cells. In addition, after, but not
before, neuraminidase treatment of the islet cells, EC52
was capable of exerting complement dependent antibody
mediated cytotoxicity towards the rat islet cells. Using
immunostaining of glycolipids separated by thin layer
chromatography, hapten inhibition assays with defined
carbohydrates and Western blots, the antigens recognized
by EC52 on RINm5F cells were identified as glycoproteins
with molecular weights of 60K and 68K. The antibody
recognizes a carbohydrate antigen containing the sequence
Gal beta 1-4 Glc NAc-R which on RINm5F cells is
predominantly hidden by covalently bound sialic acid. It
was therefore suggested that hidden antigenic
determinants on islet cells, if exposed, may then become
the target of autoimmune attack (359).
Complement-fixing islet cell antibodies, mediating islet
cell cytotoxicity, have been documented in the BB rat
(360). Using dispersed rat islet cells, CF-ICA were
detected in 13 of 14 BB rats prior to the onset of IDDM.
In 4 animals CF-ICA were present 4-8 weeks prior to the
onset of disease. In 13 of the rats CF-ICA persisted 2-3
weeks after the onset of IDDM.
A possible pathogenetic role for ICSA was supported by
Laborie et at (361). Serial serum samples were isolated
from BB rats in the prediabetic period. All sera from
animals that subsequently developed IDDM displayed
complement dependent antibody mediated cytotoxicity to
5^-Cr labelled islet cells. Toxicity was specific for
n
islet cells since hepatocytes and fibroblasts were
unaffected. Maximal toxicity occurred either just before
or immediately after disease onset. Sera from diabetic
animals also inhibited insulin secretion from normal rat
islets either in the presence or, in some cases, the
absence of complement. Beta cell specificity was shown
with glucagon and somatostatin functions unaffected
(361).
Antibodies to the 64KD islet cell protein found in human
IDDM (223, 224) are also present in the BB rat (362).
The 64KD protein was detected in rat islet cell
fractions, immunoprecipitated with sera from all diabetic
BB rats and 11 of 12 prediabetic BB DP rats. Antibodies
to the 64KD protein were also found in BB DR animals at a
lower frequency, but- were absent from WF rats. In some
BB DP animals, studied prospectively, antibodies to the
64KD protein were detected up to 8 weeks before the onset
of IDDM.
Detection of anti-64KD antibodies may precede the
development of ICSA (356), however this may only reflect
a higher sensitivity of the immunoprecipitation
technique. The 64KD rat antigen has the same
electrophoretic mobility as the human counterpart
detected in human islets with human sera (223). The
autoantigens may be identical since some human sera
precipitate the 64KD protein from normal rat islets
(227).
Other autoantibodies similar to polyendocrine
autoimmunity in humans, perhaps reflecting abnormal
immune regulation with resulting polyclonal B cell
activation, are found among BB rat strains. Antibodies
to smooth muscle, thyroid colloid and gastric parietal
cells (349, 350), along with anti-lymphocyte antibodies
(351, 353), have been reported as part of a general
Ik
autoantibody background in the autoimmune BB rat. In
older diabetic rats, parietal cell antibodies were
associated with lymphocytic gastritis and squamous
metaplasia of the gastric mucosa (349). Antibodies to
adrenocortical cells or thyroid microsomal antigens,
however, have not been found (349, 350).
Thus, several of the features of humoral autoimmunity
found in human IDDM, are also common to the BB rat.
However, as with its human counterpart, humoral
autoimmunity is believed to be of secondary importance
behind cell-mediated immunity in the pathogenesis of IDDM
in the BB rat.
CELLULAR IMMUNITY
Histopathology
In a study by Seemayer et al (312), light microscopy,
immunohistochemistry and electron microscopy were used to
document the appearance of insulitis in diabetic and
normoglycaemic BB DP rats. Three groups of diabetic rats
were identified : early diabetes (1-3 days after
detection of glycosuria); stable diabetes (41-63 days
after detection) and unstable diabetes (7-22 days after
detection).
In early diabetes, islets were extensively infiltrated
with activated lymphocytes and macrophages, and beta
cells showed marked degranulation, injury and necrosis.
Glucagon (A) and somatostatin (D) cells were largely
unaffected. In stable and unstable diabetes, islets were
small and markedly depleted of beta cells, but A and D
cells remained intact. Variable degrees of insulitis,
beta cell degranulation and necrosis were found in 65 day
old normoglycaemic BB DP rats, indicating that the
process of islet destruction is initiated well in advance
of the onset of clinical symptoms. In addition, the
pancreata from diabetic and the 65 day old BB DP rats
also showed mononuclear cellular infiltrates, distinct
from insulitis, at periductular and/or acinar locations.
Use of a pancreatic biopsy technique allowed
Logothetopoulos et al (363) to correlate the appearance
of insulitis with the subsequent development of IDDM.
Islets in biopsies taken 18-53 days before the onset of
IDDM, showed normal structure and no insulitis. Biopsies
removed 2-9 days before onset of disease, displayed
extensive insulitis. In biopsies which preceded disease
onset by 11-16 days, a small number of islets showed
small focal mononuclear cellular infiltrates. Thus,
insulitis appeared to develop rapidly from 2-3 weeks
prior to the onset of IDDM.
Cell-Mediated Immunity
Lymphocytes, with reactivity for pancreatic antigens, are
present in the circulation of BB rats. T lymphocyte
lines, specific for islet cell antigens, have been
isolated from the spleen and pancreas of newly diabetic
BB rats (364). The T cell lines appeared to be of the Tjj
phenotype and displayed MHC restricted proliferation and
IL-2 secretion in the presence of islet cell antigens.
Responsiveness to islet cell antigens was inhibited by a
MoAb against the class II RT1D antigen, suggesting that
MHC class II antigen restriction of islet cell
recognition by T cells occurs (365).
Cell-mediated immune destruction of pancreatic islet beta
cells, as assessed by decreased insulin content following
culture of rat islet cells with splenic lymphoid cells,
and lysis of -^Cr-labelled RINm5F cells, was detected in
diabetic and BB DP rats (366). Cytotoxicity was specific
for islet cells since WF or Lew rat spleen cells or a rat
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pituitary cell line were not lysed (367). Anti-islet
cellular cytotoxicity was mediated against both MIIC-
compatible and-incompatible islet cells suggesting a non-
MHC restricted killing mechanism. Natural killer cells
were identified as the cytotoxic effector cell since
incubation of spleen cells, with an antiserum to NK
cells, decreased the cytotoxicity (367).
An important role for NK cells in the pathogenesis of
IDDM in the BB rat has been supported by other studies
where NK cell numbers and NK cell activity have been
increased in BB DP rats (368) and administration of
antibodies against NK cells in vivo can prevent disease
onset (369) .
In an attempt to moriitor the involvement of cell-mediated
immunity in the target organ, autologous transfusions of
^Indium-labelled peripheral blood lymphocytes were
followed by gamma camera imaging and autoradiography
(370). However, radioactivity recovered in the pancreata
of BB DP, BB DR and WF rats were identical and labelled
lymphocytes did not image the pancreas in relation to the
presence of insulitis.
In another study, recombinant IL-2 was radio-labelled
with iodine and injected in vivo into BB DP rats (371).
Combined immunoperoxidase staining and autoradiography of
organ sections revealed that IL-2 bound specifically in
vivo to IL-2R positive cells in the spleen of both normal
and BB DP rats and to activated lymphocytes infiltrating
the pancreas of BB rats. The severity of insulitis
correlated with the degree of radioactivity in the
pancreas, and time-activity curves, generated over organs
of injected animals after gamma camera imaging, confirmed
the radioactivity was greater in the pancreas of BB DP
rats than normal WF rats.
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Lymphopenia, Circulating Lymphocytes and Abnormal
Immunoregulation
Many of the early studies in the BB rat identified a
profound T cell lymphopenia affecting peripheral blood,
spleen, lymph nodes and thymus (316), which was initially
believed to be a necessary prerequisite for the
development of IDDM (317). As already mentioned, it is
now established that lymphopenia is present in many BB
rats, but it is not obligatory for the development of
diabetes (318, 319, 338). However, the presence of
lymphopenia in some animals has made it difficult to
dissociate defects in immunoregulation, that may be
pertinent to the aetiology of IDDM, with those that
merely result from the lymphopenia defect itself.
Lymphopenia affecting total lymphocyte numbers is present
in affected animals from birth (372). The lymphopenia
primarily affects the T cell population with B cell
numbers and serum Igs levels reported as normal (373) or
slightly increased (374). Controversy exists as to which
subpopulation of T cells is primarily affected, with some
groups finding cells markedly affected (316, 373,
374), whilst others reported diminished T cyt/supp cell
numbers (375-377).
Recently, Greiner et al (378) have reported that the T
cell lymphopenia in BB DP rats is largely due to the
absence of the RT6 peripheral T cell subset. The RT6
alloantigenic system consists of 2 known antigens, RT6.1
and RT6.2 and approximately 50% of CD4 and 70% of CD8
peripheral T cells express RT6 (379). Genetic
complementation studies indicate that the BB DP rat
contains an intact RT6 gene, but fails to express the
RT6.1 alloantigen in the functional absence of an
accessory factor provided by RT6+ cells (380).
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An immunoregulatory role for the RT6 subset was suggested
when BB DR rats, with normal RT6+ cells, were treated
with an anti-RT6 MoAb from 30 days of age and diabetes
resulted within 2-3 weeks in 50% of the animals, compared
with none of the controls (381). If anti-RT6 antibody
treatment was delayed until 60 days of age, diabetes did
not occur, thereby suggesting that during a critical
developmental period, a regulatory population of RT6+
cells may prevent diabetes in BB DR rats.
Recently however, the reported absence of RT6+ cells in
BB DP rats has been questioned. Lang and Kastern (382)
have reported that the RT6 subset is present in BB DP
rats in normal proportions when it is calculated on the
basis of the total number of lymphocytes in any one
animal and suggest that the previously reported decreased
numbers of RT6 cells (378) results from, rather than
causes the lymphopenia.
Studies aimed at identifying the origin of the T cell
dysfunction, have been performed. Whereas Elder and
MacLaren (373) reported a post-thymic defect, Scott et al
(383) suggest two defects in the BB rat lead to the
development of diabetes and/or lymphopenia. One defect
occurs~at the bone marrow stem cell, the other resides in
the T cell differentiation environment.
Experiments using bone marrow transplants in both BB DP
and BB DR rats, to create reciprocal histocompatible
chimaeras, showed that disease susceptibility and
resistance resided in the donor derived bone marrow and
not the host genetic background (384). Georgiou et al
(385) suggest that bone marrow derived cells, that are
not T cell precursors (probably dendritic cells or
macrophages), influence the maturation environment in the
thymus of otherwise normal BB DP T cell precursors. This
is supported by van Rees et al (377), where it was noted
that from birth there was a marked reduction in the
macrophage subpopulations in the BB thymic cortex, but
not in spleen or lymph nodes. An intrathymic
maturational defect of CD8 cells was reported, since they
failed to increase in numbers shortly after birth.
Numerous abnormalities of immunodeficiency in cell-
mediated immune responses have been found in diabetic and
DP BB rats. Impaired ability to reject allografts (373,
375) or respond in mixed lymphocyte cultures (386), along
with decreased responsiveness to T cell mitogens (373,
387), have been reported. This anergy is not restored by
the exogenous addition of IL-2 (375, 386) and, a reduced
ability of BB lymphocytes to respond to IL-2 has been
suggested (373). The poor proliferative responses and
low IL-2 levels aire not due to an intrinsic T cell
abnormality (387), but to suppression mediated by a
population of macrophages (387, 388), since removal of
macrophages from BB spleen cells removed the suppressive
effect. Other studies (319, 373), however, have not
found any inhibition of IL-2 levels.
T cells from newly diabetic BB rats failed to exert
cytotoxicity to MHC compatible islet cells suggesting an
absence" of functional T cytotoxic cells (376). This is
supported by the findings of Woda and Padden (389) who
used a model of LCMV infection to study functional
activity of T cyt cells.
Whereas 7 days after infection BB DR rats generated
lymphocytes which were cytotoxic for LCMV infected
syngeneic fibroblasts, BB DP rats failed to generate
either functional or phenotypic T cyt cells. They
suggest that in the absence of T cyt cells, NK cells may
represent the major cytotoxic effector cell in BB DP
rats.
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The capacity of alveolar macrophages from diabetic BB
rats to phagocytose and kill bacteria is also impaired
(390). However, this appears related to the degree of
insulin deficiency, since the defect improves following
intensive insulin therapy and BB DP rats, remaining non-
diabetic, show normal macrophage function.
The involvement of suppressor T cells in disease
immunoregulation has also been suggested with decreased T
suppressor cell numbers and deficient suppressor cell
activity reported (375-377, 391). Bone marrow
transplants, from normal donors to BB DP rats, can
restore normal suppressor cell numbers and activity and
prevent the development of diabetes (391).
In common with human IDDM, elevated levels of activated
(Ia+) T lymphocytes are present in the circulation of DP
BB rats (392-394). The increased Ia+ T cell population
includes both T^ and T cyt/supp cells, but preferentially
the TH population (392). The increase in activated T
cells appears to peak shortly before disease onset, but
is independent of blood glucose levels (392).
After onset, levels usually return to normal within a
week (393). Elevated levels of Ia+ T cells (about 4%),
detected before 50 days of age, accurately identified a
prediabetic stage and predicted the future development of
IDDM with 85% sensitivity (true positives) and 83%
specificity (true negatives)(393, 394). The interval
between detection of elevated activated T cell levels and
the onset of diabetes ranged from 22-82 days (393), but
detection of elevated levels preceded detection of
insulitis which only occurred just prior to the
development of hyperglycaemia (394).
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Islet Transplantation Studies
Studies have been performed to investigate whether
failure of islet transplantation is due to recurrent
autoimmunity in the graft or due to a classical allograft
rejection process. To preclude allograft rejection, BB
DP rats were rendered tolerant of WF rat
histocompatibility antigens by inoculation of WF bone
marrow at birth, and verified by the permanent acceptance
of WF skin grafts (395). Survival of WF allografts were
compared in tolerant BB DP rats, which had developed IDDM
spontaneously, with tolerant non-diabetic littermates in
whom diabetes was subsequently induced by the injection
of streptozotocin (STZ). In contrast to the permanent
survival of WF islets, in the tolerant STZ induced
diabetics, there was a uniform recurrence of insulitis
and hyperglycaemia in the tolerant BB DP recipients with
spontaneous diabetes. Since allograft rejection was
precluded by the induction of tolerance, recurrence of
autoimmunity causing damage to the transplanted islets
was indicated.
Islet allograft destruction, due to recurrent
autoimmunity, has also been found in other studies (396—
398). Transplantation of cultured islet cells and
pituitary tissue (to control for the allograft response),
from MHC-incompatible donors into diabetic BB rats,
resulted in destruction of the grafted islets but not of
the pituitary tissue (396). Thus, recurrent autoimmunity
specific for pancreatic islet cells resulted in the
destruction of the transplanted islets.
In a study by Weringer and Like (397), cultured
pancreatic islets and adrenal cortex, from inbred rats of
variable MHC, pretreated to reduce antigenicity (399),
were transplanted into normoglycaemic BB DP rats. Islet
grafts, from MHC-compatible and MHC-incompatible donors,
evidenced lymphocytic insulitis in animals that became
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diabetic or evidenced lymphocytic insulitis in their
endogenous islets. Adrenal cortex tissue was unaffected
indicating the anti-islet response was not a normal
allograft reaction. In addition, the results suggest
that immune assault on pancreatic islets is not MHC
restricted. Furthermore, since islet transplants, from
non-BB rat sources, were also destroyed, it indicates
that the islet cell antigens in BB DP rats are not unique
or abnormal.
The persistence of memory effector cells was indicated
when islet grafts, from BB DR rats, were transplanted
into diabetic BB rats of long standing duration (in whom
insulitis was absent from their remaining endogenous
islets), and the grafts revealed lymphocytic insulitis
after transplantation (398).
However heightened autoimmunity in BB rats of recent
onset, is indicated by the shorter graft survival of both
isogeneic and allogeneic islets when transplanted into
diabetic BB rats of recent onset (duration about 20 days)
compared with established diabetics (duration over 10
weeks)(400, 401).
Allogeneic islets were less sensitive to the specific
autoimmunity and survived longer than isogeneic grafts,
in both recent onset and established diabetics.
Postoperative administration of cyclosporine prolonged
allograft survival in both diabetic groups, but only in
established diabetics when isogeneic islets were
transplanted. This suggests that immunosuppression,
given at or around a peak period of autoaggression, is
unable to protect the islets from destruction.
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Passive Transfer Studies
Pertaining to Witebsky's postulates for the establishment
of an autoimmune disease (22), perhaps the most important
criterionis that transfer of the experimental disease to
a normal recipient, by serum or lymphoid cells, should be
possible.
Nakhooda et al (402), using lymphocytes from acutely
diabetic BB rats and athymic nude mice as recipients,
reported insulitis in 58% of the recipient mice.
However, Rossini et al (403), using lymphocytes from
acutely diabetic BB rats when transferred into SWR/JM
nu/nu athymic mice and nu/nu athymic rats, failed to
produce either insulitis, hyperglycaemia or glucose
intolerance.
Since the transfer of experimental allergic
encephalomyelitis (EAE) was reportedly enhanced by
preculturing donor cells from affected animals with the T
cell mitogen ConA (404), Koevary et al (405) tried this
approach in the transfer of IDDM in the BB rat. Spleen
cells, from acutely diabetic BB rats, were harvested and
incubated with ConA for 72 hours. When given to young
(30-40 days old) BB DP rats, insulitis accompanied by
hyperglycaemia was found in 60-90% of recipient animals
within 2 weeks of transfer. Since fewer than 0.5% of BB
rats spontaneously develop IDDM before 60 days of age,
this indicated that diabetes had been successfully
transferred. In this initial study, transfer to BB DR
recipients was not successful. However, diabetes has
subsequently been transferred to other strains of rats
(406, 407).
Diabetes occurred in 15% of MHC-compatible WF rats about
12 days after transfer with ConA activated spleen cells
from acutely diabetic BB rats (406). However, transfer
was only possible following immunosuppression of
recipients with cyclophosphamide 24-48 hours before
transfer. Immunosuppression with cyclophosphamide,
neonatal thymectomy, splenectomy or rabbit anti-rat
lymphocyte serum, was again necessary for the adoptive
transfer to BB DR rats or F1 hybrid offspring produced by
diabetic BB X Lew (RTl"*-), BB X Brown Norway (RTln), BB X
Yashida (RT1U) and BB X NEDH (RT1&) matings (407).
The results indicate that alteration of the recipients
immune system, via immunosuppression, permits the
transfer of diabetes not only to BB DP animals but also
to other rats that were either homozygous or heterozygous
for the BB RT1U haplotype. Additionally, they suggest
that since antigenically normal beta cells were destroyed
by the transferred effector cells, BB derived genes in
the target beta cells are not obligatory. Irradiation of
the ConA activated lymphocytes prevents the adoptive
transfer of diabetes, indicating that proliferating
spleen cells with the propensity for cytokine production
may be necessary to enable disease transfer (408).
Recently, the transfer of diabetes to BB DP and BB DR
neonates was reported (409). Intravenous infusions of
ConA stimulated spleen cells, from acutely diabetic BB
rats i-nto 6-36 hour old neonates, induced insulitis and
diabetes. Interestingly, thymidine-labelled blast cells
initially migrated and settled in various immature lymph
nodes and in the spleen within 24 hours after injection.
Labelled and unlabelled cells did not appear in the
pancreatic islets until 5-8 days after injection. Thus,
the target-specific blast cells appeared to undergo a
short period of proliferation and maturation in the
lymphoid organs before migrating to the pancreas.
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Handler et al (410) investigated the possible role of
soluble factors in the transfer of diabetes. Conditioned
media was obtained from the incubation of spleen cells
from acutely diabetic BB rats with ConA, and fractionated
by molecular weight using Amicon filters. Conditioned
media from the fractions above 50 Kd, injected into 30
day old BB DP recipients, successfully induced diabetes
in 25% of recipients within 3-4 weeks after the first
injection. Equally, conditioned media, using ConA
activated spleen cells from BB DR, MHC-compatible WF and
MHC-incompatible Buf rats, was able to induce diabetes in
BB DP animals. Conditioned media also induced diabetes
in BB DR rats but not WF rats. The results suggest a
soluble factor obtained from normal splenocytes can
activate an effector cell population present in BB DP and
BB DR rats to cause TDDM.
Postulated candidates for this soluble factor include IL-
1 (411), Tumour necrosis factor (TNF)(412) and Interferon
(IFN) gamma (413), which are cytotoxic to islet beta
cells in vitro. Equally, IL-2 has been implicated since
treatment of BB rats with recombinant IL-2 doubled and
accelerated the rate of diabetes in BB DP rats (414).
However, another study indicates that IL-2 is not the
diabetogenic mediator (415).
Prevention Studies
Further indications for the involvement of autoimmunity,
in the pathogenesis of IDDM in the BB rat, are suggested
by the many reports documenting disease prevention
following manipulation of the immune system via
immunosuppression or immunomodulation.
Reconstitution of the BB DP rat immune system, either by
bone marrow transplants (395, 416) or blood and spleen
cell transfusions (417-422), have prevented the
development of diabetes. Weekly transfusions of whole
blood from BB DR to BB DP rats, administered from 30-120
days of age, reduced the incidence of diabetes from 39%
to 0% and restored diminished ConA responsiveness to
normal control levels (417).
Subfractionation of the whole blood components,
identified the white blood cell fraction as the active
component mediating disease prevention (418).
Furthermore, blood treated to deplete the T lymphocyte
population failed to protect against the disease (418).
A T cell mediated protection mechanism was supported by
bone marrow transplantation studies (416). Whereas
injection of MHC-compatible WF rat bone marrow into
neonatal BB DP rats prevents the development of IDDM
(395), if the bone marrow is pretreated to remove mature
T cells then no effect on the incidence of diabetes is
observed (416). Subsequently, T cell subpopulation
analysis identified that transfusions, enriched for
helper/inducer T cells, were found to afford the greatest
degree of protection (419).
Effectiveness of transfusion depends on the dose of cells
and recipients age at the time of transfusion.
Accordingly, a single transfusion of more than 50x10^
spleen cells, from either BB DR or WF rats, has been
shown to reduce the incidence of diabetes when given to
BB DP rats aged 27-46 days, but not older than 61 days
(420). This further suggests, the presence of a critical
developmental period in the BB rat around 30-60 days of
age, during which a regulatory population of T
lymphocytes may prevent the onset of IDDM. Once this
temporal window is passed however, the ability of the
regulatory T cell to ameliorate the disease process
diminishes.
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This is supported by the finding that spontaneous
diabetes was fully prevented in the highly diabetes-prone
BB/hooded (BB/h) hybrid rats, when given injections of
nonactivated or ConA activated spleen cells from normal
WF rats during the first two postnatal weeks, but the
same postnatal injections did not protect against the
adoptive transfer of diabetes later in life using ConA
activated spleen cells from acutely diabetic BB rats
(421). Therefore a regulatory mechanism may prevent the
activation of self reactive lymphocytes but is unable to
affect lymphocytes which have already been activated.
Additionally, MHC-compatibility between donor and
recipient, enabling the persistent survival of donor
cells in the recipient, is also necessary for successful
transfusion to provide the cellular mechanism capable of
abrogating the onset of IDDM (422).
Immunosuppressive protocols, including neonatal
thymectomy (423) and total lymphoid irradiation (424),
significantly reduced the incidence of diabetes. The
earliest report of immunosuppression, which successfully
reversed hyperglycaemia in 36% of diabetic BB rats and
prevented the occurrence of diabetes in BB DP animals,
was the administration of injections of rabbit anti-rat.
lymphocyte serum (ALS)(425). Subsequently, combined
therapy with ALS and glucocorticoids along with
cyclosporine A (CSA) improved the protection afforded by
ALS alone (426).
Following the initial report by Laupacis et al (427),
whereby administration of CSA from 30-100 days of age
completely prevented the onset of diabetes or insulitis
in all of 40 treated BB DP rats, the use of CSA in the
prevention of IDDM in both the BB rat (428-430) and in
human IDDM (431) has received considerable attention.
Recently, use of the streptococcal preparation OK-432,
which is a nonimmunosuppressive biological response
modifier(432), successfully decreased the frequency of
diabetes from 28% to 7% in BB DP rats (433).
Cytotoxicity of spleen cells, towards RINm5F cells from
OK-432 treated animals, was suppressed. However, the
treatment of BB rats with OK-432 showed no suppressive
effects on the spleen cell numbers, ConA responsiveness,
peripheral blood T cell populations or ICSA titres,
suggesting OK-432 has important nonimmunosuppressive
immunomodulatory properties.
Since many of the above mentioned treatments result in
widespread, almost total, suppression of the immune
system, they give no indication as to the identity of the
cells responsible for causing the disease. A role for
macrophages in the pathogenesis of IDDM was suggested by
studies whereby administration of silica (which
preferentially affects macrophage function), virtually
completely prevented the development of diabetes (434,
435) .
Use of MoAbs to eliminate specific populations of cells
has helped identify the phenotypes of potential
candidates responsible for mediating beta cell
destruction.
In studies by Like et al (369), in vivo depletion of
specific lymphocytes using MoAbs against rat T cells and
NK cells, reduced the incidence of diabetes from 61% to
0% and 12% respectively. Further support for the role of
NK cells in the pathogenesis of IDDM was indicated when
anti-asialo-GMl antibody, which although not exclusively,
primarily, affects NK cells, was given to diabetic BB
rats tolerized to WF rat islet allografts and prevented
the recurrent autoimmune destruction of the graft (436).
Prevention of IDDM in the BB rat has also been achieved
n
following administration of a MoAb against rat class II
MHC molecules (437) and antibodies to the IL-2R (438),
thereby affecting activated T cells.
Other studies, at first seemingly unrelated to the
previously mentioned immunosuppressive therapies, have
also altered the course of IDDM development in the BB
rat. Prophylactic treatment with insulin, from 50-142
days of age, prevented the development of diabetes in 28
of 36 BB DP rats (439). Since exogenous insulin
decreases the endogenous insulin synthesis and secretion,
it was suggested that beta cells having a low rate of
insulin synthesis may be less vulnerable to autoimmune
attack, or may reduce the amount of antigen(s) on the
beta cell surface to a level insufficient to propagate
autoimmunity.
In a further study, inoculation of 30 day old BB DP rats
with LCMV (Armstrong strain, clone 13) prevented the
subsequent development of diabetes in 63% of recipients
(305). Inoculation with LCMV clone 13 caused selective
immunosuppression by infecting a small subset (1-2%) of
the peripheral circulating lymphocytes.
Finally, the development of IDDM in the BB rat may be
influenced by alterations in the rat diet (303). Elliot
and Martin (440) first demonstrated that the incidence of
diabetes in BB DP animals was reduced from 50% to 15%,
when from weaning, the standard chow diet was replaced by
a semi-synthetic diet in which L-amino acids were
substituted for natural intact proteins. Whereas the
presence of wheat and milk proteins appear diabetogenic,
other proteins such as hydrolysed lactalbumin prevented
the onset of disease, and vitamin-E appeared able to
modify disease progression after its initiation (441).
Precisely how these dietary changes may influence or
alter the immune system is not known.
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Non-Obese Diabetic Mouse
The non-obese diabetic (NOD) mouse was discovered in 1974
at the Shionogi Research Laboratories in Osaka, Japan,
having been derived from a subline of outbred Jcl-ICR
mice in which spontaneous cataracts developed (442).
Overt diabetes, occurring around 14 weeks of age, is
characterized by hyperglycaemia, glycosuria and
hypoinsulinaemia reflecting a specific loss of beta cells
(442). Insulitis begins around 4-6 weeks of age and is
common in virtually all mice, but diabetes, however,
preferentially ensues in female mice (80%) compared to
10-20% of the males (442). An involvement for sex
hormones in the disease aetiology is suggested by the
increased incidence (70%) of diabetes in males following
castration, whereas female castration decreases the
incidence (20%)(443).
Electron microscopy, used to examine pancreatic beta
cells from NOD mice ranging from 18 day old embryos to 2
day old neonates, identified Type C retrovirus-like
particles in the cisternae of the rough endoplasmic
reticulum of these cells (444). The particles were found
in 1-10% of all the beta cells in every NOD mouse
examined and, as such, may have some role in the vertical
infection from mother to child. In addition, maintenance
of islets from CBA/J mice (which constitutively express
these intracisternal retroviral particles) for 48h in
16.5mM glucose-containing medium has been shown to effect
a 5-fold increase in the retroviral protein synthesis
(445).
Genetic analysis indicates that the manifestation of
insulitis is controlled by two recessive genes on
independent chromosomes (446), one of which is linked to
the mouse MHC (447). Non-obese diabetic mice have a
unique class II MHC, being unable to express I-E
molecules due to the absence of mRNA for the I-E alpha
chain. Involvement of the I-E alpha gene in the
development of diabetes was indicated when expression of
I-E molecules in NOD mice, using C57BL/6 transgenic mice,
prevented the development of insulitis (448).
Insulitis progresses from 4-6 weeks after birth and is
made up of lymphocytes, macrophages, plasma cells and
some neutrophils (449). As the mice age, the proportion
of intact islets decreases with an increase in the number
of islets showing severe insulitis. However, islets free
from insulitis coexist with those displaying intense
insulitis, indicating that the progression of insulitis
is not uniform. The lymphocytes infiltrating the islets
are predominantly Thy-1.2+ T cells, most of which are
Lyt-1+ (Tjj) cells, although Lyt-2+ (T cyt/supp) cells and
NK cells are also found (450). Approximately half of the
T cells expressed la antigens indicating their activation
and B lymphocytes tended to increase in number with
disease progression. Lymphocytic infiltration also
occurs in other organs including the submandibular
glands, thyroid and adrenal glands and testes and ovaries
(451), which in the case of the thyroid and submandibular
glands is accompanied by autoantibodies against these
tissues (452).
Antibodies to islet cell structures including ICSA (453),
ICA (452, 454, 455), and IAA (455, 456) have been found
in the sera of NOD mice. Islet cell surface antibodies
appear in the prediabetic stage in 10-50% of mice at 6-12
weeks of age and reach maximal prevalence (70%) just
prior to onset of overt diabetes.
In one study, ICA have been found only at a low frequency
(452) whereas in another study, a high frequency (60-80%)
was found (454). Insulin autoantibodies have been found
in 41% of pre-diabetic and 46% diabetic NOD mice (456).
Both ICA and IAA appear to occur before the detection of
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insulitis, but the prevalence rate for each marker, or
their degree of concordance, was different from the
expected rate of diabetes (455). However, no animal
developed diabetes without prior appearance of both ICA
and IAA (455).
Studies on aspects of cellular immunity in the NOD mouse,
in common with similar studies in the BB rat and human
IDDM, give results which are often discordant. Whereas
Kataoka et al (457) reported a decrease in the absolute
numbers and percentage of circulating T cells, Miyazaki
et al (450) found that the percentage of T cells was
increased. In the former study, Tjj cells were normal,
whereas in the latter both Tjj and T cyt/supp cells were
increased. Similarly, higher values for the absolute
number and percentage of circulating B lymphocytes was
reported in the former, but the latter study found a
lower percentage of B lymphocytes in the spleen of NOD
mice.
Antibody dependent cellular cytotoxic activity in overt
diabetics, but not prediabetic NOD mice, is increased
(458), yet complement-dependent antibody-mediated
cytotoxicity (CAMC) is not increased and there was no
correlation between ICSA levels and CANC levels in NOD
mice sera (459). Natural killer cell activity and the
function of cytotoxic T cells are found to be decreased
(457, 460). Spleen cells from NOD mice are found to
generate low IL-2 production and cell proliferation in
response to ConA (461, 462). Similar to studies in the
BB rat, evidence suggests that this impairment of IL-2
production is due to suppression mediated by activated
macrophages (462).
Splenocytes from diabetic NOD mice were found to inhibit
insulin release from stimulated islets, and depletion
studies using MoAbs, identified the Lyt-2+ population as
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being responsible for the inhibition (463). L3T4 (TIf)
cells were, however, involved in the recurrent
autoimmunity responsible for destruction of islet
allografts (464). Non-MHC-restricted cell mediated
cytotoxicity towards -^Cr labelled BALB/c islet cells has
been reported, but the effector cell population was not
identified (460). A cloned CD4+ T lymphocyte line ( BDC-
2.5), with specificity for islet cell antigens, has been
derived from NOD mouse spleen cells (465).
In an in vivo transplantation system, in which islet
grafts were made in the presence or absence of the BDC-
2.5 T cells, it was found that incorporation of the T
cell line into the graft site resulted in the complete
destruction of the transplanted islets, but not similarly
transplanted pituita-ry tissue (465).
The involvement of cell-mediated immunity in the
pathogenesis of diabetes in the NOD mouse is
substantiated by the ability to transfer the disease
using splenocytes from diabetic NOD mice (466). Transfer
was induced within 12-22 days in 95% of irradiated NOD
mice above 6 weeks of age. Spleen cells from 7 week old
non diabetic NOD mice were unable to transfer disease,
however, spleen cells obtained from 15 week old
prediabetic NOD mice were able to transfer diabetes,
indicating that sufficient effector cells are present at
this stage and that the donor need not be overtly
diabetic at the time of transfer.
Administration of 2 injections of cyclophosphamide
(150mg/kg 2 weeks apart) can induce diabetes in 50-70% of
male NOD mice (467). Injection of nicotinamide
(500mg/kg) can ameliorate the effects of cyclophosphamide
induced diabetes (468) and prevent lymphocytic
infiltration into the submandibular glands (469).
Nicotinamide injected into prediabetic NOD mice, also
successfully inhibits insulitis and diabetes and, when
given at disease onset, improves the diabetic condition
(470). Furthermore, nicotinamide inhibits the ADCC
reaction of mononuclear cells isolated from NOD mice
spleen cells (458). However, in another study,
nicotinamide was only able to prevent islet allograft
rejection when combined with the iron chelator,
desferrioxaraine (471).
Reconstitution of irradiated NOD mice with bone marrow
from BALB/c-nu/nu mice prevents the development of
insulitis (472), as does neonatal thymectomy (473).
Administration of CSA (25 mg/kg every 2 days) to 30 day
old NOD mice decreased the frequency of diabetes and
inhibited cyclophosphamide-induced diabetes (474).
Other methods of immunosuppresion, which ameliorate the
development of diabetes in the NOD mouse, include whole
body irradiation (475), the administration of silica
(476) and injection of MoAbs against T cells (475)
including the Lyt2 (476) and the L3T4 (477) T cell
subsets. Non-obese diabetic mice treated every week from
4-24 weeks of age with the immunomodulating agent OK-432,
were protected from insulitis and the development of
diabetes in all treated animals (478). The
administration of monosodium glutamate also substantially
decreased the incidence of diabetes and severe insulitis
(479). Monosodium glutamate may exert immunomodulatory
effects through elevation of corticosteroid levels
following monosodium glutamate-induced hypothalamic
lesions.
Finally, comparable with the BB rat, the manifestation of
diabetes may be abrogated by manipulation of protein-free
diets (480).
LOW-DOSE STREPTOZOTOCIN DIABETES
Streptozotocin, a metabolite of the soil fungus
Streptomyces achromogenes, was originally discovered in
1960 by Vavra and colleagues during a search for new
antimicrobial agents (481). It was three years later,
during an investigation of its antibiotic properties,
that a diabetogenic effect was first reported (482).
Thereafter, STZ was administered as a single high dose,
causing complete beta cell necrosis and diabetes within
24 hours. In 1976 Like and Rossini demonstrated that
diabetes could be induced in mice by 5 consecutive
injections of subdiabetogenic doses (40 mg/kg) of STZ
(483). Diabetes was not due to the direct toxic activity
of the drug, and microscopy revealed mononuclear cells in
and around the pancreatic islets. These observations led
to the concept that administration of multiple
subdiabetogenic doses of STZ, partially damages islets,
thereby triggering an inflammatory response causing
further beta cell loss and insulin deficiency.
Streptozotocin can damage the beta cell plasma membrane
(484), or can act intracellularly where it is reported to
deplete the islet content of NAD (485). Treatment of
islets with nicotinamide prevents depletion of NAD and
blocked the diabetogenic effect of STZ (486).
An important role for the generation of free radicals, in
the diabetogenic action of STZ, is suggested by studies
where the free radical scavenger superoxide dismutase
(SOD) has been found to alleviate STZ-induced diabetes
(487), and reduce the inhibitory effect of STZ on islet
insulin release (488). Furthermore, combined treatment
with the oxygen free radical scavengers, desferrioxamine
and nicotinamide, prolong the graft survival of islet
allografts in multiple low-dose STZ-induced diabetes
(489). Streptozotocin can also induce strand breaks in
islet cell DNA (490) and this leads to a cascade of
intracellular events including stimulation of DNA repair
via poly-ADP-ribose synthetase (491), reduction of islet
NAD content (492) and subsequent inhibition of islet
function (493). The poly-ADP-ribose synthetase
inhibitor, nicotinamide has been shown to protect the
beta cell against these effects (494).
Outside the pancreas, STZ can also affect the immune
system. Treatment with STZ has been found to reduce bone
marrow, thymus and peripheral T cell numbers (495, 496),
and suppressor T cell activity is reportedly enhanced
(270, 497).
Similar to the NOD mouse, there is a strong sex influence
on diabetes development. However, in the low-dose STZ
model, it is the females who are largely resistant to the
induction of diabetes (498); this can be overcome
following castration or the administration of sex
hormones (499). One or more genes within the mouse MHC
influences the development of hyperglycaemia (500), but
non-MHC genes also contribute to the control of diabetes
susceptibility (501).
Spleen cell transfer experiments have been unable to
induce persistent hyperglycaemia, although insulitis did
occur (502). Spleen cells with islet cell specificity
displaying non-MHC restricted cytotoxicity against RINm5F
cells have been reported (503), and ADCC activity is
enhanced in low-dose STZ-treated animals (504).
Following islet transplantation, reaction against the
grafts only occurred if the recipients subsequently
received a small dose of STZ, indicating that the grafted
islets had to be stressed to permit an immune attack
(505).
Although ICSA have been reported (506), the contribution
of humoral immunity is assumed minimal since B lymphocyte
depleted mice retain their susceptibility to STZ-induced
diabetes (507). In common with the other models
discussed and human IDDM, a multicellular insulitis
accompanies STZ-induced diabetes. Immunohistochemistry
studies have identified T cells, including both and T
cyt/supp cells, NK cells, B lymphocytes and macrophages
all contributing to the insulitis composition (508).
Administration of silica particles almost completely
prevents the development of diabetes, thereby suggesting
a role for macrophages in the pathogenesis of low-dose
STZ-induced diabetes (509). Equally, depletion of total
T lymphocytes by the injection of a MoAb to Thyl, as well
as depletion of both Tjj (L3T4) and T cyt/supp (Lyt2)
cells, protects against the development of hyperglycaemia
and indicates the involvement of T cells in the
generation of low-dose STZ-induced diabetes (508, 509).
Administration of antibodies against MHC class II
determinants (I-A) also prevents the onset of diabetes
(510).
Other treatments reported to decrease the development of
hyperglycaemia, include whole body U.V irradiation (511),
administration of an interferon inducer, PICLC (512) and
treatment with inosine pranobex, which increases IL-2
production (513). Suppression of serotonin-enhanced
vascular permeability by methysergide or pargyline also
reduced the incidence of diabetes (514).
Contrary to the findings in the BB rat and NOD mouse,
administration of CSA enhances the development of low-
dose STZ-induced diabetes (515, 516). Although CSA
treatment may inhibit the development of insulitis,
diabetes probably results from the combined toxicity of
CSA and STZ on the beta cells.
CONCLUSIONS AND AIMS
Since human IDDM is clearly a heterogenous disorder, no
animal model can fully replicate all aspects of this
multifactorial disease. However, the use of animal
models have identified many common similarities as
regards genetics, islet pathology and aspects of humoral
and cellular immunity, between the models and the human
condition. Ultimately, the use of animal models have
stressed the importance of autoimmunity in the
pathogenesis of IDDM.
The multiple low-dose STZ-induced diabetes model, is a
useful tool to study how immune processes may augment the
response to a beta cell cytotoxic agent. Nevertheless,
any model used for investigating the true pathogenesis of
beta cell destruction, must be one that spontaneously
develops diabetes.
I have used the spontaneously diabetic BB rat as the
model of choice for the experiments performed in this
thesis, primarily because at the time of their
conception, the NOD mouse was not available outside of
Japan. However, since there is no sex difference on the
propensity to develop diabetes in the BB rat, it probably
better reflects the human disease. In addition, having
the larger rodent enables certain investigations, that
would prove difficult in the NOD mouse e.g. pancreatic
biopsy, to be performed.
The aim of the studies detailed in this thesis was to
better understand the aetiology of Type 1 diabetes. In
particular : (i) to elucidate the precise sequence of
events leading to mass destruction of pancreatic beta
cells, by correlating changes in humoral and cellular
immunity with pancreatic morphology in the prediabetic
period; (ii) in vivo and in vitro investigation of the
role of aberrant expression of MHC molecules in the
disease aetiology, and (iii) to examine the effects of
immunosuppression on these events.
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Fig 1: (A) non-diabetic DP BB/E rat (105 days of age);




The Edinburgh colony of BB rats (designated EB/E) was
established in 1982 from animals donated by Dr Pierre
Thibert at the Animal Resources Division of Canada,
Ottawa and is therefore derived from the original BB
colony. The BB/E colony consists of two sublines of
animals created by selective breeding. The diabetes-
prone mainline was established by selecting breeding
pairs from high incidence litters, where at least 55% of
the litter would develop diabetes. The incidence of
diabetes in the DP BB/E line is 60-70% with a mean age at
onset of diabetes of 96 days. The diabetes-resistant
subline was derived by selecting rats from litters of low
diabetic incidence (<30%). If any of the mating pairs
subsequently developed diabetes at any stage of their
lives, they, and all of their progeny, were disregarded.
At the time of these studies, the incidence of diabetes
amongst the DR BB/E rats was <2% at 120 days of age. At
the time of writing, the incidence has been zero for the
last three generations.
BB/E rats are maintained in rooms with independent
heating, and ventilation from the rest of the Animal Unit.
Ventilation involves two sets of filters to produce 100%
fresh air which is kept heated to 21 — 2°C, with the
humidity at 50%. Animals are kept in an automatic light
cycle of 12 hrs light/dark. Animals are allowed free
access to food (No. 3 Expanded Breeding Diet, SDS, UK)
and water. All animals are weighed twice weekly to
monitor for the development of diabetes and give an
indication of diabetic control in animals receiving
insulin.
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Detection and Management of Diabetes
Diagnosis of diabetes is based on a steady decrease in
body weight (Figs. la & lb), glycosuria and
hyperglycaemia. Glycosuria is detected using Multistix
(Ames Division, Miles Laboratories Ltd, Slough, UK) and
results of 14mmol/l determined as positive. Blood
glucose is measured following tail vein sampling, using
BM-blood glucose test strips (BM-Test-1-44)(Boehringer
Corporation (London) Ltd, Lewes, UK) in conjunction with
a Reflolux-II blood glucose meter. Readings of >14mmol/l
are determined as positive.
Following diagnosis, animals are maintained on one daily
subcutaneous injection of Ultratard U-40 insulin (Novo,
Copenhagen, Denmark) administered as near to 0900 hr as
possible.
Other Animals
Normal Wistar rats, bred and maintained at the Animal
Unit of the Western General Hospital, were obtained as
controls when required.
Insulin Assay
Rat plasma insulin levels or islet insulin secretion
following in vitro perifusion were measured by radio¬
immunoassay.
O.lmg freeze dried rat insulin (Novo, Copenhagen) was
reconstituted with 1ml distilled water and used to
prepare an insulin standard curve. 10 insulin standards
(5-10QuU/ml = 0.25-5ng/ml) were prepared following
dilution in buffer B (6.2mg/ml Na^PO^. 2^0 ; 0.24mg/ml
thiomersalate; 5mg/ml BSA-Miles Fraction V; 9mg/ml NaCl
and 25/ul/ml trasylol, pH 7.4). 0.1ml of insulin
lOtf
standards prepared in triplicate and test samples
prepared in duplicate, were pipetted into LP3 tubes to
which 0.2ml of anti-insulin serum (Wellcome Diagnostics,
Dartford, UK) diluted 1:30,000 in buffer A (6.2mg/ml
Na^PO^. 2H2O ; 0.24mg/ml thiomersalate; 5mg/ml BSA) was
added. Tubes were whirlimixed and incubated for 2h at
4°C. After incubation, 0.1ml (0.12 5/iC/ml) of 125j
labelled insulin (Amersham, Aylesbury, UK) was added to
the tubes and further incubated at 4°C for 2h. Following
the second incubation, 0.4ml of charcoal reagent (50mg/ml
Norit GSX charcoal (Sigma, Poole, Dorset, UK) made up in
heat-inactivated horse serum (Wellcome Diagnostics)
diluted 1:2 with buffer A) was added and allowed to stand
for at least 10 min. at 4°C. Following centrifugation
(1500g for 25 min) at 4°C, 0.4ml of supernatant was
removed into duplicate LP3 tubes using an LKB 2075
diluter (BCL, Lewes, UK) with 0.2ml distilled water
washings between sampling. Tubes were counted using the
NE 1600 gamma scintillation counter (Nuclear Enterprises,
Edinburgh, Scotland) for 60 sees. Counts were expressed
as a percentage of the total counts (0.1ml sample of 125j
labelled insulin) and a standard curve created with
percentage total counts against units of insulin (mU/1).
Culture and Harvest of RINm5F Cells
The rat insulinoma cell line, RINm5F (352) was kindly
supplied by Dr Anne Cooke (Department of Immunology,
University College and Middlesex School of Medicine,
London). RINm5F cells were continuously cultured at 37°C
+ 5% CO2 in 50ml Falcon tissue culture flasks (A & J
Beveridge Ltd, Edinburgh, Scotland) containing 5ml of
tissue culture medium (RPMI 1640 containing glucose
(11.lmmol/1) , HEPES (20mmol/l), antibiotics (penicillin
lOOU/ml; streptomycin O.lmg/ml) and heat inactivated 10%
foetal bovine serum (Imperial Laboratories (Europe) Ltd,
Andover, Hants, UK) until confluent. At confluence,
cells were harvested and split to allow continued growth
of the cell line 2.5% trypsin (1:250) in Hanks' Balanced
Salt Solution (HBSS) without Ca^ + , Mg^ + (Imperial
Laboratories) was diluted 1:10 in HBSS - Ca^+, Mg^+ free
at 37°C and 3ml added to each confluent flask to remove
the adherent RINm5F cells, which occurred following 5
mins. incubation at 37°C. The free-floating RINm5F cells
were transferred into sterile 15ml Falcon tubes (A & J
Beveridge Ltd) and washed in 5ml tissue culture medium by
centrifugation at lOOg for 5 mins. Supernatants were
poured off; the cells resuspended in tissue culture
medium, split 1:8 and reseeded into fresh sterile tissue
culture flasks topped with 5ml tissue culture medium.
Media was changed every 2 days.
Isolation and Culture of Islets
Animals were killed by cervical dislocation and an
immediate laparotomy performed to expose the pancreas and
pancreatic duct. The distal duct was clamped off at its
point of attachment to the duodenum. The proximal duct
was cannulated with a Portex cannula (diameter
3FG)(Portex Ltd, Hythe, Kent, UK). Collagenase - type XI
(lmg/ml)(Sigma, Poole, Dorset, UK) was made up in HBSS
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with Ca , Mg (Imperial Laboratories, Andover, Hants,
UK) supplemented with penicillin (lOOU/ml) and
streptomycin (0.lmg/ml)(Imperial Laboratories) and kept
at 4°C. The pancreas was inflated by injecting 6ml of
the collagenase solution over a 30 sec. period into each
cannulated animal. The pancreata were carefully
dissected from the attached gut tissue and placed on ice
in a sterile 20ml container. Pancreata were incubated
for 15-20 mins. in a water bath at 37°C and shaken at 60
cycles/min. The reaction was stopped by pouring the
digest into 20ml cold HBSS supplemented as above and
vigorously shaken for 30 sees.
Digests were centrifuged for a few seconds at lOOg and
supernatants poured off. Following a wash in HBSS with
supplements, and removal of the supernatants, the digests
were passaged X8 in a syringe with a 14 gauge steel
needle in order to further disrupt the tissue. The
digest was then passed through a sterile 50Qum pore size
nylon mesh (Henry Simon Ltd, Stockport, UK) and the
filtrate centrifuged as previously. After decanting the
supernatants, the digests were layered onto a Dextran
gradient.
Dextran T70 (Pharmacia, Uppsala, Sweden) was made up in
HBSS containing supplements to create a gradient with the
following specific gravities: 1070, 1095, 1105 and 1125.
Gradients were centrifuged at 4°C for 20 mins. at 450g.
The first and second interfaces were removed and washed
once in 50ml HBSS, followed by a further wash in 15ml
HBSS. Islets were further purified from contaminating
exocrine tissue by hand picking under a stereomicroscope.
Separated islets were washed X2 in 15ml HBSS and once in
tissue culture medium, RPMI 1640 (Imperial Laboratories)
containing glucose (11.lmmol/1), HEPES (20mmol/l),
antibiotics (penicillin lOOU/ml; streptomycin O.lmg/ml)
and heat-inactivated 10% foetal bovine serum (Imperial
Laboratories). Islets were maintained in free-floating
culture (37°C + 5% C02) in sterile petri dishes
containing 5ml of RPMI tissue culture medium. Tissue
culture media was changed 24h after islet isolation and
thereafter every 2 days.
Determination of Islet Cell Surface Antibodies
Islet cell surface antibodies were estimated using a
125i_protein A radioligand assay as described by Dyrberg
et al (351). Dispersed islet cell suspensions were
toi
prepared from beta-cell-rich foetal rat islets, or
alternatively RINm5F cells were used as the islet antigen
source (353). Plasma samples (lOjul) were diluted 1:10 in
RPMI 1640 (Imperial Laboratories) + BSA (5mg/ml)(Miles
Laboratories Ltd, Slough, UK), and heat-inactivated (30
min. at 56°C). 0.1ml of islet cell suspensions or RINm5F
cells (10^ cells/ml) were incubated with the heat-
inactivated plasma samples for 60 min. at 4°C. After
washing in RPMI + BSA (2 min. at 200g) the cells were
incubated with 0.1ml ^^I-protein ^ (2x10^
cpm/ml)(Amersham International pic, Aylesbury, Bucks, UK)
for 30 min. at 4°C. After 3 washes in RPMI + BSA and
centrifugation at 200g, the radioactivity in the cell
pellet was determined in a gamma scintillation counter
(Nuclear, Enterprises, Edinburgh, Scotland). Cell bound
IgG was expressed a's cpm/10^ islet cells. Intra - and
inter-assay variation was 6% and 14% respectively (N=8)
with non-specific binding (islets incubated in the
absence of plasma) contributing <0.02% of the total
counts. Animals were regarded as being ICSA-positive
when counts bound exceeded the mean binding values (-^SSD)
for normal Wistar rats (518—159 cpm/10^ cells; N=32) and
DR BB/E rats (486^138 cpm/10^ cells; N=32).
Detection of Insulin Autoantibodies
Insulin autoantibodies were measured by Dr Betty Dean
(Department of Immunology, University College and
Middlesex School of Medicine, London) using a micro-
enzyme-linked immunosorbent assay (ELISA) modified from
that described for the measurement of human IAA (243).
Purified rat, human or pig insulin (kindly donated by
Novo, Copenhagen, Denmark) was dissolved in 0.05mol/l
sodium carbonate-bicarbonate buffer, pH 9.6 and 0.1ml
aliquots containing lOOng of insulin were pipetted into
alternate rows of a 96-well flat bottomed microplate
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(Nunc Immunoplate II, Gibco, Paisley, Scotland); the
remaining rows (control wells) received 0.1ml of coating
buffer alone. After 5h incubation the plates were
emptied and washed (3x3 min., 22Qul/well) with 0.015mol/l
phosphate buffered saline (PBS) containing 0.1% Tween 20
(poly-oxyethylene sorbitan monolaurate)(Sigma, Poole,
Dorset, UK). These and all subsequent incubations and
washings were carried out at room temperature.
All wells were blocked for non-specific binding by
incubation with PBS containing 20% normal rabbit serum
(NRS)(Sera-Lab, Crawley Down, Sussex, UK) for 18h
(12Qul/well). The blocking solution was removed and rat
plasma test samples (lOQul diluted 1:50 in PBS containing
5% Tween 20 and 10% NRS) applied to the antigen-coated
and control wells i'n triplicate and incubated for 2h.
After removal and washing of the test samples, the plates
were incubated for lh with affinity purified rabbit anti-
rat immunoglobulin horse radish peroxidase conjugate
(Miles Scientific, Slough, UK), diluted 1:1000 in PBS
containing 0.1% Tween 20 and 10% heat-inactivated NRS.
The conjugate was removed and after 3 washes, 0.1ml of
substrate was added to each well. Substrate solutions
were prepared freshly by dissolving 3-3'-5-5'-tetramethyl
benzidine (Aldrich, Gillingham, UK) in dimethyl
sulphoxide (lOmg/ml) in 0.05mol/l citric acid, 0.1mol/l
phosphate buffer (pH 5.0, 100ml) and adding 20% Vol H2O2
(0.1ml) immediately prior to use. The reactions were
terminated after 30 min. by addition of 12% H^SO^
(5Qul/well) and plates were read at O.D. 450nm on an
automated MR 580 microelisa reader (Dynatech, Santa
Monica, CA, USA). For each assay, the instrument was set
at zero using a well containing PBS - 0.1% Tween 20
(150ul).
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The mean specific optical density at 450nm (Ao.D.) was
calculated by subtraction of the mean non-specific
reading in the corresponding control wells. Reference
plasma from normal Wistar and diabetic BB/E rats were
included in each assay as controls. The intra - and
inter-assay variation were 5.6% (N=5) and 15.2% (N=3)
respectively using rat insulin and a standard diabetic
rat plasma. The specific binding observed for plasma
samples from normal Wistar rats (90-150 days of age;
N=12) was A O.D. = 0.014-0.018, 0.071—0.015 and
0.070^0.013)(mean — SD) for rat, human and pig insulin
respectively. Readings for test samples were considered
positive when A O.D. values were at least twice the
corresponding non-specific binding value and greater
than mean — 3SD of the normal Wistar rat group for the
relevant species of insulin.
IMMUNOFLUORESCENCE STAINING
Antisera
Table I lists the range of mouse anti-rat monoclonal
antibodies used in these studies. I am greatly indebted
to Dr Don Mason (Sir William Dunn School of Pathology,
Oxford)-who over several years has generously supplied me
with clone supernatants of many of the MoAbs listed in
Table I (0X-6, 0X-8, OX-12, 0X-17, 0X-18, 0X-19 and
W3/25). The additional MoAbs, listed in Table I, were
obtained as ascites fluid from Serotec, Oxford, UK.
Antisera to islet endocrine hormones were also used.
Monoclonals HUI018 (anti-human insulin); GLU001 (anti-
glucagon) and SOM018 (anti-somatostatin) and polyclonal
antisera, M1183 & M1187 (guinea pig antibodies against
insulin) were kindly donated by Novo, Copenhagen,
Denmark. Polyclonal antisera against insulin (guinea pig
antibody against beef/pork insulin) and glucagon (rabbit
uo
anti-glucagon) were obtained (Incstar Ltd, Atlantic
Antibodies, Winnersh, Berks, UK).
Tissue Preparation
Tissue on removal was immediately snap-frozen in
isopentane at -70°C. Isopentane in a pyrex beaker was
placed into a metal kidney dish containing acetone. Dry
ice pellets were added to the acetone to cool the
mixture, and the tissue dropped into the isopentane and
allowed to stand for 1 min. All frozen tissue was stored
at -70°C until required.
Tissues were mounted in O.C.T mounting medium (Raymond
Lamb, London, UK) and serial sections (4um) were cut on a
cold microtome cryostat (Slee Medical Equipment Ltd,
London, UK) and sections placed on PTFE specialised
coated multispot microscope slides (C.A. Hendley Ltd,
Loughton, Essex, UK). Slides were air dried for lhr and
stored at -70°C.
Immunofluorescence
Cryostat sections, on removal from storage, were air
dried under a cool air fan for lhr, acetone fixed for 10
mins. at room temperature and screened with antisera.
Clone supernatants were used at 1:2 - 1:10 dilution in
phosphate buffered saline (0.05mol/l, pH 7.6) containing
10% normal rat serum (Sera-Laboratories Ltd, Crawley
Down, Sussex, UK). Ascites fluids and polyclonal
antisera were applied at 1:50 - 1:100 dilution in PBS
containing 10% normal rat serum for ascites preparations,
or 10% nonimmune serum from the host species in which the
antisera were raised for the polyclonal antisera. All
antisera were individually titrated using normal Wistar
rat pancreas and/or spleen to establish optimal
dilutions.
in
Sections were incubated with the antisera for 60 min. at
25°C in a humid chamber staining tray (Ortho, High
Wycombe, Bucks, UK). Reactions of MoAb binding were
revealed with species-specific biotinylated sheep F(ab^)2
anti-mouse IgG (Amersham, Aylesburgh, UK) diluted 1:50 -
1:100 in PBS containing 10% normal sheep serum, incubated
for 40 mins., followed by fluoresceinated or Texas red-
conjugated streptavidin (Amersham) diluted 1:100 - 1:200
in PBS and incubated for 20 mins. Alternatively,
reactions of MoAbs were revealed after a 30 min.
incubation with either fluoresceinated or rhodaminated
rabbit anti-mouse immunoglobulins (Dakopatts, Weybridge,
Surrey, UK). Polyclonal antisera were identified with
the corresponding fluoresceinated or rhodaminated
antibodies to guinea pig or rabbit immunoglobulins
(Cambridge Bio Science, Cambridge, UK) diluted 1:20 -
1:60 in PBS containing 10% nonimmune host derived serum
and incubated for 30 mins. at 25°C.
A 10 min. washing period, incorporating 3 changes of PBS,
followed each antibody application. After the final
wash, slides were mounted using a glycerol-phosphate
buffered solution with an anti-fading agent (Citifluor
Ltd, London, UK). Sections were examined under a Leitz
Orthoplan microscope (E. Leitz Instruments Ltd, London,
UK) fitted with a fluorescence vertical illuminator and
filter blocks for revealing fluorescein and
rhodamine/Texas red fluorochromes. Photographs were
taken on Ektachrome ASA 400 film with automatic exposure
using an Orthomat-W automatic microscope camera (E.
Leitz).
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TABLE I: MONOCLONAL ANTIBODIES USED IN STUDIES
MoAB Isotype Antigen or cell type recognised Reference
MRC OX-6 IgG 1 MHC Class II (RT1B) - monomorphic [517]
MRC OX-8 IgG 1 CD8 - thymocytes, T cyt/supp,
NK cells [518, 519]
MRC OX-12 IgG 2a B lymphocytes (kappa light chain) [520]
MRC OX-17 IgG 1 MHC Class II (RT1D) - monomorphic [521]
MRC OX-18 IgG 1 MHC Class I (RTIA) - monomorphic [521]
MRC OX-19 IgG 1 CD5 - thymocytes, T cells (pan T) [522]
MRC OX-33 IgG 1 Rat LCA present on B lymphocytes [523]
MRC OX-35 IgG 2a CD4 - thymocytes, Tjj, [524]
W3/25 IgG 1 CD4 - thymocytes, Tjj, ¥$ [525, 526]
MRC OX-39 IgG 1 CD25 - Interleukin 2 receptor [527]
MRC OX-52 IgG 2a CD5 - thymocytes, T cells (pan T) [528]
EDI IgG 1 Monocytes, M0, Dendritic cells [529]
ED2 IgG 2a Tissue macrophages [529]
U3




As in man, IDDM in the BB rat develops against a
background of heightened autoimmunity where multiple
autoantibodies can be detected in the prediabetic
period. Antibodies to islet cell surface antigens (351,
353), gastric parietal cells and smooth muscle cells
(349, 350), have all been found. The precise
relationship of these autoantibodies to the development
of diabetes, however, is uncertain. One way to evaluate
the possible role of humoral immunity in the pathogenesis
of IDDM is to ascertain if the antibodies appear before
the clinical onset of diabetes. A positive affirmation
would suggest that the presence of specific
autoantibodies is a long-term process, preceding the
manifestation of the disease, whereas the appearance of
humoral markers only at, or after the onset would
suggest they are a consequence of the disease.
Longitudinal prospective studies required to answer these
questions are essentially impossible to perform in man.
One value of a model such as the BB rat is its potential
for performing longitudinal studies in which various
parameters can be assessed for their predictive power.
The studies detailed in this chapter were designed to
investigate the role of humoral autoimmunity in the
pathogenesis of IDDM, by attempting to correlate changes
in humoral immunity with changes in both pancreatic
morphology (i.e. insulitis) and function (i.e. islet
insulin secretion).
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30 8 4 4 16
45 8 4 4 16
60 8 4 4 16
75 8 4 4 16*a
90 9 3 4 16*b
105 13 1 2 16*c
TOTAL 54 20 22 96
Excluded from study: *a 3 rats; *b \ rat; *c 3 rats
all DP BB/E (DxND mating). Diagnosed diabetic




Two types of longitudinal study were performed.
STUDY I
Animals
Details of the cohort of BB/E rats used in this study are
shown in Table II. 96 normoglycaemic rats (74 DP BB/E,
22 DR BB/E) were studied in groups of 16 animals at 15
day intervals between 30-105 days of age. During the
study 7 DP BB/E animals were subsequently diagnosed
diabetic (mean plasma glucose - SEM; 19.8-1.2) and
excluded from the study (Table II).
Protocol
At each time point, animals were sacrificed under light
halothane anaesthesia. Following cardiac puncture, 5ml
of blood was removed and plasma separated for the
determination of plasma glucose (glucose analyser -
Beckmann Instruments Inc, Fullerton, CA), insulin
concentration and autoantibodies. Plasma samples were
stored at -20°C until required. The pancreata were
rapidly^ excised and a portion snap-frozen for
immunofluorescence studies (Chapter 6) as detailed in
Chapter 4. A further portion of the pancreata was used
to prepare isolated islets for insulin secretion studies
in a multichannel perifusion system.
Autoantibodies
Islet cell surface antibodies and insulin autoantibodies
were estimated as previously detailed in Chapter 4.
Cytoplasmic islet cell antibodies, and antibodies to
gastric parietal cells (GPCA), smooth muscle (SMA) and
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thyroid colloid antigens (TCA) were investigated by
indirect immunofluorescence.
Details of the immunofluorescence studies are given in
Chapter 4. Briefly; plasma samples were applied
undiluted to cryostat sections of normal Wistar rat
pancreas, stomach or thyroid and incubated for 20 mins.
at 25°C. Following washing in PBS, the sections were
incubated with fluoresceinated goat anti-rat
immunoglobulins (Nordic, Maidenhead, Berks, UK) diluted
1:20 - 1:40 in PBS, and incubated for 20 mins. After
washing in PBS, the slides were mounted and examined
under a fluorescence microscope. Positive and negative
control sera, including incubation with the second layer
conjugate alone, were included in all studies.
Islet Insulin Secretion
Insulin secretion from isolated islets was estimated
following perifusion of islets in a multichannel system
(530), by my colleague Dr Bone. Islets were isolated by
collagenase digestion from pooled pancreatic tissue of
ICSA-positive (N=16) and ICSA-negative (N=15) rats,
sacrificed at 75, 90 and 105 days of age. On each
experimental day, the islet insulin secretion was
determined for up to 8 batches of 30 islets (4 channels
each from the ICSA-positive and ICSA-negative rats). In
the multichannel system, islets were equilibrated by a 40
min. perifusion with basal media (2.7mmol/l glucose) and
then subjected to two consecutive stimulations with
16.7mmol/l glucose applied 20 min. apart. Samples of the
perifusate were collected throughout and stored at -20°C
until assayed for insulin (Chapter 4) by Mrs Myra
Gilchrist. At the end of the second high glucose
stimulation period, the islets were perifused for a
further 20 mins. with basal medium containing no BSA and
recovered from the perifusion chambers. The islets were
ug
ultrasonically disrupted, and their protein content
determined (Bio-Rad protein assay kit, Richmond CA).
Insulin secretion was expressed as ai\J IRI per jug islet
protein so as to correct for any possible differences in
the size of islets isolated from ICSA-positive and ICSA-
negative animals.
Insulitis
Detailed immunological examination of the pancreata are
described in Chapter 6. However, insulitis was
determined on pancreatic sections stained with
Haematoxylin and Eosin in addition to immunofluorescence
studies, using the MHC class II MoAb (OX-6)(Table I). A
positive result was given when pancreatic sections showed
infiltration covering \ of 3 or more islets. Sections
were viewed independently by two observers (Dr Betty Dean
and myself).
STUDY II
Plasma samples obtained from the tail vein of 102 BB/E
rats (61 DP BB/E, 41 DR BB/E) who had received 1-3
pancreatic biopsies between 30-150 days of age, were
screened for ICSA and IAA as previously described.
Pancreatic biopsies were performed by my colleague, Dr
Adrian Bone, with the view to investigate beta cell
replication (531). Although reference may be made to




Plasma Glucose and Insulin Concentrations
Table III shows the plasma glucose and plasma insulin
concentrations of the study animals. Plasma glucose
concentration increased significantly in DP BB/E rats
from 30 to 45 days of age and thereafter remained
relatively constant at 8.3mmol/l. There was a 6-fold
increase in the mean plasma insulin concentration between
30 and 90 days of age, which subsequently declined by 50%
at 105 days of age. DR BB/E rats showed a similar
pattern of results with a 5-fold increase in the plasma
insulin levels between 30 and 75 days of age, and a
significant increase in plasma glucose concentration
between 30 and 45 days of age, which levelled out to a
mean plasma glucose concentration of 8.2mmol/l from 60
days onwards. There were no significant differences in
either plasma glucose or insulin values between age-
matched DP BB/E and DR BB/E rats.
Incidence of Autoantibodies/Relationship with Insulitis
Antibodies against islet cell cytoplasmic antigens (ICA)
and thyroid colloid antigens were not detected in any of
the study animals.
Table IV shows the incidence of IAA in the DP BB/E
animals. A low incidence of IAA was observed from 30
days of age, with the peak incidence of activity
occurring at 90 days, close to the mean age of onset of
diabetes in the BB/E colony. Insulin autoantibodies were
never observed in outbred Wistar rats of comparable age.
Table IV also shows the species binding specificity of
the insulin antibodies. Most of the rat IAA appeared to
recognize shared epitopes on rat, human and pig insulins.
Although human and pig insulin appeared more reactive
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than rat insulin in this assay system, among the 11 IAA
positive DP BB/E rats, six plasma samples bound
preferentially to rat insulin, three to human and one to
both pig and human insulins. As expected, a high
incidence of insulin antibodies was seen in diabetic
animals maintained on injections of heterologous insulin.
Table V shows the incidence of rat IAA along with ICSA,
GPCA and SMA in relation to the presence of insulitis in
the DP BB/E animals. Antibodies against gastric parietal
cells and smooth muscle were detected in some animals at
all ages, with the frequency of GPCA approximately twice
that of SMA. No apparent trend towards increased
frequency, as the mean age for onset of diabetes
approached or correlation with the presence of insulitis,
was detected.
Islet cell surface antibodies were not detected in DP
BB/E rats prior to 60 days of age, but were demonstrated
with increased frequency thereafter. Insulitis was also
not detected prior to 60 days of age but increased in
frequency thereafter. Table VI shows the relationship
between ICSA and IAA and the development of insulitis in
the DP BB/E rats. Although ICSA was found in animals
without" insulitis (11/51) and insulitis was present in
some animals without ICSA (3/16), a strong correlation
(r=0.91; p<0.01) was detected between the presence of
ICSA and insulitis. Insulin autoantibodies showed no
significant correlation (r=0.38; p<0.25) with the
development of insulitis, and there was no correlation
(r=0.18; p<0.4) between ICSA and IAA in individual DP
BB/E study animals.
m
Islet Cell Surface Antibodies and Insulin Secretion
The numbers of age-matched ICSA-positive and negative
rats, did not allow a full statistical evaluation of
islet insulin release. Therefore, the insulin secretory-
response to a glucose challenge (16.7mmol/l) was compared
between pooled batches of islets isolated from groups of
ICSA-positive and ICSA-negative rats aged 75, 90 and 105
days. Table VII shows the findings from three experiments
and indicates a diminished total secretion of insulin in
islets from ICSA-positive rats compared with animals
without ICSA, with first phase insulin release being
particularly affected.
STUDY II
Islet Cell Surface Antibodies, Insulin Autoantibodies and
the Development of Diabetes
Only 4/39 (10%) and 1/31 (3%) of the DP and DR BB/E rats,
respectively, were positive for IAA before 60 days of
age. Thereafter, IAA were found in 16/48 (33%) and 3/29
(10%) of DP and DR BB/E rats respectively.
Table VIII shows the incidence of IAA and ICSA in
relation to the development of diabetes. Since no animal
younger than 60 days of age was positive for ICSA, only
data from rats aged 60-150 days have been included for
analysis. In this group (N=77; 48 DP BB/E; 29 DR BB/E),
28 (58%) of the DP animals and 4 (14%) of the DR rats
subsequently developed IDDM. Among the DP rats which
became diabetic, 20 had ICSA, 11 had IAA and 7 were
positive for both antibodies. By contrast, in the group
of 20 DP BB/E animals remaining non-diabetic, 4 had ICSA,
4 were IAA-positive and one animal was positive for both.
In the DR BB/E rats, all four animals which developed
IDDM were ICSA-positive, IAA-negative, but equally among
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the 25 animals remaining non diabetic, 4 had ICSA and a
further three rats had IAA.
A strong association of ICSA with the development of
diabetes was observed (x^=8.3; p<0.005). Insulin
autoantibodies were less significantly associated with
IDDM (p<0.03), using Mann-Witney U-rank test analysis of
values from all Study II rats which developed diabetes
(N=32) versus those remaining non-diabetic (N=45), and
this low level of significance was confirmed (p<0.05) if
DP BB/E rats alone were considered in the analysis.
Similar analysis of the data from DP BB/E rats, revealed
no significant association (p<0.4) of IAA with ICSA-
positive (N=25) versus ICSA-negative animals (N=23).
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TABLE III: PLASMA GLUCOSE AND INSULIN CONCENTRATIONS IN
PREDIABETIC BB/E RATS
DP BB/E RATS PLASMA GLUCOSE PLASMA INSULIN
(age in days) (mmol/1) (mU/1)
30 (N=12) 7.1 + 0.2 5.0 + 1.1
[6.6 +_ 0.1] [4.4 + 1.0]
p<0.0005 p<0.005




60 (N=12) 8.7 + 0.1 22.7 + 2.1
[8.8 + 0.4] [18.6 + 4.1]
75 (N=9) 8.0 + 0.2 26.2 + 5.1
[7.9 + 0.3] [27.2 + 5.5]




105 (N=ll) 8.5 + 0.4 15.3 + 2.1
[8.3 + 1.3] [23.5 + 8.9]
Results are expressed as mean values - SEM. Numbers in parentheses
are results from age-matched DR BB/E rats (N=4 for 30-90 day
periods; N=2 at 105 days). P values indicate the significant
differences between DP BB/E mean values for the groups of animals
shown (Students two-tailed t-test).
TABLE IV: INCIDENCE OF IAA (STUDY I)
INSULIN
DP BB/E RATS . RAT HUMAN PIG
(age in days) (% positive per group)
30 (N=12) 17 17 8
45 (N=12) 0 0 0
60 (N=12) 17 17 8
75 (N=9) 22 22 33
90 (N=ll) 36 64 64
105" (N= 11) 9 18 9
Insulin treated




TABLE V: INCIDENCE OF AUTOANTIBODIES AND INSULITIS (STUDY I)
DP BB/E RATS
(age in days)
INSULITIS ICSA IAA GPCA
(% positive per group)
SMA
30 (N=12) 0 0 17 58 33
45 (N=12) 0 0 0 50 50
60 (N=12) 8 33 17 75 33
75 (N=9) 22 22 22 89 33
90 (N=ll) 54 45 36 54 27
105 (N=ll) 64 82 9 82 36
Total"DP BB/E
(N=67) 24 30 16 67 36
Total DR BB/E
(30-105 days)
(N=22) 4 32 27 36 9
1U
















TABLE VII: ICSA STATUS AND INSULIN SECRETION
INSULIN SECRETION
ICSA STATUS FIRST PHASE INSULIN TOTAL INSULIN
(uU IRlAig islet protein i SEM)
ICSA positive 98 — 14 414 - 43
(N=3)
p<0.025 p<0.05
ICSA negative 151 - 9 577 - 42
(N=37
(P values: students two tailed t-test ICSA positive v ICSA negative)
TABLE VIII: INCIDENCE OF ICSA AND IAA IN RELATION
TO THE DEVELOPMENT OF IDDM (STUDY II)










(% antibody positive rats)
ICSA 71 25 100 16
. IAA 39 25 0 12
ICSA/IAA 25 5 0 0
aq
DISCUSSION
These studies have assessed metabolic status, presence of
circulating autoantibodies, islet cell function and
pancreatic morphology in individual potentially diabetic
animals, prior to the development of overt diabetes.
In these studies, ICA were not detected in any animal and
thereby are in agreement with other published studies
(349, 350). Since ICA are common in newly diagnosed IDDM
patients (189), this remains a point of difference
between the human and BB rat studies.
Antibodies against thyroid colloid cells were also absent
from the sera of animals used in these studies. This
differs from other studies which report the presence of
TCA in the sera of prediabetic (349) and diabetic (350)
BB rats. However, in the former study, animals from 2
different BB rat colonies were used, and marked
differences were observed in the incidence of the various
autoantibodies between the colonies. The failure to
detect TCA in our studies may in part reflect differences
between the various BB rat colonies.
Alternatively, it may reflect differences in methodology,
since our studies used normal WF rat tissue as substrate,
whereas Like et al (350) used tissue from non diabetic DR
BB/W rats. In addition, much older animals (3-8 months)
were used in the studies by Like et al (350).
Furthermore, although we did not investigate the presence
of lymphocytic thyroiditis in these animals, the presence
of TCA does not correlate with thyroiditis since 50% of
animals without thyroiditis have TCA (350).
Although we did not detect TCA, in a subsequent study,
autoantibodies to thyroglobulin were found in
approximately 30% of BB/E rats, the presence of which was
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unrelated to MHC haplotype or the development of either
diabetes or thyroiditis (532).
In these studies, antibodies against smooth muscle and
gastric parietal cells were found in some animals at all
ages but did not appear to correlate with the development
of insulitis. In these studies, GPCA were approximately
twice the frequency of SMA. In a similar study by Elder
et al (349), GPCA were more prevalent than SMA in one BB
rat colony, but less frequent in another colony; once
again showing colony related variations. We did not
investigate any relationship between the presence of GPCA
with gastric functional abnormalities e.g. achlorhydria,
however, in other studies although GPCA was associated
with histologic evidence of lymphocytic gastritis, no
functional abnormalities were detected in any such
animals followed for 9 months (349).
Insulin autoantibodies have been detected in the sera of
newly diagnosed IDDM patients (235), but there is much
debate as to their value as a predictive marker for
impending IDDM. Whereas some studies have found no
association of human IAA with the presence of ICA (237,
239), Dean et al (243), on examining the class
distribution of IAA, reported that the presence of both
IgG IAA and CF-ICA confer increased risk for future
diabetes development than either marker alone. Although
subclass analysis was not performed, our studies on the
prevalence of IAA in the BB/E rat, do not indicate a
significant role for IAA in the development of IDDM.
Furthermore, within individual animals no significant
correlation was found between the presence of IAA with
ICSA which proved to be a much better indicator for the
development of insulitis and diabetes.
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The studies herein described, I believe, are the first to
demonstrate the presence of IAA in the BB rat, but, as
with GPCA and SMA, probably arise as a corollary of
heightened genetic susceptibility in these animals rather
than representing a prerequisite for the development of
IDDM. How IAA, along with the other autoantibodies,
develop in these animals is unknown. Tolerance to self
antigens can be broken following the administration of
cross-reactive antigens (92, 93) which provide new
carrier determinants to which the recipient is not
tolerant and thereby, can generate carrier specific T^
cells which can help autoreactive B cells, recognizing
shared determinants on the cross-reacting antigen.
Although tolerant to their own insulin, BB rats would not
be expected to be tolerant to proinsulin, which is
normally sequestered*in the beta cell.
In the event of beta cell damage following insulitis,
insulin precursors may come into contact with the immune
system and permit the development of IAA if cross
reactivity with proinsulin existed. However, since IAA
were detected in some animals from 30 days of age, at
which time insulitis with beta cell destruction has never
been observed, this explanation seems unlikely. Since
IgM class IAA have been demonstrated following common
viral infections such as mumps, measles, chicken pox and
rubella ( 533), it is possible that IAA arise as the
development of anti-idiotypic antibodies to idiotypic
determinants on anti-viral antibodies that perhaps cross
react with the insulin receptor or share antigenic
determinants with insulin itself (127).
Related to the idiotypic network (32), it has previously
been shown that mice, immunized to ungulate insulins,
develop in the primary response an idiotypic antibody
that is directed against the epitope of insulin that is
recognized by the insulin receptor (124). These receptor
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mimicking idiotypic antibodies, designated DM-Ids, were
replaced spontaneously by anti-idiotypic antibodies
(anti-DM-Id), that were insulin mimetic and recognized
the insulin receptor as well as the DM-Id (539).
Using sera, obtained from animals of our BB/E colony,
Dana Elias at the Weizmann Institute, Rehovot, Israel has
demonstrated that BB/E rats developing IDDM,
spontaneously produce anti-DM-Id; anti-idiotypic
antibodies that also acted as anti-receptor antibodies
(submitted for publication). BB rats that did not
develop IDDM did not produce anti-DM-Id. However, IAA
were present both in rats developing IDDM and those
remaining non diabetic. In addition, 75% of those rats
developing IDDM carried the DM-Id compared with 25% of
rats that did not develop IDDM. Thus, a spontaneous DM
idiotypic network may herald the onset of autoimmune
diabetes mellitus, where the anti-DM-Id has a higher
association with disease than the DM-Id.
The strong association of ICSA with both the development
of insulitis and diabetes, found in our studies, suggest
a prominent role for these antibodies in the aetiology of
IDDM in the BB rat. Although ICSA were first detected in
the sera of diabetic animals (351), subsequent studies
(353, 354),confirmed by our studies, report the presence
of ICSA in the prediabetic period. In a recent study,
the beta cell specificity of ICSA was reported (355) and
hence relates to similar observations in human IDDM
(219). However in the study of Pipeleers et al (355),
ICSA were only detected at clinical onset of disease, and
not during the prediabetic period. Furthermore, the
detection of ICSA appeared to be age related. However,
it is possible that their inability to detect ICSA in the
prediabetic period, reflects a lower sensitivity of their
indirect immunofluorescence assay compared to the
protein-A radioligand assay used in our studies.
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Equally, since they used purified islet beta cells, it is
possible they are identifying a subset of ICSA which are
only prevalent at high titre at onset of diabetes when
most of the islet beta cells are lysed and beta cell
specific antigens are in the circulation at high
concentration.
In our studies, ICSA were not detected prior to 60 days
of age, at which age insulitis was also first observed.
Dyrberg et al (353), however, detected ICSA in 38% of
animals aged approximately 50 days, but no details are
given as to whether or not these animals simultaneously
presented with insulitis. In our studies, ICSA were
found in some animals without evidence of insulitis,
thereby suggesting ICSA may precede the development of
insulitis. However, since the whole pancreas was not
examined for insulitis, it cannot be excluded that
insulitis was not present in other areas of the pancreas
not examined. Equally, insulitis was found in some
animals without detectable ICSA. It is possible that
titres of detectable ICSA may fluctuate similar to ICA in
humans (202) and therefore were not detectable at the
time of sampling. Therefore, these studies do not
establish whether or not ICSA precedes the development of
insulitis or vice versa. However they do indicate a
strong correlation between ICSA and the development of
diabetes and its pathological substrate insulitis, and
therefore promote ICSA as a useful predictive marker for
IDDM in the BB rat.
Although the numbers of age-matched ICSA-positive and
negative rats did not allow a full statistical evaluation
of islet insulin release, the results using pooled islets
from ICSA-positive and negative animals, demonstrated a
perturbed pattern of biphasic insulin release from ICSA-
positive animals. This confirmed previous studies from
our laboratory in which larger numbers of animals were
13H-
used and a positive correlation was found between the
level of ICSA in individual BB rats and the amount of
insulin released following glucose stimulation of islets
isolated from the same animals (534).
In another study by Svenningsen et al (535), pancreas
perifusion of 45-50 day old DP BB rats showed that,
despite normal kinetics of insulin release, the total
amount of insulin release during glucose stimulation was
reduced compared with the DR BB rats. This was
attributed to a lower pancreatic insulin content, and is
supported by a recent report indicating a reduction in
the beta cell volume in DP BB rats prior to the
development of insulitis (536). However, in our studies
the results are expressed per unit islet protein and
islets from ICSA-fJosi tive and negative rats have a
similar relative insulin content (534).
The observed differences in the pattern of insulin
release between the studies of Svenningsen et al (535)
and the studies herein described, may be due to different
experimental techniques (perifused pancreas against
isolated islets) or by age differences of the study
animals. Nevertheless, a progressive decline in first
phase "insulin release during an intra-venous glucose
tolerance test was reported in prediabetic BB rats, 25-50
days prior to the onset of IDDM (537). However, a
similar impairment of beta cell function was observed in
some animals remaining normoglycaemic, thereby indicating
that although DP BB rats with circulating ICSA and/or
abnormal islet insulin secretory function often go on to
develop IDDM, this is not always the case. Whereas ICSA
may indicate that an autoimmune response against the
islet beta cells has been initiated, other factors, e.g.
the ability to increase islet cell replication (538), may
determine the final outcome of disease severity.
The impairment of insulin release from ICSA-positive rats
may suggest a pathogenic role for ICSA in the development
of IDDM. Islet cell surface antibody-positive sera from
human IDDM patients can mediate complement-dependent
cytotoxicity of rat islet cells (213, 218, 219) and ADCC
against human insulinoma cells (228). In the BB rat,
sera from 13 of 14 diabetic BB rats showed complement-
dependent cytotoxicity against rat islet cells, and in
the majority, the cytotoxic ICSA appeared prior to the
onset of IDDM (360). The presence of complement-
dependent cytotoxic ICSA was confirmed in prediabetic and
diabetic animals using a Cr-release assay (361). In
addition, ICSA- positive sera suppressed insulin but not
glucagon or somatostatin release from isolated islets.
Furthermore, although islet cytotoxicity was observed in
the prediabetic period, maximal potency occurred just
prior to, and immediately after, the onset of overt
diabetes.
At present the nature of the autoantigen against which
ICSA are directed, is unknown. In an attempt to identify
autoantigens detected by BB rat sera, homogenates of
normal rat islets were immunoprecipitated with BB rat
serum (362). As a result, sera from 25 of 26 diabetic or
DP BB -rats reacted with a 64KD rat islet cell protein,
which was not present on rat spleen lymphocytes.
Measurement of ICSA revealed 22 of the 26 BB rats were
also positive for ICSA. Whether the immunoprecipitating
islet cell antibodies are the same as those identified in
the protein-A radioligand assay, remains to be
determined.
In summary, these studies have described the presence of
a variety of autoantibodies in the circulation of
prediabetic BB/E rats. The majority of these antibodies
showed no pathologic sequelae and support the findings
that autoantibodies that react with multiple organs are a
common feature of the normal immune repertoire (80, 81).
Amongst the detectable autoantibodies, only ICSA showed a
significant correlation with the presence of insulitis
and the development of diabetes. The results do not
allow us to conclusively ascertain whether or not ICSA
appear prior to beta cell damage and thereby perhaps
initiate beta cell destruction, or whether they occur
only after beta cell damage has been initiated.
Nevertheless, the close association between ICSA and
insulitis, and ultimately diabetes, suggests an important
role for ICSA in the pathogenesis of IDDM. Our findings
of impaired insulin release in ICSA-positive rats, when
taken together with other studies, indicate the potential
of ICSA to participate in antibody-mediated beta cell
destruction. However, it remains to be established
whether ICSA play .a primary or secondary role in the
process of beta cell destruction.
CHAPTER 6 - MHC EXPRESSION AND INSULITIS
THE BB/E RAT PANCREAS
INTRODUCTION
The characteristic histopathology of Type 1 diabetes is
"insulitis" (255), representing a mononuclear cellular
infiltrate of the islets of Langerhans, leading to
insulin deficiency as a result of selective beta cell
destruction (194). It is not known what initiates this
process or what cells of the immune response are
responsible for mediating beta cell damage. However, an
attractive hypothesis suggested that aberrant expression
of MHC class II molecules on pancreatic beta cells may
initiate an autoimmune reaction against the insulin
containing cells (540).
The major histocompatibility complex antigens are cell
surface glycoproteins, associated with the regulation of
immune responses. Class I antigens are located on most
nucleated cells and are responsible for restriction of T
cyt cells (149). Class II antigens are required for
presentation of antigen and are normally present only on
the surface of antigen-presenting cells, activated T
cells and B lymphocytes (148, 150). The observation
that class II molecules were expressed on follicular
cells in autoimmune thyroid disease (541), and that this
expression could be induced on normal thyroid cells by
the lectin phytohaemagglutinin (PHA)(542), led to the
suggestion that aberrant expression of class II antigens
may allow the presentation of specific autoantigens to
potentially autoreactive TH lymphocytes, thereby leading
to autoimmune disease (540).
Such aberrant expression of MHC class II antigens on
pancreatic beta cells has been described in human Type 1
diabetes (261). In this report of a single case with
recent onset of Type 1 diabetes, examination of fresh
frozen autopsy pancreas revealed two major abnormalities
of MHC expression in some islets: firstly expression of
class II MHC products specifically confined to islet
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beta cells and secondly, marked hyperexpression of class
I MHC molecules on all islet endocrine cells. However,
since the patient presented at a time when the majority
of the beta cells have been destroyed, the relevance of
these findings to the events of the prediabetic pancreas
are uncertain.
The studies detailed in this chapter aimed to elucidate
the sequence of pancreatic events which lead to the
development of IDDM in the BB/E rat. In particular,
they sought to document the role of aberrant MHC
expression in the disease aetiology and to perform
phenotypic analysis of the infiltrating immunocytes.
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Fig 2 : Pancreatic biopsy procedure :
(a) incision along the linea alba
(b) exteriorization of splenic pancreas
(c) clamping of biopsy
(d) removal of biopsy
(e) application of thrombin to cut surface
(f) release of clamp
(g) suturing of wound





Two longitudinal cohort studies were performed.
STUDY I
Pancreata examined in this study, were obtained from and
correspond to the animals of Study I detailed in Chapter
5.
STUDY II
This study employed serial pancreatic biopsy, thereby
allowing sequential study of pancreatic changes within
individual animals. This study is not related to Study
II described in the previous chapter.
Pancreatic Biopsy Procedure
In 1984, a technique for the complication-free removal
of splenic pancreas from rats, was described by
Logothetopoulos et al (363). I have visited Dr
Logothetopoulos and observed this technique in his
laboratory. Subsequently we have used this technique to
study the development of IDDM in individual animals.
Pancreatic biopsy was performed, essentially as
described by Logothetopoulos, by my colleague Dr A J
Bone with myself assisting.
Animals were anaesthetised with 2.5% halothane and a 2-
3cm incision made along the linea alba from the
umbilicus to the xiphisternum (Fig. 2a). The spleen
with attached pancreas was gently lifted out and
exteriorized on sterile gauze soaked in sterile saline.
The splenic pancreas was carefully unfolded so that its
vascular connections with the spleen were clearly
visible (Fig. 2b). A portion (50-75mg) of pancreas from
just above the lateral splenic attachment was clamped
off using a surgical haemostatic clamp, in which the
arms were finely machined so that their thickness did
not exceed 0.2-0.3mm (Fig. 2c). The biopsy was then
removed using fine scissors (Fig. 2d). The cut surface
was dabbed with sterile bovine thrombin (lOOU/ml)(Miles
Scientific, Illinois, USA) without releasing the clamp
(Fig. 2e). After 3-4 mins. the clamp was gently
released (Fig. 2f), if bleeding occurred the clamp was
left for a further 2 mins. The exposed spleen and
pancreas were covered during this "clotting" period with
sterile gauze soaked in sterile saline. The spleen and
pancreas were then returned to the abdominal cavity
which was closed using a tight running stitch with
number 3/0 synthetic (coated vicryl) absorbable sutures
(Ethicon Ltd, Edinburgh, Scotland)(Fig. 2g) , followed by
skin closure with wound clips (Fig. 2h). Although
occasionally sutures were required to control
haemorrhage, no difficulty was encountered in repeating
pancreatic biopsy up to four times in individual
animals.
Tissue obtained at biopsy was immediately snap-frozen
for subsequent immunohistological examination.
Protocol
Eight groups (N=5) of DP BB/E rats were biopsied twice
(with a 10 day interval) between 30 and 110 days of age
and subsequently followed up to 200 days of age for the
development of IDDM. Animals developing diabetes
received a third biopsy at onset of disease. Subsequent
maintenance on daily insulin was withheld from six
animals to allow the formation of ketones. Following
the detection of ketones, the animals were sacrificed
and their remaining pancreata removed. Similarly, a
group (N=6) of animals with established diabetes (mean
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duration of diabetes; 23 — 5 days), having been
maintained on daily insulin injections, received a
pancreatic biopsy prior to the cessation of their
insulin treatment and received a second biopsy at the
onset of ketoacidosis. Biopsies were also performed on
DR BB/E animals (N=12) and on normal Wistar rats (N=6)
between 100 and 120 days of age.
One hundred and twenty serial cryostat sections (V1"1)
were cut from each biopsy. Scan slides with 8
sect ions/slide, each section taken at a different level
through 8Qum of tissue, were used as an initial screen
to detect areas of pancreatic infiltration with class II
MHC positive cells using the MRC OX-6 MoAb (Table I).
Detailed analysis of areas with infiltration, via the
antisera listed in Table I, were performed by referring
back to subsequent serial sections coincident with the
areas represented by the scan slides.
Immunofluorescence Staining
Labelling of cryostat sections for immunohistological
examination, by immunofluorescence procedures, were
performed as detailed in Chapter 4.
Quantitation of Insulitis
Due to the heterogeneity of the insulitis process,
quantitative analysis on both the total numbers and
individual subset analysis of infiltrating cells,
contributing to the insulitis is not practical.
However, to give some degree of quantitation, I have
studied a total of 46 islets from biopsies taken from 3
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animals which subsequently developed diabetes 10-15 days
later. At this stage, the insulitis process is at its
peak, yet heterogeneity in the degree of insulitis
within individual islets is observed.
Individual islets showing insulitis were classified
according to the number of MHC class II positive cells
(OX-6) within the islet, in conjunction with the
relative amount of insulin positive staining beta cells
as follows:
+ ; 50-100 0X6+ cells; insulitis located mainly at the
islet periphery and the majority of the beta cells
intact.
++; 100-150 0X6+ cells, insulitis affecting h~\ of the
islet with resultant loss of of the insulin
containing beta cells.
+++; more than 150 0X6+ cells; insulitis covers most of
the islet and there is a virtual absence of insulin
staining cells (Fig. 3).
Two cell counts were performed on each islet area using
X60 and X25 objective lenses, with the mean of the two
scores reported. Except for the MoAb EDI, which
recognizes a cytoplasmic vacuole antigen, cell surface
staining was counted. Where difficulties existed in
identifying the morphology of individual cells, the
count was underscored.
Detection of Ketoacidosis
Ketones (3.9-15.7mmol/I) were detected using Multistix
(Ames Division, Miles Laboratories Ltd, Slough, UK) and
ketoacidosis confirmed by measurement of plasma carbon
dioxide, sodium, potassium, glucose and creatinine
levels on a Synchron AS4 (Beckman Instruments, Fullerton
CA, USA). Typically raised potassium levels, due to
insulin-deficiency, causing increased release of
intracellular potassium and lowered CO2 levels,
reflecting the formation of acidic ketone bodies, were
found (Table IX).
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TABLE IX: ELECTROLYTE AND OTHER BLOOD CONSTITUENTS







22.4^1.9 144±5.0 9.1—1.0 38.4±6.4 71-11.4




20.3±2.1 147-2.6 6.4-0.7 36.5±5.2 73±15.0




28.0-1.1 147-0.7 4.2-0.2 8.6-0.4 42-0.9
P values indicate the significant differences compared with the DR BB/E
group (students two-tailed t-test).
Fig 3 : Double exposure of MHC class II positive
(OX-6) cells (green) and insulin-containing
cells (red) on pancreatic biopsy from DP
BB/E rat (90 days of age). Biopsy was taken
11 days before onset of diabetes. Three
islets with different levels of insulitis are
identified (arrows). (Magnification X 125).
Fig 4 : (a) Insulin staining (M1183) of DP BB/E rat
pancreas (aged 90 days). Intact insulin-
containing islet in one pancreatic lobule
appears alongside three shrunken "end
stage" islets with diminished insulin
content (arrows). X 125
(b) Double exposure of OX-6 (green) and
insulin (red) staining on DP BB/E rat
—
pancreas (90 days). An insulin deficient
islet (i) with insulitis appears along¬
side another insulin-containing islet
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At the outset the heterogeneity of the pancreatic events
in the prediabetic pancreas must be stressed.
Therefore, each biopsy can only reflect a part of the
total pancreas at a single time point. As such, these
studies describe changes in pancreatic morphology
leading to insulitis within individual and multiple
islets. It is only with unrestricted spreading of this
process, from one pancreatic lobule to the next, that
eventually when sufficient beta cells have been
destroyed that clinical overt diabetes ensues. Figure 4
shows the lobular distribution of pancreatic events
typical of this "patchy" disease. In Figure 4a, the
beginning and end of the destruction process are
indicated, with three end stage shrunken islets with
virtually no remaining insulin containing beta cells
appearing alongside an intact insulin containing islet
in an adjacent pancreatic lobule. In Figure 4b, the
varied intensity and distribution of the insulitis
process, responsible for beta cell destruction, is shown
with the lower islet heavily infiltrated and no residual
insulin-positive cells, whereas the islet in the lobule
above the large blood vessel, shows only the early
stages of insulitis.
STUDY I
Pancreata were screened with a MoAb against rat MHC
class II (la) antigens to detect areas of infiltration
and/or altered la expression on non lymphoid cells.
Table X shows the percentages of pancreata revealing
insulitis or abnormal la expression in the study
animals. Figure 5 shows la expression in the normal non
diabetic pancreas where 0-15 spheroidal or stellate
cells of presumed monocytic origin may be found within
islets or adjacent to capillaries scattered throughout
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the exocrine tissue (543, 544). The first change was
observed in the pancreata of 45 day old BB/E animals and
consisted of increased expression of class II molecules
on the vascular endothelium (Fig. 6). This preceded
pancreatic lymphocytic infiltration and insulitis which
was first detected in one animal at 60 days of age.
From 60 days onwards, 16 pancreata presented with
various degrees of insulitis which increased in
frequency and severity as the mean age of onset of
diabetes for the BB/E colony approached (Table X).
Analysis of the infiltrating cells revealed that in all
cases, cells reactive with the W3/25 MoAb; indicative of
Tjj and macrophage phenotypes, were the predominant cell
types representing approximately 60% of the infiltrating
cells (Fig. 7a). Double fluorochrome studies indicated
that the majority of these cells also expressed class II
molecules suggesting their recent activation (Fig. 7b).
0X-8 positive cells which can represent T cyt, T supp or
NX cells identified approximately 15-20% of the
infiltrates (Fig. 7c). Up to 90 days the presence of B
lymphocytes amongst the infiltrating cells was
approximately 10-15%, however in older animals
approximately 30% of the infiltrate was composed of B
lymphoe-ytes, including plasma cells (Fig. 7d).
Interestingly, the T and B lymphocytes appeared to
occupy distinct areas within the infiltrated islets.
Among 3 of the 16 pancreata with insulitis (1 pancreas
at 60 days; 2 pancreata at 75 days), occasional
endocrine-like cells were observed to express class II
molecules (Fig. 8). When sections were double stained
for endocrine hormones, a few insulin containing cells
appeared to be expressing class II antigens (Fig. 8c).
The expression of MHC class II molecules on endocrine
cells was specific for the insulin containing cells and
was never observed on the glucagon or somatostatin cells
which remain intact and unaffected in this beta cell
specific disease (Fig. 9). Aberrant class II expression
on endocrine cells was however an infrequent phenomenon,
being observed in only 3 pancreata, within which only a
few of the islets with remaining insulin containing
cells were affected. In all cases, this aberrant
expression of MHC class II molecules was accompanied and
coincident with lymphocytic infiltration of the islets.
STUDY II
The longitudinal cohort study described above, had
several inherent limitations: (i) since the incidence of
IDDM in the BB/E colony is about 70% it was not known
which animals with 'insulitis would have subsequently
gone on to develop IDDM; (ii) it was not possible to
assess the time scale of the insulitis and beta cell
destructive processes with any degree of accuracy; (iii)
at the time the study was performed, the MoAbs available
were unable to distinguish between the Tjj subset and
certain populations of macrophages. More recently
however, several MoAbs identifying distinct rat
macrophage subpopulations, have been described (Table
I)(529). Using these antibodies in conjunction with
serial pancreatic biopsy, which allows sequential study
of individual animals over prolonged periods, this
second study aimed to remedy the deficiencies of the
previous study and refine its conclusions.
Although it is recognized that each biopsy only reflects
the events within a portion of the pancreas, at a single
time point, the performance of serial biopsy in
individual animals at least allows the morphology of
each biopsy to be interpreted as regards its
relationship with the subsequent development of IDDM in
the animal.
By pooling the observed changes in pancreatic
morphology, within individual animals and relating them
to the time interval in which diabetes thereafter
developed in the animal, I have attempted to produce a
composite concept of the sequence of pancreatic events
which lead to the development of IDDM in the BB/E rat.
Table XI relates the time interval between the
appearance of insulitis in pancreatic biopsies of
individual animals, and the subsequent development of
diabetes in those animals. Twenty two of the AO study
animals (55%) developed IDDM with the mean age at onset
of diabetes occurring at 102^ 29 days (mean iSD).
Intervals between the time of the last pancreatic biopsy
performed in the prediabetic period, and the subsequent
time of diabetes onset, ranged from 7 to 130 days.
With one exception, insulitis was never observed in
biopsies which preceded the onset of diabetes by more
than three weeks. Between 2 to 3 weeks before the onset
of diabetes, although insulitis was occasionally found
in some animals, the major pancreatic development was
the appearance of infiltrates at periductal,
perivascular and peri-islet sites. Biopsies taken one
to two-weeks before disease onset, consistently showed
extensive and intensive infiltration of the islets.
These results suggest that in the majority of cases, the
onset of diabetes in the BB/E rat is a rapid process
occurring within two weeks of the initial insulitis.
Monoclonal antibodies against lymphocyte and macrophage
subsets, were used to characterize the composition of
these pancreatic infiltrates and MoAbs against rat MHC
molecules were used to further document the expression
of MHC antigens in the prediabetic and diabetic BB/E rat
pancreas.
Fig 5 : Double exposure of OX-6 (green) and insulin
(red) staining on DP BB/E rat pancreas
(aged 30 days). Shows extent and
distribution of MHC class II positive cells
in the normal non-diabetic pancreas. X125
Fig 6 : 0X6 staining revealing MHC class II
expression on vascular endothelium of
DP BB/E rat pancreas (aged 45 days'). X640
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TABLE X: PANCREATA WITH INCREASED MHC CLASS II EXPRESSION
ON NON LYMPHOID CELLS AND THOSE WITH INSULITIS
(STUDY I J
INCREASED
DP BB/E RATS " NORMAL NON LYMPHOID INSULITIS
(age in days) la expression
(% positive per group)
30 (N=12) 100 0 0
45 (N=12) 58 42 0
60 (N=12) 42 50 8
75 (N=9) 33 44 22
-90 (N=ll) 36 9 54
105 (N=11) 18 18 64
Total DP BB/E (N=67) 49 27 24
Total DR BB/E (N=22) 64 32 4
(30-105 days)
IS*
Fig 7 : Sequential sections Irom a 105 day old
DP BB/E rat with insulitis. X 400
(a) W3/25 (anti-T and some macrophages).H
(b) double exposure for W3/25 (red) and
0X6 *(green).
(c) OX-8 (anti-Tcyt/supp and NK cells).





Fig 8 : DP BB/E rat pancreas (75 days old). X640
(A) OX-6 staining reveals insulitis and
class II MHC expression on "endocrine-
like" cells.
(B) anti-insulin staining (M1183) on serial
section.
(C) double exposure for insulin and OX-6
indicates expression of MHC class II
proteins on insulin-containing cells.
\b\
 
Fig 9 Double exposure for glucagon-containing
cells (red) and insulin-containing cells
(green).
(A) Normal islet with glucagon cells at
islet mantle and insulin cells at
islet core. (DP BB/E rat aged 60
days). X312
(B) Islet from DP BB/E rat aged 105 days.
Showing selective destruction of
insulin-containing cells. X500
IbV-
The first change observed in the biopsies of prediabetic
DP BB/E rats, was seen in some biopsies taken from 40
and 50 day old rats and consisted of an increase in the
expression of MHC class I molecules on the vascular
endothelium and on islet cells within some pancreatic
lobules (Fig. 10). The increase in intra-islet class I
expression appeared to initially occur on the beta cells
at the islet core and gradually spread to the adjacent
cells to include the glucagon cells at the islet mantle.
This increased expression of class I molecules occurred
in the absence of insulitis which has never been
observed in any animal before 60 days of age (Table X,
Table XI). Although there is variation in the time
scale of pancreatic changes within individual animals,
this altered class I expression could be detected
onwards of 30 days prior to the onset of IDDM.
The next phase of altered pancreatic morphology was
represented by the beginnings of pancreatic infiltration
coincident with the expression of MHC class II molecules
on endothelial cells of some ducts and vessels.
As already mentioned and indicated in Table XI, this
phase of pancreatic infiltration occurs 2-3 weeks before
the onset of diabetes and is characterized by the
presence of infiltrates at periductal and perivascular
sites (Fig. 11a). Analysis of the infiltrates revealed
that the majority of infiltrating cells at this stage
were identifiable with the MoAb EDI which recognizes a
population of macrophages (Fig. lib).
In the pancreas of normal Wistar rats, DR BB/E rats and
young (30-40 day old) DP BB/E rats, EDl-positive cells
were infrequently observed (Fig. 12a). This is in
contrast to another population of macrophages which are
recognized by the MoAb ED2 and which were much more
numerous than ED1+ cells in the control pancreata.
\t>5
Fig 10 : (a) Normal class I MHC antigen expression
(non-diabetic DP BB/E rat aged 50
days). Islet (i) is negative whilst
endothelial cells of an adjacent
blood vessel are positive (arrows).
X 312
(b) Higher magnification of islet in (a).
X 625
(c) DP BB/E rat pancreas (aged 50 days)
showing increased expression of
class I MHC molecules on the vascular
endothelium (arrows) and within the
adjacent non-infiltrated islet (i).
(Biopsy taken 28 days prior to onset
of IDDM). X 312





Fig 11 : DP BB/E rat aged 100 days. Biopsy taken
18 days before onset of diabetes. X 312
(a) OX-6 staining showing perivascular
infiltrates of MHC class II positive
cells and expression of class II MHC
antigens on some vascular endothelial
cells.
(b) EDI staining on serial section.
Fig 12 : Normal Wistar rat pancreas (aged 100 days).
X 125
(a) double exposure for EDI (green) and
insulin (red).
(b) double exposure for+ED2 (green) and
insulin (red). ED2 cells are




Studies revealed that ED2 MoAb identified a resident
population of tissue macrophages present in all biopsies
from all groups of rats. These cells were prominent,
lining the septa between pancreatic lobules and were
widely dispersed throughout the connective and acinar
tissues but were not present within pancreatic islets
(Fig. 12b). Fluctuations in the degree of dispersion
and number of ED2+ cells, found between sequential
biopsies in individual rats, were minimal and may have
been a consequence of the biopsy procedure. Biopsies
from DP BB/E animals at all ages, showed a similar
tissue distribution irrespective of the presence or
absence of insulitis.
Figure 13a graphically illustrates the early stages of
pancreatic infiltration where many MHC class II bearing
cells are seen accumulated around the pancreatic ducts
and blood vessels. The cells then seemingly home to the
nearby islets where cuffings of peri-islet infiltrates
are formed (Fig. 13c). Staining of serial sections
revealed that most of the class II-positive infiltrating
cells were ED1+ macrophages (Fig. 13b, Fig. 13d). In
addition, class II expression on endothelial cells, of
ducts and vessels as well as capillary cells within both
the endocrine and exocrine tissue, was observed.
However, at this stage of pre- or early insulitis,
expression of class II MHC molecules was not observed on
islet beta cells (Fig. 13a, Fig. 13c). Initially, this
infiltration could be quite focal whereby most islets
within a few pancreatic lobules were affected but islets
in other areas were unaffected (Fig. 13a, Fig. 13e).
This initial accumulation of ED1+ cells, at perivascular
locations, was not a non specific consequence of the
biopsy procedure since it was never observed following
similar serial biopsies performed on control normal
Wistar or DR BB/E rats. Subsequent to their recruitment
and accumulation at peri-islet sites, the ED1+ cells
l*o
then proceeded to infiltrate the islets within the
affected lobules (Fig. 13f), and this appeared to occur
before there was any apparent involvement of other
immune effector cells.
Following this initial infiltration, the development of
insulitis and its severity progressed as other immune
effector cells were recruited. As indicated by Table
XI, the height of the autoimmune reaction against the
islet beta cells appeared to occur approximately 10 days
before the onset of IDDM. Therefore, in an attempt to
quantitate the cell populations contributing to the
insulitis, biopsies taken 10-15 days prior to the onset
of diabetes were screened.
Table XII shows the number of each subset of cells
infiltrating individual islets with different degrees of
insulitis severity, examples of which are illustrated in
Figures 3 and 14. Marked numbers of T lymphocytes
(0X19+) were observed only in islets showing more
advanced stages of insulitis, where a significant loss
of insulin staining beta cells was also observed (Fig.
14c). In all cases, within infiltrated islets
irrespective of the degree of insulitis, cells
recognlTzed by the EDI MoAb were the most numerous, being
at least twice as frequent as cells recognized by the
OX-19 MoAb. The greater number of W3/25+ cells when
compared to the number of 0X-19+ cells, is not
unexpected since many of the W3/25+ cells also express
the EDI marker. However, although double labelling for
the EDl and W3/25 antigens has not been done, from
staining of serial sections 75-80% of the ED1+ cells are
also recognized by the W3/25 marker. It appeared that
most of the 0X-19+ T cells were however of the TH
phenotype (Fig. 15c, Fig. 15d), and that some of the 0X-
8+ cells did not express the OX-19 antigen suggesting
that they were NK cells (Fig. 16c, Fig. 16d).
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TABLE XI: TIME COURSE ON THE APPEARANCE OF INSULITIS PRIOR TO
THE SUBSEQUENT DEVELOPMENT OF IDDM (STUDYTfT
Last previous Onset of
Rat Sex biopsy diabetes Time interval Insulitis
(N=22) (days)
Age of rat (days)
1 M 60 190 130 Absent
2 M 60 170 110 Absent
3 M 50 108 58 Absent
4 F 60 108 48 Absent
5 M 50 98 48 Absent
6 F 50 94 44 Absent
7 F 50 94 44 Absent
8 M 90 123 33 Absent
9 F 70 101 31 +
10 F 50 80 30 Absent
11 F 60 83 23 +/-
12 M 80 101 21 ++
13 M 90 108 18 +
14 F 100 118 18 +/-
15 M 80 96 16 +/-
16~ F 70 83 13 +/-
17 F 70 83 13 +
18 M 90 101 11 ++
19 F 60 70 10 ++
20 F 80 90 10 ++
21 M 60 68 8 +
22 F 70 77 7 ++
+/- : Pancreatic infiltration at perivascular and peri-islet sites.
+ : Insulitis affecting of 1-5 islets.
++ : Insulitis extensive over 5 or more islets.
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Fig 13 : A - D; serial sections from biopsy of
DP BB/E rat (aged 70 days). Biopsy was
taken 20 days before onset of diabetes.
(A) double exposure for cells expressing
MHC class II molecules (green) and
insulin (red). X 125
(B) serial section to (A) stained for
EDI (green) and+insulin (red) sh^ws
many of the 0X6 cells to be EDI
macrophages. X 125
(C) OX-6 (green) and insulin (red)
staining at higher magnification
(X 312) of islet marked with arrows
in (A).
(D) serial section of (C) stained for EDI.
(E) OX-6 (green) and insulin (red)
staining of another area from the
same biopsy as A-D above, reveals no
infiltration, and emphasizes the
"patchy" heteregenous histopathology
of the disease. X 125
(F) double exposure of ED1+ cells (green)
infiltrating insulin-containing islet
(red). Biopsy taken from same animal






TABLE XII: QUANTITATIVE ANALYSIS OF INSULITIS IN DP BB/E RATS
BIOPSIES 10-15 DAYS PRIOR TO ONSET OF DIABETES
NUMBER OF INFILTRATING CELLS (MEAN - SEM) / ISLET
Degree of
insulitis OX-6 ' EDI W3/25 OX-19 OX-8 OX-33
+ (N=12) 65±2.1 43±2.3 44±3.4 13±0.8 10±0.7 1*0.4
++ (N=16) 122-3.2 72-2.8 71*4.2 38*1.7 28*1.8 5*1.0
+++ (N=18) 200*8.9 99-7.4 113*12.3 52*5.0 42*3.9 31*3.1
+ : 50-100 OX=6+ cells; Insulitis mainly at islet periphery;
— Majority of beta cells intact.
++ ; 100-150 0X-6+ cells; Insulitis affecting of islet;
Loss of beta cells.
+++ : >150 0X-6+ cells; Insulitis affecting most of islet;
Virtual absence of beta cells.
177
Fig 14 : Serial sections from biopsy of DP BB/E
rat (aged 90 days). Biopsy was taken
11 days before onset of diabetes. X 125
(A) double staining for MHC class II
antigen positive cells (green) and
insulin (red). Three islets with
increasing severity of insulitis and
accompanying reduction of residual
insulin are shown.
(B) EDI staining on serial section of (A).
(C) OX-19 (pan T cell) staining on
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Fig 15 : Serial section staining of insulitis (+++)
in islet from DP BB/E rat (aged 90 days).
Biopsy was taken 11 days before onset of
diabetes. X 312
(a) MHC class II positive cells
(b) double exposure for EDI (red) and
insulin (green) on serial section of
(a) :
(c) OX-19 (pan T cells) staining on
serial section of (a).
(d) W3/25/OX-35 (T cell and macrophage)
staining on serial section of (a).
\So
 
Fig 16 : Serial section staining of insulitis (++)
in islet from DP BB/E rat (aged 90 days).
Biopsy.was taken 11 days before disease
onset. X 312
(a) MHC class II positive cells
(b) EDI positive cells
(c) pan T cell staining




Significant numbers of B lymphocytes (OX-33+) only
appeared in islets showing a marked loss of insulin
producing cells, thereby indicating they appear late in
the disease process.
At this stage in the disease process, hyperexpression of
MHC class I antigens, within infiltrated islets, is
markedly enhanced. This enhanced expression of class I
molecules is no longer confined to the islet endocrine
cells but extends beyond the islet periphery into the
surrounding exocrine tissue, until once again the
lobular architecture of the pancreas appears to create a
physical barrier to this phenomenon (Fig. 17). At this
point in the study, within the infiltrated islets, the
expression of class II molecules on insulin containing
cells was rarely seen with class II expression being
restricted to the infiltrating immunocytes (Fig. 18).
Progressive spreading of this insulitis process, from
lobule to lobule with resultant beta cell loss, will
eventually result in the onset of overt diabetes.
Biopsies taken at onset of diabetes, contained some
islets with residual insulin containing cells which also
hyperexpressed class I molecules in the presence of
insulitTis (Fig. 19a-c). Other islets however no longer
retained an infiltrate and appeared as end stage islets
where the glucagon cells, in the absence of the beta
cell core, collapse inwards to form a clump (Fig. 19d).
In biopsies taken from animals developing ketoacidosis,
virtually all of the insulin containing islets had
disappeared and consequently insulitis was rarely
observed. Most islets were end stage in character with
occasional ED1+ cells remaining around the collapsed
islets (Fig. 20).
.134-
Hyperexpression of MHC class I molecules was no longer
observed in end stage islets and was only occasionally
observed in areas where small foci of class II bearing
infiltrates remained.
Figure 21 describes, in a flow diagram presentation, the
sequence of pancreatic events that may lead to the
development of IDDM in the BB/E rat. It is recognized
that some of the DP BB/E animals remaining non diabetic
or even some of the DR BB/E animals, may show some of
these individual features but not of sufficient severity
to result in overt disease.
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Fig 17 : DP BB/E rat pancreas (aged 70 days). Biopsy
taken 7 days before onset of diabetes.
(A) OX-18 staining, showing hyperexpression
of MHC class I molecules accompanying
insulitis in some pancreatic lobules,
whilst adjacent pancreatic lobules are
normal. X 50
(B) High'er magnification (X 312) of one of
the islets (i) in (A), shows hyper¬
expression of MHC class I molecules
extends into the surrounding exocrine
tissue. (arrows indicate the islet
boundary).
 
Fig 18 : DP BB/E rat pancreas (aged 90 days). Biopsy
taken 11 days before onset of diabetes.
(A) & (B)*double staining for MHC class II
positive cells (green) and insulin
(red) reveals expression of la
antigens only on the infiltrating
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Fig 19 : DP BB/E rat pancreas at onset of diabetes
(aged 101 days).
(a) OX-18 staining showing hyperexpression
of MHC class I molecules within an
islet retaining both infiltrating
leucocytes and residual insulin-
containing cells. X 312
(b) EDI staining on serial section of (a).
(c) Insulin staining (M1183) on serial
section of (a).
(d) glucagon staining of another islet
within same biopsy shows "end stage"
characteristic clumping of intact
glucagon cells. X 500
Uo
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Fig 20 : DP BB/E rat pancreas at onset of
ketoacidosis (aged 115 days). X 312
(A) Double staining for glucagon (red)
and MHC class II positive cells.
(B) Double staining for glucagon (red)












FIGURE 21: SCHEMATIC PRESENTATION OF THE SEQUENCE OF
PANCREATIC EVENTS LEADING TO THE DEVELOPMENT
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In 1983 Bottazzo et al (540), based on observations in
thyroid tissue derived from patients with Graves'
disease, postulated that aberrant expression of MHC
class II antigens on target cells may permit
presentation of cell specific autoantigens to
potentially autoreactive T cells, thereby initiating an
autoimmune response. Since many autoimmune diseases,
including Type 1 diabetes, have HLA class II linked
genetic susceptibilities (545), this was an attractive
hypothesis linking the genetic susceptibility with an
event on the target cell. However, the relationship of
cause and effect between expression of class II MHC
antigens and the development of autoimmunity has
engendered much debate and controversy (546-548).
The finding of aberrant class II expression on some
insulin containing cells in the fresh autopsy pancreas
of a young child, with recent onset diabetes who died
from ketoacidosis, provided some support to the
hypothesis (261). However, in this single case, it was
not possible to discern if the class II expression on
beta cells preceded the development of insulitis.
Evidence substantiating the above single case history,
has recently been provided by the detailed studies of
Foulis et al (549), who examined approximately 3000
islets in blocks of fixed pancreas obtained at autopsy
from 35 diabetic patients who died from ketoacidosis.
Aberrant class II expression was found selectively on
islet beta cells in 14% of insulin containing islets.
However, whereas some islets were observed to contain
class II expression on beta cells in the apparent
absence of insulitis, other islets were found with
insulitis but without aberrant class II expression. In
pancreata examined from patients with recent onset
US
disease, 16% of the insulin containing islets displayed
inappropriate class II expression on beta cells, of
which 56% showed no evidence of insulitis. It was
stressed that insulitis and aberrant class II expression
could be quite focal within the islets and only by
screening serial sections to study "whole" islets, could
an accurate frequency of these phenomena be obtained.
This was evident when "whole" islet analysis was
performed on 130 islets from 3 patients with recent
onset disease. Insulitis was found in 44% of islets,
where previously only 12% of islets had been found to be
infiltrated when only a single section had been used for
analysis on these patients. Similarly, aberrant
expression of class II MHC molecules on islet beta cells
was found in 67% of islets, compared with 26% on
previous single sect'ion examination.
Analysis of "whole" islets was performed in my studies,
by initially screening scan slides containing 8
sections/slide; each section having been taken at a
different level through 80um of tissue. The results
reported were based on the use of a mouse anti-rat MoAb
directed against a nonpolymorphic determinant of the rat
RT1B molecule. However, similar results were also
obtained using another anti-rat class II MoAb, directed
against the rat homologue of the mouse I-E molecule
(RT1D).
The studies I have described in the BB/E rat, do not
lend support to the proposal that aberrant expression of
MHC class II molecules on pancreatic beta cells have a
primary role in the process which ultimately leads to
their destruction. Although occasional expression of
MHC class II molecules, coincident with insulin
containing cells, were observed in the first
longitudinal cohort study, this occurred only in islets
already heavily infiltrated. This suggests that, where
IH
present, aberrant class II expression is a consequence,
rather than a cause, of the disease process. It is
possible that the aberrant class II expression may be
induced by lymphokines such as interferon gamma released
by activated T cells within the infiltrated islets (550,
551). However, in the subsequent and more detailed
biopsy study, aberrant expression of class II MHC
molecules on beta cells in islets, either with or
without insulitis, was not apparent. It is possible
that the occasional MHC class II expressing beta cells
observed in Study I may represent the phagocytic uptake
of fragments of damaged insulin-containing cells by
macrophages which are themselves expressing class II
molecules (552). Indeed, electron microscopy and
immunohistological studies on islets isolated from BB
rats and streptozdtocin treated rats at onset of
diabetes, have revealed numerous class II .positive islet
cells that presented ultrastructural features of
monocytes with vacuoles containing insulin
immunoreactive granules (553). Equally in multiple low-
dose streptozotocin-induced diabetes of mice, expression
of MHC class II antigens was not found on endocrine
cells but was restricted to phagocytic cells containing
beta cell debris (554).
In a further study in the BB rat; Issa-Chergui et al
( 555 ) failed to detect class II MHC molecules on beta
cells at the onset of disease. However, in this study,
diabetes was induced in young BB rats by the passive
transfer of ConA activated spleen cells from acutely
diabetic BB rats and therefore the results might differ
from the spontaneously occurring disease.
In the NOD mouse, conflicting results concerning the
role of aberrant MHC class II expression, have been
reported. Whereas Signore et al (556, 557) did not
detect class II expression on endocrine cells, Hanafusa
et al ( 558) reported the expression of class II MHC
antigens preferentially, but not specifically, on beta
cells in 63% of islets of which 55% showed no evidence
of insulitis. However, class II expression was also
found on islet cells from non diabetes prone BIO.GD and
BALB/c mice. It is possible that cross reaction of the
anti-class II MoAb with other tissue antigens, might
have occurred. Equally, the use of Bouins fixed tissue
and mouse anti-class II MoAbs in the latter studies, as
opposed to cryostat sections and rat anti-class II MoAbs
in the former studies, may contribute to the
differences.
Recent studies which generated transgenic mice
expressing MHC molecules on islet beta cells, aimed to
determine if enhanced MHC expression on beta cells was
in itself sufficient to lead to the development of IDDM
(559-561). Major histocompatibility complex genes
coding for the class I molecule H-2K^ (559) and the
class II molecules, I-E^ (560) and I-A^ (561) were
placed under the control of the insulin promoter.
Strong expression of the transgenes were found in the
targeted beta cells with only Lo et al (560) finding
some expression also in the kidney tubule. In each
case, IDDM ensued in the transgenic mice, but without
the development of autoimmunity as determined by the
complete absence of insulitis either in mice syngeneic
or allogeneic with the transgenes. Moreover, the effect
on islet histology was variable. In the I-E transgenic
animals, the islets remained intact. However, in the H-
2K transgenics, fewer islets were observed, within which
beta cell numbers were depleted and islet infrastructure
was altered i.e. glucagon cells normally located at the
periphery were intermingled with the remaining beta
cells. In the I-A transgenics, immunoperoxidase
staining for insulin showed reduced insulin staining in
the transgenic mice.
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Parham has suggested that IDDM in these transgenic
animals results from the disruption of the pathway for
biosynthesis, maturation and secretion of insulin (562).
It is envisaged that active competition between insulin
and class II molecules for factors in the
intracytoplasmic compartments, may lead to the
production of an inactive insulin. Alternatively,
insulin secretion may be impaired by the binding of
insulin to a peptide binding site on the class II
molecule, similar to that described for the class I
molecule (74).
Moreover, it was reported that expression of the H-2K^
and I-E^ transgenes rather than inducing an autoimmune
response, resulted in the establishment of tolerance to
the transgenes. In the study by Lo et al (560), T cells
from transgenic mice gave strong proliferative responses
in mixed lymphocyte cultures against allogeneic
stimulators demonstrating their immunocompetence, but
gave only weak responses to the I-E^ transgenic
stimulator cells. Thus the T cells appeared tolerant to
the I-E^ molecule despite the absence of I-E^ in the
thymus or other lymphoid tissue. In addition, thymic
lymphocytes from transgenic mice also responded poorly
to the"transgene product, suggesting that induction of
tolerance to I-E occurs during T cell development in the
thymus. Furthermore, Allison et al (559) reported the
absence of T cells, even in mice allogeneic to the H-2K^
transgene, implying the development of tolerance to the
transgene product. The authors suggested that shedding
of transgenic molecules from the beta cell surface, may
reach the thymus where they are reprocessed to induce
tolerance. This is similar to the report by Adams et al
(563) who studied transgenic mice expressing the SV40 T
antigen, under the control of the insulin promoter.
They found that expression of the transgene early in
ontogeny induced tolerance to the SV40 T antigen.
Although these transgenic mice models of IDDM have not
provided a valid test for the role of enhanced MHC
expression in the development of Type 1 diabetes, they
have provided interesting information on thymic
education and mechanisms of tolerance. In this regard,
Iwatani et al (564) have proposed that expression of
class II MHC antigens on non lymphoid cells may
ultimately induce tolerance against self antigens by
protecting self from the immune response raised against
nonself which might otherwise interact with self.
Although it was observations made in autoimmune thyroid
disease which initially suggested a potential role for
aberrant MHC class II expression in the initiation of
autoimmunity (541), most of the subsequent studies in
thyroid disease suggest that ectopic class II expression
is not the primary event leading to the infiltration of
autoreactive lymphocytes but rather is a consequence of
that infiltration (565-567). Accordingly, the
topographical distribution of ectopic class II
expression on the follicular epithelium of autoimmune
thyroid glands in vivo is particularly pronounced in the
vicinity of the lymphoid infiltrates (568).
Similar findings to those I have described in the BB/E
rat, have been reported for experimental autoimmune
thyroiditis induced by neonatal thymectomy, where MHC
class II positive thyroid follicular cells were found
only in association with a T cell infiltrate in a few
animals and was rare even in them (569). In the
spontaneous thyroiditis of BB rats, thyroid epithelial
cells remained negative for class II MHC determinants
throughout the process of autosensitization (570).
In addition to autoimmune diseases, enhanced expression
of class II antigens has also been reported on
appropriate target cells during allograft rejection
loo
(571) as well as many different organs during immune
responses against antigens which are unrelated to the
tissues themselves as in graft-versus-host disease (572-
574). Moreover, although crypt epithelial cells in the
gut are generally negative for MHC class II antigens, it
is found that those cells adjacent to Peyer's patch
follicles express class II molecules (575). These
observations suggest that in many cases, the expression
of MHC class II antigens on tissue cells is a normal
physiological phenomena resulting from close proximity
to an active immune system.
However, physiological expression of MHC class II
molecules may also occur in the absence of immunological
stimuli, as is found on mammary gland epithelium during
lactation (576). * Equally, class II MHC antigen
expression has been reported on normal adrenal cortex
tissue in the absence of lymphocytic infiltration,
suggesting physiological expression of class II antigens
may occur even in the absence of adjacent lymphocytes
(577). Therefore, the finding in patients with IDDM of
class II molecules on pancreatic beta cells in islets
devoid of insulitis (549), may not be "aberrant" but
"physiological".
Pertinent to the hypothesis of aberrant expression of
MHC class II antigens on non lymphoid cells being the
trigger for autoimmunity, is the assumption that the
mere acquisition of MHC class II molecules can bestow
sufficient properties of a classical APC such as the
macrophage (578) to permit the presentation of antigen.
Several studies have reported the presentation of
nominal antigens by a variety of non traditional class
II positive accessory cells, including vascular
endothelial cells (579), astrocytes (580) and
fibroblasts (581). Cultured human thyroid epithelial
cells with lymphokine induced class II expression, have
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been shown able to present already processed viral
antigen to antigen specific T cells (582). However, the
presence of small numbers of classical APC's
contaminating the cultures may have been responsible for
the antigen presentation (583). The presence of
contaminating cells among thyrocyte cultures, has been
suggested by other studies. Whereas Pujol-Borrel et al
(542) reported the induction of thyrocyte class II
expression by the lectins PHA and ConA, subsequent
studies have indicated that this lectin induced MHC
class II expression is dependent on the presence of
contaminating T cells within the cultures (567, 584).
Furthermore, although murine thyroid follicular
epithelial cells (TFEC) could be induced following
culture with IFN-gamma to express MHC class II antigens
and produce IL-1, the TFEC were consistently unable to
present antigens either nominal (requiring processing)
or alloantigens (not requiring processing) to a variety
of sensitized T cells, T cell clones or hybridomas
(585).
In Type 1 diabetes, a recent report by Markmann et al
(586) addressed the antigen presenting function of MHC
class II expressing beta cells by using transgenic mice
that expressed a foreign class II (I-E) molecule on
their islet beta cells. In vivo antigen presentation
was assessed by the graft survival of foetal pancreas
from I-E+ transgenic mice when transplanted into I-E~
recipients. Whereas I-E expressing beta cells could be
recognized and rejected by immune effector cells if the
response was initiated by convential APCs following the
injection of I-E+ spleen cells, class II positive beta
cells were themselves unable to initiate an immune
response by naive non tolerant T cells. In vitro
studies using a T cell line specific for a peptide
fragment of herpes simplex virus glycoprotein D (gD),
indicated that although anti-gD specific T cells
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proliferated when cultured with antigen and MHC
compatible spleen cells, no proliferation of the T cells
resulted from culture with antigen in the presence of I-
E bearing islet cells. Thus, in both in vivo and in
vitro experiments, I-E+ beta cells of transgenic mice
were unable to present antigen to immunoreactive T
cells.
Furthermore, it was found that rather than initiating an
autoimmune response, antigen presented along with class
II positive islet cells resulted in paralysis of antigen
specific T cells, thereby inducing tolerance.
In concluding this part of the discussion, the studies
in the BB/E rat and other animal models of IDDM, do not
support the hypothesis that aberrant expression of class
II molecules on beta cells is an essential event in the
triggering of Type 1 diabetes. In the BB/E rat,
expression of class II molecules was a rare phenomenon,
which whenever found was always accompanied by
insulitis. Discrepancies between these studies and
those in human IDDM, as reported by Foulis et al (549),
where some islets were found with beta cell class II
expression in the apparent absence of insulitis, may
reflect" real species differences in the development of
IDDM. However, they may also be accounted for by the
fact that all the human pancreata studied, so far, have
been obtained from patients already diabetic at which
time it is difficult to define the sequence of earlier
preceding events.
Presentation of nominal antigens has been described for
a variety of class II bearing non lymphoid cells.
However, there have been no reports demonstrating such
antigen presentation capabilities of class II positive
islet beta cells.
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The steadily growing number of reports in the
literature, documenting the induction of class II MHC
molecules on an increasing variety of non lymphoid cells
by cytokines such as IFN-gamma and their expression on
many tissue cells following immune responses against
unrelated antigens, suggests that such inappropriate
class II expression may be more "physiological" than
"aberrant". The purpose (if any) of this physiological
class II expression is unclear, but it has been
suggested that it may serve as an extrathymic mechanism
for maintaining self tolerance (567, 586).
In their original report, Bottazzo et al (261), in
addition to the aberrant expression of MHC class II
antigens on beta cells, also described a marked increase
in class I (HLA- A,* B, C,) molecule expression in many
islets irrespective of the presence of infiltration.
In the BB/E rat, using serial pancreatic biopsy to study
sequential changes in individual animals, the first
observed change was the increased expression of MHC
class I molecules within some islets of animals aged 40
and 50 days, and therefore in the absence of insulitis,
which in common with other BB rat colonies, has seldom
been observed prior to 60 days of age (363, 587).
Furthermore, enhanced MHC class I heavy chain gene
expression has been demonstrated in pancreatic islets of
40 day old DP BB rats prior to the detection of low
levels of complementary RNA for the TCR beta chain and
IFN-gamma used as indicators of insulitis (588).
Leading up to the onset of IDDM, marked hyperexpression
of class I molecules on both endocrine and non endocrine
cells, in association with the presence of infiltration
was observed, and this is similar to the findings of
other groups (588, 589). At this stage in the disease
process, the observed hyperexpression of class I
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molecules is probably due to the release of cytokines
such as IFN-gamma and TNF from the infiltrating
immunocytes, where such cytokines are well known to be
capable of upregulating MHC class I expression on a wide
variety of cells (551, 590-592).
The observations in the BB/E rat, are supported by the
findings of Foulis et al (549) in their studies of human
IDDM using autopsy material derived from patients who
died from diabetic ketoacidosis. Whilst recognizing the
limitations imposed by cross-sectional data collected at
a time when 80-90% of the beta cells have been
destroyed, hyperexpression of class I MHC antigens on
all endocrine cells was found in 92% of insulin
containing islets, but in only 1% of insulin deficient
islets. Although' all insulin containing islets,
affected by insulitis, hyperexpressed class I MHC
antigens, many of the islets in which hyperexpression of
class I molecules was observed were without insulitis.
The cause of the enhanced class I expression in the
absence of insulitis, is unknown. However, in a further
study by Foulis et al (593), hyperexpression of class I
MHC molecules was associated with the presence of
immunoreactive interferon-alpha within insulin
containing beta cells. It is possible that chronic
viral infections, which can stimulate the release of
interferons from epithelial cells which in turn have
been shown to enhance the expression of class I MHC
molecules on pancreatic endocrine cells (591), may be
responsible for the upregulation of MHC class I antigens
within islet beta cells. This is supported by the
report of Campbell et al (594), demonstrating the
enhancement of class I expression on both human beta
cells and RINm5F cells following their infection with
reovirus types 1 and 3.
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A role for viral or bacterial infection in the
pathogenesis of IDDM in the BB rat, had been discounted
on the basis of an early study by Rossini et al ( 595)
which raised animals under germ free conditions.
Despite the gnotobiotic environment, the expected
percentage of rats developed diabetes. However, this
study does not exclude the possibility that vertically
transmitted viruses, slow viruses or any agent that was
not specifically tested for, may be involved in the
aetiology of IDDM.
In human IDDM, evidence that viral infections are
associated with the development of diabetes is derived
from epidemiological studies, where evidence of
Coxsackievirus B4 (596, 597) and rubella virus (598,
599) infections are "common amongst IDDM patients. Yoon
et al (600), reported that isolation of a strain of
Coxsackievirus B4, from the pancreas of a child who died
of ketoacidosis; when inoculated into certain strains of
mice, induced diabetes. Furthermore, infection of mice
with Coxsackievirus B4 has been shown to enhance the
expression of the putative 64KD islet cell autoantigen
on infected islets (601).
In rodents, diabetes following infection with
encephalomyocarditis virus (602), Mengovirus (603) and
Coxsackievirus B4 (604) is believed to result from
direct cytolysis of the infected beta cells. In
contrast, reovirus Type 1 (605) and rubella virus (606)
infections can cause a mild transient form of diabetes,
which can be prevented by immunosuppression (607)
suggesting a role for autoimmunity in its development.
However, whilst some viruses may be involved in the
pathogenesis of some cases of IDDM, there remains no
conclusive demonstration that IDDM is caused by viral
infect ion.
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The suggestion that some factor being produced within
the beta cells themselves is responsible for the
enhanced islet cell MHC class I expression, is
compatible with the pancreatic morphology observed in
both the BB/E rat and human IDDM studies. In the BB/E
rat, the enhanced class I expression appeared to
initially affect the beta cells at the islet core with
subsequent spreading to affect all the endocrine cells
within the islet. Since the order of the islet cellular
perfusion and interaction is from the beta cell core,
outward to the glucagon mantle (608), the observed class
I expression on the glucagon cells would be in keeping
with a possible paracrine effect caused by release of
beta cell factors into the islet microvascular system.
Furthermore, this is also suggested by the absence of
increased class I expression in end stage islets where
insulin containing beta cells and insulitis are no
longer found.
The role of the enhanced islet cell class I expression
in the pathogenesis of Type 1 diabetes, is unknown. In
human IDDM, where cytotoxic T lymphocytes are reportedly
the major infiltrating immunocyte (261), the
upregulation of class I MHC proteins on islet cells may
provide for their recognition and destruction by
cytotoxic T cells. However, transplantation studies in
the BB rat suggest that islet cell destruction is not
MHC restricted (397). In addition, other studies have
reported an absence of functional cytotoxic T cells in
the BB rat (376, 389). In the BB/E rat, although some
CD8 positive cells were detected amongst the
infiltrating cells, they were not numerous.
Furthermore, it is not possible to identify the CD8 +
cells as T cyt cells, since this phenotype is also
expressed by suppressor T cells. Accordingly, the
enhanced class I expression may invoke the activation of
a T supp cell population in an attempt to down regulate
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autoaggressive immune responses (57, 58). It is also
possible that the observed enhanced class I MHC
expression has no pathological function but merely
results as a consequence of pertubations within the
islet microenvironment, where a decrease in beta cell
volume in DP BB rats has been found to precede insulitis
(536). As such, enhanced class I expression within
pancreatic islets, represents an early marker of
impending immune assault on the islets.
Immune assault on the pancreatic islets of the BB/E rat
as determined by insulitis, was not observed in either
of the longitudinal studies in any animal prior to 60
days of age. This appears to be a common finding
amongst studies using BB rats from other colonies (312,
363, 536, 587). Howfever, prior to insulitis, pancreatic
infiltration coincident with expression of MHC class II
molecules on the ductular and vascular endothelium, is
observed with cells accumulated around the pancreatic
ducts and blood vessels.
The results from the pancreatic biopsy study, indicate
that a population of macrophages identified by the MoAb,
EDI are prominent during this early phase of pancreatic
infiltration. The studies revealed that ED1+
macrophages infiltrated the pancreas around the ducts
and vessels and then migrated to the islets,
approximately 2-3 weeks before the onset of IDDM. This
is followed by infiltration of the islets by the ED1 +
cells, thereby initiating insulitis. This appeared to
occur before the recruitment of other effector cells,
since even by "whole" islet analysis, using serial
sections, T- and B- lymphocytes were inconspicuous at
this stage. Subsequent infiltration by Tjj cells and to
a lesser extent T cyt/supp cells, NK cells and B
lymphocytes was only marked in biopsies taken 1-2 weeks
before the onset of diabetes.
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These results are similar to those recently reported by
two other groups. The study by Hanenberg et al (589)
used the same anti-rat macrophage MoAbs as employed in
my studies, whereas Lee et al (587) used the MoAb OX-41
which recognizes granulocytes as well as macrophages
(609). Equally, in low-dose streptozotocin-induced
diabetes of mice (508), and in NOD mice (476, 610), a
similar involvement for macrophages in the pathogenesis
of IDDM has been reported. However, in the NOD mice
studies, diabetes was induced by cyclophosphamide
treatment, and thus may not reflect the spontaneous
disease. In addition, no immunohistological studies
identifying macrophages were performed and as such, the
involvement of macrophages was inferred when insulitis
was prevented following the administration of silica,
which is believed ' to selectively inhibit macrophage
function (611).
Similar observations, to those found in the BB/E rat,
have been reported for other autoimmune conditions.
Induction of experimental autoimmune thyroiditis in the
rat, following neonatal thymectomy, was associated with
increased endothelial la expression and infiltration of
the thyroid by ED1+ macrophages (569). De novo
expression of class II MHC antigens, by ductular
epithelium and vascular endothelium accompanied by
perivascular infiltration by phagocytic mononuclear
cells, is observed in streptozotocin-induced diabetes of
mice (554). In the inflammatory central nervous system,
lesions of Lewis rats with experimental allergic
encephalomyelitis, ED1+ macrophages were prominent among
the perivascular infiltrates (612).
Previous ultrastructural studies had suggested the
involvement of macrophages in the development of IDDM in
the BB rat (312). These studies were performed on
diabetic animals at onset of disease and, therefore,
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gave no indication of the prediabetic events. A further
study, whereby administration of silica to BB rats
prevented diabetes, also suggested a role for
macrophages in the pathogenesis of IDDM (434). This
study, however, did not provide histological data and
therefore gave no indication as to where in the disease
process, macrophages may be involved. As already
mentioned, from the serial pancreatic biopsy study, it
appeared that macrophages were the initial infiltrating
cells causing insulitis. This is supported by the study
of Hanenberg et al (589) where administration of silica
was shown to prevent both the infiltration of ED1 +
macrophages and subsequent T lymphocyte recruitment.
Furthermore, in low-dose streptozotocin-induced
diabetes, in vivo administration of MoAbs, against T
lymphocyte subsets, "prevented the islet infiltration by
T cells but not by macrophages (508). Thus, the
evidence suggests that macrophage infiltration precedes
lymphocytic infiltration and that lymphocyte recruitment
is dependent upon the presence of macrophages.
However, although macrophages appear involved in the
early stages of the disease process, the studies in the
BB rat (369), the NOD mouse (476) or in low-dose
streptcnzotocin-induced diabetes (508), which show that
in vivo depletion of T cell subsets can ameliorate the
disease, indicates that T cells are also necessary for
the manifestation of the disease.
Although it is not known what activates the immune
response against the pancreatic islets, the immune
response involves the diapedesis of lymphoid elements
from the circulation to the pancreatic islets.
Accordingly, inhibition of vascular permeability has
been shown to prevent low-dose streptozotocin-induced
diabetes (514). Recently, Majno et al (613) found
evidence of a specific pancreatic venular defect in the
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BB rat. Ultrastructural studies suggested that a
population of marginating intravascular monocytes, when
activated, may induce venular leakage through the
release of IL-1 (614), and hence allow enhanced
diapedesis of lymphoid cells.
It is possible that this population of intravascular
monocytes may correspond to ED1+ cells since EDI, but
not ED2, stains the majority of peripheral blood
monocytes (529), and ED1+ cells have been seen trapped
in the vascular endothelium of Wistar rats (615).
Following their accumulation at perivascular sites, the
ED1+ macrophages are attracted to the pancreatic islets
and although the agent responsible for this has not been
identified, Leiter (616) has shown that insulin itself
can be chemotactic for activated macrophages. Having
infiltrated the islets, ED1+ cells may release cytokines
such as IL-1 (411) and TNF (412) which not only affect
insulin secretion but also can be cytotoxic to islet beta
cells. Furthermore, release of such cytokines can lead
to the generation of a self-perpetuating inflammatory
response. Accordingly, IL-1 (617, 618), TNF (619, 620)
and IFN-gamma (620, 621) can activate endothelial cells,
of pancreatic vessels and ducts, to bind increased
numbers of lymphocytes. Subsequent migration of
lymphocytes, through the endothelial cell layer, is
enhanced by release of IFN-gamma (622). The
infiltrating lymphocytes may then be attracted to islets
already infiltrated by macrophages by an IL-1
chemotactic gradient (618, 623).
Lymphocyte emigration may also be influenced by the
expression of MHC class II molecules on the vascular and
ductular endothelium and on islet capillary endothelial
cells, whereby endothelial cell class II expression
could be used to recruit antigen-specific Tjj cells into
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the site of a developing immune response, serving as an
amplification mechanism (624). As such, MHC class II
expression, on endothelial cells, can favour homing of
lymphocytes to particular tissues in autoimmune diseases
as has been shown for rheumatoid arthritis (625).
In lymphoid tissue, emigration from the circulation of
the mononuclear cells which participate in immune
responses, occurs in specialized post capillary venules
known as high endothelial venules (HEV)(626). High
endothelial venules can also develop in chronically
inflamed tissues (627) and recently, Kabel et al (628)
described the late development of HEV, containing
intrathyroid lymphoid tissue in BB rats with spontaneous
autoimmune thyroid disease. Similar HEV might be
expected to develop *in the pancreas of BB rats, thereby
improving the homing and recruitment of lymphocytes to
the sites of inflammation.
Furthermore, Jalkanen et al (625) found that some B cell
clones, that adhered to HEV of lymph node and mucosa-
associated lymphoid tissue (MALT), were unable to bind
to HEV in rheumatoid synovium. In addition, use of the
MoAb MEL-14, which blocks lymphocyte adherence to MALT-
HEV, did not inhibit the binding of lymphocytes to
synovial HEV. This suggested that there may be a novel
class of homing receptors on certain subpopulations of
lymphocytes distinct from the receptors for the
"classical" HEV of secondary lymphoid tissues, thereby
enabling their specific homing to the synovium. It
would be speculative to suggest that similar lymphocyte
homing receptors, specific for possible pancreatic HEV,
might exist.
Cytokines produced in the inflammatory response e.g. IL-
1, TNF and IFN-gamma, can also induce certain
intercellular adhesion molecules (ICAM) such as ICAM-1
on a variety of cell types including endothelial,
epithelial and myeloid cells (629). ICAM-1 is the
ligand for the antigen LFA-1 (lymphocyte function
associated) which is present on all leucocytes and is
believed to strengthen the adhesion between leucocytes
and their target cells (630). Thus, within infiltrated
islets, local cytokine production may induce ICAM-1
expression on islet beta cells, thereby enhancing
specific leucocyte-beta cell interactions. Recently, at
the 7th International Congress of Immunology, Campbell
et al (631) reported the in vitro induction of ICAM-1
expression by TNF and IFN-gamma, on islet beta cells.
The ICAM-1 expression was however also induced on the
other islet endocrine cells and therefore does not
reflect the beta cell specificity of IDDM. However, in
vivo, it may be that islet ICAM-1 expression is more
selectively distributed.
Although both macrophages and T cells appear necessary
for the development of IDDM in the BB rat, phenotypic
analysis, such as I have performed in the BB/E rat, does
not allow the elucidation of their functional roles. In
biopsies taken 1-2 weeks before the onset of IDDM,
infiltrated islets contained a variety of different cell
types." Whereas ED1+ macrophages were the most numerous
cell population within the infiltrated islets, this does
not necessarily imply they are the most important.
Accordingly, it is not known which of the infiltrating
cells ultimately deliver the lethal-hit to the beta
cells and which cells, "like the crowd gathered at the
scene of an accident", merely represent innocent
bystanders.
Macrophages infiltrating the islets may directly damage
the pancreatic beta cells, perhaps via release of beta
cell cytotoxic cytokines (411, 412), and/or may act as
classical APCs and present beta cell specific antigens
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to MHC class II restricted Tjj cells which infiltrate the
islets. Evidence for macrophage mediated cytotoxicity
towards cultured pancreatic islets has been reported
(632). In addition, Nagy et al (633) recently
demonstrated that splenic macrophages isolated from
diabetic BB rats, exhibited enhanced killing of islet
cells isolated from DR BB rats. Furthermore, they
suggested that the potential for splenic macrophage
mediated cytotoxicity develops prior to insulitis, and
that trafficking of macrophages from the spleen to the
islets may occur.
Amongst the infiltrating T cell population, TH cells
were the predominant phenotype in the BB/E rat, and this
has similarly been reported for the NOD mouse (557) and
low-dose streptozotocin-induced diabetes (508).
Activation of the Tjj cells, following presentation of
antigen by MHC compatible macrophages within the
pancreatic islets may serve to initiate activation and
recruitment of other effector cells. Alternatively,
some of the CD4+ cells, may directly exert a cytolytic
effect on the beta cells (634, 635). Equally, NK cells,
which are also present amongst the infiltrating cells,
may mediate beta cell destruction as has been suggested
by other studies (367-369).
The lytic process of beta cell destruction is not fully
understood, but recent studies based on the Okamoto
model, for pancreatic beta cell damage (493), suggest an
involvement of free radicals in the mediation of islet
cell damage (636). The Okamoto model views the
generation of free radicals such as superoxide anions
and hydroxyl radicals produced in the inflammatory
response, as principal mediators of islet tissue damage.
In addition to attack on the cellular membrane, these
radicals can induce strand breaks in the islet cell DNA
(490). DNA strand breakage promotes activation of the
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enzyme poly-ADP-ribose synthetase to initiate DNA
repair. This consequently depletes the islet NAD
content, thereby inhibiting proinsulin synthesis and
increasing islet sensitivity to further free radical
damage (493).
Support for the model comes from studies whereby
inhibition of the formation of these free radicals can
prevent islet cell damage. Combined treatment with the
iron chelator desferrioxamine, and the poly-ADP-ribose
synthetase inhibitor nicotinamide, has been shown to
prolong islet allograft survival in diabetic NOD mice
(471), and in multiple low-dose-streptozotocin-induced
diabetes (489). Interestingly, in the NOD mouse,
treatment with dimethyl sulphoxide (DMSO), a hydroxyl
radical scavenger, contrary to expectations, increased
the rate and frequency of diabetes whereas its in vivo
metabolite, dimethyl sulphide (DMS) reduced the
incidence and rate of diabetes (637).
In the BB rat, a time-course study was performed to
evaluate the intra-islet activity of the superoxide
radical scavenger; superoxide dismutase in relation to
the development of IDDM (638). Although SOD activity
did not- alter with age or the development of diabetes,
BB rats were found to have a lower endogenous SOD
activity than Wistar control rats. Thus, the lower SOD
activity may be a susceptibility factor that favours the
development of IDDM in the BB rat.
Accordingly, a high susceptibility for oxygen radicals
by beta cells compared with the other islet cells, due
to a low radical scavenger potential by the insulin
producing cells, has been suggested to account for the
specificity of beta cell destruction in IDDM (639).
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In conclusion, whilst the precise mechanism of beta cell
destruction is still unclear, the use of serial
pancreatic biopsy has enabled documentation of the
following sequence of events in the development of IDDM
in the BB/E rat.
The first phenomenon observed, is enhanced expression of
MHC class I molecules on islet cells. The cause of this
is unknown, but chronic viral infection remains a
possibility. This is followed by emigration from the
circulation, by a population of macrophages which
accumulate adjacent to pancreatic ducts and blood
vessels expressing MHC class II molecules on their
endothelium. Migration of these macrophages, into the
pancreatic islets, soon follows thereby initiating
insulitis. Release of cytokines from the activated
macrophages may directly injure the pancreatic beta
cells, but probably initiates a cascade of events
including the induction of adhesion molecules and homing
receptors and increasing vascular permeability, all of
which aid and abet the subsequent recruitment of T- and
B- lymphocytes into the inflammatory lesions. Within
the infiltrated islets, the invading immunocytes either
individually or collectively serve to selectively
destroy the islet beta cells.
The progressive spreading of these pathological
phenomena, with resultant beta cell loss, will
eventually result in the onset of IDDM when 80-90% of
the beta cell mass has been destroyed, at which point
administration of exogenous insulin is required to
sustain life.
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CHAPTER 7 - CYTOKINE MODULATION OF MHC EXPRESSION ON
RAT PANCREATIC ISLETS:IN VITRO STUDIES
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INTRODUCTION
Cytokines are a group of soluble, small molecular weight
(<80KD), antigen non-specific, protein cell regulators,
collectively including lymphokines, monokines,
interleukins and interferons (640). They are
synthesized and secreted by a wide variety of cells in
picomolar concentrations where they play an important
role in regulating the amplitude and duration of both
physiological and pathological immune responses.
Individual cytokines can exert multiple effects on a
variety of cells and thus, overlap in their biological
effects on lymphoid, myeloid and connective tissue cells
(641, 642). Consequently, a network of cytokine
interactions exists, whereby cytokines can induce each
other; modulate their cell surface receptors; and exert
synergistic or antagonistic functions on their target
cells (640).
Interferon-gamma, a lymphokine produced by activated T
lymphocytes (642, 643), can enhance expression of MHC
class I molecules and induce MHC class II molecules on a
variety of cell types (644, 645). Interferon-gamma has
been shown to enhance MHC class I expression and induce
class II antigen expression on both rat (646) and human
(551) thyroid cell cultures. However, whilst IFN-gamma
has unequivocally been found to enhance MHC class I
proteins on isolated mouse (647), rat (648) and human
(591, 649) pancreatic islet cells, there are conflicting
reports regarding the induction of class II molecules on
isolated islet cells. Whereas some studies have failed
to induce MHC class II molecules (591, 647, 649), other
studies have reported the induction of class II antigens
on dispersed mouse (650) and human (651) islet
parenchymal cells, and on isolated rat islets (648).
However, induction of MHC class II molecules on islet
cells by IFN-gamma was limited to 10-40% of the mouse
islet cells (650) and 15-20% of the human islet cells
(651). The study by Markmann et al (648) did not
provide any quantitative data, but the authors
emphasized that "not all treated islets in a given
section nor all cells within a single islet were ever
found to be highly positive for la". Furthermore, dual
immunofluorescence studies revealed that the induction
of MHC class II molecules included both beta and non-
beta cells (650).
Further studies have shown that where IFN-gamma alone
was unable to induce MHC class II molecules on monolayer
cultures of human pancreas (652), or isolated human and
mouse pancreatic islets cells (592); when combined with
tumour necrosis factor (653), induction of class II MHC
proteins on 30-50% of the islet beta cells was observed.
However, in addition to the islet beta cells, class II
expression was also found on the islet glucagon-and
somatostatin-containing cells (652).
It is possible that the propensity to induce MHC class
II molecules by IFN-gamma on pancreatic beta cells may
depend on genetic influences, and this may account for
some of the discrepancies between the above mentioned
studies. Accordingly, the in vivo susceptibility of
mice to the cytotoxic action of streptozotocin on islet
beta cells is MHC related (500), and the levels of
cytokine production may be related to MHC genotype
(654).
Following the in vivo observations, concerning
pancreatic MHC class II expression in the BB/E rat;
which I have described in the previous chapter, it was
important to investigate the role of cytokines on the
modulation of both MHC class I and class II molecules on
pancreatic islet cells isolated from BB/E rats. In
particular, we investigated the possibility that islet
cells isolated from autoimmune, diabetes-prone animals,
may be more susceptible to the induction of MHC class II




ISLET ISOLATION, CULTURE AND DISPERSION
Islets were isolated by collagenase digestion as
described in Chapter 4, from the following groups of
animals: (i) ICSA positive DP BB/E rats aged 80-90 days;
(ii) ICSA negative DP BB/E rats aged 80-90 days; (iii)
DP BB/E rats aged 30 days; (iv) DR BB/E rats aged 80-90
days; (v) DR BB/E rats aged 30 days; (vi) normal Wistar
rats aged 80-90 days; (vii) normal Wistar rats aged 30
days.
For each experiment, isolated islets were pooled from 4
rats in each animal group. Batches of pooled islets
(350-400) were precultured for 2-3 days in tissue
culture medium (RPMI 1640 containing ll.lmmol/1 glucose;
20mmol/l HEPES; lOOU/ml penicillin; O.lmg/ml
streptomycin and 10% heat inactivated foetal bovine
serum). Islets were further maintained in free-floating
culture (37°C + 5% CO2) for 3-10 days in tissue culture
medium with or without the addition of the following
cytokines, either singly or in combination: (i)
recombinant (r) rat interferon-gamma (r.IFN-gamma; 10-
102U/ml); (ii) human or murine recombinant tumour
necrosis factor (r.TNF; 10-10^U/ml); (iii) murine
recombinant interleukin 1 (r.IL-1; 5-10^U/ml). The
fully supplemented culture medium was changed every
three days. At the end of the culture period, single
cell suspensions from the cultured islet cells were
prepared using an enzyme dispersion technique (655).
The islets were washed twice in sterile 15ml Falcon
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tubes containing 6ml of ice cold Ca and Mg -free
Hanks' balanced salt solution (pH 7.4) containing
penicillin and streptomycin (as above) and BSA
(5mg/ml)(HBSS-Ca2 + /Mg2 + ) . The washed islets were
resuspended in 5ml of HBSS-Ca2+/Mg2+ containing the
following additions: 3mg/ml collagenase; 2.5mg/ml
trypsin (Difco Laboratories, Detroit, MI); lmg/ml
hyaluronidase (Sigma, Poole, Dorset); l.Qug/ml DNase
(Sigma) and lmmol/1 EGTA (Sigma) and incubated for 20
mins. at 37°C in a shaking water bath to disperse the
islet cells. Cell dispersion was completed by repeated
(10 times) aspiration in a Pasteur pipette. The cell
suspension was washed by repeated centrifugation (1 min.
at lOOg); twice in HBSS-Ca^+/Mg^+ and once in RPMI 1640
(supplemented as above). Cell numbers and viability
were estimated by acridine orange/ethidium bromide
(0.25jug/ml; 5ug/ml) (Sigma) staining of cell preparations
on a haemocytometer. Cell viability exceeded 90% and
islet cell suspensions containing 5xl0^cells/ml were
finally resuspended in RPMI 1640 for subsequent
immunofluorescence detection of rat MHC antigens.
ISLET CELL IMMUNOFLUORESCENCE STAINING
The MoAbs (Table I) MRC 0X-6 and MRC 0X-18 were used to
detect rat MHC class II and class I antigens
respectively. MRC 0X-8 and MRC OX-19 were used as
controls for non specific reactivity, and EDI and ED2
used to detect potential contaminating cells of
monocytic origin.
The MoAbs were made up in PBS (0.05mol/l, pH7.6)
containing 10% normal rat serum, 1% BSA and L-lysine
(20mmol/l)(Sigma) and used at 1:2-1:5 dilution for the
clone supernatants, and 1:100-1:300 for the ascites
preparations. lOQ/ul of dispersed islet cell suspensions
(2xl0^cells/ml) were incubated with the diluted MoAbs
(lOQul) at 0-4°C for lhr. Following three washes with
0.2ml PBS containing 1% BSA and L-lysine (20mmol/l),
surface staining was revealed after a similar incubation
with 0.1ml rhodaminated rabbit anti-mouse
immunoglobulins (Dakopatts, Weybridge, Surrey, UK),
XIL
previously adsorbed with rat liver acetone powder
(lOmg/ml)(Sigma) and diluted 1:20 in PBS+BSA/L-lysine.
After three washes (0.2ml PBS+BSA/L-lysine), the
surface-stained cells were fixed in 0.1ml ice-cold 2%
paraformaldehyde in 0.9% NaCl containing HEPES
(20mmol/l) and BSA (lmg/ml) pH7.4 for 30 mins. The cell
suspensions were washed three times in 0.2ml PBS
containing 1% BSA, L-lysine (20mmol/l) and 2% foetal
bovine serum and finally resuspended in 50;ul of PBS.
The surface-stained cells were put onto PTFE coated
glass slides (4 multispot)(C.A. Hendley, Essex, UK) and
allowed to air dry. The slides were placed in ice-
chilled acetone for 15 mins, air-dried and washed in
PBS.
Subsequent double immunofluorescence staining to
identify endocrine hormones was performed by incubating
the slides for lhr at 25°C with the following antisera:
clone supernatants of monoclonal anti-insulin (2F1),
anti-glucagon (GLU001) or anti-somatostatin (S0M018) and
the polyclonal antisera M1183 and M1187 (guinea pig
antibodies against insulin) were kindly provided by
Novo, Copenhagen, Denmark. Further polyclonal antisera
against insulin and glucagon hormones were obtained from
Atlantic Antibodies (Winnersh, Berks, UK). Reactions of
MoAb binding were revealed using biotinylated horse
anti-mouse immunoglobulins (Sera Lab, Crawley Down,
Sussex, UK) diluted 1:50 in PBS+BSA/L-lysine containing
10% normal horse serum (Sera-Lab), incubated for 40
mins., followed by fluoresceinated streptavidin
(Cambridge Bioscience, Cambridge, UK) diluted 1:100 in
PBS+BSA/L-lysine and incubated for 30 mins. Polyclonal
antisera were identified with fluoresceinated antibodies
to guinea pig or rabbit immunoglobulins (Cambridge
Bioscience) diluted 1:20-1:40 in PBS+BSA/L-lysine
JU3
containing 10% nonimmune host derived serum and
incubated for 30 mins. at 25°C.
A rabbit polyclonal antibody specific for factor VIII
related antigen (Cambridge Bioscience) was used as a
control for non-specific binding. Further controls,
included primary incubations with PBS+BSA/L-lysine,
followed by the fluoresceinated or rhodaminated
conjugates, or primary incubations with normal mouse,
rat, sheep, goat, guinea pig or horse serum (Sera-Labs)
followed by the labelled conjugates.
Slides were examined under a Leitz Orthoplan microscope
fitted with a fluorescence vertical illuminator and
filter blocks for revealing fluorescein and rhodamine
fluorochromes. Photographs were taken on Ektachrome ASA
400 film with automatic exposure.
CYTOKINE PREPARATIONS
Rat recombinant interferon-gamma (4xl0°U/mg protein) was
a generous gift from Dr Peter van der Meide (The Primate
Centre, TNO, Rijswijk, The Netherlands). Its production
in Chinese hamster ovarian cells transfected with a
chromosomal rat IFN-gamma gene, and its purification by
antibody affinity chromatography have previously been
described (656, 657).
O
Recombinant human tumour necrosis factor (2xl0°U/mg)
produced by Genentech, San Francisco, CA, was a gift
from Dr G.R. Adolf (Boehringer-Ingelheim, Vienna,
Austria). Recombinant murine tumour necrosis factor
produced in E.Coli containing an appropriate plasmid,
and purified to homogeneity (658) was kindly donated by
Dr Jan Tavernier (Biogent, Geneva, Switzerland). The
specific activity, as measured in a cytotoxicity assay




The results to be described, represent consistent
findings using batches of pooled islets from experiments
involving four animals per group. Each experiment has
been reported on at least four separate occasions.
INTERFERON-GAMMA
Enhancement of MHC class I antigens on RINm5F cells by
IFN-gamma has been well documented (592, 659-662).
Therefore, in each set of experiments, cultures of
RINm5F cells with or without added IFN-gamma were
stained for class I MHC molecules to provide a positive
control for the biological activity of the IFN-gamma
preparation.
Figure 22 indicates the enhancement of MHC class I
antigens on RINm5F cells after 3 days culture with
lOOU/ml r.IFN-gamma. This concentration of r.IFN-gamma
had previously been established as optimal for la
induction on cultured rat thyroid cells (646). Culture
of islets with r. IFN-gamma (lOOU/ml for 3-10 days)
increased the expression of MHC class I molecules on the
surface of beta and non-beta islet cells, isolated from
all the groups of animals studied (Fig. 23). The level
of enhanced class I expression was not uniform, with
some cells showing more intensive staining than others
(Fig. 23a, Fig. 23c).
Islets isolated from the various animal groups and
cultured with rat r.IFN-gamma were examined for the
presence of class II MHC proteins. After 4 days in
culture with r.IFN-gamma (lOOU/ml), islets isolated from
both ICSA-positive and ICSA-negative DP BB/E rats, aged
80-90 days, were found to express MHC class II molecules
(Fig. 24b). The islet cell suspensions prepared by
ru
enzyme dispersion contain predominantly (>80%) beta
cells (413), and approximately 50% of the insulin-
containing cells were positive for class II antigens.
The induction of class II antigens, although not present
on all beta cells, was nevertheless specific for
insulin-containing cells, since class II antigens were
not detected on any glucagon-or somatostatin-containing
cells from the same islet cell suspensions (Fig. 24d).
Further-more, MHC class II molecules were not observed
on any endocrine cells isolated from age-matched DR BB/E
rats, normal Wistar rats or young (30 days of age) DP
BB/E rats.
A small population (3-5%) of cells bearing MHC class II
antigens were identified in cell suspensions from all
groups of animals cultured with r.IFN-gamma (Fig. 25a).
This probably reflects in part, some non-specific
binding since reactions with the irrelevant antibodies
0X-8 and 0X-19 identified approximately 2% of the cells
in all the cultures irrespective of the presence or
absence of r.IFN-gamma (Fig. 25b). Equally, some of the
non-endocrine class II expression may represent
induction by r.IFN-gamma on surviving contaminating
pancreatic ductal or exocrine cells (591). However,
contamination of the cultures with macrophage-like cells
was minimal, since reactivity of the cell suspensions to
the MoAbs EDI and ED2 were only comparable with the 1-2%
non-specific binding of other irrelevant antibodies.
TUMOUR NECROSIS FACTOR AND INTERLEUKIN-1
The failure to induce class II MHC antigens on islet
cells isolated from young DP BB/E rats suggested the
possibility that islets isolated from the older DP BB/E
animals may be susceptible to induction of class II
molecules by r.IFN-gamma because of previous cytokine-
mediated damage in vivo, prior to their isolation.
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Thus, islets isolated from DR BB/E rats and normal
Wistar rats, both aged 30 days, were cultured with r.TNF
(both human and murine) or r.IL-1 either singly or in
combination with r.IFN-gamma and examined for expression
of MHC antigens.
Islets from both groups of animals, when cultured with
r.TNF (lOU/ml) alone for 3 days, showed enhanced levels
of MHC class I expression (Fig. 26b), which was further
augmented when combined with lOOU/ml r.IFN-gamma (Fig.
26c) .
Induction of MHC class II antigens on islet endocrine
cells were not observed in either of the animal groups
following incubation with r.TNF alone (10-10^U/ml) or in
combination with r.IFN-gamma (lOOU/ml) over a 3-10 day
culture period. Incubation of islets with r.IL-1 (5-
lOOOU/ml) did not enhance class I expression, nor when
combined with r.IFN-gamma (lOOU/ml) induce MHC class II
proteins on islet endocrine cells.
Although these investigations were aimed to study
cytokine modulation of MHC expression, it was observed
that the numbers of islet cells recovered from the
cultures containing r.TNF or r.IL-1 with or without
r.IFN-gamma appeared decreased. Accordingly, it was
found that r.TNF (>50U/ml) or r.IL-1 (>10U/ml) exerted
cytotoxic effects on islets isolated from both DR BB/E
rats and normal Wistar rats. After 4-5 days of culture,
in the presence of either r.TNF or r.IL-1, marked
morphological disruption of islet plasma membranes were
observable under the stereomicroscope (Fig. 27).
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Fig 22 : Expression of MHC class I proteins on
RIN m5F cells after 3 days culture in the
absence (A) or presence (B) of lOOU/ml of





Fig 23 : MHC class I antigen expression on dispersed
islet cell suspension from islets cultured
with lOOU/ml of r. IFN-gamma for 4 days.
(a) OX-18 staining of islet cells from DR
BB/E rats (80-90 days of age). X 312
(b) double exposure for insulin-containing
cells (green) and MHC class I positive
cells.
(c) OX-18 staining of normal Wistar rat
islet cells (80-90 days of age). X 500.
(d) double exposure for insulin (green) and
class I MHC antigens (red).
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Fig 24 : Dispersed islet cell suspensions from isolated
islets of ICSA-positive DP BB/E rats (aged
80-90 days) cultured with lOOU/ml of r. IFN-
gamma for 4 days. X 500.
(a) OX-6 staining for MHC class II positive
cells.
(b) double exposure of (a) for insulin (green)
and OX-6 (red) shows the induction of
MHC class II antigens on the insulin-
containing cells in this field.
(c) glucagon/somatostatin staining within
the same cell suspensions.
(d) double staining of the cells in (c)




Fig 25 : Dispersed islet cell suspensions from
isolated islets of 30 day old DR BB/E rats.
(A) Double staining for insulin (green)
and OX-6 (red) in cell suspensions
cultured for 4 days with lOOU/ml
r.lFN-gamma shows some non-endocrine
class II positive cells. X 500
(B) Double staining for glucagon (green)
and OX-8 (red) in cell suspensions
cultured without r.IFN-gamma shows




Fig 26 : MHC class I molecule expression on dispersed
islet cell suspensions from 30 day old DR
BB/E rats. X 625
(A) control MHC class I antigen levels
after 3 days culture.
(B) OX-18 staining after 3 days culture
with lOU/ml of r.TNF.
(C) Class I MHC antigen expression following




Fig 27 : "Whole" normal Wistar rat islets (aged 90
days) cultured for 5 days in the presence
of r.IL-1 (20U/ml) or r.TNF (lOOU/ml).
(a) control cultures. X 312
(b) islets cultured with r.IL-1 show
disruption of islet cell membranes.
X 312.
(c) islets cultured with r.TNF. X 125.
(d) acridine orange/ethidium bromide





Although IFN-gamma has been shown to induce MHC class II
molecules on a wide variety of cell types (550, 551,
644-646), the studies herein described, in agreement
with other studies (591, 592, 647, 649), indicate that
islet beta cells are not readily stimulated by IFN-gamma
to express class II MHC antigens.
It was found that islets isolated from DP BB/E rats aged
80-90 days, when cultured with lOOU/ml of rat r.IFN-
gamma for >4 days, expressed MHC class II molecules on
approximately 50% of the insulin-containing beta cells.
In contrast, induction of class II expression by r.IFN-
gamma was never observed on (i) glucagon- or
somatostatin-containing cells in islets from any
animals; (ii) beta cells from either normal Wistar or DR
BB/E rats, or (iii) beta cells from young (30 days of
age) DP BB/E rats.
In the older DP BB/E rats, the presence or absence of
ICSA did not appear to be related to the sensitivity of
the beta cells to r.IFN-gamma. However, since
circulating ICSA levels fluctuate in the prediabetic
period, it is likely that some animals categorised as
ICSA negative, had been ICSA positive at some time
previously. Since expression of class II MHC antigens
was not observed on any endocrine cells cultured in the
absence of r.IFN-gamma, the expression of class II
molecules specifically on beta cells isolated from DP
BB/E rats, is unlikely to be due to adsorption of MHC
class II proteins, shed from passenger macrophages.
Furthermore, islet cell suspensions stained with MoAbs
against macrophages did not identify any significant
macrophage contamination of the cultures. Indeed, this
is not unexpected, since maintenance of isolated islets
in free-floating culture for several days has been shown
to act as a purification step for removal of non-
endocrine cells (663). By the same arguments, the
observed induction of class II MHC molecules on DP BB/E
beta cells is unlikely to represent phagocytic uptake of
fragmented beta cells by macrophages which are
themselves expressing class II MHC antigens (552, 553).
Since expression of class II molecules was only found on
approximately 50% of the isolated beta cells, it is
possible that the susceptibility of these beta cells was
related to their differentiation state. Thus, the
systemic induction of class II molecules on previously
negative parenchymal and stromal cells, following
intravenous infusions of r.IFN-gamma, appeared related
to the differentiation stage of each cell population
(664). Equally, the effect of IFN-gamma, on induction
of class II antigens on various cell lines, appeared
related to their differentiation state (645). This
could be related to the methylation state of the DNA
since treatment of certain non-responsive cells with 5-
azacytidine, a DNA-demethylating agent, results in
acquisition of susceptibility to IFN-gamma induced la
expression (665). Accordingly, previous autoradiography
studies in the DP BB/E rat have indicated an increase in
islet "cell replication in pancreatic sections obtained
from animals of similar ages to those from which the
islets susceptible to r.IFN-gamma induction of class II
molecules were isolated (538).
Although most studies indicate that islet cells are
refractory to the induction of MHC class II antigen
expression by IFN-gamma alone, a few studies have
reported class II induction on normal islets with IFN-
gamma alone (648, 650, 651). In the studies by Wright
et al (650, 651), longer culture periods and 10-20 fold
higher concentrations of IFN-gamma were used when
compared with our studies. Thus, culture of mouse
islets for >6 days (650) or human islets for 10 days
(651), in high concentrations (>10JU/ml) of r.IFN-gamma,
induced class II molecules on 15-20% of islet
parenchymal cells, which included both beta and non-beta
cells. Culture with a 5% lymphokine supernatant
isolated from a T-cell line sensitized to Listeria
monocytogenes, induced class II antigens on 10-40% of
dispersed islet cells cultured for >9 days (650).
However, the lymphokine supernatant could contain
cytokines other than IFN-gamma, which may act to
influence the islet class II expression. In the report
by Markmann et al (648), mouse r.IFN-gamma (500U/ml)
cultured for 6 days with islets isolated from Lewis
rats, induced MHC class II proteins on the surface of
whole islets. However, immunohistological staining for
endocrine hormones Was not performed and therefore the
identity of the class II positive cells was not
established.
The induction of MHC class II proteins on beta cells
from DP BB/E rats, could suggest that the genotype of
the diabetes-prone animals may confer a greater
susceptibility to gamma-IFN induction of class II
antigens, than the genotype of diabetes resistant
animals. However, the failure to induce class II
molecules on beta cells isolated from young DP BB/E rats
indicated that the possession of a particular genotype
was in itself not sufficient; and suggested the
possibility that prior in vivo cytokine-mediated damage
to the islets isolated from the older DP BB/E rats may
have sensitized them to subsequent IFN-gamma induced
class II expression. Since the mean age at onset of
IDDM in the BB/E colony is about 96 days, and insulitis
appears at least 2 weeks before disease onset, it is
likely that some of the islets isolated from the older
DP BB/E rats would have already been damaged by
infiltrating immunocytes.
The possibility that at least two signals were necessary
to induce MHC class II antigens on islet cells was
supported by other studies. In these studies on human
(592, 652) and mouse (592) islets, whilst IFN-gamma
alone was without effect, when combined with TNF or
lymphotoxin (LT), induction of MHC class II molecules
was observed on 30-50% of islet beta cells.
Tumour necrosis factor (TNF-alpha) is a cytokine
primarily produced by activated macrophages (653),
although T cells can also produce this form of TNF in
addition to LT (666). Equally, amongst a variety of
cell types (667); macrophages and T cells can synthesize
and secrete interleukin-1, which has been reported to
mediate islet cell damage in vitro (All, 412). Thus,
since macrophages hnd T cells are prominent in the
insulitis of BB/E rats, it is likely that TNF and IL-1
are being produced in the islet microenvironment.
Furthermore, synergy between IFN-gamma and these
cytokines, have been well documented for a variety of
effects (668), including; enhancement of cytotoxicity
against either tumour cells (669) or pancreatic islets
(413, 670); augmentation of antiviral activity (671) and
amplification or induction of MHC antigens on
endothelial (672) or thyroid (673) cells. Consequently,
TNF and IL-1 seemed the most likely candidates to
combine with IFN-gamma to induce MHC class II antigens
on islet beta cells.
However, in our culture systems neither r.TNF or r.IL-1,
either individually or in combination with r.IFN-gamma,
were able to induce class II antigens on islet beta
cells isolated from DR BB/E rats or normal Wistar rats
aged 30 days.
These results are disparate from those of Pujol-Borrell
et al (652) and Campbell et al (592) which describe the
induction of MHC class II antigens on 30-50% of islet
beta cells following culture with TNF or LT in
combination with IFN-gamma. In the former study, human
pancreatic monolayer cultures containing >80% non-
endocrine cells, including ductal cells, macrophages and
fibroblasts were used. Therefore, it is possible that
the induced class II expression could have been
potentiated via cytokines other than TNF released by
other cell types within the monolayers.
In the latter study, isolated human and mouse islets
were used, but induction of class II MHC proteins
required using concentrations of 500-1000U/ml of both
r.TNF and r.IFN for'5-6 days. In both studies, however,
the induction of class II MHC molecules was not specific
for the beta cells, being found also on the glucagon and
somatostatin cells (652) and some unspecified non-beta
cells (592). Accordingly, the results are at variance
with the in vivo observations on pancreata from IDDM
patients, where induction of MHC class II antigens is
specific to the islet beta cells (261, 549).
Interestingly, in the above study by Campbell et al
(592), the same combination of TNF and IFN-gamma when
added to cultures of RINm5F cells, failed to induce MHC
class II molecules on the cells. This could further
suggest that the differentiation state of the beta cell
might determine its susceptibility to cytokine induced
expression of class II MHC proteins. This is supported
by the findings of Varey et al (662); whereas freshly
cultured RINm5F cells were readily induced by IFN-gamma
to express class II MHC antigens, the induction was not
so pronounced when long-term cultured cells were used.
The failure to induce MHC class II antigens on normal
Wistar or DR BB/E rats with combinations of r.TNF, r. IL-
I and r.IFN-gamma suggests that this particular triad of
cytokines do not, at least in vitro, act to induce class
II antigens on normal rat islets. However, it may be
that where more than one signal is required, the
different signals have to be delivered in an appropriate
sequence. Thus, the susceptibility of thyroid
epithelial cells to the cytotoxic action of TNF is
enhanced by incubating the cells with IFN-gamma before
exposure to TNF (674). This synergy between IFN-gamma
and TNF may ensue following induction of TNF receptors
on cells by preincubating the cells with IFN-gamma
(675). In our experiments, when combinations of
cytokines were used, they were added simultaneously.
Therefore, it cannot be excluded that different results
might have been obtained if, for example, the islets had
been preincubated with IFN-gamma and then incubated with
TNF or IL-1.
Synergistic effects between TNF and IFN-gamma were
however observed as regards their effects on islet class
I MHC expression. In agreement with Campbell et al
(592), incubation of islets from both normal Wistar and
DR BB/E rats, with r.TNF alone, enhanced the expression
of MHC class I proteins on all endocrine cell types.
Addition of r.IFN-gamma further augmented the levels of
islet class I expression. Similar enhancement of MHC
class I proteins, by TNF, have been reported for human
endothelial cells (672), rat thyroid cells (673) and rat
astrocytes (676).
Cytotoxic and cytostatic effects of TNF (674, 677) and
IL-1 (678, 679) against a variety of normal and
transformed cells have been documented. Both TNF (670)
and IL-1 (411) have been shown to exert cytotoxic
effects towards cultured islet cells. Furthermore,
reports on the synergism between these cytokines as well
as with IFN-gamma; causing enhanced islet cell
cytolysis, have been described (412, 413, 670).
As an adjunct to our experiments, it was noticed that
islets cultured with r.TNF (>50U/ml) or r.IL-1 (>10U/ml)
either singly or in combination with r.IFN-gamma
(lOOU/ml), showed evidence of morphological damage after
4 days in culture. After 3 days of culture, with
2000U/ml of murine r.TNF, inhibition of glucose-
stimulated insulin release from isolated mouse islets
was reported by Campbell et al (670). This effect was
augmented by the addition of murine r.IFN-gamma, such
that after 6 days of culture with both cytokines,
complete morphological disintegration of the islets was
observed (670).
Using a ^ ■'•Cr-release assay and rat pancreatic islets in
monolayer culture, Pukel et al (413) did not observe any
cytotoxic effects on the monolayers with human r.TNF
(lOOU/ml) or human r.IL-1 (lOU/ml) alone. However,
combinations of these cytokines with each other or rat
r.IFN-gamma proved cytolytic to the monolayer cultures,
with maximal effect obtained with the combination of all
three ""cytokines. Where human r.TNF was used on rat
islets (412, 413), the failure to detect TNF mediated
islet cytotoxicity, could suggest that to some degree
this effect is species specific (680). Thus, in the
studies by Pukel et al (413), both rat and mouse, but
not human r.IFN-gamma exerted a small dose dependent
lysis of the rat islet monolayers. In our studies
however, both human and murine r.TNF were used; and both
were capable of disrupting the morphology of the free-
floating rat islets.
iH-7
Over the last few years several reports, mainly from
Jorn Nerup and his group at the Steno Memorial Hospital
in Denmark, have described the cytotoxic effects of IL-1
on isolated islets (411, 412, 681-684) and these have
recently been reviewed (685).
Initially, culture of rat or human islets for 7 days
with a crude supernatant obtained by stimulating
peripheral blood mononuclear cells from healthy human
donors with antigen or PHA, was found to affect glucose-
stimulated insulin secretion, and reduce the islet
insulin and glucagon content (681). Subsequently, the
identity of the cytotoxic activity was determined when
adsorption with a purified antibody to IL-1 eliminated
the cytotoxic activity from the crude supernatant (682).
Thereafter, the addition of highly purified human IL-1
to cultures of isolated rat islets for 6 days led to
inhibition of glucose-induced insulin release, reduction
of islet contents of insulin and glucagon, and
disintegration of the islets (411). Factors which
reduced the IL-1 islet cytotoxicity included, increasing
the glucose concentration in the culture medium, and the
addition of normal human or rat serum, thereby
indicating the presence of IL-1 inhibitors or
antagonists within normal serum (683).
These inhibitory effects of IL-1 on islet insulin
secretion have been corroborated by other groups (686-
688). However, in addition to its inhibitory effects,
IL-1 at lower concentrations (20-26 ug/1) can also
potentiate glucose-stimulated insulin release (689).
Therefore, depending on the parameters of IL-1
concentration and duration of exposure, IL-1 can be
stimulatory or inhibitory for glucose-induced insulin
release from isolated islets (684, 686, 687, 690).
Thus, Comens et al (687) found that IL-1 (5pM) incubated
for 15h, stimulated glucose-induced insulin secretion,
3M
whereas a similar incubation with a 10-20 fold greater
IL-1 concentration was inhibitory. Equally, the larger
doses given for shorter time periods (90 mins), also
proved stimulatory. The inhibitory effects were not due
to beta cell death since islets were morphologically
intact, displayed normal islet plasma membrane
permeability, and the effects were reversible following
removal of IL-1 (687). Thus IL-1 in short term cultures
can influence beta cell function without inducing cell
death.
It has been proposed that IL-1 may be involved in the
pathogenesis of IDDM by mediating selective destruction
of the pancreatic beta cells (685). However, it is
contentious whether or not IL-1 induced islet
cytotoxicity is specific for the beta cells. In their
initial studies (411, 681, 682, 684), Mandrup-Poulsen
and colleagues found that incubation of islets with IL-1
in addition to affecting insulin synthesis and
secretion, also reduced the glucagon content of the
islets. However, in a more recent time course study,
ultrastructural analysis revealed that whereas beta
cells were already subjected to pathological changes
after 30 mins. exposure to 25U/ml of IL-1, no changes
were observed in glucagon cell morphology during 24h
exposure (691). Thus it is suggested that a short half-
life in vivo, together with a high local IL-1
concentration, may allow for the selective destruction
of islet beta cells by IL-1 (685).
In conclusion, our in vitro studies on the ability of
cytokines to modulate expression of MHC antigens on
isolated islets, are compatible with our in vivo
findings, whereby expression of MHC class II molecules
on pancreatic beta cells represents a secondary
phenomenon, probably influenced by release of cytokines
from infiltrating macrophages and lymphocytes. In
general, islet beta cells appear refractory to the
induction of class II MHC proteins by cytokines.
The preferential induction of class II antigens on beta
cells isolated from DP BB/E rats, suggested that
genotype could influence islet cell susceptibility to
the effects of various cytokines. Thus, murine JHM
Coronavirus, induced la expression in rat strains
susceptible to JHM virus-induced demyelinating disease,
but not in rat strains resistant to the disease (692).
However, Mandrup-Poulsen et al (683) reported that
genetic background did not influence the susceptibility
of isolated rat islets to the cytotoxic effects of IL-1,
with no differences observed amongst four inbred rat
strains. This study did not however include any
diabetes-prone rats-or rat strains susceptible to other
autoimmune diseases.
Subsequently, Anderson et al (693) isolated islets from
DP and DR BB rats, as well as from three inbred non-
diabetic rat strains and cultured them with human r.IL-1
for 7 days. Strain related differences in the
sensitivities of the islets to the cytotoxic effects of
IL-1 were detected, but these differences were unrelated
to the~ propensi ty to develop IDDM. However, the study
used newborn rat islets, and therefore it is possible
that detection of strain-related differences to the
effects of IL-1 may be missed. Furthermore,
cyclosporine (CSA) was given to the pregnant diabetes-
prone rats in order to prevent them developing diabetes
during pregnancy. Since CSA can also inhibit insulin
synthesis and secretion, i.e. similar to IL-1 (694),
this may alter the IL-1 sensitivities of the islets
isolated from the offspring of these animals.
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Alternatively, the differentiation state or the
activation state of the islets at their time of
isolation, may be important in determining their
sensitivity to the effects of cytokines. Thus, Palmer
et al (695) have recently shown that the resting beta
cell is more resistant to IL-1 mediated cytotoxicity
than the stimulated beta cell.
Although many studies have investigated the effects of
cytokines on islet MHC antigen expression or cytokine
mediated islet destruction, their results have not
always been in agreement. These disparate results
indicate that in attempting to mimic the in vivo
situation, in vitro studies have limitations which
necessitate that caution must be exercised in
extrapolating their . results to the in vivo situation.
Accordingly, variations in the source, species and
concentration of cytokines employed, combined with
differences in the culture conditions and duration of
cytokine exposure, will produce varying results between
different centres. Furthermore, in vivo, the levels of
cytokine production are likely to be under genetic
control (654), and the network of their interactions
with each other, producing synergistic or antagonistic
effects- on target cells are also likely to be finely
controlled, such that it is unlikely that in vitro
studies can accurately mimic the in vivo situation.
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CHAPTER 8 - EFFECT OF CYCLOSPORINS ON THE DEVELOPMENT
OF IDDM IN THE BB/E RAT.
INTRODUCTION
Cyclosporine (CSA) is a small hydrophobic cyclic
undecapeptide derived from the fungus, Tolypocladium
inflatum Gams, and is widely used as a potent immuno¬
suppressive agent (696, 697). Its immunosuppressive
properties were first described by Borel et al (698,
699). Cyclosporine inhibited humoral immunity as shown
by a reduction of plaque forming cells, and suppressed
cell-mediated immune responses by preventing skin graft
rejection and inhibiting the development of GVHD and EAE
in rodents (698). In addition, CSA blocked delayed type
hypersensitivity (DTH) responses to tuberculin and
oxazolone (699). Its failure to prohibit antibody
synthesis to LPS in nude mice, suggested a selective
effect on T lymphocytes (699). However, subsequent
studies have demonstrated CSA mediated suppression of B
lymphocyte activation by anti-Ig antibodies (700).
Cyclosporine can affect both TH (699, 701) and T cyt
(702) cells, but T supp cells are reportedly resistant
to its actions (702, 703).
However, it is suggested that the effect of CSA on the
generation of T cyt cells is a consequence of its
primary effect on TH cells (701). This is assumed to
result following blockage of lymphokine production by
CSA (704). Impairment of IL-2 production in mixed
lymphocyte cultures (701, 705) and following mitogen
stimulation (706), has been demonstrated. This blockade
of IL-2 production by CSA, has been shown to act at the
mRNA level (707, 708), where CSA acts after antigen
binding and before transcription of lymphokine encoding
mRNA (709). Thus, in vivo, CSA does not appear to
inhibit the initial process of T cell priming by antigen
(710, 711), but since CSA affects lymphokine synthesis,
the priming event does not result in observable in vivo
reactions, provided that inhibitory levels of CSA are
maintained. However, CSA cannot block the translation
of lymphokine mRNA once it has been formed in the cell
(712). Therefore, once T cells have been activated to
produce message for lymphokine synthesis, they become
insensitive to CSA. Thus, clonal expansion of activated
T cells by preformed IL-2 is unaffected by CSA (713).
In addition to its effects on IL-2 production, CSA has
also been shown to inhibit the production of other
lymphokines and cytokines. The generation of
lymphokines affecting macrophage activities, e.g.
migration inhibition factor, lymphocyte-derived
chemotactic factor and procoagulant-inducing factor, are
blocked by CSA (714). Cyclosporine mediated inhibition
of IL-1 release from monocytes and macrophages (701,
715) and from a human macrophage cell line (706), have
been demonstrated. However, Wagner (716) failed to
observe suppression of IL-1 release from macrophages in
response to LPS and suggested that CSA may only inhibit
T cell-dependent IL-1. Equally, CSA can also affect the
production of TNF (717) and IFN-gamma (718).
Since CSA does not display significant toxicity towards
haemopoietic tissues (699), but inhibits lymphokine-
dependent immune responses, whilst sparing non-specific
defense functions such as the phagocytic activity of
macrophages (719), it has widely become the agent of
choice in the clinical management of graft rejection
(720). More recently, CSA has been used in the
treatment of certain autoimmune diseases (721, 722)
including uveitis (723), Graves ophthalmopathy (724),
some skin disorders (725) and IDDM (726).
Laupacis et al (427) was the first to demonstrate that
CSA administered to young (30 day old) DP BB rats could
completely prevent the development of IDDM. This
success prompted Stiller et al (727) to perform an
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uncontrolled trial on the effects of CSA on recently
diagnosed IDDM patients. Whereas 16 of 30 patients
treated within 6 weeks of diagnosis became insulin
independent, only 2 of 11 (18%) who entered the study 8-
44 weeks after diagnosis went into remission. Although
this open pilot study did not control for the
possibility of spontaneous remissions, it provided
sufficiently beneficial results to encourage further
studies. Accordingly, two placebo-controlled double-
blind trials were subsequently initiated (431, 728).
In the French multicenter trial (431), CSA was initially
given to 122 patients at a dose of 7.5mg/kg/day for 3
months, which in the absence of remission was increased
to lOmg/kg/day before systematically reducing to
5mg/kg/day after 6 months. The rates of complete
remission at 6 months and 12 months of treatment were
37.5% and 32.3% respectively, compared with 18.6% and 0%
for the placebo group. The Canadian-European trial
(728) administered CSA (lOmg/kg/day) for 12 months to
188 patients and obtained a 38.7% and 24.2% remission
rate after 6 and 12 months respectively as compared to
19.1% and 9.8% with placebo. If CSA was administered
within 6 weeks of diagnosis, the remission rates
increased to 55.3% and 31.6% after 6 and 12 months of
treatment. Both studies however indicated that
withdrawal of CSA treatment was associated with the
return of progressively increasing insulin requirements.
Thus, maintenance of remission necessitated continual
administration of CSA.
Following the initial report by Laupacis et al (427),
further studies of CSA treatment in BB rats have
produced a spectrum of findings, including: (i) complete
prevention of diabetes (428); (ii) reduced frequency and
delayed onset of disease (426, 429, 729, 730); and (iii)
no effect on the incidence of hyperglycaemia, but
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producing a milder diabetic syndrome (430). Thus,
although there are some indications that CSA may be of
benefit in the treatment of Type 1 diabetes in the BB
rat, the mechanism of its action in inhibiting the
autoimmune destruction of the beta cells has not been
defined.
Therefore, we have used serial pancreatic biopsy to
monitor the effect of CSA on the development and
progression of diabetes in individual DP BB/E rats
followed for the duration of their natural life-span.
In relation to the discrepancies between previous
studies, it was important to address the questions -
Does CSA treatment: (i) prevent or merely delay the
onset of diabetes? (ii) improve the prognosis after




































DP BB/E rats from 11 litters were divided into two
groups (N=38 per group) and subsequently treated orally
from 30-100 days of age with either CSA (lOmg/kg body
weight/day) or olive oil vehicle. Cyclosporine was
kindly donated by Dr J F Borel (Sandoz Ltd, Basle,
Switzerland). Body weight and urinary glucose were
measured daily in all animals during and after treatment
to detect the onset of IDDM. Animals developing
diabetes were allocated alternatively to treatment with
a single daily subcutaneous injection of insulin
(Ultratard bovine insulin, Novo, Copenhagen, Denmark)
only, or insulin and oral CSA (lOmg/kg/day) for 50 days.
The dose of insulin was adjusted individually on the
basis of daily measurement of body weight and glycosuria
in both groups of diabetic animals. Animals not
developing IDDM were followed to the end of their
natural life span.
PANCREATIC BIOPSY
Pancreatic biopsy was performed, as described in Chapter
6, on groups of CSA treated (N=5 per group) and oil
treated (N=5 per group) rats between 40 and 100 days of
age. Each rat was biopsied twice with a 10 day interval
(Fig. 28). Animals developing IDDM were biopsied for a
third time at the onset of disease and a fourth biopsy
was taken at sacrifice after 50 days of treatment with
either insulin alone or insulin and CSA. Animals not
developing IDDM were also biopsied for a third time to
provide age matched control samples for the biopsies
taken from diabetic animals 50 days after the onset of
diabetes.
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Tissue obtained at biopsy was immediately snap frozen
for subsequent immunohistological examination. Blood
samples were also obtained from the tail vein at the
time of each biopsy and assayed for plasma glucose
(glucose analyser - Beckmann Instruments, Fullerton, CA)
and circulating white blood cells (WBC). In addition,
ICSA and IAA were measured as previously described.
IMMUNOHISTOLOGY
Cryostat sections from the pancreatic biopsies were
screened with antibodies directed against rat MHC
antigens, lymphocyte and macrophage subsets (Table I),
and islet endocrine hormones and detected by indirect
immunofluorescence procedures as described in Chapter 4.
OTHER ASSAYS
Tail vein blood samples (0.1ml) were extracted with 2ml
of ice cold 2.5% (w/v) trichloroacetic acid. Samples
were centrifuged immediately at 4°C (1500g for 20 mins.)
and the supernatant stored at -20°C. Blood glucose,
lactate, glycerol, alanine and 3-hydroxybutyrate were
assayed in the supernatants using modified enzymatic
fluorimetric methods (731) by Dr J Burrin (Hammersmith
Hospital, London).
Enzymatic determination of plasma cholesterol and
triglycerides were performed by calorimetric detection
methods on a technicon autoanalyzer using test-kits
obtained from Boehringer Mannheim (Lewes, East Sussex,
England).
Plasma creatinine was measured by a Creatinine Analyzer
(Beckmann Instruments Incorporated, Fullerton,
California).
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White blood cell counts were measured on blood samples
obtained from the tail vein. Whole blood (0.1ml) was
mixed with 0.2ml of distilled water; whirlimixed for 15
sees, to lyse the red blood cells, after which 0.2ml of
HBSS was added before centrifugation at 4°C (200g for 10
mins.). The cell pellet was resuspended in HBSS (0.1ml)
and WBC numbers estimated on a haemocytometer following


































The development of diabetes in the oil treated control
and CSA treated rats, is shown in Fig. 29. During the
treatment period (30-100 days of age), 13 of the oil
treated control rats developed IDDM compared with none
of the CSA treated animals. By 150 days of age, 20
control rats were diabetic and there were still no
diabetic animals in the CSA treated group. Between 150
and 200 days of age, however, 8 animals that had
previously received CSA, developed diabetes along with
one more control animal. By 450 days of age, a further
4 control animals and 6 CSA treated rats became
diabetic. No further cases of diabetes occurred in
either group thereafter, giving a final incidence of
diabetes of 66% (25/38) and 37% (14/38) with the mean
ages at onset; 114 — 16 days (— SEM) and 223 — 21 days
in control and CSA treated groups respectively.
Thus, treatment with CSA in the prediabetic period both
postponed the onset and reduced the overall incidence of
diabetes in DP BB/E rats.
During the treatment period, whereas IAA were detected
in 6 of 38 (16%) animals receiving CSA, ICSA were not
found in any of the CSA treated rats. However, the
subsequent development of IDDM following withdrawal of
CSA therapy, was associated with the corresponding
appearance of ICSA (Table XIII). Islet cell surface
antibodies were identified in 31 of 39 diabetic and 5 of
37 non-diabetic study animals. The incidence of ICSA
was similar in oil treated (20/25) and CSA treated
(11/14) rats at the onset of diabetes. Circulating IAA
were found with similar frequency (15 — 2.1%; mean —SEM)
in diabetic and non-diabetic animals irrespective of the
treatment regime.
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The effect of CSA on circulating intermediary metabolite
levels in non-diabetic DP BB/E rats, towards the end of
the treatment period, is compared in Table XIV.
Although the plasma glucose concentration was
significantly raised in CSA treated animals, it
subsequently returned to control levels following
discontinuation of CSA. Equally, although the
concentrations of plasma triglycerides were elevated in
CSA treated rats when compared with untreated DR BB/E
rats, they were similarly raised in the oil treated
controls (Table XV). Table XV also shows there was no
difference in plasma creatinine concentrations between
non-diabetic CSA treated, and oil treated DP BB/E rats,
and age matched non-diabetic DR BB/E rats. In addition,
administration of CSA to DP BB/E rats, did not
significantly reduce their numbers of circulating white
blood cells, when compared with their oil treated
controls (Table XVI).
At onset of diabetes, the effects of administering
insulin and insulin combined with CSA, on the subsequent
progression of diabetes was assessed by monitoring daily
insulin requirements and body weight measurements (Fig.
30). Administration of CSA, in addition to insulin,
failed to induce remission of diabetes in any animal.
Body weight gained during the 50 days post onset of
hyperglycaemia was similar in both treatment groups:
increasing from 295 — 31g (mean — SEM), to 327 — 30g in
rats given insulin, whilst rats maintained on insulin
with CSA increased from 279 — 28g to 326 28g. The
daily insulin dose required to maintain aglycosuria
during the 50 day treatment period was similar in both
















































































































































































































TABLE XVI: EFFECTS OF CSA TREATMENT ON LEVELS OF CIRCULATING
WHITE BLOOD CELLS
















Diabetic Oil treated (N=19)
DP BB/E rats
at onset of disease CSA treated (N=ll)
2.7 - 0.3
2.6 ± 0.5
Insulin treated (N=13) 4.4 - 0.5*Diabetic
DP BB/E rats





Untreated 3.0 ± 0.1
















Immunofluorescence studies using MoAbs directed against
rat MHC antigens and leucocyte subsets, on cryostat
sections of pancreatic biopsies obtained from oil
treated controls who developed IDDM either during or
after the treatment period (30-100 days of age),
produced similar results to those previously discussed
in Chapter 6. Thus, the first change observed, occurred
in some pancreatic lobules about 30 days before the
onset of diabetes and consisted of increased expression
of MHC class I molecules within islets and on the
vascular endothelium. Subsequently, between 2-3 weeks
before the onset of IDDM, expression of MHC class II
molecules on vascular endothelium accompanied
accumulation of ED1+ cells at periductal and
perivascular sites. These cells then infiltrated the
adjacent islets thereby initiating insulitis. About 10
days before disease onset, increasing numbers of other
immune effector cells were found infiltrating the
islets. At this point, hyperexpression of MHC class I
molecules within infiltrated islets was markedly
enhanced, extending beyond the islet periphery into the
surrounding exocrine tissue. At disease onset, although
several of the islets presented with intense insulitis
and some residual insulin-containing cells, most of the
islets~presented without surviving beta cells and intra-
islet infiltrates.
Biopsies taken from CSA treated rats during the
treatment period showed a complete absence of insulitis
in all of the animals. At most, 10-15 ED1+ cells were
occasionally observed around some of the larger blood
vessels adjacent to islets. However, in biopsies taken
from CSA treated animals during the treatment period, 11
animals showed enhanced intra-islet MHC class I
expression of which 7 subsequently developed diabetes
(mean age at onset = 176 — 5 days (— SEM); and mean
duration of time lapsed between observed increased islet
class I expression and disease onset = 100 — 11 days).
Thus, treatment with CSA in the prediabetic period had
no effect on the expression of class I MHC antigens, but
markedly inhibited accumulation of ED1+ cells at extra-
islet sites, the subsequent recruitment of immune
effector cells and islet infiltration (Fig. 31).
In biopsies taken from 6 animals that had previously
been treated with CSA but had remained non-diabetic by
158 days of age, 2 animals presented with perivascular
infiltrates and mild insulitis. Both these animals
subsequently developed IDDM 10 days and 25 days later.
The biopsies from the 4 remaining rats showed no
evidence of pancreatic infiltration, insulitis or
altered MHC class I expression. Three of these animals
remained non-diabetic throughout their lives, whilst one
became diabetic, but not until 400 days of age.
At onset of diabetes, biopsies removed from animals
previously treated with CSA did not appear different
from those similarly removed at onset from oil treated
controls. Thus, there were no differences in the
severity of insulitis or numbers of islets with residual
insulin-containing cells. Following the diagnosis of
diabetes, animals were either maintained on insulin or
combined insulin and CSA treatment for 50 days. In the
main, the biopsies taken at the end of this 50 day post
disease onset period, showed no differences between the
two groups. Thus, virtually all of the islets were end
stage in appearance, with no observable infiltrates or
enhanced MHC class I expression. However, in 3 of 13
biopsies removed from rats treated with insulin and CSA,
there were several islets which still retained an
infiltrate, some insulin containing cells and
hyperexpression of class I MHC molecules.
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FIGURE 31; EFFECT OF CYCLOSPORINS ON THE SEQUENCE OF
PANCREATIC EVENTS THAT LEAD TO THE
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In this study, serial pancreatic biopsy was used to
further document the sequence of pancreatic events
leading to the development of IDDM in the BB/E rat, and
to examine the effect of CSA administered for a limited
time in the prediabetic period on the events, and on the
development of IDDM in DP rats held throughout their
natural life span. None of the previous reports on the
effects of CSA given in the prediabetic period (426-430,
729, 730) have involved such an extended follow-up, and
the variable results obtained in these studies may in
part be related to the differences in the period of
observation following treatment.
The complete prevention of diabetes by CSA in BB/E rats
aged less than 150 days is in agreement with the initial
study by Laupacis et al (427) in which there was no
subsequent follow-up. However, our study showed that
cessation of CSA treatment was followed by the
development of IDDM in 37% of the rats, although the
frequency of diabetes was still considerably lower than
that of the oil treated controls. Similar findings have
been reported by other groups (429, 729, 730).
Thus, complete prevention of IDDM after administration
of CSA from 34-121 days of age, was followed by the
onset of diabetes in 24% of animals at 169 days of age,
after withdrawal of CSA (729). Equally, a reduced
incidence of diabetes and delayed onset was reported by
Brayman et al (730) using a protocol of intermittent CSA
therapy. They administered high doses (15mg/kg/day) of
CSA initially for 2 weeks commencing between 30-49 or
50-55 days of age, followed by a similar twice weekly
maintenance doge until 160 days, which resulted in low
trough plasma CSA levels. Although 9 animals developed
diabetes during CSA treatment, and a further 14 rats
followed until 275 days of age subsequently became
in
diabetic, the overall incidence of diabetes was
approximately half that of the controls (27% £ 48%).
Using a limited protocol, whereby CSA was administered
only for 10 day periods at different ages, Like et al
(429) also delayed the onset and reduced the frequency
of diabetes in DP BB rats. Although follow-up was
limited to 120 days of age, CSA administered between 60-
70 days of age decreased the incidence of diabetes to
23% compared with 73% in controls. However, similar
administration of CSA either before 60 days or after 70
days had no effect on the incidence of diabetes thereby
suggesting that the presence of CSA only at a critical
stage in the prediabetic period may induce long-term
prevention.
The observations from our study do not agree with other
reports, demonstrating either the complete prevention of
diabetes by CSA (428) or its lack of effect in reducing
the development of glycosuria (430). In the former
study, prevention of IDDM was achieved only by sustained
treatment (from 5 to 25 weeks of age) with higher doses
of CSA (10-20mg/kg/day). In addition, the follow-up
period did not exceed 150 days post withdrawal of CSA.
Further-more, this protocol also prohibited the
development of thyroiditis and gastritis and therefore
differs from the results of Like et al (429) where CSA
failed to protect against the development of lymphocytic
thyroiditis.
In the study by Yale et al (430), although CSA did not
affect the incidence of hyperglycaemia, it did however
result in a milder form of diabetes with no weight loss,
persistence of islet beta cells and only intermittent
insulin requirements. Indeed, the observed diabetic
syndrome was similar to the hypoinsulinaemic glucose
intolerance induced in DR BB rats given CSA (694).
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However, it is noted that in their study, the incidence
of diabetes among the controls was only 29% i.e. still
less than the incidence among our CSA treated animals,
and this low spontaneous frequency may contribute to
their failure to detect an effect of CSA on the
incidence of diabetes (430).
Our findings that CSA administered at disease onset,
along with insulin, failed to induce remission of
diabetes or even lower the insulin requirements
necessary to maintain normoglycaemia, are in agreement
with other studies. Yale et al (732) found that CSA
(lOmg/kg/day) administered to 10 diabetic rats of recent
onset, had no beneficial effect, as their daily insulin
requirements over a 2 month period were identical to
those of the controls. Equally, in an earlier study,
where CSA was used as part of a multiple drug therapy,
administration of CSA at disease onset only induced
remission in one (2%) animal (426). This contrasted
with a 22% cure rate when animals were given
methylprednisolone combined with 3 injections of rabbit
antiserum to rat lymphocytes. In addition, although
combined treatment of CSA and a MoAb against the IL-2
receptor normalized the plasma glucose levels of BB rats
with mild hyperglycaemia, neither CSA nor IL-2R MoAb on
their own had any effect (733).
Taken together the results suggest the necessity of a
functional beta cell reserve for successful
immunotherapy of IDDM in the BB rat. This is supported
by the results from CSA trials in human IDDM patients,
where the major differences between those patients with
remission and those without, include: the shorter
duration of symptoms before diagnosis; the lesser degree
of weight loss; lower initial haemoglobin Ale levels;
higher initial C-peptide concentrations and lower
frequency of ketoacidosis (734). Furthermore,
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pancreatic biopsies taken from BB/E rats at onset of
diabetes when stained for insulin, showed that many of
the islets were insulin deficient. After disease onset
the autoimmune destruction of surviving beta cells
continued, such that biopsies removed 50 days after
onset, with the animals having been maintained on
insulin or insulin and CSA, in most cases showed a
complete absence of insulin-containing cells.
Direct inhibitory effects of CSA on pancreatic insulin
release have been reported both in vitro (735) and in
vivo, where impaired glucose tolerance in normal Wistar
(736) and DR BB (694) rats ensues. Electron microscopy
of islets from normal Wistar rats, treated with
40mg/kg/day for 7 days showed severe degranulation,
cytoplasmic vacuolization and dilation of endoplasmic
reticulum in the beta cells (737). In addition, islets
isolated from CSA treated animals showed a 50% reduction
in mRNA (737). In our study, plasma concentrations of
glucose and its gluconeogenic substrates, lactate and
alanine, appeared elevated, although only the glucose
levels reached statistical significance. These changes
were reversible and not associated with the increase in
lipolysis and rise in glycerol and 3-hydroxybutyrate
levels,— normally associated with onset of diabetes in
BB/E rats (309). Thus, in addition to its
immunosuppressive properties, CSA may have toxic effects
on pancreatic beta cells, and this may contribute to the
surprising observation that CSA administered to DR BB
rats from 45-155 days of age, induced the development of
diabetes in 5 of 16 (31%) animals (738).
The necessity to administer CSA in an olive oil vehicle
due to its hydrophobic nature (696), resulted in
elevated plasma triglycerides of comparable levels in
both CSA treated and control groups. Thus, CSA per se
did not affect plasma triglycerides, and nonetheless,
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the levels returned to those of untreated controls
shortly after withdrawal of treatment.
Administration of CSA in organ transplantation has been
associated with several side effects of which
nephrotoxicity is the most common and most severe (739).
Nephrotoxicity induced by CSA therapy can be divided
into two major groups: (i) functional toxicity without
morphological lesions, and (ii) morphologic toxicity
with tubular and/or vascular-interstitial lesions (740).
In our study, CSA therapy did not induce functional
nephrotoxicity as measured by plasma creatinine levels.
This is in agreement with Brayman et al (730) who
observed no difference in serum creatinine levels
between CSA treated DP BB rats and controls.
Furthermore, they and Laupacis et al (427) found no
histologic evidence of vasculopathy or
tubulointerstitial disease following treatment with CSA.
However, Yale et al (732) reported a 50% increase in
plasma creatinine after 5 weeks of CSA therapy when
given at disease onset, and suggested that CSA induced
nephrotoxicity may be enhanced in the presence of
hyperglycaemia.
Concerning other potential side effects, in agreement
with the early studies of Borel et al (699), we failed
to observe any deleterious effect of CSA on peripheral
blood leucocyte numbers suggesting that CSA does not
exert its immunosuppressive actions by eliminating
clones of cells. This is supported by the observation
that IDDM still developed in some animals after
withdrawal of CSA.
Examination of pancreatic biopsies from oil treated and
CSA treated animals, was aimed to further document the
sequence of pancreatic events that lead to IDDM in the
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BB/E rat, and determine the effect(s) of CSA on these
events.
Analysis of biopsies from oil treated controls further
substantiated the findings of our previous biopsy study;
which I have described in Chapter 6. Amongst the
biopsies removed from CSA treated animals during
treatment, the only abnormality observed was enhancement
of islet MHC class I expression. Thus, in some animals,
CSA was unable to block the increase in intra-islet
class I expression, but in all animals prevented
subsequent pancreatic infiltration and insulitis. As
mentioned previously, the cause of this increased islet
class I expression is unknown, but release of viral
induced interferons within the islets has been suggested
(593). Thus, although CSA can inhibit the synthesis of
IFN-gamma by human T lymphocytes (741), the report that
demonstrates its failure to inhibit production of IFN-
alpha/beta by virus-infected human or mouse lymphocytes
and fibroblasts (742) lends support to this postulate
and is in keeping with our in vivo observations.
Two different models are generally proposed to explain
the biological activity of CSA (743). The first
proposers that different T cell subsets show differing
sensitivities to CSA. Accordingly, CSA can inhibit the
activation of Tjj cells, and since "help" is needed to
activate the cytotoxic subset, it consequently inhibits
the generation of T cyt cells (701). Equally, the model
postulates that T supp cells are resistant to the
actions of CSA (702, 703). Thus, the observation that
autologous splenic lymphoid cells from "not-yet"
diabetic NOD mice, when cultured for 72h with CSA and
IL-2 before reinfusion into the animal from which they
were isolated, prevented the development of diabetes in
68% of the animals, is suggestive of an ex vivo
preferential IL-2 activation of specific suppressor
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cells for the autoimmune process, with CSA blockade of
the helper/cytolytic activities (744).
The second model does not distinguish between the
activities of subsets as defined by antigenic markers.
This model proposes that CSA interrupts the transmission
of the antigen-specific signal from the surface to the
interior of the cell after binding of antigen and T cell
receptor (745). This is supported by the observation
that whereas antigen or mitogen induced lymphokine
release from activated T cells is inhibited by CSA, it
does not inhibit binding of antigen to the T cells
(713). Equally, constitutive lymphokine production by
tumour cell lines is unaffected by CSA (709), and once T
cells have been activated to produce mRNA for lymphokine
synthesis, they become insensitive to CSA (712).
Therefore, CSA does not block the translation of
lymphokine encoded message once it has been formed.
Thus in the main, CSA is believed to exert its
immunosuppressive effect by inhibiting the production of
mRNA for lymphokine production by primed T cells.
However, in our study, the most striking feature in
biopsies from CSA treated animals was the prevention of
the initial accumulation of ED1+ cells at perivascular
or periductal sites adjacent to islets free from
infiltration, thereby suggesting a direct inhibitory
effect of CSA on macrophage recruitment. It cannot be
completely excluded that this apparently direct effect
of CSA on macrophages is not secondary to a primary
action of CSA in blocking the function of primed T
cells. Nevertheless, T lymphocytes were certainly not
conspicuous in any of the biopsies examined during
treatment, and other studies in the BB rat (589) and the
low-dose streptozotocin model (508) have indicated that
T cell infiltration is macrophage dependent.
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Certain macrophage functions, including phagocytosis of
bacteria (719), blood clearance of colloidal carbon
(746) and migration in response to lymphokines (714),
are all reportedly unaffected by CSA. However, other
studies indicated that CSA impaired monocyte/macrophage
IL-1 production (701) and chemotaxis (747).
Furthermore, several studies have demonstrated that CSA
inhibits monocyte accessory functions in oxidation -
(748), mitogen - (749), alloantigen - (750), and antigen
- dependent T cell proliferation assays (751-754).
Varey et al (752) reported that CSA affected the ability
of irradiated mouse spleen cells to present preprocessed
antigen to mouse thyroglobulin and purified protein
derivative - specific T-cell lines. Similarly, Palay et
al (753) and Snyder et al (754) demonstrated that
pretreatment of macrophages with CSA resulted in a cell
population with a markedly diminished capacity to
support the activation of murine and human T cells
respectively. Both studies showed that this effect of
CSA on antigen presentation was unrelated to decreases
in IL-1 production, increases in prostaglandin
production or changes in the levels of surface la
expression. In contrast, Whisler et al (750) found that
the impaired ability of human macrophages to trigger
mixed lymphocyte responses following pre-exposure to
CSA, was associated with a decrease in macrophage HLA-DR
expression. Palay et al (753) suggest that the
hydrophobic nature of CSA permits it to insert into the
phospholipid bilayer of plasma membranes where it may
destabilize the complexing of processed antigen with la
molecules on the surface membrane, such that the T cell
receptor cannot bind them and thus become activated.
Therefore, in addition to its extensively documented
effects on T lymphocyte activities, CSA can also
directly inhibit certain macrophage accessory functions.
Thus, since macrophages and other accessory cells play a
critical role in the activation of certain T cell
responses (578), the immunosuppressive actions of CSA
may be explained in part by its inhibitory effect on the
induction of immune responses by macrophages.
However it should be stressed that most of the studies
aimed at investigating the mechanisms of CSA
immunosuppression have been performed in vitro, and it
is possible that the mode of CSA action is quite
different in vivo (755). Accordingly, Kroczek et al
(756) reported that the administration of CSA in vivo
had no effect on alloantigen-induced increases in cell
size, percentage of cells expressing the IL-2 receptor,
the spontaneous or IL-2 driven proliferation of freshly
explanted cells, or the induction of cytotoxic T
lymphocyte activity.
In addition to the absence of macrophage infiltration,
biopsies from CSA treated animals also failed to show
the accompanying expression of MHC class II molecules on
the vascular endothelium. Such an observation is
compatible with the demonstration that CSA inhibits la
expression on occular tissues in guinea pigs with
experimental autoimmune uveitus (757). Equally CSA has
been shown to inhibit lymphokine-induced class II MHC
expression on vascular endothelium both in vitro (758)
and in vivo (759).
In conclusion, CSA administered from 30-100 days of age
completely prevented the development of IDDM up to 150
days of age and reduced the incidence of diabetes to
approximately 50% of controls at 450 days. Whereas ICSA
paralleled the development of diabetes, IAA were
unrelated to diabetes onset and unaffected by CSA.
Analysis of pancreatic biopsies showed that CSA had no
effect on pancreatic hyperexpression of MHC class I
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molecules but markedly inhibited accumulation of ED1+
cells at extra islet sites, the subsequent recruitment
of other immune effector cells and islet infiltration.
This resulted in a delay on the onset of diabetes in
some animals and prevention of diabetes in others.
Commencement of CSA therapy at disease onset failed to
ameliorate the disease and is compatible with the view
that once effector cells have been activated, CSA has
little or no effect.
The reason why treatment with CSA prevented the
development of IDDM in some animals, whilst merely
delaying its onset in others, is not clear. It possibly
reflects individual animal variation in the stage of
disease development at the time of CSA treatment. This
is supported by the study of Like et al (429) which
showed that only when CSA was administered between 60-70
days of age was a protective effect observed, thereby
suggesting a "critical window" for intervention. Thus,
it is possible that administration of CSA for a limited
period, started at a critical point in the autoimmune
process, could lead to long term protection. However
the difficulty would be in establishing this critical
period in individual subjects.
Meanwhile, ongoing clinical trials suggest that whilst
CSA can induce remission in some recently diagnosed IDDM
patients, maintenance of this remission probably
necessitates continual long term CSA therapy. These
trials have not been running sufficiently long enough to
ascertain the possible hazards of long term CSA therapy.
However, in addition to nephrotoxicity, evidence from
organ transplantation centres, where CSA has been used
to prevent graft reject since 1977, indicate an
increased risk for developing cancers (760) which in
turn may arise from an increased susceptibility to viral
infections (761). Whereas the average time of cancer
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appearance in patients receiving conventional
immunosuppressive therapy (CIT) (azathioprine and
prednisolone) was 68 months, cancers that appeared after
CSA therapy occurred at an average of only 26 months
after transplantation (760). In addition, analysis of
data from the Cincinnati Transplant Tumour Registry
shows a disproportionately high incidence of lymphomas
(27% v 11%) and Kaposi's sarcoma (11% v 3%) in CSA
patients compared with CIT patients (760).
Thus, until such time that an accurate early predictive
marker for the disease becomes available, at which point
short term intermittent CSA therapy may be applicable
and provide long term prevention, I would not favour the
use of CSA in the treatment of patients with IDDM.
CHAPTER 9 - SUMMARY AND CONCLUDING REMARKS
W
TABLE XVII: COMPARISON OF HUMAN IDDM AND ITS ANIMAL MODELS
Characteristics Human BB NOD LD-STZ
Clinical Features

























Association with MHC genes
Increased levels of
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+ + + +
+ + ?
+/- + + +/-
+ + + +
+ + + +
+ + + +/-
Altered islet MHC antigen expression
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In this thesis I have attempted to promote the relevance
of the BB rat as a model for human IDDM. Table XVII
summarizes some of the characteristics of human IDDM and
its animal models, and clearly shows that most of the
individual features of human IDDM are also observed in
the BB rat. The results from our studies in the BB/E
rat, supplement many other studies which also document
the presence of immunological abnormalities in the BB
rat. However, the mere presence of certain
immunological phenomena, does not necessarily imply that
IDDM in the BB rat is an autoimmune disease.
Nevertheless, when considering Witebsky's postulates for
determining the relationship of immunological phenomena
to disease aetiology (22), there is strong support that
IDDM in the BB rat is of autoimmune aetiology:
(i) The autoimmune response is regularly associated
with the disease. * ~~~~
Although the development of insulitis does not
always lead to the onset of diabetes,
nevertheless, diabetes is invariably associated
with the characteristic histologic appearance of
insulitis. In addition, the presence of
antibodies against islet cell antigens, e.g.
ICSA, are commonly associated with the
development of the disease.
(ii) A replica of the disease should be inducible in
experimental animals-
Although the spontaneously diabetic BB rat
represents an "experimental" animal model of
human IDDM, a replica of the disease in DP BB
rats can be induced by immunomodulatory protocols
on the DR BB rat. Thus, depletion of the RT-6+ T
cell population in DR BB rats results in the
development of IDDM (381).
(iii) The animal develops pathological changes that are
basically similar to those of the human.
Table XVII shows that most of the changes in
pancreatic morphology associated with the
development of IDDM in the human are also
replicated in the BB rat. The two main
differences are: (i) expression of MHC class II
antigens on pancreatic beta cells is never
observed in the absence of insulitis in the BB
rat, but has been observed in infiltrate free
islets in man ( 549), (ii) macrophages have not
been reported to be a prominent feature of the
infiltrate of the human pancreata examined (10%
of infiltrates - Alan Foulis, personal
communication), whereas the majority of cells
infiltrating the islets at all stages of disease
development in the BB rat are macrophages.
(iv) The experimental disease should be transferable
to non-immunized animals by serum or lymphoid
cells.
Initially, transfer of diabetes into young (30-40
days old) DP BB rats was reported using ConA
activated spleen cells from acutely diabetic BB
rats (405). Subsequently, transfer of diabetes
into immunosuppressed MHC-compatible WF rats and
DR BB rats as well as BB hybrid rats (containing
at least one RT1U allele) was demonstrated
(406,407). Furthermore, conditioned media, using
ConA activated spleen cells from acutely diabetic
rats, DR BB rats, WF rats and MHC-incompatible
Buf rats was able to induce diabetes in both DP
and DR BB rats but not WF rats (410).
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In addition to the above criteria, the ability to
prevent or ameliorate the disease by manipulation of the
immune system via immunosuppression with cyclosporine or
reconstitution of the immune system by bone marrow
transplantation (416), or spleen cell transfusions
(422), further substantiates the concept of an
autoimmune aetiology for IDDM in the BB rat.
The demonstration of passive transfer of diabetes in
both DP and DR BB rats using conditioned media from BB
and non-BB rat strains (410) suggests that a soluble
factor obtained from normal splenocytes can activate an
effector population in both DP and DR BB rats. Equally,
the development of IDDM in DR BB rats following
depletion of the RT6+ T cell population (381) suggests
that RT6+ lymphocytes may regulate beta cell cytotoxic
effector cells in the DR BB rat to prevent the
development of diabetes in these animals.
Thus in the BB rat it is postulated that expression of
diabetes depends on the balance between beta cytotoxic
effector cells and regulatory cells. In both the DP and
DR BB rats, "forbidden clones" of autoreactive
lymphocytes specific for beta cell antigens or cross
reactive antigens are part of the normal immune
repertoire. Accordingly, it is not uncommon to find
evidence of insulitis and accompanying beta cell
destruction in some DR as well as DP BB rats. However,
in the DR BB rat, as well as some of the DP BB rats
(i.e. the 30-40% who do not develop IDDM), it is
envisaged that a regulatory population of lymphocytes
(possibly T suppressor cells) either acting directly or
through the idiotypic network can restrict the
autoaggressive immune response to prevent the onset of
IDDM. Other factors which may influence the
"susceptibility" or "resistance" to diabetes include the
ability to increase beta cell replication and thereby
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partly counteract the forces of beta cell aggression.
Equally, differences in the strength of the autoimmune
assault within individual animals may determine whether
or not they succumb to the disease.
Recently, Molvig et al (762) reported that TNF-alpha
secretion by isolated human monocytes stimulated by LPS
show marked interindividual differences. Since TNF-
alpha can mediate islet cell cytotoxicity and potentiate
both IL-1 (412) and IFN-gamma (670) mediated islet cell
damage, Nerup et al (763) have proposed that
"quantitative" differences in the magnitude of the
autoimmune response propagated by a high TNF-alpha
secretor phenotype may contribute to the
"susceptibility" of individuals for developing IDDM.
Since the genes encoding for TNF-alpha in both man (764)
and mouse (765) are linked to the MHC genes on
chromosome 6 and 17 respectively, it is suggested that
the MHC associated genetic susceptibility for IDDM
reflects linkage disequilibrium between MHC class II
genes and the TNF-alpha gene (763).
Although the genetic susceptibility for IDDM is strongly
associated with class II MHC genotypes in both man (146)
and the BB rat (338), the susceptibility is not due to
unique or mutant class II alleles in either species.
Whereas the presence of a non charged amino acid (ser,
val, ala) at position 57 of the first domain of the DQ
beta chain is positively associated with the development
of IDDM in Caucasians, the possession of Asp 57-positive
DQ beta alleles provides resistance (177). However,
IDDM in Japanese and Chinese patients is associated with
the DQ beta 3.3 chain which has an aspartic acid residue
at position 57 thus suggesting that other amino acid
residues contribute to susceptibility (766).
In the BB rat, although both the RT1B beta and RT1D beta
chains possessed a serine residue at position 57, the
class II beta chains were identical in both DP and DR BB
rats which led the authors to suggest that the allelic
form of amino acid 57 is not a disease susceptibility
marker in the BB rat (341). Nevertheless, since both DP
and DR BB rats harbour autoreactive clones with
specificity for beta cell antigens and both sublines can
develop insulitis, it is possible that the beta chain
sequences of the MHC class II genes in the BB rat do
confer an increased susceptibility for IDDM, but
subsequent manifestation of the disease depends on other
genes perhaps in linkage disequilibrium with the class
II MHC genes. Thus, it is unlikely that one specific
allele determines disease susceptibility and therefore
assessment of MHC disease association must consider the
extended MHC haplotype.
The aim of the studies in this thesis was to better
understand the aetiology of IDDM in the BB rat. The use
of serial pancreatic biopsy within individual BB/E rats
and MoAbs against rat MHC antigens, lymphocyte and
macrophage subsets has enabled the documentation of the
sequence of pancreatic events that lead to development
of IDDM in the BB/E rat.
The first change observed; increased expression of MHC
class I antigens within some islets and on vascular
endothelium, could be observed at least 30 days before
the onset of diabetes. Between 2 and 3 weeks before
disease onset, expression of MHC class II molecules on
vascular endothelium is associated with the emigration
from the circulation of a population of macrophages into
the pancreatic tissue. Subsequent migration of these
recruited macrophages into the adjacent islets soon
follows, thereby initiating insulitis.
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Release of cytokines e.g. IL-1 and TNF-alpha by these
activated macrophages may directly injure the islet beta
cells, but can also influence the production of
chemotactic factors, synthesis of adhesion molecules,
and vasodilation of the nearby endothelial cells (767)
thereby aiding the subsequent recruitment of other
leucocytes. Thus by 10 days before onset of diabetes,
insulitis comprising macrophages, T-cells, B-cells and
NK cells is observed in most of the islets. At this
stage, hyperexpression of MHC class I molecules within
infiltrated islets is markedly enhanced, extending
beyond the islet periphery into the surrounding exocrine
tissue. "Aberrant" expression of MHC class II molecules
on insulin-containing cells was a rare phenomenon and
was never observed in the absence of insulitis.
Within a week of onset of diabetes, ketoacidosis will
develop unless insulin is administered. In biopsies
from both ketoacidotic and recently diagnosed but
insulin treated animals, virtually all of the islets are
"end-stage", devoid of insulin-containing cells,
insulitis and enhanced MHC class I antigen expression.
Thus the use of serial pancreatic biopsy has enabled us
to perform time course studies in individual animals
where changes in pancreatic morphology have been
correlated with the development of IDDM. Nevertheless,
our studies have still left several important questions
unanswered:
(i) What initiates the autoimmune response?
The proposal that aberrant expression of MHC
class II antigens on pancreatic beta cells may
permit presentation of beta cell antigens to
potentially autoreactive T lymphocytes (540), was
not supported by our studies. Since "classical"
antigen presenting cells such as macrophages are
prominent among the insulitis and indeed appear
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to be the first cells which infiltrate the
islets, it can be postulated that presentation of
beta cell antigens by macrophages to autoreactive
TH cells will propagate the autoimmune response.
Thus any agent which can perturb the islet beta
cell and result in the release of sequestered
antigen(s) can lead to the development of the
autoimmune response if the antigen(s) is taken
up, processed and presented to the appropriate
"forbidden clones". Thus, no specific
aetiological agent is necessary but rather
anything e.g. beta cytotropic viruses, dietary
toxins, metabolic stress, or increased systemic
IL-l/TNF concentrations, which can damage the
islet beta cells, may trigger the autoimmune
response. Equally, the studies on the DR BB rat
suggest that any process e.g. immunosuppression
which disturbs the balance between effector and
regulatory cell populations may also trigger the
autoimmune response.
(ii) What cell(s) mediate beta cell destruction?
Within the insulitis, there are a variety of
different leucocytes including macrophages, T-
lymphocytes (both CD4+ and CD8+), NK cells, and
B-lymphocytes, however it is not known which of
these cells mediate beta cell damage and which
are merely "innocent bystanders". Evidence
suggests that islet cell destruction is non-MHC-
restricted (397) which may favour a role for NK
cells, however both CD4+ and CD8+ T cell
populations can also initiate MHC-unrestricted
killing of target cells (768) and T cells with
MHC-unrestricted cytotoxic function have been
found in inflammatory rheumatoid synovial fluid
(769). In the NOD mouse, cloned T cells specific
for islet beta cells can be either CD4+ or CD8+,
however diabetes can only be transferred to naive
NOD mice using both the CD4+ and CD8+ clones
(770). It is therefore likely that several
different lymphocyte clones are involved in beta
cell destruction.
This is supported by a recent study which
demonstrated the prevention of diabetes in NOD
mice following treatment with an anti-V beta 8
TCR MoAb (771). However, examination of the
insulitis lesions showed that not all the cells
were V beta8+ and in treated animals despite the
absence of V beta 8+ T cells, diabetes still
developed in some animals.
(iii) What is the mechanism of beta cell destruction?
In vitro studies have demonstrated that the
cytokines IL-1, TNF and IFN-gamma either singly
or more potently in combination can mediate beta
cell cytotoxicity (412, 413, 670). Since these
cytokines can be synthesized by either
macrophages or T-lymphocytes both of which are
present in the insulitis, it is possible that
these cytokines are present in high local
concentrations within infiltrated islets, where
they can cause beta cell cytolysis. Amongst the
proposed mechanisms for cell killing by
cytokines; the generation of oxygen free radicals
in the target cell coupled with a low oxygen free
radical scavenging enzyme activity for beta
cells, is favoured. This was supported by a
recent study which demonstrated that oxygen free
radical scavengers could protect rat islet cell
monolayers from the cytotoxic effects of the
above mentioned cytokines (772).
XV-
In conclusion: Although replacement therapy has been
available for Type 1 diabetes mellitus for almost 70
years, treatment with insulin remains unsatisfactory as
it is still associated with increased morbidity and
mortality. This stresses the importance of research
into the aetiological factors of the disease, with the
aim of developing protocols leading to disease
prevention. However, the development of a rational
therapeutic approach to prevention necessitates the
identification of accurate markers for the development
of clinical disease as distinct from genetic
susceptibility, and elucidation of the precise sequence
of events that lead to the destruction of islet beta
cells. Difficulties in correlating changes in cellular
and humoral immunity with pancreatic morphology and
function in man, as well as ethical problems in the
application of certain intervention studies,
necessitates the need for studies using animal models.
In this thesis, I have hopefully shown that diabetes in
the BB rat can be considered of autoimmune aetiology,
and that the diabetic syndrome of the spontaneously
diabetic BB rat closely resembles the human disease.
Without the help of animal models, patients with IDDM
would still be dying in ketoacidosis. With the help of
animal models such as the BB rat, the possibility of
predicting and preventing IDDM is not unrealistic.
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Rapid communications
Pre-diabetes in the spontaneously diabetic BB/E rat:
lymphocyte subpopulations in the pancreatic infiltrate
and expression of rat MHC class II molecules in endocrine cells
B. M. Dean1,2, R. Walker3, A. J. Bone3, J. D. Baird3 and A. Cooke1
'Department of Immunology, The Middlesex Hospital Medical School, and "Department of Diabetes and Immunogenetics, St. Bartholomew's
Hospital, London, England; "Metabolic Unit, University Department of Medicine, Western General Hospital, Edinburgh, Scotland
Summary. Use of monoclonal antibodies specific for rat lym¬
phocyte subsets and an anti-insulin marker has allowed us to
document the following sequence of events leading to the de¬
velopment of clinical diabetes in this animal model. The first
change observed in the pancreas is increased expression of
MHC class II molecules on vascular endothelium and this
precedes lymphocytic infiltration. Next, T cells of the T helper
phenotype infiltrate the pancreas around blood vessels. Many
of the infiltrating T cells show class II expression indicating
that they are activated. A few cytotoxic and suppressor cells
and B lymphocytes are also present and their numbers in¬
crease proportionately with rat age. Some macrophages are al¬
so seen. Finally, at a late stage class II MHC molecules can be
detected in partially destroyed islets on ft cells which are still
actively synthesising insulin. We have never observed expres¬
sion of class II molecules on glucagon or somatostatin secret¬
ing cells which are invariably well preserved.
Keywords: Pre-diabetes, BB rat, lymphocyte subsets, /? cell,
MHC class II expression.
The BB rat is probably the best available animal model
of human Type 1 (insulin dependent) diabetes mellitus
[1]. In these animals islet cell surface antibodies and a
mononuclear cell pancreatic infiltrate precede the de¬
velopment of the disease which has been shown to be
associated with the RTIU haplotype of the rat MHC [2],
As part of a longitudinal study designed to show the
relationship between autoimmunity markers, islet mor¬
phology and /Tcell function [3] we have examined the
distribution of subpopulations of lymphocytes infiltrat¬
ing the pancreas. Since there is some evidence in organ
specific autoimmune states that affected glands aber¬
rantly express class II molecules [4, 5] the pancreas were
also extensively screened for the presence of la mole¬
cules on endocrine cells.
Materials and methods
Animals
The animals used in this study were from the Edinburgh colony (BB/
E), the nucleus of which was kindly donated in 1982 by Dr P.Thibert,
Animal Resources Division of Canada, Ottawa. The average inci¬
dence of diabetes in this colony is 60-70% and the mean age at on¬
set —96 days. A cohort of 96 BB/E rats was studied prospectively with
eight male and eight female normoglycaemic rats being selected for
study every 15 days between 30 and 105 days of age.
Protocol
At each time point, selected rats received an IP injection of 3H thymi¬
dine (0.5 pCi/g body weight) 1 h before being killed under light halo-
thane anaesthesia. The pancreases were rapidly excised sand serum
samples were taken and stored at — 20°C for determination of glu¬
cose and insulin concentrations and autoantibodies to thyroglobulin,
gastric parietal cells, smooth muscle, islet cell surface and cytoplasm
and insulin. Pancreatic tissue was divided into three portions which
were either (a) immediately snap-frozen in isopentane at — 70°C for
examination of lymphocytic infiltration and expression of class II rat
MHC molecules, (b) fixed in Bouin's solution for autoradiography, or
(c) used to prepare isolated islets for insulin secretion studies. This re¬
port describes only the observations relating to lymphocytic infiltra¬
tion and class II MHC antigen expression on frozen sections.
Antisera
The following monoclonal antibodies were generously provided by
Dr. D.Mason, Sir William Dunn School of Pathology, Oxford. OX6,
specific for rat la; W3/25 which recognises T helper (Th) cells and
macrophages; OX8, a T cytotoxic/suppressor (Tc/s) cell marker and
OX19 (pan T). B lymphocytes were recognised using OX12 which is
specific for rat Kappa chains. Novo, Copenhagen, supplied the fol¬
lowing monoclonals specific for endocrine cells: anti-human insulin
(HU1 018); anti-glucagon (GLU 001) and anti-somatostatin (SOM
018) and rabbit anti-glucagon sera and a guinea pig antibody (M 1183)
used to detect insulin containing cells. Rabbit anti-somatostatin sera
was generously provided by Dr. Patel, Montreal.
Immunofluorescence
Serial sections (4 pm) of snap-frozen pancreas were scanned for lym¬
phocytic infiltration, endocrine cells and aberrant I a expression using
the above monoclonal antibodies. Clone supernatants were used at
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Fig. la-e. Cryostat sections of pre-diabetic BB/E rat pancreas
stained by immunofluorescence using antibodies as described in
Materials and Methods, a OX6 revealing I a expression on vascular
endothelium. Rat age 45 days (x 640) b-e Double exposure photo¬
graphs taken successively using normal green and red filters of the
Zeiss photomicroscope II. b-d Sequential sections from a 105-day-
old rat (x 400): b W3/25 (anti-T helper and some macrophages) and
OX6 (anti-la), c OX8 (anti-T cytotoxic/suppressor) and 0X6.
d OX12 (anti-immunoglobulin Kappa chain) and OX6. e Ml 183
(guinea pig antibody reacting with pro-insulin) and OX6 clearly
show the expression of class II molecules on some insulin-produc¬




1:1 dilution in PBS (0.05 mol/1, pH 7.6) containing 20% normal rabbit
serum, except for OX12 which was in PBS only. Ascitic fluids and po¬
lyclonal antibodies were employed at 1:20 dilution in PBS. Sequen¬
tial acetone fixed sections of prancreas were incubated with individu¬
al antibodies for 20 min at 25 °C and reactions were revealed after a
similar incubation with either fluoresceinated rabbit antimouse im¬
munoglobulin (Dako, High Wycombe, Bucks, UK) or biotinylated
horse anti-mouse immunoglobulins followed by fluoresceinated or
rhodaminated avidin (Vector, Burlinghame, California, USA). A
15-min washing period in PBS followed each application and to pre¬
vent non-specific binding, rabbit or horse antisera were adsorbed with
rat liver acetone powder (Sigma, Poole, Dorset, UK) prior to use.
In double fluorochrome experiments to recognise lymphocyte
subsets, first layer antibodies W3/25, OX8 or OX12 were applied to
sequential sections followed by biotiiiylated anti-mouse immunoglob¬
ulin and rhodaminated avidin. Second layer antibodies OX6 or OX19
were then applied and revealed using fluoresceinated rabbit anti-
mouse IgG. To identify endocrine cells expressing la antigens, the
first layer antibody Ml 183 or polyclonal rabbit antibodies to glucag¬
on or somatostatin were revealed with the corresponding rhodaminat¬
ed antibody to guinea pig or rabbit immunoglobulins (Nordic, Maid¬
enhead, Berks, UK). The second layer antibody OX6 was revealed
with fluoresceinated rabbit anti-mouse immunoglobulin. After
mounting, sections were examined under a Zeiss photo microscope II
fitted with epi-illumination. Photographs were taken on Kodachrome
ASA 200 film with automatic exposure and development at ASA 400.
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Results and discussion
This preliminary paper is based on scanning studies us¬
ing at least 8 pancreases at each time point. The first
change observed was an increased expression of class II
molecules occurring on what appeared to be vascular
endothelium (Fig. 1 a); This preceded lymphocytic infil¬
tration of the gland, which was not apparent until 60
days of age in these animals. Insulitis was observed by
scanning adjacent sections with monoclonal anti-la
and it was confirmed using Bouin-fixed tissue stained
with haematoxylin and eosin. Twenty five percent of the
pancreases were infiltrated by 60 days and 62% by 105
days. These lymphocytic infiltrates, mainly consisting
of cells which were OX19+ and W3/25+ appeared to
emanate from the vessels and converge on islets. By
double fluorochrome staining on sequential sections it
was established that the majority of invading lympho¬
cytes were also Ia+, suggesting recent activation
(Fig. 1 b). It has been shown that la expression on rat T
cells is an early and perhaps transient indication of acti¬
vation (P. Chisholm, personal communication).
A few isolated cells were double stained with W3/25
and OX6 and had a morphological resemblance to
macrophages. The latter have been observed in pancre¬
atic infiltrates by electron microscopy [6]. There is un¬
fortunately as yet no marker in the rat for differentiating
Tc from Ts, thus we are unable to determine whether the
few OX8+ cells found in infiltrates represent mainly
cytotoxic effectors or whether they are suppressor cells
acting to dampen the immune response. Most of the in¬
filtrating OX8+ cells were I a- (Fig. lc).
B lymphocytes were identified in all pancreatic infil¬
trates, their numbers increasing proportionally with rat
age. A few plasma cells could also be identified among
the infiltrating B lymphocytes by their cytoplasmic im¬
munoglobulin staining (Fig. 1 d). It is interesting that T
and B lymphocytes appeared to occupy distinct areas in
the infiltrates.
Coincident with infiltration by activated lympho¬
cytes, occasional endocrine-like cells were seen to ex¬
press I a. When sections were double stained with anti¬
body to insulin, some (3 cells were identified containing
insulin and expressing I a (Fig. 1 e). This is the first time
this has been demonstrated in the BB rat and is strik¬
ingly similar to the observations of Bottazzo and Dean
of aberrant expression of class II MHC molecules in f3
cells in the pancreas of a diabetic child [5]. We have
never observed expression of class II molecules on glu¬
cagon or somatostatin secreting cells, which are in¬
variably well preserved. The cytoplasmic nature of the
/?-cell staining with OX6 and lack of OX6+ glucagon or
somatostatin secreting cells would seem to preclude
passive acquisition of la molecules. However, proof of
active synthesis of these antigens by insulin-producing
cells can come only from studies employing in situ hy¬
bridisation for messenger RNA class II MHC probes.
Ia+ positive /3 cells have been observed mainly in par-
it. M. Dean et al.: Pre-diabetes in the BB/E rat
tially disrupted islets. Several workers have shown ei¬
ther increased I a expression or de novo I a expression
on cells exposed to y interferon [7, 8] and it is not incon¬
ceivable that this or another lymphokine is being pro¬
duced locally by the Ia+ T cells. In the prediabetic rat
the finding of some islets with full insulin expression
surrounded by Ia+ lymphocytes while the endocrine
cells were I a negative, suggests that /9-cell I a expression
does not precede lymphocytic infiltration and may be a
secondary rather than a primary phenomenon. The trig¬
ger initiating the whole process remains obscure.
Elucidation of the precise aetiology of Type 1 (insu¬
lin dependent) diabetes and detailed examination of the
effects of possible therapeutic intervention is clearly dif¬
ficult in man. This animal model offers the possibility of
such studies.
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Summary. The ability of recombinant Interferon-/to induce
class II expression in vitro on pancreatic islet B cells has been
investigated by exposing islets isolated from BB/E and nor¬
mal Wistar rats to Interferon-/ and then staining successively
with monoclonal antibodies specific for rat class 11 MHC an¬
tigens and insulin. Induction of class II expression was never
observed on islet cells obtained from either normal Wistar rats
or rats from the BB/E low diabetes incidence (<2%) subline.
In contrast, pancreatic B cells from rats from the BB/E high
diabetes incidence (60-70%) subline expressed class II anti¬
gen following culture with Interferon-/.
Keywords: BBrat, diabetes, Interferon-/, pancreatic Bcell,
MHC class II expression.
We have previously shown that aberrant expression of
class II MHC antigens occurs on pancreatic B cells in
the spontaneously diabetic, insulin-dependent BB/
Edinburgh (BB/E) rat [1]; this phenomenon has been
described also in a case report of human Type 1 (insu¬
lin-dependent) diabetes mellitus [2]. Neither the signifi¬
cance of this finding nor the mechanism by which it oc¬
curs is understood. Recombinant Interferon-/(r IFN-
/) has been shown to induce class II MHC antigens on
both rat (DC Rayner, HJ de Assis-Paiva, PM Lydyard, S
Bidey, P van der Meide, A Cooke, unpublished obser¬
vations) and human [3] thyroid epithelial cells in vitro
but not on normal rodent [4] or human [5] pancreatic
B cells. Susceptibility to autoimmune disease in both
man and BB rats [6] is known to be linked to the MHC
complex. We have therefore examined the ability of rat
r IFN-/to induce class II antigens on pancreatic B cells
isolated from normal Wistar and BB/E rats.
Materials and methods
Animals
The animals used in this study were from the Edinburgh colony of
BBrats, the nucleus of which was kindly donated by Dr. P.Thibert,
Animal Resources Division of Canada, Ottawa in 1982. The colony
now consists of two sublines created by selective breeding. In the high
diabetes incidence line (BB/E/H) the incidence of insulin-dependent
diabetes is 60-70% and the mean age at onset 96 days. In the low dia¬
betes incidence line (BB/E/L) <2% of animals become diabetic by
120 days of age. BB/E/H animals were screened for circulating islet
cell surface antibodies (ICSA) using a modified l25I-protein A radio¬
ligand assay [7]. We have previously observed that over 90% of ICSA
positive animals subsequently develop insulin-dependent diabetes
(AJ Bone, unpublished observations). However, some ICSA negative
animals also become overtly diabetic and require treatment with insu¬
lin.
Islet isolation, culture and dispersion
Islets were isolated by collagenase (Serva, Uniscience, London, UK)
digestion from the following groups of animals, all of which were
aged 80-90days: 1)ICSA positive BB/E/H rats; 2)ICSA negative
BB/E/H rats; 3) BB/E/L rats; 4) normal Wistar rats. For each exper¬
iment isolated islets were pooled from four rats in each animal group.
Batches of pooled islets (350-400) were maintained in free-floating
culture for 4-5 days in tissue culture medium (RPM1 1640, Imperial
Laboratories, Salisbury, UK) containing glucose (11.1 mmol/1),
HEPES (20mmol/1), antibiotics (penicillin lOOU/ml; streptomycin
0.1 mg/ml), heat-inactivated 10% fetal bovine serum (Imperial Labo¬
ratories) with or without rat r IFN-y (100 U/ml), a concentration we
have previously established as optimal for la induction on cultured
rat thyroid cells (DCRayner et al., unpublished). The medium was
changed after 2 days of culture. At the end of the culture period
(4-5 days) islets were washed twice in ice-cold Ca2+ and Mg2+-free
Hanks' Balanced Salt Solution containing penicillin and streptomycin
(as above) and BSA (5 mg/ml) (HBSS-Ca2+/Mg:+). To prepare cell
suspensions the washed islets were resuspended in HBSS-
Ca2+/Mg2+ (1.5 ml) containing EGTA (2 mmol/1, Sigma Poole, Dor¬
set, UK) and incubated for 20 min at 37 °C in a shaking water bath to
disperse the islet cells. Cell dispersion was completed by repeated
(10 times) aspiration in a Pasteur pipette. The cell suspension was
washed once in HBSS-Ca2 + /Mg2 + , once in RPM1 1640 (supplement¬
ed as above) and finally resuspended in RPM1 1640 (approximately
5 x 105 cells/ml) for staining.
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Fig. 1 a and b. Cell suspension (primary magnification x 400) from BB/E/H rats cultured with r 1 FN-y and stained by immunofluorescence us¬
ing monoclonal antibodies, a Expression on all 3 cells in this field; b Double exposure photograph taken successively using normal green and red
filters on a Leitz fluorescence microscope showing that the 3 class II positive cells contain insulin.
Islet cell immunofluorescence staining
The following monoclonal antibodies were generously provided by
Dr. D. Mason, Sir William Dunn School of Pathology, Oxford: MRC
OX-6, which recognises a non-polymorphic determinant on rat la,
MHC Class II antigen; MRC OX-8, which recognises Tcytotoxic
lymphocytes and was used as a control for non-specific binding.
Clone supernatants were used at 1:5 dilution in PBS (0.05 mol/1
pH 7.6) containing 10% normal rat serum and L-lysine (20mmol/l,
Sigma). Islet cells (2xl04) were incubated in the monoclonal anti¬
body (100 p.1) at 0-4°C for 1 h. Following washing in PBS (0.05 mol/1,
pH 7.6) containing L-lysine, (20 mmol/1) surface staining was re¬
vealed after a similar incubation with rhodaminated rabbit anti-
mouse immunoglobulin (Dako Ltd., High Wycombe, Bucks, UK)
previously adsorbed with rat liver acetone powder (Sigma). After
washing, surface-stained cells were fixed in ice-cold 2% paraform¬
aldehyde in 0.9% NaCl containing HEPES (20mmol/1) and BSA,
(1 mg/ml) pH 7.4 for 30min. The cell suspensions were washed and
put on to glass slides, air-dried and treated with 50% ethanol for
15 min at — 20°C and washed again in PBS. Slide preparations were
incubated for 40 min at 25 °C with clone supernatants of monoclonal
anti-insulin (2 Fl), anti-glucagon (GLU001) or anti-somatostatin
(SOM018) antibodies (kindly donated by Novo, Copenhagen, Den¬
mark). Reaction was revealed using biotinylated horse anti-mouse im¬
munoglobulins (Sera-Lab, Crawley Down, Sussex, UK) followed by
fluoresceinated streptavidin (Cambridge Bioscience, Cambridge,
UK). Slides were examined under a fluorescence microscope (Leitz,
Luton, UK) equipped for double fluorochrome studies. Photographs
were taken on Ektachrome ASA 400 film with automatic exposure.
Experimental protocol
Batches of pooled islets obtained from 4 animals on each occasion
were isolated, cultured and stained from: 1)ICSA positive BB/E/H
rats on 5 separate occasions (n = 20); 2)ICSA negative BB/E/H rats
on 4 separate occasions (n = 16); 3) BB/E/L rats on 4 separate occa¬
sions (n = 16); and 4)normal Wistar rats on 3 separate occasions
(n = 12).
Results and discussion
In agreement with other groups [4], induction of class 11=
MHC antigen by r IFN-/was never observed on any is¬
let cells obtained from normal Wistar rats. Additionally,
we found that rIFN-y failed to induce expression of
class II antigen on the surfaces of insulin containing
B cells from BB/E/L animals. In contrast, islet B cells
from BB/E/H animals, whether ICSA positive or nega¬
tive, expressed class II antigen following culture with
the same dose of r IFN-y(Fig. 1). In agreement with our
previous findings [1] class II expression was not in¬
duced on glucagon or somatostatin secreting islet cells
from BB/E/H animals.
In our experiments 80% of the endocrine cells in any
field were B cells, and on average 50% of these were in¬
duced to express class II antigen. Incubation of islet
cells with the irrelevant monoclonal antibody
MRC OX-8 (as a check for non-specific binding) pro¬
duced no cell surface staining. OX-6 positive non-
endocrine cells were seen only occasionally in any of
the cell suspensions, which was not unexpected, since
maintenance of isolated islets in free-floating culture for
several days has been shown to act as a purification step
for removal of non-endocrine cells [8],
Since expression of class II MHC antigen was not
observed on any islet cells cultured in the absence of
rIFN-y, the expression of la antigen on B cells from
BB/E/H animals is unlikely to be due to adsorption of
shed la from passenger macrophages. These findings
therefore suggest that the ability of rIFN-y to induce
class II expression may depend on genotype. Genetic
factors could influence islet cell susceptibility to r I FN- y
R.Walker et al.: Induction in vitro of class II MHC antigens on pancreatic B cells 751
by several possible mechanisms. Islets obtained from
diabetes prone (BB/E/H) animals may have been dam¬
aged already; for example, by cytokines such as Tu¬
mour Necrosis Factor or Interleukin 1 produced by ac¬
tivated macrophages. The presence or absence of ICSA
does not appear to be related to the sensitivity of B cells
to r I FN-/. However, since circulating ICSA levels fluc¬
tuate in the pre-diabetic period it is likely that some ani¬
mals categorised as ICSA negative had been ICSA posi¬
tive at some time previously.
It has been suggested that aberrant expression of
class II antigen on endocrine cells may be an initiating
feature of autoimmune disease [2, 9], However, our pre¬
vious studies in the BB/E rat led us to postulate that ex¬
pression of class II antigen on pancreatic B cells was a
consequence rather than a cause of pancreatic mono¬
nuclear cell infiltration [1], Since IFN-/is produced on¬
ly by T cells, our present findings add further weight to
our concept of the sequence of events leading to the de¬
velopment of overt insulin-dependent diabetes.
Acknowledgements. This work was supported by grants from the Med¬
ical Research Council (UK), the Scottish Hospital Endowments Re¬
search Trust, The Wellcome Trust and The British Diabetic Associa¬
tion. We would like to thank Mr. D. Brown and W. Smith for their skill
in caring for the animals involved in these studies. We are also grate¬
ful to Professor I. M. Roitt for his support and encouragement.
References
1. Dean BM, Walker R. Bone AJ, Baird JD, Cooke A (1985) Pre-dia-
betes in the spontaneously diabetic BB/E rat: lymphocyte subpop-
ulations in the pancreatic infiltrate and expression of rat MHC
Class II molecules in endocrine cells. Diabetologia 28: 464-466
2. Bottazzo GF, Dean BM, McNally JM, Mackay EH, Swift PGF,
Gamble DR (1985) In situ characterisation of autoimmune phe¬
nomena and expression of HLA molecules in the pancreas in dia¬
betic insulitis. New Engl J Med 313: 353-360
3. Todd I, Pujol-Borrell R, Hammond LJ, Bottazzo GF, Feldman M
(1985) Interferon-y induces HLA-DR expression in thyroid epithe¬
lium. Clin Exp Immunol 61: 265-273
4. Campbell IL, WongGHW, Schrader JW, Harrison LC (1985) Inter¬
feron- y enhances the expression of the major histocompatability
Class I antigens on mouse pancreatic beta cells. Diabetes 34:
1205-1209
5. Pujol-Borrell R, Todd I, Mala Doshi D, Gray M, Feldmann M, Bot¬
tazzo GF (1986) Differential expression and regulation of MHC
products in the endocrine and exocrine cells of the human pan¬
creas. Clin Exp Immunol 65: 128-139
6. Colle E, Guttman RD, Seemayer T (1981) Spontaneous diabetes
mellitus syndrome in the rat. I. Association with the major histo¬
compatability complex. J Exp Med 154: 1237-1242
7. Dyrberg T, Nakhooda AF, Baekkeskov S, Lernmark A, Poussier P,
Marliss EB (1982) Islet cell surface antibodies and lymphocyte anti¬
bodies in the spontaneously diabetic BB Wistar rat. Diabetes 31:
278-281
8. Nielsen JH, Lernmark A (1983) Purification of islets and cells from
islets. In: Pretlow TG, Pretlow TP (eds) Cell separation methods
and selected applications, 2. Academic, New York, pp 96-126
9. Anonymous Leader (1985) What triggers autoimmunity? Lancet 2:
78-79
Received: 29 July 1986
and in revised form: 1 September 1986
Dr. A.Cooke
Department of Immunology





Acta Endocrinologica (Copenh) 1987,115:447-454
Pre-diabetes in the spontaneously diabetic BB/E rat:
pancreatic infiltration and islet cell proliferation
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Abstract. A cohort of BB/E rats derived from litters
vith a high and low incidence of IDDM was studied
trospectively to examine the relationship between em¬
ulating autoantibodies, islet insulin secretion, pancrea-
ic infiltration, and islet cell replication during the
>re-diabetic period. Although a higher incidence of
slet cell surface (ICSA) and insulin autoantibodies
IAA) was detected in the diabetes-prone than in the
ow diabetic-incidence BB/E rats there was no correla-
ion between the two antibodies in individual animals,
doreover, ICSA, but not IAA, were associated with loss
>f first phase islet insulin release. Between 75 and 105
lays of age the number of diabetes-prone rats with
CSA and impaired islet insulin secretory function
ncreased. Over the same period, there was a concomi-
ant increase in the proportion of diabetes-prone ani-
nals with pancreatic infiltration, and increased islet
■ndocrine cell proliferation. All these interrelated
ihenomena were observed in diabetes-prone BB/E rats
it a time when the animals were normoglycaemic.
rhe spontaneously diabetic insulin-dependent BB
at displays a diabetic syndrome closely rescin¬
ding that of human type I (insulin-dependent)
diabetes mellitus (IDDM) in several important
ispects Nakhooda et al. (1977). In particular,
here is a genetic predisposition linked to the
najor histocompatibility complex RT1 (Colle et
tl. 1981), a long pre-diabetic period, and a mono-
rhis work was presented in part at the 20th Annual
deeting of the European Association for the Study of
liabetes, 12—15 September 1984, London, UK.
nuclear cell pancreatic infiltrate associated with
selective destruction of islet P-cells (insulitis),
which invariably precedes and accompanies the
appearance of 'clinical' diabetes. The pathogen¬
esis of the disease has been extensively investi¬
gated and there is evidence (reviewed by Yale &
Marliss 1984) suggesting an involvement of cellu¬
lar and humoral immunity in the destruction of
P-cells. These findings together with the reported
prevention of diabetes in this animal model by
immunosuppression in the pre-diabetic period
JLauptlcis et al. 1983; Boitard et al. 1985) confirm
its importance as a tool for defining precisely the
sequence of events leading to the development of
Type I diabetes.
Loss of pancreatic P-cell mass leading to overt
IDDM results from a negative balance between
islet cell proliferation and destruction. Attention
has focussed on the latter process and there is no
information about P-cell regeneration as spon¬
taneous IDDM develops. We have therefore
examined directly the relationship between circu¬
lating autoantibodies, islet morphology, and P-cell
function/replication in the pre-diabetic period.
Materials and Methods
Animals
The animals used in this study were from the Edin¬
burgh colony (subsequently designated BB/E), the nu¬
cleus of which was kindly donated in 1982 by Dr Pierre
447
Table 1.
Normoglycaemic study rats (age in days) Rats not included in study
Parental No. of
Total





ND x ND 4 4 4 4 4 4 2 0 7
12* (all ND) 41
Diabetes-prone * retaining for breeding




D x D 3 4 4 4 4 3 1 2 1 (D) 23
Total 17 16 16 16 16*3 16*b 16*c 23 31 150
Excluded from study: *a 3 rats; 1 rat; *c 3 rats (N x D mating) diagnosed diabetic on study day.
D: diabetic. ND: non diabetic.
Thibert from the colony maintained at the Animal
Resources Division of Canada, Ottawa (designated BB).
The BB/E colony consists of two sub-lines of animals
created by selective outbreeding. The diabetes-prone
line, predominantly maintained by crossing diabetic
males with non-diabetic females, has a diabetic inci¬
dence of approximately 60% with a mean age at onset
of diabetes of approximately 96 days. The low diabetes
incidence subline has an incidence of diabetes of < 2%
at 120 days of age. Details of the cohort of BB/E rats
used in the study are shown in Table 1. Groups of 16
normoglycaemic rats were selected (as shown in Table
1) for study every 15 days between 30 and 105 days of
age.
Protocol
At each time point, selected animals received an ip
injection of tritiated thymidine (0.5 pCi/g body weight)
one hour before being killed under light halothane
anaesthesia. The pancreata (splenic portion) were then
rapidly excised and plasma samples were taken for
determination of plasma glucose (glucose analyser —
Beckmann Instruments Inc, Fullerton, CA), insulin
concentration, and autoantibodies to islet cell surface
(ICSA), cytoplasm (ICA), and rat insulin (IAA). A
portion of the excised pancreatic tissue was fixed in
Bouin's solution for autoradiography and examination
of mononuclear cell infiltration. The remainder was
used to prepare isolated islets for insulin secretion
studies in a multichannel perifusion system.
Autoantibodies
Plasma samples were applied undiluted to cryostat
sections (4 pm) of normal Wistar rat pancreas for
detection of ICA using fluoresceinated goat anti-r:
immunoglobulins (Nordic, Maidenhead, Berks, UK) ;
the second layer. ICSA were estimated using a 125
protein A radioligand assay Dyrberg et al. (1982
Briefly, dispersed islet cell suspensions were prepare
from (3-cell-rich foetal rat islets and were incubated wit
plasma samples for 60 min at 4°C. The cells were the
washed and incubated for a further 30 min at 4°C wit
125I-protein A. After washing and centrifuging, tl
radioactivity in the cell pellet was determined in
gamma scintillation counter (Nuclear Enterprise
Edinburgh, UK). Cell-bound IgG was expressed ;
cpm/105 islet cells. Intra- and inter-assay variation w;
6% and 14%, respectively (N = 8) with non-specif
binding (islet cells incubated in absence of plasm
contributing < 0.02% of total counts. Animals wei
regarded as being ICSA-positive when counts boun
— 3 sd exceeded mean binding values (± 3 sd) for no
mal Wistar (518 ± 159 cpm/10s cells; N = 32) and lo
diabetes incidence BB/E rats (486 ± 138 cpm/105 cell
N = 132). IAA were measured by a modified dire
immunospecific enzyme-linked immunosorbent ass;
(Elisa) (Dean et al. 1987), employing purified rat insul
(Novo Industri A/S, Copenhagen, Denmark) and hors
radish peroxidase conjugated rabbit anti-rat immun
globulins (Miles Laboratories, Stoke Poges, Sloug
UK). Reference plasma from normal Wistar and diab
tic BB/E rats were included in each assay as contro
Intra- and inter-assay variation were 5.6% (N = 5) ar
15.2% (N = 3), respectively. Plasma samples we
considered IAA-positive when od values were two dm
the mean non-specific binding value and mean ± 3 sd
binding for normal Wistar rats (od = 0.014 ± 0.01
N = 12; aged 90—150 days).
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slet insulin secretion
rhe numbers of age-matched ICSA-positive and nega-
ive rats did not allow a full statistical evaluation of islet
nsulin release, but we considered it important to con-
Irm that islets from the present study animals showed a
tattern of insulin secretion similar to that observed in a
irevious study of diabetes-prone BB/E rats Bone et al.
1983).
Thus, islets were isolated from pooled pancreatic
issue of ICSA-positive or negative rats sacrificed at 75,
>0 and 105 days of age. On each experimental day the
slet insulin secretion was determined for up to 8
latches of 30 islets (4 channels each from the ICSA-
lositive and ICSA-negative groups) and the data com-
lined to compare the pattern of insulin secretory re-
ponse of ICSA-positive and ICSA-negative rats. The
nultichannel system and experimental protocol used
or islet perifusion have previously been described in
letail (Ashby & Shirling 1980). Briefly, the islets were
quilibrated by a 40-min perifusion with basal media
2.7 mmol/1 glucose) and then subjected to two conse-
utive stimulations with 16.7 mmol/1 glucose applied 20
ain apart. Samples of the perifusate were collected
hroughout and stored at -20°C until assayed for
nsulin. At the end of the second high glucose stimula-
ion period, the islets were perifused for a further 20
ain with basal media containing no BSA and recovered
rom the perifusion chambers. The islets were ultra-
onically disrupted, and their protein content deter-
lined (Bio-Rad protein assay kit, Richmond, CA).
nsulin secretion was expressed as pU IRI per pg islet
irotein so as to correct for any possible differences in
he size of islets isolated from ICSA-positive and nega¬
te animals.
Mtoradiography
ncorporation of tritiated thymidine into DNA during
ae S phase of the cell cycle has been widely used as an
idex of islet cell proliferation (Logothetopoulos 1972).
,utoradiography is considered to be the most sensitive
tethod for detecting tritiated thymidine incorporated
lto islet DNA (Hellerstrom 1977).
Pancreatic paraffin sections (5 pm) of Bouin fixed
ssue were mounted on gelatinised slides. The slides
ere dipped in Kodak NTB2 photographic emulsion
nd exposed for five weeks at 4°C. After developing for
min in Kodak D19 and fixing for 10 min in Kodak
24, the emulsion layer was allowed to dry overnight
nd the sections were then lightly counterstained with
aematoxylin and eosin. The labelling index was deter-
lined by counting the number of radioactively labelled
let cell nuclei and expressing this value as a percentage
f the total number of islet nuclei scored. Evaluation of
;ctions containing several islets ensured that a mini-
lum of 800—1000 nuclei were examined for each
(dividual pancreatic tissue sample. Pancreatic sections
ere also examined for the presence of mononuclear
Table 2.
Plasma glucose and insulin concentrations in BB/E rats
during the pre-diabetic period.
BB/E rats Plasma glucose Plasma insulin
(age in days) (mmol/1) (mU/1)
30 (N = 16) 7.0 ± 0.2 4.9 ± 0.8
P< 0.001 P< 0.005
45 (N = 16) 8.2 ± 0.1 9.3 ± 1.3
60 (N = 16) 8.7 ± 0.1 21.7 ± 1.8
75 (N = 13) 8.0 ± 0.2 26.5 ± 7.4
90 (N = 15) 8.1 ± 0.2 27.2 ± 3.6
105 (N = 13) 8.2 ± 0.2 17.6 ± 2.1
Results expressed as mean values ± sem for the numbers
of animals given in parentheses. P values indicate signifi¬
cant differences between mean values for the groups of
animals shown (Student's unpaired t-test).
cell infiltration. All observations were performed blind
on coded samples.
Samples of pancreas from a subsequent biopsy study
(Bone et al. 1986) were examined to confirm that a
possible proliferative activity of infiltrating cells was not
contributing towards the islet cell labelling index re¬
corded in those rats showing pancreatic infiltration.
Cryostat sections of pancreas from 2 confirmed pre-
diabetic BB/E rats (biopsied 10 and 13 days prior to
onset of IDDM) were pre-stained with a monoclonal
antibody to rat class II antigens and subjected to auto¬
radiography as described above. The infiltrating mono¬
nuclear cells showing class II antigen expression did not
possess radiolabelled nuclei whether located either at
the periphery of islets or at a distance from islet tissue.
Results
Table 2 shows the plasma glucose and plasma
insulin concentrations of the study animals, de¬
tails of which are given in Table 1. Plasma glucose
concentration increased significantly in the
groups of animals from 30—45 days of age but
thereafter remained constant at 8 mmol/1. There
was a five-fold increase in the mean plasma insulin
concentration between 30 and 75 days of age, the
values remained steady at 90 days, and declined at
105 days of age. There were no significant dif¬
ferences in either plasma glucose or insulin values
between age-matched low diabetic incidence and
diabetes-prone rats.
Cytoplasmic ICA were not detected in any ani-
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Fig. 1.
Percentage of BB/E rats with circulating islet cell surface and rat insulin antibodies in the different age group
studied. The numbers of low diabetic-incidence and diabetes-prone animals per group are detailed in Table 1.
mal. The numbers of study animals with ICSA
and IAA at the ages studied are shown in Fig. 1.
ICSA were not detected in diabetes-prone animals
prior to 60 days of age, but were demonstrated
with increased frequency thereafter (60 days =
4/12; 75 days = 2/9; 90 days = 6/11; 105 days =
9/11 animals). IAA were found in diabetes-prone
rats at 30 (3/12), 45 (2/12), 60 (6/12), 90 (8/11) and
105 (3/11) days of age. There was no correlation (r
= 0.104) between IAA and ICSA in individual
study animals.
Circulating ICSA and IAA were detected in
only a small number of the low diabetic-incidence
rats.
The insulin secretory response to glucose was
compared between pooled batches of islets iso¬
lated from groups of ICSA-positive and 1CSA-
negative rats aged 75, 90 and 105 days. Findings
from three experiments indicated a diminished
total secretion of insulin in islets from ICSA-
positive rats (414 ± 74 pU IRI/pg islet protein)
compared with islets from animals without ICSA
(577 ± 72 pU IRI/pg islet protein) with first phase
release (98 ± 24 vs 151 ± 16 pU IRI/pg islet
protein) being particularly affected.
Fig. 2 shows pancreatic autoradiographs from a
low diabetic-incidence (A) and a diabetes-prone
(B, C) rat both aged 75 days. The section from the
low diabetic-incidence animal shows no mono-
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nuclear cell infiltration and no labelled islet eel
nuclei. Mild peripheral infiltration and many cen
trally located, radiolabelled islet cell nuclei ar
present in the pancreas of the diabetes-prone rat.
Fig. 3 shows labelling index values and th
presence of pancreatic infiltration in all individua
study animals. The labelling index was remark
ably constant at or below 1% in the low diabetic
incidence rats throughout the age range. Th
diabetes-prone rats showed a similar 1% labellin
index up to 75 days of age, but at 90 and 105 day
4/11 and 6/10 rats, respectively, showed a labellin
index of greater than 4%. These animals witl
a high labelling index also showed some degre
of pancreatic infiltration. However, mononuclea
cell infiltration was also observed in 7 diabetes
prone rats not showing an increase in labellin
index values.
Discussion
In this study we have investigated the regulatio
of islet growth during development of IDDM i
the spontaneously diabetic BB/E rat. We hav
therefore assessed in parallel, 1) metabolic statu;
2) occurrence of circulating islet cell and insuli
autoantibodies; 3) islet cell function (both insuli
Fig.2.







































Islet cell proliferation values (labelling index) and pancreatic infiltration for each individual low diabetic-incideno
and diabetes-prone rat studied at the ages shown. Data at each age point is arranged with values for male and femal
rats shown to the left and right hand side, respectively.
secretion and cell replication; and 4) pancreatic
morphology in individual, potentially-diabetic
BB/E rats prior to the development of 'clinical'
diabetes. All findings being recorded at a time
when the animals were normoglycaemic and had
normal insulin levels.
In agreement with previous findings (Dyrberg
et al. 1982, 1984), we were unable to detect ICA in
any animal. ICSA and IAA were detected pre¬
dominantly in diabetes-prone animals but there
was no correlation between the presence of these
two autoantibodies in individual rats. In addition,
of the 19 animals showing pancreatic infiltration,
11 possessed circulating ICSA whilst only 5 had
IAA. Our findings confirm the previously re¬
ported presence of ICSA in potentially diabetic
BB rats (Dyrberg et al. 1982, 1984). On the other
hand, our evidence would not appear to support
the hypothesis that IAA are potentially useful
markers for either autoimmune insulitis or immi¬
nent development of diabetes in BB rats (Diaz et
al. 1986).
The present islet insulin secretion studies, whil
not showing full statistically significant differer
ces between ICSA-positive and negative rats, di
indicate a perturbed pattern of biphasic insuli
release in the ICSA-positive animals. A lowere
pancreatic insulin release has been reported i
young potentially diabetic BB rats (Svenningse
et al. 1986) but the pattern of release was norm;
and was shown to occur as a result of a lowere
pancreatic insulin content. Such an explanatio
cannot account for the present findings, sine
results are expressed per unit islet protein an
islets from ICSA-positive and negative rats have
similar relative insulin content (Bone et al. 1983
The observed differences in the pattern of insuli
release between these two studies could, howeve
be explained either by different experiment;
technique (isolated islets vs perfused pancreas) c
by age difference of the study animals. Interes
ingly, a progressive decline in first phase insuli
release during an IVGTT has recently been ri
ported in pre-diabetic BB rats 25—50 days pric
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to onset of overt IDDM (Reddy et al. 1986). These
authors also noted a similar impairment of fl-cell
lunction in some BB rats which remained normo-
glycaemic. Taken altogether, these studies suggest
.hat diabetes-prone BB rats with circulating ICSA
and/or abnormal islet secretory function often go
an to develop overt IDDM, but this is not always
.he case.
Whilst previous studies have investigated islet
growth regulation in response to the hypergly¬
cemia of diabetes (for a review see Hellerstrom
1977), nothing is known about islet cell replication
luring development of IDDM. We have therefore
nvestigated islet cell replication in groups of
tormoglycaemic but potentially diabetic BB/E
ats. Low diabetes-incidence and young (< 75
lays of age) diabetes-prone BB/E rats showed a
ate of islet cell replication comparable to that of
tormal rats (Blum et'al. 1963). However, as dia-
jetes-prone rats approached the mean age for
tnset of IDDM (approximately 96 days), a num¬
ber of animals showed a marked increase in islet
:ell labelling. All of these animals showed some
ireas of mononuclear cell infiltration within the
tancreatic sections although it should be noted
hat both the periphery and overall integrity of
heir islets remained intact. Increased islet cell
abelling was not always associated with mononu-
lear cell infiltration, since 7 diabetes-prone rats
vith a pancreatic infiltrate had a normal islet cell
abelling index. This finding provides indirect
•vidence precluding a possible contributory effect
if actively proliferating infiltrating cells towards
n elevated labelling index value. Indeed, exam-
nation of cryostat sections from a subsequent
liopsy study confirmed that infiltrating cells ex-
iressing class II antigens do not possess radio-
abelled nuclei and were therefore unlikely to be
esponsible for the increased islet cell labelling
ibserved in diabetes-prone rats.
From the present study it is not possible to
letermine whether increased islet cell replication
nay have a protective or preventative effect on
he onset of overt IDDM in the BB rat. However,
ince pancreatic infiltration was observed in the
bsence of a raised islet labelling index, it is
empting to speculate that autoimmune attack of
he pancreas may, in some animals, be able to
rigger an increase in the rate of islet cell replica-
ion. Such an increase may help to explain why
ome BB rats showing impaired glucose tolerance
nd histological evidence of insulitis are able to
maintain normoglycaemia (Reddy et al. 1986). It
is equally possible, however, that animals re¬
mained non-diabetic because the autoimmune at¬
tack was less severe rather than because of a
compensatory increase in islet growth.
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SUMMARY
The presence of insulin autoantibodies (IAA) and islet cell surface antibodies (ICSA) was
sought in two longitudinal studies, involving BB/Edinburgh rats of high (BB/E/H,
n= 157) and low (BB/E/L, n = 61) susceptibility to diabetes development. Both studies
were designed to correlate pancreatic morphology with cellular and humoral immunity.
In Study I, groups of eight male and eight female non-diabetic rats of the BB/E/H line
were killed at 15 day intervals from 30-105 days and plasma samples were obtained by
cardiac puncture. In study II, 61 BB/E/H and 41 BB/E/L rats underwent pancreatic
biopsy 1-3 times from 30 days of age until onset of diabetes or 150 days, plasma samples
being taken from the tail vein at biopsy. Both studies revealed a higher prevalence for
ICSA than IAA in BB/E rats. Whereas a highly significant association of ICSA with
diabetes development was observed in study II (x2 = 8-30, P < 0-005), IAA were associated
with diabetes development only weakly (Re0 03, Mann-Witney (/-rank test). No
correlation between the presence of ICSA and IAA in individual rats was observed and
IAA were not significantly associated with BB/E/H in preference to BB/E/L rats, although
positive IAA values were significantly elevated in the former compared with the latter
(P < 0-01). These observations support the concept that IAA form part of a background of
heightened autoimmunity against which frank diabetes develops in some animals.
Keywords BB rats insulin autoantibodies islet cell surface antibodies spontaneous
diabetes
INTRODUCTION
The spontaneously diabetic BB rat provides a good animal model for human Type I diabetes, a
iisease with autoimmune features (Nakhooda et al., 1977). Animals characteristically develop
glycosuria and hyperglycaemia between 60 and 150 days of age, the incidence of diabetes being
:quivalent in the male and female animals. Evidence for an immunological basis of the diabetes in
his model (reviewed by Yale & Marliss, 1984) is provided by the observed insulitis and selective fi-
:ell destruction in the pancreas and the ability to prevent the disease by immunosuppressive
reatments such as anti-lymphocytic serum, neo-natal thymectomy, anti I-E antibody administra-
ion or cyclosporine therapy.
Correspondence: Dr B. M. Dean, Department oflmmunology, Middlesex Hospital Medical School, Arthur
Stanley House, 40-50 Tottenham Street, London W1P 9PG, UK.
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As in man, diabetes develops in the animals against a background of heightened autoreactivity,
multiple autoantibodies being detectable during the prediabetic period. These include antibodies to
islet cell surface (ICSA) and gastric parietal cells, thymocytotoxic antibodies and antibody to
smooth muscle (Dyrberg et at., 1982; Elder et at., 1982). The precise relationship of these
autoantibodies to the development of diabetes, however, is uncertain. Recently, insulin autoantibo¬
dies (IAA) have been detected in newly diagnosed untreated patients and in normoglycaemic
potentially diabetic individuals (Palmer et at., 1983; Arslanian et at., 1985; Srikanta et at., 1985).
The predictive value of IAA for clinically overt diabetes is at present in dispute as published reports
conflict (Karjalainen et at., 1986; Dean et at., 1986; Atkinson et at., 1986).
One value of a model such as the BB rat is that it is possible to carry out longitudinal studies in
which various parameters can be assessed for their predictive power. We report here the results of
two such longitudinal studies in which plasma samples have been assayed for the presence of both
IAA and ICSA and their significance for diabetes development analysed.
MATERIALS AND METHODS
The animals used in this study were from the Edinburgh colony (BB/E), the nucleus of which was
kindly donated in 1982 by Dr P. Thibert, Animal Resources Division of Canada, Ottawa. This
colony now has two components which have been created by selective breeding over the past 3
years; high susceptibility litters (BB/E/H) in which the average incidence ofdiabetes is 60-70%, with
the mean age at onset 96 days, and low susceptibility litters (BB/E/L), in which the incidence of
diabetes at the time of experimentation was below 10%.
Plasma samples
The plasma samples tested in this study were derived from rats used in two longitudinal studies
designed to correlate pancreatic morphology with cellular and humoral immunity. Study I involved
96 BB/E/H animals with batches of eight male and eight female rats being killed at 15 day intervals
from 30-105 days. In this group, samples were obtained by cardiac puncture at killing. For
comparative values, plasma samples were obtained likewise from 20 BB/E/L animals (aged 90-120
days), 12 normal Wistar rats (90-150 days), and 32 diabetic BB/E/H rats (90-150 days) treated daily
with insulin (Ultratarde, Novo, Copenhagen).
Study II consisted of 102 animals (61 BB/E/H; 41 BB/E/L rats) which were biopsied 1-3 times
between 30 and 150 days of age and also at onset of diabetes if symptoms developed. Plasma
samples were obtained from the tail vein at the time of pancreatic biopsy.
Insulin antibodies
A micro-enzyme-linked immunosorbent assay (ELISA) as described for the measurement of human
IAA (Dean et at., 1986) was used with the following modifications:
Insulins. Microwells were coated using 100 ng purified rat, human or pig insulin (kindly donated
by Novo).
Conjugate. Rabbit anti-rat immunoglobulin horse radish peroxidase (Miles Scientific, Slough,
UK) was employed at 1:103 dilution in 0-015 m PBS containing 0-1% Tween 20 (poly-oxyethylene
sorbitan monolaurate, Sigma, Dorset, UK) and 10% heat-inactivated normal rabbit serum (NRS,
Sera Laboratories, UK).
Test plasma and blocking for non-specific binding. Rat plasma were screened at 1:50 dilution in
0 015 m PBS containing 5% Tween 20 and 10% NRS. All microwells were blocked for non-specific
binding by overnight incubation in PBS containing 20% NRS.
Substrate. Reactions with the substrate 3,3'-5,5'-tetramethyl benzidine were terminated after 30
min incubation at room temperature. Samples were screened in triplicate in both antigen-coated
and control wells. The latter were pre-treated with coating buffer alone (0 05 m Na carbonate-
bicarbonate buffer, pH 9-6) and blocked for non-specific binding in the same manner as the antigen-
coated wells. It was established that the presence of heparin or insulin in the physiological/diabetic
range did not affect the assay.
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Calculation of results
For each sample, the mean specific Optical Density at 450 nm (a OD) was calculated by subtraction
of the mean non-specific reading in the corresponding control wells. Reference plasma from normal
Wistar and diabetic BB/E rats were included in each assay as controls. (The intra- and inter-assay
C.V. were 5-6% (n = 5) and 15-2% (n = 3) respectively, using rat insulin and a standard diabetic rat
plasma.
The specific binding observed for plasma samples from normal Wistar rats (n= 12, age 90-150
days) was a OD = 0014±0018, 0 071 ±0 015 and 0-070±0 013 (mean + s.d.) for rat, human and
pig insulin respectively. Readings for other samples were considered positive when OD values were
at least twice the corresponding mean non-specific binding value and greater than mean + 3 s.d. of
the normal Wistar rat group for the relevant species of insulin.
Islet cell surface antibodies
ICSA were estimated using an l25I-protein A radioligand assay essentially as described by Dyrberg
et al. (1982). Dispersed islet cell suspensions were prepared from /i-cell-rich fetal rat islets (Bone &
Swenne, 1982) and 5 x 104 cells were incubated with plasma samples (10 p\\ final dilution I :20) for
60 min at 4°C. The cells were then washed in PBS and incubated for a further 30 min at 4°C with 125I-
protein A. After washing and centrifuging, the radioactivity in the cell pellet was determined in a
gamma Scintillation counter (Nuclear Enterprises, Edinburgh, UK). Cell-bound IgG was expressed
as ct/min/105 cells. Intra and interassay variation was 6% and 14% respectively (m = 8), with non¬
specific binding (islet cells incubated in the absence of plasma) contributing < 0-02% of total counts.
Statistical analyses
The Mann-Witney C-rank test has been employed for the analysis ofassociations of IAA within the
various groups studied, P = 0 05 being chosen as the level of statistical significance.
RESULTS
The incidence of insulin autoantibodies in rats. Both studies showed the spontaneous occurrence
of IAA in untreated diabetes prone BB/E rats. The results of study I are summarized in Table 1,
from which it can be seen that a low incidence of IAA was observed from 30 days of age, with the
peak incidence of activity occurring at 90 days, close to the mean age of onset of diabetes in the BB/
E/H rat colony (96 days). IAA were also found in BB/E/L rats aged 90-120 days, but were never
observed in outbred Wistar rats of comparable age. The presence of IAA in BB/E rats was
confirmed in the serial biopsy study (study II). Only 4/39 (10%) and 1/31 (3%) of the high and low
incidence lines respectively were positive for IAA before 60 days of age. Thereafter, 16/48 (33%) of
biopsied BB/E/H rats were IAA positive, temporal variation in the presence of IAA occurring in
eight of these animals; 3/29 (~ 10%) of the BB/E/L rats biopsied after 60 days of age were IAA
positive, but aOD values were low in these three rats (3-4 s.d. > mean of Wistar rat values).
Table 1 also shows the species binding specificity of the insulin antibodies. Most of the rat IAA
appeared to recognize shared epitopes on rat, human and pig insulin. Although human and pig
insulin appeared more reactive than rat insulin in this assay system, among the 18 IAA positive BB/
E/H rats (study I), six plasma samples bound preferentially to rat insulin, three to human and one to
both pig and human insulins. As expected, a higher incidence of insulin antibodies was seen in
diabetic animals maintained on injections of heterologous insulin.
Islet eelI surface antibodies, insulin autoantibodies and diabetes development. The prevalence of
ICSA with age in BB/E/H rats is shown in Table 1. Unlike insulin and other autoantibodies (such as
parietal cell and smooth muscle antibodies) measured in this group (study I), ICSA were not
observed before 60 days of age, but were found with increasing incidence rising to >75% at 105
days. In study I, there was no correlation (r = 0-104) between ICSA and IAA in individual BB/E/H
rats.
The distribution of ICSA and IAA in relation to diabetes development in study II is presented in
Fig. 1. As in study I, no animal younger than 60 days old was positive for ICSA, so only data from
rats aged 60-105 days have been included for analysis. Among this group 28 (58%) of the BB/E/H
and four (14%) of the BB/E/L rats subsequently developed diabetes. In the high incidence line, 20/
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Table 1. Incidence of antibodies to insulin and islet cell surface (ICSA) in BB/Edinburgh rats (study 1)
Insulin
Age (days) n Rat Human Pig ICSA
(% positive per group) (%positive)
BB/E/H rats
30 16 13 13 6 0
45 16 0 0 0 0
60 16 13 13 38 25
75 16 31 25 38 25
90 16 38 63 56 56
105 16 19 31 31 75
BB/E/L rats
90-120 days 20 35 45 45 NT
Insulin treated
diabetic BB/E rats
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Fig. 1. Insulin autoantibodies (IAA) in relation to diabetes development. The presence of islet cell surface
antibodies is indicated by solid symbols in high (BB/E/H) and low (BB/E/L) susceptibility rats (study II). The
highest iOD values observed for IAA (rat insulin) in individual animals at any age between 60 and 150 days (or
diabetes onset) is shown in relation to the number of s.d. above the mean of normal Wistar rat values (n= 12),
values >3 s.d. ( —) being regarded as IAA positive.
28 (71%) of the rats that became diabetic had ICSA, whereas only seven (35%) of these rats were
also IAA positive. By contrast, in the group of 20 BB/E/H rats which did not develop diabetes, four
had ICSA, a further four were IAA positive and one animal alone was positive for both antibodies.
In the BB/E/L rats, all four animals which developed diabetes were ICSA positive/IAA negative,
but among the 25 animals of this group that remained healthy at 150 days, four had ICSA and a
further three rats had IAA (albeit of low value).
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A strong association of ICSA with diabetes development was thus observed in the biopsy study
(^2 = 8-30, P<0005). Insulin autoantibodies were less significantly associated with diabetes
development (P< 0-03), using Mann-Witney [/-rank test analysis of values from all study II rats
which developed diabetes (« — 32) versus those remaining healthy (« = 45), and this low level of
significance was confirmed (/><0 05) if BB/E/H rats alone were considered in the analysis.
Similar analysis of the data from BB/E/H rats (Fig. 1) revealed no significant association
(P=QA) of IAA with ICSA positive (/i = 25) versus ICSA negative animals (« = 23), confirming the
earlier observation in study I. Likewise, no significant association (F = 015) was found for the
presence of IAA in BB/E/H rats (« = 48) compared with BB/E/L rats (« = 29), presumably due to the
low incidence of IAA in these animals. A further analysis, based solely on all positive IAA values
recorded in the biopsy study, however, shows that higher aOD values for IAA are significantly
associated (P-cO-Ol) with the BB/E/H observations (« = 47) compared with those for the BB/E/L
rats (n= 19).
DISCUSSION
Tolerance to self antigens can be broken following administration of an antigen crossreactive with
self (Weigle, 1965), thus thyroglobulin or insulin autoantibodies are induced in genetically
susceptible mice or humans following injection of rat thyroglobulin or pig insulin. These induced
autoantibodies arise as the result of the provision of a new carrier determinant on the immunogen to
which the recipient is not tolerant. This situation generates carrier specific T helper cells, which can
help autoreactive B cells, recognizing shared determinants on the cross-reacting antigen. The
occurrence of insulin autoantibodies in established diabetic BB/E rats could therefore be viewed as a
breach of self-tolerance by this process, since these animals are maintained on heterologous insulin.
However, the presence of autoantibodies in untreated BB/E rats and their absence in age-matched
Wistar rats requires further explanation. Although tolerant to their own insulin, healthy rats would
not be expected to be tolerant to pro-insulin, which is normally sequestered in the /J-cell. In the
prediabetic period of the BB/E rat, we have shown that insulitis (and attendant /I-cell destruction)
occurs from 60 days onwards. Thus, it is not inconceivable that insulin precursors (pre-proinsulin
and proinsulin) come into contact with the immune system during this period, and this could
generate an autoantibody response, which by definition would be wholly cross-reactive with pro-
insulin. The occurrence of these autoantibodies may be restricted to animals of a certain genetic
background.
Insulin autoantibodies have been detected in the sera of non-diabetic individuals. In man,
complement fixing islet cell antibodies are thought to have some predictive value for insulin-
dependent diabetes. Wilkin et al. (1985) have found no association of human insulin autoantibodies
with the presence of islet cell antibodies and have suggested that their presence is more compatible
with individual genetic susceptibility rather than established disease. However, Dean et al. (1986)
have examined the class distribution of these autoantibodies and have found that the presence of
both IgG insulin autoantibodies and complement fixing islet cell antibodies confers increased risk
for future diabetes development than the presence ofeither marker alone. In the BB/E rat, although
we observed a preferential association of antibodies to rat insulin with the group of animals which
subsequently became diabetic, the finding was of low significance and there was no correlation
between the presence of these antibodies and islet cell surface antibodies, which proved a much
better indicator for diabetes development. However, subclass analysis of the spontaneous rat
insulin autoantibodies will have to be performed before any definitive statement can be made.
Autoantibodies can arise not only through antigenic cross reactivity but also via perturbations
of the idiotype network. For example, studies by Wasserntan and his colleagues (1983) have shown
in animals that administration of BISQ (an acetyl choline agonist) results in the production of
autoantibodies to the acetyl choline receptor. Additionally Cohen and his coworkers (1984) have
shown that administration of insulin to genetically susceptible mice leads to the production not only
of insulin autoantibodies, but also to antibodies to the insulin receptor, presumably via
perturbation of the idiotype network. Wc have previously already discussed the ways in which
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tutoantibodies to the insulin receptor or to insulin could arise following viral infection (Cooke,
Lydyard & Roitt, 1985) and a recent report (Bodansky et at., 1986) has demonstrated a high
ncidence of IgM class insulin autoantibodies following such common viral infections as mumps,
neasles, chickenpox and rubella. Whether these arise as a consequence of viral mediated
lestruction of the yS-cell with concomitant release of insulin precursors leading to insulin
lutoantibodies as described above or via perturbation of the idiotype network as hypothesized
Cooke et at., 1984), remains to be elucidated. If the autoantibodies prove to be wholly cross
eactive with insulin precursors, /(-cell attack by a virus would appear to be the initiating event. A
/iral aetiology of the disease in the BB rat cannot be excluded. Examination of serial plasma
;amples for autoantibodies to insulin and the insulin receptor should at least allow us to decide
vhich autoantibody arises first and which develops as a consequence of the idiotype network.
rhis work was supported by grants from the MRC, the Scottish Hospital Endowments Research Trust, the
Vellcome Trust and the BDA. Anne Cooke is a Wellcome Trust Senior Lecturer. We are greatly indebted to
Douglas Brown and William Smith for their skill in caring for the animals involved in these studies and to Miss
>. C. Bunce for careful typing of the manuscript.
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SUMMARY
Several immunological responses of the spontaneously diabetic BB rat colony in Edinburgh
designated (BB/E) have been studied. The proliferative responses to Con A and LPS, ability to make
1L-2 and to show NK activity have been studied using diabetic and non-diabetic BB/E rats and
normal Wistar rats. Our data suggest that the diabetic animals in the BB/E colony do not have
marked deficiencies in any of these parameters. Lymphopenia and depressed T-cell responses do not
appear to be a prerequisite for the development of diabetes in the BB/E colony.
INTRODUCTION
I rats are a partially inbred line of rats that have a high
:idence of development of insulin-dependent diabetes mellitus
e Review by Yale & Marliss, 1984). This disease has an
toimmune involvement and makes the BB rat a good animal
)del for human Type 1 (insulin-dependent) diabetes mellitus.
veral workers have demonstrated immunological deficiencies
the diabetic BB rat (Bellgrau et a/., 1982; Maclaren et al.,
-83; Prud'Homme et al., 1984; Guttmann et al., 1983), and
•lie, Guttmann & Seemayer (1981) have shown lymphopenia
d diabetes to be genetically linked in the BB rat. However, this
s not been a uniform finding, and since we are attempting to
isect those factors that determine whether an animal pro-
;sses towards the development of diabetes, it was important
r us to ascertain the immunological status of the BB colony in
linburgh. We describe in this paper our comparative studies of
me immunological parameters in the diabetic BB/E rat.
MATERIALS AND METHODS
limals
ie Edinburgh colony of BB rats (BB/E) was derived from a
icleus which was kindly donated in 1982 by Dr P. Thibert,
nimal Resources Division of Canada, Ottawa. The BB/E
ilony has been selectively inbred to generate two lines: the high
cidence, diabetes-prone animals (incidence of diabetes is 60-
1% with the mean age of onset at 96 days) and the non-diabetic
bline (now in its eighth generation with a very low incidence of
abetes, <4%). Wistar rats used in these experiments were
•tained from Olac 1976 Ltd, Bicester, Oxon.
The animals used in these experiments were established
abetic rats, non-diabetic subline rats and Wistar rats that were
I age-matched.
Correspondence: Dr A.-M. Varey, Dept. of Immunology, Middle-
x Hospital Medical School, London W1P 9PG, U.K.
Proliferation assays
Spleen cells from individual rats were washed three times in BSS
and cultured at 2 x 105 cells per well in 96-well, flat-bottomed
microtitre plates (Sterilin, Teddington, Middlesex) in RPMI-
1640 (Flow Laboratories, Irvine, Ayrshire) supplemented with
5% (v/v) fetal calf serum (FCS), 2 ntM L-glutamine, 5x10 5m 2-
mercaptoethanol, 100 U/ml penicillin G and 100 /(g/ml strepto¬
mycin (final volume 200 pi). The mitogens used were concanava-
lin A (Con A) from ICN Biomedicals (High Wycombe, Bucks)
used at doses indicated in the experiment, and lipopolysacchar-
ide (LPS) from Difco Laboratories (West Molesey, Surrey) used
at a final concentration of 20 /rg/ml. After 48 hr at 37° in a
humidified atmosphere of 5% CO: in air, the cultures were
pulsed with 0-5 ^Ci 125I-deoxyuridine (Amersham International,
Amersham, Bucks) in 50 p\ RPMI. Eighteen hours later, the
cultures were harvested onto glass fibre discs using a Titertek cell
harvester (Flow Laboratories) and incorporated radiolabel
assessed by gamma counting.
IL-2 release assay
Spleen cells were cultured as above with 2 p%jm\ Con A. After 24
hr 100 ^1 of supernatant were removed from each well, and IL-2
was measured by its ability to maintain the growth of CTL-L
cells (Kendal Smith, Dartmouth Medical School, Dartmouth,
New Hampshire) at 2 x 104 cells per well (assessed in a 24-hr
proliferation assay).
NK assay
The NK-sensitive cell line YAC-1 was grown in RPMI-1640
with 10% (v/v) FCS and supplements as above. 5lCr-!abelled
YAC-1 were plated out at 104 cells per well into flat-bottomed
96-well microtitre plates with fresh spleen cells (effector cell
ratios of 12-5 : 1, 25 : 1, 50 : 1 and 100 : 1) in a final volume of
200 p\ in RPMI plus 10% FCS and supplements as above. After
4 hr of incubation at 37°, 100 p\ of supernatant were removed
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from each well and counted on a gamma counter. The
percentage specific lysis was calculated by:
Table 1. IL-2 release and LPS responses
% specific lysis =
c.p.m. experimental release — c.p.m. spontaneous release
c.p.m. maximum release - spontaneous release
x 100.
RESULTS
Response to Con A
Responses of BB/E (diabetic and non-diabetic) and age-
matched Wistar rat spleen cells are shown in Fig. 1. There was
considerable variation in the responses of spleen cells from
diabetic animals to Con A (Fig. lb) but these responses were
significantly lower than those found with cells from Wistar rats
(Fig. la). However, this lowered response to Con A did not
correlate with the diabetic status of the animals since spleen cells
from the non-diabetic subline gave markedly poorer responses
(Fig. Ic) than those from either Wistar or diabetic animals.
Ability of Con A-stimulated spleen cells to make IL-2
From Table 1 it can be seen that spleen cells from diabetic
animals produce normal levels of IL-2 following stimulation
with Con A. Both Wistar and diabetic rat spleen cells produced
more IL-2 than those from the non-diabetic subline. It is
interesting to note that one animal in the diabetic group
appeared to be spontaneously releasing IL-2, which probably
reflects the presence of activated T cells in vivo.
Response to LPS
The ability of rat spleen cells to respond to LPS was assessed and
the data are presented in Table 1. Spleen cells from all these rat
strains responded significantly but poorly to LPS, no difference
being detected between those spleen cells derived from diabetic
or normal age-matched control animals.
NK activity
Previous work has suggested that the numbers of NK cells may
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Figure I. Each line represents an individual animal. All groups are
significantly different from each other (P<001).
Response measured
Rat number IL-2 release* LPS (20 /rg/ml)
— Con A + Con A -LPS + L
Wistar
1 368 + 103 10,377 ±760 2758 ±226 48405
2 1511+96 7826 ±138 1415 ± 314 41805
3 240 ±48 14,652 ±1020 557 ±40 1354 H
Non-diabetic
(BB/E)
1 296 + 29 4422 ±89 791 ±213 1429 H
2 354 + 79 5051 ±269 418 + 19 1357 H
3 405 + 55 4514±1421 636 ±201 1451 5
4 640 ±157 2460 ±162 581 ±102 1742 H
5 190 ±18 4528 ±581 431 ±83 1252 H
6 227 ±46 2450±181 300 ± 18 1080 H
Diabetic
(BB/E)
I 573 ±120 7266 ±320 455 ±44 13685
2 516±122 9269 ± 3046 5889 ±42 72615
3 686 ±89 7113 ±297 1876 ± 356 73975
4 2067 ±158 5884 ±371 741 ±36 20865
5 13,578 ±662 14,812 ± 251 527±29 14615
6 2188 ± 961 6873 ±105 476 ±56 14535
Twenty-four hour supernatants were used at 50% in the assay.
* Twenty-four hour assay using the CTL-L line at 2 x 104/well. V
and diabetic were not significantly different, but both were different
the non-diabetic group (P<0 001).
t Seventy-two hour assay with 2x 105 spleen cells/well. Wistai
diabetic were not significantly different but both were different frot
non-diabetic group (PcOOOl).
Rabinovitch, Mackay & Boulton, 1985; Woda et al., 1986. T
NK activity in spleen cells from the BB/E (diabetic and nc
diabetic) and Wistar rats was therefore measured using YAC
cells as targets. From Fig. 2 and Table 2 it can be seen that
significant difference in NK activity at any effector to tari
ratio was demonstrated using spleen cells from diabetic a
non-diabetic BB/E and normal rats.
DISCUSSION
Studies on Con A responses in BB rats (Jackson et al., 19!
Yale & Marliss, 1984) have produced conflicting data. T
findings that responses to Con A were low in rats with insuli
but normal in rats without insulitis (Rossini et al., 1979) cot
provide one explanation for the discrepancies. Bellgrau (I9£
found normal responses in BB diabetic and non-diabe
animals to Con A, but allogeneic responses were not found
mixed lymphocyte cultures. Prud'Homme et al. (1984) att
buted this defect in the response of BB spleen cells to Con A
suppressor macrophages. Our results suggest that BB/E diabe
rats can make a significant response to Con A and do n
manifest any defect related to diabetic status.
In our studies, normal levels of IL-2 could be demonstrat
in supernatants from diabetic spleen cells following Con
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(a) Wistar ( b) Diabetic (c ) Non-diabetic
12-5:1 25:1 50:1 100:1 12-5:1 25:1 50:1 100:1 12-5:1 25:1 50:1 100:1
Effector: target cell ratio
>ure 2. Each line represents an indivudal animal assayed at various effector: target ratios. There is no significant difference between any of the
oups.
Table 2. NK assay
Rat number % cytotoxicity
Wistar
I 49-5 + 2-7
2 516 + 2 6
3 22-7 ±1-7
Non-diabetic
1 32-2 + 3-3
2 39-5 + 0-9
3 42-5 + 5-2
Diabetic
1 38-6 + 3-7









Four hour 51Cr-release as¬
say, with an effector: target
ratio of 100 : 1.
Groups are not signifi¬
cantly different
mulation. This confirms the data of Maclaren et al. (1983) and
der & Maclaren (1983) but conflicts with those of Prud'-
ommc et al. (1984) who found a defect in 1L-2 release. While
saying for IL-2 release following Con A stimulation, sponta-
ous IL-2 release following simple culture of spleen cells was
certained. One of the diabetic animals spontaneously pro-
iced large amounts of IL-2, suggesting the presence in vivo
'
preactivated T cells. Francfort et al. (1985) have shown
tivated T lymphocytes in pre-diabetic BB (diabetes-prone)
ts, the presence of which peaks before onset of diabetes and
iclines with onset. These authors conclude that elevated Ia-
jsitivc T lymphocytes may be a marker for susceptibility to
abetes. Since all the diabetes-prone rats used were established
abetics, we may have missed the activated T-cell response in
the majority of animals used in this study and only observed one
animal with endogenously activated T cells.
The cell-surface marker studies of Marliss, Grose & Yale
(1985) showed an increased population of cells (possibly NK
cells) in diabetic animals, which was not present in non-diabetes-
prone BB rats. Recently Woda et al. (1986) showed an increased
number of OX8 + , OXI9~ (NK) cells in diabetes-prone and
acute diabetic rats. The results from our study show comparable
levels of NK activity in all three types of rats, although slight
variations between individual spleens were observed. We con¬
clude that NK cell activity does not appear to be deficient or
elevated in the spleens of diabetic BB/E rats.
Our data suggest that the diabetic animals in the BB/E
colony, unlike those in other BB rat colonies, do not manifest
marked deficiencies in their ability to respond to T-cell or B-cell
mitogens, to make IL-2 or to generate NK activity. Lympho¬
penia and depressed T-cell reponses do not therefore appear to
be a prerequisite for the development of diabetes in the BB/E
colony. Yale & Marliss (1984) have suggested that the immuno¬
logical disorder is more severe in BB rats when compared to
humans, since man does not have lymphopenia or functional T-
cell defects. Thus, the BB/E colony may resemble human Type 1
diabetes mellitus more closely than other colonies previously
described.
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Aberrant expression of class IIMHC molecules on pancreatic
B-cells during development of insulin-dependent diabetes:
sause or consequence?
Robert WALKER, Adrian J. BONE, Anne COOKE* and Joyce D. BAIRD
Metabolic Unit, Western General Hospital, Crewe Road South, Edinburgh EH4 2XUand
^Department of Immunology, The Middlesex Hospital Medical School, London W1P
IPG, UK.
["he major histocompatibility complex (MHC)
.ntigens are cell surface glycoproteins, associ-
ited with the regulation of immune responses.
l"hese molecules are divided into two main
;roups: class I antigens, located on most
lucleated cells and responsible for restriction of
["-cytotoxic lymphocyte responses and class II
nolecules, required for antigen presentation
.nd normally present only on the surface of
.ntigen-presenting cells such as macrophages,
.ctivated T-cells and B-lymphocytes1. The
ibservation that class II molecules were
xpressed on follicular cells in autoimmune
hyroid disease2, and that this expression could
>e induced on normal thyroid cells® by the
ectin phytohaemagglutin, led to the hypothesis
hat aberrant expression of class II antigens
nay allow the presentation of specific auto-
ntigens to potentially autoreactive T-helper
ymphocytes, thereby leading to autoimmune
lisease4. Such aberrant expression of MHC
lass II antigens on pancreatic B-cells has been
[escribed in human type I diabetes5. In this
eport of a single case with recent onset of type I
liabetes, examination of fresh frozen autopsy
lancreas revealed two major abnormalities of
JHC expression in some islets: firstly expres-
ion of class II MHC products specifically con¬
ned to pancreatic B-cells and secondly marked
yperexpression of class I MHC molecules on
11 types of endocrine cells. Similar abnormal-
:ies of MHC expression were found in the
ancreases of 35 patients who had died with
ype I diabetes and showed classical histo-
athology, namely monoclear cell infiltration of
ilets (insulins).11 Aberrant expression of class
II MHC molecules was observed on the surface
of pancreatic B-cells in some islets and
hyperexpression of class I MHC molecules was
seen in most insulin-containing islets. Whereas,
all insulin-containing islets affected by insulitis
hyperexpressed class I MHC antigens, some
were seen with insulitis but no class II express¬
ion on B-cells, and others showed class II MHC
expression on B-cells in the absence of insulitis.
While recognizing the limitations imposed by
cross-sectional data collected at a time when
80-90% of B-cells were already destroyed,
Foulis et al,6 proposed a possible sequence of
preceding events occurring within individual
islets which culminated in specific destruction of
B-cells, namely hyperexpression of MHC class I
molecules followed either directly by insulitis
with no aberrant expression of class II MHC
antigens by pancreatic B-cells or by aberrant
expression of class II molecules on B-cells fol¬
lowed by insulitis. Finally the inflammatory
process leads to destruction of B-cells leaving an
islet deficient in insulin-containing cells and no
longer hyperexpressing class I MHC molecules.
Direct study of the sequential changes occur¬
ring in the pancreas in the prediabetic period is,
however, only possible using an animal model
such as the spontaneously diabetic, insulin-
dependent BB rat7 which has a long prediabetic
period (>3 months) during which time selective
destruction of islet B-cells occurs8. The degree of
insulitis varies between animals but in all cases
is observed well in advance of the onset of overt
hyperglycaemia. Using this animal we perfor¬
med a longitudinal study designed to examine
the relationship between markers of autoim-
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munity, islet morphology and B-cell function in
the prediabetic period9,10.
Expression of MHC class II molecules in
the BB/E rat pancreas
The nucleus of the Edinburgh colony of BB rats
(BB/E) was kindly donated in 1982 by Dr Pierre
Thibert from the colony maintained at the
Animal Resources Division of Canada, Ottawa.
The BB/E colony consists of two sublines of
animals created by selective breeding. The
diabetes-prone BB/E subline (DP) has an inci¬
dence of diabetes of 56-65 % and a mean age at
onset of ~ 96 days. The diabetes-resistant BB/E
subline (DR) has an incidence ofdiabetes of zero
in the last two generations. A cohort of 96 BB/E
rats was studied prospectively with eight male
and eight female normoglycaemic rats being
selected for study every 15 days between 30 and
105 days of age. At each time point the selected
animals were killed and the pancreas removed.
The pancreatic tissue was examined for the
presence of a mononuclear cell infiltrate and
processed for autoradiography for investigation
of islet cell replication. Serum samples were also
taken and stored at — 20°C for determination of
glucose and the presence of autoantibodies.
Using monoclonal antibodies (Mab) specific for
rat lymphocyte subsets and MHC class II
molecules, the frozen sections of pancreas were
extensively screened for the distribution of sub-
populations of lymphocytes infiltrating the pan¬
creas and also for the presence of la molecules on
endocrine cells.
The first change observed in the pancreas of
normoglycaemic DP animals was increased
expression of MHC class II molecules on vascu¬
lar endothelial cells and this preceded any
mononuclear cell infiltration. Next, T helper cells
(identified by co-expression ofW3/25 and OX19
antigens) infiltrated the pancreas around blood
vessels and these infiltrating T-cells were
expressing class II molecules indicating their
activation. In older DP rats the pancreatic
infiltrate also contained T-cytotoxic/suppressor
cells and B-lymphocytes. Finally in pancreases
showing severe insulitis, expression of class II
molecules was occasionally detected on B-cells
which still contained insulin in partially
destroyed islets. Expression of class II molecules
was never observed on glucagon or somatostatin
containing cells9. The incidence of islet cell
surface (ICSA) and insulin autoantibodies
(IAA) was higher in DP than in I)R rats, but
there was no correlation between the two antibo¬
dies in individual animals. The proportion of DP
rats with circulating ICSA increased as the
mean age of onset of diabetes approached. Over
the same time period there was a concomitant
increase in the proportion of DP rats with
insulitis and an associated increase in islet cell
proliferation10. Our overall conclusion from
these studies was that expression of MHC class
II molecules on pancreatic B-cells did not pre¬
cede lymphocytic infiltration and was therefore
likely to be secondary rather than a primary
initiating phenomenon.
In-vitro induction of MHC class II
molecules
That class II MHC expression on insulin-con¬
taining islet cells was a consequence rather than
a cause of islet infiltration was supported by
subsequent in-vitro studies in which we investi¬
gated the role of cytokines in the induction ol
MHC class II molecules on islets isolated from
BB/E rats. We found that islets isolated by
collagenase digestion from 90-day-old DP rats,
when cultured with 100 U/ml of rat recombinant
interferon-y (rIFN-y) for >4 days, expressed
MHC class II molecules on ~50% of the
insulin-containing B-cells11. In contrast, induc¬
tion ofexpression ofclass 11 molecules by rIFN-]
was never observed on: (1) glucagon or somatos¬
tatin cells in islets from any animals; (2) B-cell:
from either normal Wistar or BB/E DR rats, oi
(3) B-cells from young (30-day-old) DP rats
This suggested the possibility that islets isolatec
from older DP rats might have been renderec
susceptible to the induction of class II molecule:
by IFN-ybecause ofprevious cytokine-mediatec
damage in vivo.
Some support for this concept was providec
by the studies of Pujol-Borrell et al.12, showing
that IFN-yin combination with tumour necrosi:
factor (TNF) or lymphotoxin could induct
expression of MHC class II molecules on endoc
rine cells in monolayer cultures of human pan
creas. However, since this cytokine combinatior
also induced class II molecules on glucagon anc
somatostatin containing cells it is difficult tc
reconcile these findings with in-vivo observa
tions in both human5 and BB rat9. Moreover, wt
have been unable to induce expression of MHC
class II molecules on islets isolated from eithe
normal Wistar or BB/E DR rats using TNE
(both recombinant human and rat), as well a;
Interleukin 1 (IL— 1) with or without rIFN-'
(unpublished). Although synergism betweei
IFN-y and other cytokines may occur15, then
are studies suggesting that IFN-y is sufficient bt
itself to induce class II molecules on isolatec
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murine14, and human15 islets. It is possible,
however, that these effects may result from
synergism of IFN-y with cytokine products
released from macrophages present in the cul¬
tures. Whereas, Campbell et a/.16'17 and Pujol-
Borrell et a/.18 reported enhanced expression of
MHC class 1 but not class II molecules on
isolated mouse16 and human17'18 islets when
cultured with IFN-y alone, these authors used a
much lower concentration of IFN-y and a shor¬
ter culture period than that used in studies
performed by Wright14'15.
These disparate results suggest that the use of
in-vitro studies to examine the possible role of
cytokines in the destruction of pancreatic B-cells
has limitations and caution must be exercised in
extrapolations to the in-vivo situation. Variation
in the source, species and concentration of
cytokine employed and the conditions and dura¬
tion of culture and cytokine exposure undoub¬
tedly affect the results obtained and probably
account for apparent discrepancies in the results
reported from different centres.
Studies on the pathogenesis of diabetes in
the BB/E rats using serial pancreatic
■biopsies
The longitudinal cohort study9 discussed above
had several inherent limitations: (1) it was not
known which animals with insulitis would have
gone on to develop IDD subsequently; (2) it was
not possible to assess the time scale of the
lymphocytic infiltration/B-cell destructive pro¬
cesses with any degree ofaccuracy; (3) the Mabs
used to characterize the lymphocytic infiltrate
were unable to distinguish between T-cell sub¬
sets and certain populations of macrophages. In
an attempt to remedy these deficiencies we have
employed serial pancreatic biopsy as described
by Logothetopoulos eta/.19. This allows sequen¬
tial study of individual animals over prolonged
periods. Groups of DP rats were biopsied
between 40 and 100 days of age with each
individual animal being biopsied twice at a 10-
day interval. Rats developing diabetes were
biopsied for a third time at onset ofdiabetes. The
biopsied pancreatic tissue was immediately snap
frozen and cryostat sections prepared for immu-
nohistochemical examination. Sections were
screened with Mab for both class I and class II
MHC molecules and the subpopulations of cells
comprising the mononuclear cell infiltrates were
also examined. In addition to Mab identifying
rat T- and B-lymphocytes, Mab directed against
distinct antigenic determinants (EDI and ED2)
on rat macrophages20 were also employed.
Macrophages in pathogenesis
A resident population of tissue macrophages
(ED2 positive) was observed in all biopsy
sections. These cells were observed around the
perimeter of the pancreatic lobules and were also
widely dispersed throughout the connective and
acinar tissues. The distribution and numbers of
ED2-positive macrophages did not vary between
biopsies in individual animals and did not
change as the mean age at onset of diabetes
approached. The Mab EDI revealed a separate
population of pancreatic macrophages which
were usually located either periductally or
around islets and which in normal Wistar, BB/E
DR and young (40-50 days of age) DP rats were
much less numerous than ED2-positive cells.
Although there was some variation in time scale
in individual DP animals, between 14 and 21
days before onset of overt diabetes marked
recruitment and accumulation of EDl-positive
cells occurred in the pancreas at periductal,
perivascular and peri-islet locations and this was
followed by infiltration of islets by these cells
before there was any apparent involvement of
other immune effector cells. T-lymphocytes
(OX 19 positive) including T-helper cells, NK-
cells and B-lymphocytes, were recruited
into the areas of insulitis, ~10 days before the
onset of diabetes. At this time there was marked
hyperexpression of MHC class I molecules on
the surface of all islets cells. Expression of MHC
class II molecules was, however, restricted to
infiltrating immunocytes with no expression of
MHC class II on pancreatic B-cells. Pancreatic
biopsies obtained at onset of overt diabetes
revealed almost total destruction of pancreatic
B-cells with very few insulin-containing cells
remaining. Double Huorochrome labelling re¬
vealed that only very occasionally were MHC
class II antigens expressed in association with
insulin-containing cells.
It is possible that our earlier observation of
class II positive insulin-containing cells in
end-stage islets9 may represent the phagocytic
uptake of fragments ofdamaged insulin-contain¬
ing cells by cells which are themselves expressing
class II antigens21. These results support an
earlier report describing an initial phase ofsingle
cell insulitis, which on electron microscopy
appeared to consist mainly of macrophages22. It
is interesting that a virtually identical pattern of
distribution of EDI and ED2 macrophages was
recently described in the central nervous system
of rats with early experimental allergic
encephalomyelitis23. The suggestion that mac-
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rophages may have an important role in IDD
pathogenesis in the BB rat is supported also by
the observation that diabetes can be prevented
in this animal by administration ofsilica"4 which
is known to block macrophage function.
Conclusive remarks
While the precise mechanism of the death of B-
cells is still uncertain, the sequence ofpancreatic
events leading up to their mass destruction can
now be described in the BB/E rat. The first
phenomenon observed is hyperexpression of
MHC class I molecules on islet cells. The cause
of this is unknown but it has been suggested that
chronic viral infection (which is known to be a
common stimulus for the release of interferons
from epithelial cells and has been shown to
enhance expression ofclass I MHC molecules by
pancreatic endocrine cells in vitrols) could be
responsible"5. Subsequent infiltration of these
islets by EDI-positive macrophages may release
cytokines which could be directly cytotoxic to
islet B-cells26, and/or via local release of IL-1
and TNF activate the endothelial cells of pan-
1 Kaufman JI\ Auflray C, Korman AJ etal. The class II
molecules of the human and murine major histocom¬
patibility complex. Cell 36: 1-13, 1984.
2 Hanafusa T, Pujol-Borrell R, Chiovata L et al. Aber¬
rant expression of HLA-DR antigen on thyrocytes in
Graves' disease: relevance for autoimmunity. Lancet 2:
1111-1115, 1983.
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1983.
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leads to their destruction.
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III. IMMUNOLOGICALLY MEDIATED DIABETES; TRANSGENIC MICE
III.9
Development of BB rat diabetes is delayed or prevented by
infections or applications of immunogens
I. KLOETING, S. SADEWASSER, S. LUCKE, L. VOGT, and H. J. HAHN
Central Institute ofDiabetes 'Gerhardt Katsch', Karlsburg, 2201 GDR.
/
The spontaneously diabetic BB rat has become
an accepted model for insulin-dependent dia^
betes (IDD). Several lines of evidence suggest
that immunological mechanisms are central to
the initiation of a diabetic state resembling
human IDD. Therefore, many studies were
undertaken to prevent the development of dia¬
betes in BB rats by modulating their immune
system, e.g. by neonatal thymectomy1, total
lymphoid irradiation2, treatment with anti-
lymphocyte sera3, cyclosporine Al_f> and/or
glucocorticoids ' and by transfusion of whole
blood7, white blood cells8, or T-lymphocyte
subsets11 from diabetes-resistant rats. The
immune system is also influenced by factors /
from the natural environment, e.g. by microbes;
toxins, or chemicals with stimulatory effects/On
the immune system. Some of them might <yct on
the immune system in a way similar ,t6 that
effective in artificial modulation. In rttan, dia¬
betes concordance of 50% only hi' identical
twins10 suggests that such natural factors are of
importance. Observations in our/BB rat colony
have also supported this assumption. Two
latent mycoplasma infections/reduced the inci¬
dence of diabetes from 70.(yto 14.9% and from
77.3 to 38.6%, respectively". The increase of
diabetes incidence frony/38.6 to 92.8% in the
first generation after tjleir transfer into a germ-
free environment using hysterectomy confirmed
. u„ ™..i—1——
Animals and method;
From the 11th inbred generation of our BB/OK
rat colony, obtained from Dr Thibert's colony in
Canada in 1983/33 males and 59 females were
the stimulatory action of mycoplasma as
'natural modulatdrs' of the immune system.
These facts pronrlpted us to simulate the effect of
exogenous im/nune stimuli by application of
two weak inamunogens—insulin and tubercu¬
lin—on th^r development of IDD in BB rats.
Both imrfi'unogens were chosen because these
BB rats/are low- or non-responders to insulin,
and tuberculin is a purified hapten-like protein.
used. These animals were the progeny of first
and second .fitters of the same parents which
descended /from the same grandparents and
served b<>(n as control and experimental animals
as shoWn in Table 1. They were kept under
stancjardized hygienic conditions, and were
caged in groups of 4—6 animals in the same room
a^ detailed before12. Pelleted food (Rezeptur 13,
,-Zentralinstitut fuer Ernaehrung, Rchbruecke,
GDR) and water were provided ad libitum.
Crystallized bovine insulin (100 pg) dissolved
in 0.1 ml saline or 0.1 ml tuberculin (PPD vet.
'Dessau', Institut fuer Impfstoffe, Dessau,
GDR) were applied i.p. with 0.1 ml complete
Freund's adjuvant (CFA) at 5 weeks of age. One
week later, the experimental animals were given
the same amount of immunogens without CFA
twice per week until the 20th week of life. The
control animals were treated only with 0.1 ml
CFA at 5 weeks of age.
From the 3rd until the 32nd week of life the
following parameters were monitored; body
weight and plasma glucose weekly, polymor¬
phonuclear leucocytes (PMNL) and lympho¬
cytes at 4, 6 and 8 weeks and then monthly,
glucose tolerance at 10, 15, 20, 25 and 30 weeks,
percentage of infiltrated pancreatic islets
(biopsy) at 20 and 31 weeks, host versus graft
reaction (HVGR) at 20 and 32 weeks, and
pancreatic insulin content at 32 weeks. The rats
were considered diabetic if their plasma glucose
concentration was >20 mmol/1.
Blood was taken by puncture of tail vein
between 06.00 and 08.00 hours from non-fasting
animals. Plasma glucose was measured on a
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Rapid Publications
Distinct Macrophage Subpopulations in
Pancreas of Prediabetic BB/E Rats
Possible Role for Macrophages
in Pathogenesis of IDDM
ROBERT WALKER, ADRIAN J. BONE, ANNE COOKE, AND JOYCE D. BAIRD
Use of monoclonal antibodies directed against rat
macrophages and serial pancreatic biopsy in the
prediabetic period have enabled us to document the
involvement of macrophages in the pancreatic events
leading to onset of diabetes in the spontaneously
diabetic BB/E rat. A few weeks before onset of
disease, there is marked recruitment and accumulation
of ED1' macrophages at periductal and perivascular
locations adjacent to noninfiitrated islets. These
recruited cells, distinct from the resident ED2+ tissue
macrophages, then infiltrate the islets. Infiltration of
the pancreas by ED1 macrophages is therefore a very
early event in the prediabetic period and suggests a
possible role for macrophages in the pathogenesis of
insulin-dependent diabetes mellitus (IDDM) in this
animal model. Diabetes 37:1301-304, 1988
The BB rat develops a diabetic syndrome closelyresembling human insulin-dependent diabetesmellitus (IDDM) (1). In a prospective longitudinalcohort study in which batches of prediabetic BB/
Edinburgh (BB/E) rats were killed at intervals in the predi¬
abetic period, we have previously reported the presence of
0X19+ (T-) and W3/25* (helper T-) lymphocytes in the early
stages of pancreatic infiltration (2). However, because W3/
25 also recognizes certain macrophage populations (3), it
is important to use a different marker to allow discrimination
between T- lymphocytes and macrophages. Recently, sev¬
eral monoclonal antibodies (MoAbs) identifying distinct rat
macrophage subpopulations have been described (4). We
have used these along with serial pancreatic biopsy in in-
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dividual animals to investigate a possible role for macro¬
phages in the development of diabetes in BB/E rats.
MATERIALS AND METHODS
The animals used in this study were from the Edinburgh
colony of BB rats, the nucleus of which was kindly donated
in 1982 by P. Thibert (Animal Resources Division of Canada,
Ottawa). The BB/E colony consists of two sublines of animals
created by selective breeding. The diabetes-prone main line
has a 60-70% incidence of diabetes, with the mean age of
onset ~96 days. The diabetes-resistant subline has an in¬
cidence of diabetes of <1% at 120 days. Animals (20 male,
20 female) were selected at random from age-matched di¬
abetes-prone litters. All animals were monitored daily in re¬
lation to body weight and glycosuria. Animals developing
overt diabetes were maintained on a single daily subcuta¬
neous injection of Ultratard insulin (Novo, Copenhagen). An¬
imals from the diabetes-resistant subline and normal Wistar
rats were used as nondiabetic and non-BB control rats, re¬
spectively.
Protocol. Pancreatic biopsy was performed essentially as
described by Logothetopoulos et al.(5). Eight groups (n = 5)
of diabetes-prone animals were biopsied twice (with a 10-
day interval) between 30 and 110 days of age. Animals de¬
veloping diabetes received a third biopsy at onset of dis¬
ease. Biopsies were also performed on diabetes-resistant
animals (n=12) and on normal Wistar rats (n = 6) between
100 and 120 days of age. Biopsies (50-75 mg of tissue)
were immediately snap frozen in isopentane at -70°C for
subsequent immunohistochemical examination. One hun¬
dred twenty serial cryostat sections (4 |j.m) were cut from
each biopsy. Scan slides with 8 sections/slide, each section
taken at a different level through 80 |xm of tissue, were used
as an initial screen to detect areas of pancreatic infiltration
with class II MHC-positive cells. Detailed analysis of areas
with infiltration via the antisera listed below were performed
by referring back to subsequent serial sections coincident
with the areas represented by the scan slides.
Antisera. The following MoAbs were generously provided
as clone supernatants (D. Mason, Sir William Dunn School
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FIG. 1. Cryostat sections of pancreatic biopsies stained by indirect immunofluorescence with antibodies as described in materials and methods.
A: double exposure of ED2 (green) and insulin (red) staining on normal Wistar rat pancreas (aged 100 days). ED2* cells are found prominent
within septa of pancreatic lobules, x 125. B: double exposure of ED1 (green) and insulin (red) in normal Wistar rat pancreas (aged 100 days).
Occasional ED1* cells observed periductally. Elsewhere in sections, few cells stain with ED1. x 125. C-E: serial sections from biopsy of
diabetes-prone animal (aged 70 days). Biopsy was taken 20 days before onset of diabetes. C: double exposure for cells expressing MHC class II
molecules (green) and insulin (red). Four islets within same pancreatic lobule show early peri-islet infiltration; cells were recruited from vascular
sites supplying the lobule, x 125. D: serial section of C stained for ED1 (green) and insulin (red) shows many OX6* cells to be ED1 *
macrophages. x125. E: ED1 staining (red) at higher magnification (x300) of an islet shown in D. ED1 * cells accumulate at perivascular site, with
mild peri-islet infiltration. F: double exposure of ED1 * cells (green) infiltrating insulin-containing islet (red). Biopsy taken from same animal 10
days later from sections shown in C-E, x300.
of Pathology, Oxford, UK): MRC-OX6 (rat la or MHC class II
antigen); MRC-OX8 [cytotoxic/suppressor T-lymphocytes
and natural killer (NK) cells]; MRC-OX19 (pan-T-lympho-
cytes); MRC-OX33 (rat leukocyte-common antigen, present
only on B-lymphocytes); W3/25 (helper T-lymphocytes and
macrophages). The MoAbs ED1 and ED2 directed against
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distinct antigenic determinants on rat macrophages were
obtained as ascites fluid (Serotec, Oxford, UK; 4). Novo sup¬
plied the polyclonal antiserum M1183, raised in guinea pig
against insulin-containing cells. A rabbit anti-glucagon anti¬
serum was obtained from Immunodiagnostics (Washington,
UK).
Immunofluorescence staining. Cryostat sections (4 |xm) of
biopsy samples were air dried, acetone fixed for 10 min, and
screened with the antisera. Clone supernatants were used
at 1:2 to 1:10 dilution in phosphate-buffered saline (PBS, pH
7.6) containing 10% normal rat serum. Ascitic fluids and
polyclonal antisera were applied at 1:50 to 1:100 dilution in
PBS containing 10% normal rat serum for ascites or 10%
nonimmune serum from the host species in which the anti¬
sera were raised for the polyclonal antisera. Sections were
incubated with the antisera for 60 min at 25°C. Reactions of
MoAb binding were revealed with species-specific biotin-
ylated sheep F(ab')2 anti-mouse IgG (Amersham, Ayles-
burgh, UK), followed by fluoresceinated or Texas red-con¬
jugated streptavidin (Amersham). Endocrine cell markers
were revealed with the corresponding fluoresceinated or rho-
daminated antibodies to guinea pig or rabbit immunoglob¬
ulins (Cambridge Bio Science, Cambridge, UK). A 10-min
washing period with 3 changes of PBS followed each ap¬
plication. After mounting, sections were examined under a
Leitz Orthoplan microscope fitted with a fluorescence ver¬
tical illuminator and filter blocks for revealing fluorescein and
rhodamine/Texas red fluorochromes. Photographs were
taken on Ektachrome ASA 400 film with automatic exposure.
RESULTS AND DISCUSSION
Each biopsy can only reflect a part of the total pancreas at
a single time point. However, by using scan slides to screen
whole islets within many pancreatic lobules, we can describe
changes in pancreatic morphology leading to insulitis within
individual and multiple islets.
The normal tissue distribution of cells identified by MoAbs
ED1 and ED2 was assessed by use of pancreatic sections
from normal Wistar rats and animals from the diabetes-re¬
sistant subline. ED2 revealed a resident population of tissue
macrophages present in all biopsies from all groups of an¬
imals. These cells were prominent lining the septa between
pancreatic lobules and were widely dispersed throughout
the connective and acinar tissues but were not present within
islets (Fig. 1 A). Fluctuations in the degree of dispersion and
number of ED2+ cells found between biopsies in individual
animals were minimal and may have been a consequence
of the biopsy. Biopsies from diabetes-prone animals at all
ages showed a similar tissue distribution. There was no cor¬
relation between distribution of ED2+ cells and onset of di¬
abetes in individual animals. Indeed, ED2+ cells were not
found in any islets showing insulitis.
In contrast, ED1 revealed a separate population of pan¬
creatic macrophages distinct from ED2+ cells. In the normal
control pancreases and biopsies from diabetes-prone ani¬
mals at an age when insulitis has never been observed (40
days), ED1+ cells were much less numerous than ED2+ cells.
Occasionally, a few ED1+ cells were observed periductally
or rarely at peri-islet sites (Fig. 1B).
Approximately 14-21 days before onset of diabetes, the
first sign of mononuclear cell infiltration was observed in
diabetes-prone animals at periductal, perivascular, and peri-
islet sites in some lobules (Fig. 1C). Further analysis with
serial sections revealed that this infiltrate consisted mainly
of ED1+ cells (Fig. 1, D and E). Initially this was focal, with
most islets in one pancreatic lobule showing some degree
of peri-islet infiltration (Fig. 1D), whereas islets in adjacent
lobules could appear unaffected. This initial accumulation
of ED1+ cells at perivascular locations was not a nonspecific
consequence of the biopsy, because it was never observed
in sequential biopsies from normal Wistar or diabetes-re¬
sistant BB rats. The recruited ED1+cells then proceeded to
infiltrate islets within affected lobules (Fig. 1F). In all cases,
most initially infiltrating cells appeared to be ED1+, with sub¬
stantial numbers of T-lymphocytes (OX19+), including helper
T-lymphocytes (OX19+, W3/25+), NK cells (OX8 + , OX19-),
and B-lymphocytes (OX33+) seen only subsequently at
-10-14 days before the onset of diabetes. Progressive
spreading of this insulitis process from lobule to lobule will
eventually result in overt diabetes.
These results support the observations of Kolb et al. (6),
who have described "single-cell insulitis" early in the pre-
diabetic period, which on electron microscopy appeared to
consist mainly of macrophages. Other ultrastructural studies
have described macrophages containing ingested p-cell de¬
bris within islets of diabetic BB rats (7). In addition, the prom¬
inent appearance of ED1+ macrophages in the perivascular
infiltrates associated with experimental allergic encephalo¬
myelitis, another autoimmune disease (8), agrees with our
observations.
It has been reported that the administration of silica, which
blocks macrophage function, can prevent the onset of dia¬
betes in BB rats (9). Our findings, together with the evidence
cited, would suggest a possible role for macrophages in the
pathogenesis of IDDM in the spontaneously diabetic BB/E
rat. The precise nature of this role is still unclear.
Interestingly, a recent article has postulated that a pop¬
ulation of intravascular monocytes may induce venular leak¬
age and hence allow enhanced diapedesis of lymphoid cells
from the circulation into the pancreas of susceptible BB
rats (10). We speculate that this population of intravascular
monocytes may correspond to ED1+ cells, because ED1 but
not ED2 stains most peripheral blood monocytes (4), and
ED1+ cells have been seen trapped in the vascular endo¬
thelium of Wistar rats (11). Having infiltrated the islets, ED1 +
cells may release cytokines, e.g., interleukin 1 (IL-1) and
tumor necrosis factor, which may be cytotoxic to islet p-cells
(12,13) and/or may, via these mediators, activate the en¬
dothelial cells of pancreatic venules and ducts to bind in¬
creased numbers of lymphocytes (14). The infiltrating lym¬
phocytes could then be attracted to islets already infiltrated
by macrophages by a chemotactic gradient of IL-1 (15).
Within the infiltrated islets, presentation of p-cell—specific
antigens by ED1+ OX6+ macrophages to MHC class II-
restricted helper T-lymphocytes may serve to initiate further
immune mechanisms leading to the specific destruction of
islet p-cells.
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